0000950170-21-003753.txt : 20211109 0000950170-21-003753.hdr.sgml : 20211109 20211109161644 ACCESSION NUMBER: 0000950170-21-003753 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211109 DATE AS OF CHANGE: 20211109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Design Therapeutics, Inc. CENTRAL INDEX KEY: 0001807120 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 823929248 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40288 FILM NUMBER: 211392422 BUSINESS ADDRESS: STREET 1: 6005 HIDDEN VALLEY ROAD STREET 2: SUITE 110 CITY: CARLSBAD STATE: CA ZIP: 92011 BUSINESS PHONE: 858-293-4900 MAIL ADDRESS: STREET 1: 6005 HIDDEN VALLEY ROAD STREET 2: SUITE 110 CITY: CARLSBAD STATE: CA ZIP: 92011 10-Q 1 dsgn-20210930.htm 10-Q 10-Q
http://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarnedhttp://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned--12-310.613497falsehttp://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned0001807120http://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarnedQ30001807120us-gaap:LeaseAgreementsMember2021-07-012021-09-300001807120dsgn:UnsecuredPromissoryNoteMemberdsgn:JanuaryNoteMember2019-02-280001807120dsgn:NovemberNoteMemberdsgn:UnsecuredPromissoryNoteMember2021-01-012021-09-300001807120us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-09-300001807120dsgn:CoFounderMemberdsgn:MayNoteMember2021-01-012021-09-300001807120us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001807120us-gaap:CommonStockMember2021-01-012021-09-300001807120dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember2021-01-012021-09-300001807120us-gaap:RetainedEarningsMember2021-06-300001807120us-gaap:GrantMember2020-01-012020-09-300001807120dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember2021-03-252021-03-250001807120us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001807120dsgn:InvestigationNewDrugMemberdsgn:LicenseAgreementMembersrt:MinimumMember2021-09-300001807120us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001807120us-gaap:CertificatesOfDepositMember2020-12-310001807120us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-09-3000018071202021-07-012021-09-300001807120us-gaap:RetainedEarningsMember2021-01-012021-09-300001807120dsgn:ResearchConsultingAgreementsMember2021-07-012021-09-300001807120dsgn:SeriesAConvertiblePreferredStockMember2020-02-012020-02-290001807120us-gaap:LeaseholdImprovementsMember2021-09-3000018071202020-09-300001807120srt:MaximumMemberdsgn:LicenseAgreementMemberus-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001807120us-gaap:GrantMember2021-07-012021-09-300001807120us-gaap:RestrictedStockMember2020-12-310001807120us-gaap:ConvertiblePreferredStockMember2020-12-310001807120us-gaap:USTreasurySecuritiesMember2021-09-3000018071202021-06-300001807120us-gaap:AdditionalPaidInCapitalMember2019-12-310001807120us-gaap:CommonStockMember2020-07-012020-09-300001807120dsgn:SeriesAConvertiblePreferredStockMember2020-03-012020-03-3100018071202020-02-012020-02-290001807120dsgn:CoFounderMemberus-gaap:ConvertibleNotesPayableMember2018-07-310001807120us-gaap:RetainedEarningsMember2020-12-310001807120us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2020-12-310001807120us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001807120us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2020-12-3100018071202021-03-012021-03-310001807120us-gaap:AdditionalPaidInCapitalMember2020-09-3000018071202020-06-300001807120us-gaap:IPOMember2021-01-012021-09-300001807120us-gaap:MoneyMarketFundsMember2020-12-310001807120srt:MaximumMemberdsgn:UnsecuredPromissoryNoteMemberdsgn:JanuaryNoteMember2019-01-310001807120dsgn:LicenseAgreementMembersrt:MaximumMemberus-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001807120dsgn:ConsultingAgreementsMember2020-12-310001807120dsgn:UnsecuredPromissoryNoteMemberdsgn:JanuaryNoteMember2019-01-310001807120us-gaap:IPOMember2021-03-012021-03-310001807120dsgn:WithinOneYearMemberus-gaap:CertificatesOfDepositMember2021-01-012021-09-300001807120us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310001807120us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001807120us-gaap:USTreasurySecuritiesMemberdsgn:WithinOneYearMember2021-01-012021-09-300001807120us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300001807120dsgn:InvestigationNewDrugMemberdsgn:LicenseAgreementMember2021-09-300001807120us-gaap:SeriesAPreferredStockMemberdsgn:CoFounderMemberus-gaap:ConvertibleNotesPayableMember2020-02-012020-02-290001807120us-gaap:LeaseAgreementsMember2020-12-310001807120us-gaap:CommonStockMember2021-06-300001807120us-gaap:LeaseAgreementsMember2021-01-012021-09-300001807120dsgn:SeriesBConvertiblePreferredStockMember2021-01-310001807120us-gaap:ConvertiblePreferredStockMember2020-01-012020-09-3000018071202021-09-300001807120us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001807120us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2021-09-300001807120us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001807120srt:MaximumMember2020-07-012020-09-300001807120us-gaap:AdditionalPaidInCapitalMember2021-06-300001807120dsgn:ComputerEquipmentAndSoftwareMember2021-09-300001807120dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2021-03-252021-03-250001807120dsgn:CrossingHoldingsLLCMember2021-09-300001807120dsgn:InvestigationNewDrugMemberdsgn:LicenseAgreementMember2021-01-012021-09-300001807120us-gaap:USTreasurySecuritiesMemberdsgn:OneYearToTwoYearsMember2021-01-012021-09-300001807120dsgn:MarlinspikeGroupLLCMemberdsgn:TwoThousandTwentyConsultingAgreementMember2020-03-012020-03-310001807120dsgn:NovemberNoteMemberdsgn:UnsecuredPromissoryNoteMember2019-12-310001807120us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001807120dsgn:TwoThousandEighteenEquityIncentivePlanMember2021-03-250001807120dsgn:InitialClosingOfSeriesAPreferredStockMemberdsgn:LicenseAgreementMember2020-02-012020-02-290001807120us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300001807120dsgn:ConsultingAgreementsMember2021-09-300001807120us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001807120dsgn:May2018NoteMember2021-01-012021-09-300001807120dsgn:July2018NoteMember2021-01-012021-09-300001807120us-gaap:USTreasurySecuritiesMember2020-12-310001807120dsgn:LicenseAgreementMembersrt:MaximumMemberus-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-3000018071202021-01-012021-09-300001807120us-gaap:ConvertiblePreferredStockMember2020-09-300001807120srt:MaximumMemberdsgn:LicenseAgreementMemberus-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001807120us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001807120dsgn:WithinOneYearMemberus-gaap:CertificatesOfDepositMember2020-01-012020-12-310001807120srt:MaximumMember2020-12-310001807120dsgn:LicenseAgreementMember2019-01-012019-12-310001807120us-gaap:CommonStockMember2021-07-012021-09-300001807120dsgn:MarlinspikeGroupLLCMemberdsgn:ConsultingAgreementsMember2020-01-012020-09-300001807120dsgn:MarlinspikeGroupLLCMemberdsgn:TwoThousandNineteenConsultingAgreementMembercountry:CA2019-01-012019-01-310001807120dsgn:SeriesBConvertiblePreferredStockMember2021-01-012021-09-300001807120dsgn:OneYearToTwoYearsMemberus-gaap:CertificatesOfDepositMember2021-09-300001807120dsgn:UnsecuredPromissoryNoteMemberdsgn:JanuaryNoteMember2019-03-310001807120dsgn:LicenseAgreementMember2021-01-012021-09-300001807120srt:MaximumMember2021-09-300001807120dsgn:MarlinspikeGroupLLCMemberdsgn:ConsultingAgreementsMember2021-07-012021-09-3000018071202020-07-012020-09-300001807120us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001807120us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001807120dsgn:MarlinspikeGroupLLCMemberdsgn:ConsultingAgreementsMember2021-01-012021-09-300001807120us-gaap:USTreasurySecuritiesMemberdsgn:OneYearToTwoYearsMember2021-09-300001807120dsgn:FebruaryAndMarch2019DrawsMemberdsgn:UnsecuredPromissoryNoteMemberdsgn:JanuaryNoteMember2021-09-300001807120dsgn:SeriesAConvertiblePreferredStockMember2020-01-012020-09-300001807120us-gaap:EquipmentMember2020-12-310001807120dsgn:ConsultingAgreementsMember2021-01-012021-09-300001807120us-gaap:EquipmentMember2021-09-300001807120us-gaap:RetainedEarningsMember2020-07-012020-09-300001807120us-gaap:LeaseAgreementsMember2021-09-300001807120dsgn:NovemberNoteMemberdsgn:UnsecuredPromissoryNoteMember2019-11-300001807120dsgn:SeriesBConvertiblePreferredStockMember2021-01-012021-01-310001807120dsgn:CrossingHoldingsLLCMember2021-02-012021-02-280001807120us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001807120us-gaap:RestrictedStockMember2021-09-300001807120us-gaap:CommonStockMember2020-06-300001807120dsgn:LicenseAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2019-02-012019-02-280001807120us-gaap:RetainedEarningsMember2020-01-012020-09-300001807120us-gaap:RetainedEarningsMember2020-09-300001807120dsgn:MarlinspikeGroupLLCMemberdsgn:ConsultingAgreementsMember2020-07-012020-09-3000018071202021-09-012021-09-300001807120us-gaap:ConvertiblePreferredStockMember2021-01-012021-09-300001807120srt:MaximumMemberus-gaap:GrantMember2020-07-012020-09-300001807120us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001807120dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2021-01-012021-09-3000018071202019-12-310001807120dsgn:February2019NoteMember2021-01-012021-09-300001807120dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember2021-03-250001807120us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001807120us-gaap:ConstructionInProgressMember2021-09-300001807120us-gaap:GrantMember2021-01-012021-09-3000018071202020-01-012020-09-300001807120us-gaap:RetainedEarningsMember2020-06-300001807120us-gaap:CommonStockMember2021-09-3000018071202020-12-310001807120us-gaap:CommonStockMember2020-01-012020-09-300001807120dsgn:LicenseAgreementMember2019-02-012019-02-280001807120us-gaap:RetainedEarningsMember2019-12-310001807120dsgn:UnsecuredPromissoryNoteMemberdsgn:JanuaryNoteMember2021-01-012021-09-300001807120us-gaap:IPOMember2021-03-310001807120us-gaap:EmployeeStockMember2021-01-012021-09-300001807120dsgn:InvestigationNewDrugMembersrt:MaximumMemberdsgn:LicenseAgreementMember2021-09-300001807120dsgn:SeriesAConvertiblePreferredStockMember2020-03-310001807120us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001807120dsgn:ConsultingAgreementsMemberdsgn:CoFounderMember2017-12-012017-12-310001807120dsgn:JulyNoteMemberdsgn:CoFounderMember2021-01-012021-09-300001807120us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300001807120us-gaap:RetainedEarningsMember2021-07-012021-09-300001807120dsgn:SharesSubjectToRepurchaseMember2020-01-012020-09-300001807120dsgn:CrossingHoldingsLLCMember2021-01-012021-09-3000018071202019-02-280001807120dsgn:SeriesAConvertiblePreferredStockMember2020-02-2900018071202021-11-050001807120dsgn:NovemberNoteMemberdsgn:UnsecuredPromissoryNoteMember2020-01-310001807120dsgn:WithinOneYearMemberus-gaap:CertificatesOfDepositMember2021-09-300001807120us-gaap:USTreasurySecuritiesMemberdsgn:WithinOneYearMember2020-01-012020-12-310001807120us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001807120dsgn:OneYearToTwoYearsMemberus-gaap:CertificatesOfDepositMember2021-01-012021-09-300001807120us-gaap:USTreasurySecuritiesMemberdsgn:WithinOneYearMember2020-12-310001807120us-gaap:CommonStockMember2019-12-310001807120dsgn:ConvertibleNotesIssuedInMayAndJuly2018Member2021-09-300001807120dsgn:CoFounderMemberus-gaap:ConvertibleNotesPayableMember2018-05-310001807120dsgn:ResearchConsultingAgreementsMember2021-01-012021-09-300001807120us-gaap:ConvertiblePreferredStockMember2020-01-012020-09-300001807120us-gaap:CommonStockMember2020-12-310001807120us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001807120us-gaap:AdditionalPaidInCapitalMember2020-06-300001807120dsgn:Jan2020AndDec2019DrawsMemberdsgn:NovemberNoteMemberdsgn:UnsecuredPromissoryNoteMember2021-09-300001807120us-gaap:MoneyMarketFundsMember2021-09-300001807120us-gaap:AdditionalPaidInCapitalMember2020-12-310001807120us-gaap:AdditionalPaidInCapitalMember2021-09-300001807120us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001807120dsgn:SharesSubjectToRepurchaseMember2021-01-012021-09-300001807120srt:MaximumMemberus-gaap:LeaseAgreementsMember2021-09-300001807120us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001807120us-gaap:CommonStockMemberus-gaap:IPOMember2021-03-310001807120us-gaap:USTreasurySecuritiesMemberdsgn:WithinOneYearMember2021-09-300001807120us-gaap:RestrictedStockMember2021-01-012021-09-300001807120us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001807120dsgn:WithinOneYearMemberus-gaap:CertificatesOfDepositMember2020-12-310001807120dsgn:NovemberNoteMembersrt:MaximumMemberdsgn:UnsecuredPromissoryNoteMember2019-11-300001807120us-gaap:RetainedEarningsMember2021-09-300001807120us-gaap:RestrictedStockMemberus-gaap:CommonStockMemberdsgn:TwoThousandEighteenEquityIncentivePlanMember2021-01-012021-09-300001807120us-gaap:PrimeRateMemberdsgn:UnsecuredPromissoryNoteMemberdsgn:JanuaryNoteMember2019-01-012019-01-310001807120us-gaap:CommonStockMember2020-09-300001807120us-gaap:PrimeRateMemberdsgn:NovemberNoteMemberdsgn:UnsecuredPromissoryNoteMember2019-11-012019-11-300001807120dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2021-03-250001807120us-gaap:ConvertiblePreferredStockMember2020-06-300001807120us-gaap:FairValueInputsLevel1Member2021-09-300001807120us-gaap:CertificatesOfDepositMember2021-09-300001807120dsgn:CrossingHoldingsLLCMember2021-02-280001807120us-gaap:FairValueInputsLevel1Member2020-12-31xbrli:pureutr:sqftdsgn:Securityxbrli:sharesiso4217:USDxbrli:sharesiso4217:USD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-40288

 

Design Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

82-3929248

( State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer
Identification No.)

6005 Hidden Valley Road, Suite 110

Carlsbad, California

 

92011

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (858) 293-4900

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

DSGN

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

The number of outstanding shares of the registrant’s common stock, $0.0001 par value per share, as of November 5, 2021, was 55,662,501.

 

 


 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

our plans to research, develop and commercialize our product candidates;
the initiation, progress, success, cost and timing of our preclinical studies, clinical trials and product development activities;
the therapeutic potential of our product candidates, and the disease indications for which we intend to develop our product candidates;
our ability and timing to advance our product candidates into, and to successfully initiate, conduct, enroll and complete, clinical trials;
our ability to manufacture our product candidates for clinical development and, if approved, for commercialization, and the timing and costs of such manufacture;
the performance of third parties in connection with the development and manufacture of our product candidates, including third parties conducting our preclinical studies and clinical trials as well as third-party suppliers and manufacturers;
our ability to obtain funding for our operations, including funding necessary to initiate and complete clinical trials of our product candidates;
the size and growth of the potential markets for our product candidates and our ability to serve those markets;
the potential scope, duration and value of our intellectual property rights;
our ability, and the ability of our licensors, to obtain, maintain, defend and enforce intellectual property rights protecting our platform technologies and product candidates, and our ability to develop and commercialize our product candidates without infringing the proprietary rights of third parties;
our ability to recruit and retain key personnel;
the effects of the COVID-19 pandemic on our operations; and
other risks and uncertainties, including those described under Part II, Item 1A, “Risk Factors” of this Quarterly Report.

Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part II, Item 1A, “Risk Factors” of this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Unless the context otherwise indicates, references in this Quarterly Report to the terms “Design”, “the Company”, “we,” “our, and “us” refer to Design Therapeutics, Inc., and references to our “common stock” refers to our voting common stock.

 

 

 

i


 

SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS

 

An investment in shares of our common stock involves a high degree of risk. Below is a list of the more significant risks associated with our business. This summary does not address all of the risks that we face. Additional discussion of the risks listed in this summary, as well as other risks that we face, are set forth under Part II, Item 1A, “Risk Factors” in this Quarterly Report. Some of the material risks associated with our business include the following:

We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it.
We are early in our development efforts and all of our research programs are still in the preclinical or discovery stage. We have no history of conducting clinical trials to test our product candidates in humans.
Preclinical and clinical development involves a lengthy and expensive process with uncertain timelines and outcomes, and results of earlier studies and trials may not be predictive of future trial results. If development of our programs is unsuccessful or delayed, we may be unable to obtain required regulatory approvals and be unable to commercialize our product candidates on a timely basis, if at all.
Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.
Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue planned clinical trials, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
The regulatory approval process is lengthy, expensive and uncertain, and we may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our ability to generate revenue, our business and our results of operations.
The COVID-19 pandemic could adversely impact our business and affect our operations, as well as the business or operations of our manufacturers or other third parties with whom we conduct business.
We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
We may rely on third parties to conduct, supervise, and monitor our planned clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.
We contract with third parties for the manufacturing and supply of our product candidates for use in preclinical testing and planned clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity.
Any approved products may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.
If the market opportunities for any of our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.
If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved.
We may not realize the benefits of any acquisitions, in-license or strategic alliances that we enter into.
We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.
We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws,

ii


 

transparency laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.
We may not be able to protect our intellectual property rights throughout the world.
We may rely on trade secrets and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
The price of our common stock could be subject to volatility related or unrelated to our operations.

 

 

iii


 

Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

 

Item 1.

Financial Statements (Unaudited)

1

 

Condensed Balance Sheets

1

 

Condensed Statements of Operations

2

 

Condensed Statements of Comprehensive Loss

3

 

Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

4

 

Condensed Statements of Cash Flows

5

 

Notes to Condensed Financial Statements

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

18

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

25

Item 4.

Controls and Procedures

25

PART II.

OTHER INFORMATION

 

Item 1.

Legal Proceedings

26

Item 1A.

Risk Factors

26

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

71

Item 3.

Defaults Upon Senior Securities

71

Item 4.

Mine Safety Disclosures

71

Item 5.

Other Information

71

Item 6.

Exhibits

72

Signatures

73

 

 

 

 

iv


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

DESIGN THERAPEUTICS, INC.

CONDENSED BALANCE SHEETS

(in thousands, except share and par value data)

 

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

 

(unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

357,662

 

 

$

2,379

 

Investment securities

 

 

36,056

 

 

 

33,712

 

Prepaid expense and other current assets (including related party amounts of $60 and $0, respectively)

 

 

1,572

 

 

 

142

 

Total current assets

 

 

395,290

 

 

 

36,233

 

Property and equipment, net

 

 

1,320

 

 

 

71

 

Right-of-use asset

 

 

3,743

 

 

 

 

Deferred offering costs

 

 

 

 

 

212

 

Total assets

 

$

400,353

 

 

$

36,516

 

Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable (including related party amounts of $20 and $20, respectively)

 

$

2,216

 

 

$

1,399

 

Accrued expenses and other current liabilities (including related party amounts of $10 and $0, respectively)

 

 

3,289

 

 

 

931

 

Total current liabilities

 

 

5,505

 

 

 

2,330

 

Operating lease liability, net

 

 

3,273

 

 

 

 

Other long-term liabilities

 

 

11

 

 

 

145

 

Total liabilities

 

 

8,789

 

 

 

2,475

 

Commitments and contingencies (See Note 9)

 

 

 

 

 

 

Convertible preferred stock, $0.0001 par value; no shares and 22,500,000 shares authorized, no shares and 22,012,499 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively; liquidation preference of zero and $45,625 as of September 30, 2021 and December 31, 2020, respectively

 

 

 

 

 

45,356

 

Stockholders’ equity (deficit):

 

 

 

 

 

 

Common stock, $0.0001 par value; 200,000,000 and 60,000,000 shares authorized, 55,654,833 and 16,604,774 shares issued, 55,224,420 and 15,957,821 shares outstanding at September 30, 2021 and December 31, 2020, respectively

 

 

6

 

 

 

1

 

Additional paid-in capital

 

 

427,953

 

 

 

451

 

Accumulated deficit

 

 

(36,391

)

 

 

(11,923

)

Accumulated other comprehensive income

 

 

(4

)

 

 

156

 

Total stockholders’ equity (deficit)

 

 

391,564

 

 

 

(11,315

)

Total liabilities, convertible preferred stock and stockholders’ equity (deficit)

 

$

400,353

 

 

$

36,516

 

 

The accompanying notes are an integral part of these financial statements.

1


 

DESIGN THERAPEUTICS, INC.

CONDENSED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Grant revenue

 

$

 

 

$

20

 

 

$

 

 

$

193

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development (including related party amounts of $98, $0, $188 and $8, respectively)

 

 

8,539

 

 

 

1,914

 

 

 

17,441

 

 

 

3,352

 

General and administrative (including related party amounts of $82, $60, $202 and $232, respectively)

 

 

2,798

 

 

 

489

 

 

 

7,263

 

 

 

1,310

 

Total operating expenses

 

 

11,337

 

 

 

2,403

 

 

 

24,704

 

 

 

4,662

 

Loss from operations

 

 

(11,337

)

 

 

(2,383

)

 

 

(24,704

)

 

 

(4,469

)

Other income, net (including related party expense amounts of $0, $0, $0, and $30, respectively)

 

 

19

 

 

 

63

 

 

 

236

 

 

 

44

 

Net loss

 

$

(11,318

)

 

$

(2,320

)

 

$

(24,468

)

 

$

(4,425

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share, basic and diluted

 

$

(0.21

)

 

$

(0.09

)

 

$

(0.57

)

 

$

(0.17

)

Weighted-average shares of common stock outstanding, basic and diluted

 

 

55,155,030

 

 

 

25,701,737

 

 

 

42,759,656

 

 

 

25,606,779

 

 

The accompanying notes are an integral part of these financial statements.

2


 

DESIGN THERAPEUTICS, INC.

CONDENSED STATEMENTS OF COMPREHENSIVE LOSS

(in thousands)

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net loss

 

$

(11,318

)

 

$

(2,320

)

 

$

(24,468

)

 

$

(4,425

)

Other comprehensive gain (loss):

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on available-for-sale securities

 

 

8

 

 

 

(42

)

 

 

(160

)

 

 

152

 

Comprehensive loss

 

$

(11,310

)

 

$

(2,362

)

 

$

(24,628

)

 

$

(4,273

)

 

The accompanying notes are an integral part of these financial statements.

3


 

DESIGN THERAPEUTICS, INC.

CONDENSED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share data)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

Total

 

 

 

Convertible

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

Stockholders’

 

 

 

Preferred Stock

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Equity

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income

 

 

Deficit

 

 

(Deficit)

 

Balance at June 30, 2021

 

 

 

 

$

 

 

 

 

55,114,729

 

 

$

6

 

 

$

426,680

 

 

$

(12

)

 

$

(25,073

)

 

$

401,601

 

Exercises of stock options and vesting of restricted stock

 

 

 

 

 

 

 

 

 

109,691

 

 

 

 

 

 

30

 

 

 

 

 

 

 

 

 

30

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,243

 

 

 

 

 

 

 

 

 

1,243

 

Unrealized gain on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

8

 

 

 

 

 

 

8

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(11,318

)

 

 

(11,318

)

Balance at September 30, 2021

 

 

 

 

$

 

 

 

 

55,224,420

 

 

$

6

 

 

$

427,953

 

 

$

(4

)

 

$

(36,391

)

 

$

391,564

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2020

 

 

22,012,499

 

 

$

45,356

 

 

 

 

15,957,821

 

 

$

1

 

 

$

451

 

 

$

156

 

 

$

(11,923

)

 

$

(11,315

)

Issuance of Series B convertible preferred stock, net of $288 of issuance costs

 

 

19,083,979

 

 

 

124,712

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock converted into shares of common stock

 

 

(41,096,478

)

 

 

(170,068

)

 

 

 

25,212,548

 

 

 

4

 

 

 

170,064

 

 

 

 

 

 

 

 

 

170,068

 

Initial public offering of common shares, net of $21,728 of issuance costs

 

 

 

 

 

 

 

 

 

13,800,000

 

 

 

1

 

 

 

254,270

 

 

 

 

 

 

 

 

 

254,271

 

Exercises of stock options and vesting of restricted stock

 

 

 

 

 

 

 

 

 

254,051

 

 

 

 

 

 

35

 

 

 

 

 

 

 

 

 

35

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,133

 

 

 

 

 

 

 

 

 

3,133

 

Unrealized loss on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(160

)

 

 

 

 

 

(160

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(24,468

)

 

 

(24,468

)

Balance at September 30, 2021

 

 

 

 

$

 

 

 

 

55,224,420

 

 

$

6

 

 

$

427,953

 

 

$

(4

)

 

$

(36,391

)

 

$

391,564

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at June 30, 2020

 

 

22,012,499

 

 

$

45,356

 

 

 

 

15,782,575

 

 

$

1

 

 

$

14

 

 

$

194

 

 

$

(5,748

)

 

$

(5,539

)

Vesting of restricted stock

 

 

 

 

 

 

 

 

 

104,771

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

15

 

 

 

 

 

 

 

 

 

15

 

Unrealized loss on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(42

)

 

 

 

 

 

(42

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(2,320

)

 

 

(2,320

)

Balance at September 30, 2020

 

 

22,012,499

 

 

$

45,356

 

 

 

 

15,887,346

 

 

$

1

 

 

$

29

 

 

$

152

 

 

$

(8,068

)

 

$

(7,886

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2019

 

 

 

 

$

 

 

 

 

15,640,133

 

 

$

1

 

 

$

 

 

$

 

 

$

(3,643

)

 

$

(3,642

)

Issuance of Series A convertible preferred stock, net of $270 of issuance costs

 

 

21,710,814

 

 

 

44,731

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Conversion of convertible debt and interest to Series A convertible preferred stock

 

 

301,685

 

 

 

500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Settlement of bifurcated conversion liability

 

 

 

 

 

125

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vesting of restricted stock

 

 

 

 

 

 

 

 

 

247,213

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

29

 

 

 

 

 

 

 

 

 

29

 

Unrealized gain on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

152

 

 

 

 

 

 

152

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,425

)

 

 

(4,425

)

Balance at September 30, 2020

 

 

22,012,499

 

 

$

45,356

 

 

 

 

15,887,346

 

 

$

1

 

 

$

29

 

 

$

152

 

 

$

(8,068

)

 

$

(7,886

)

 

The accompanying notes are an integral part of these financial statements.

4


 

DESIGN THERAPEUTICS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

 

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

Cash flows from operating activities

 

 

 

 

 

 

Net loss

 

$

(24,468

)

 

$

(4,425

)

Reconciliation of net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation

 

 

47

 

 

 

1

 

Stock-based compensation

 

 

3,133

 

 

 

29

 

Amortization of premiums on investment securities, net

 

 

(103

)

 

 

(69

)

Non-cash interest expense

 

 

 

 

 

12

 

Non-cash interest expense—related party

 

 

 

 

 

26

 

Non-cash lease expense

 

 

5

 

 

 

 

Change in operating assets and liabilities:

 

 

 

 

 

 

Prepaid expense and other assets

 

 

(1,158

)

 

 

(71

)

Prepaid expense and other assets—related party

 

 

(60

)

 

 

 

Deferred revenue

 

 

 

 

 

(193

)

Accounts payable and other liabilities

 

 

2,444

 

 

 

708

 

Accounts payable and other liabilities—related party

 

 

10

 

 

 

(1,843

)

Net cash used in operating activities

 

 

(20,150

)

 

 

(5,825

)

Cash flows from investing activities

 

 

 

 

 

 

Purchases of investment securities

 

 

(36,356

)

 

 

(55,589

)

Proceeds from maturities of investment securities

 

 

33,955

 

 

 

20,092

 

Purchases of property and equipment

 

 

(1,184

)

 

 

(62

)

Net cash used in investing activities

 

 

(3,585

)

 

 

(35,559

)

Cash flows from financing activities

 

 

 

 

 

 

Proceeds from initial public offering, net of issuance costs

 

 

254,271

 

 

 

 

Proceeds from issuance of convertible preferred stock, net of issuance costs

 

 

124,712

 

 

 

44,731

 

Proceeds from the exercise of stock options and vesting of restricted stock

 

 

35

 

 

 

 

Proceeds from the issuance of notes payable, net of issuance costs—related party

 

 

 

 

 

200

 

Repayment of notes payable—related party

 

 

 

 

 

(400

)

Net cash provided by financing activities

 

 

379,018

 

 

 

44,531

 

Net increase in cash and cash equivalents

 

 

355,283

 

 

 

3,147

 

Cash and cash equivalents at beginning of period

 

 

2,379

 

 

 

77

 

Cash and cash equivalents at end of period

 

$

357,662

 

 

$

3,224

 

Supplemental disclosures

 

 

 

 

 

 

Initial recognition of operating lease right-of-use asset and operating lease liability

 

$

3,786

 

 

$

 

Purchases of property and equipment included in accounts payable and accrued expenses

 

$

112

 

 

$

 

Conversion of convertible notes to convertible preferred shares, including bifurcated
   conversion liability

 

$

 

 

$

271

 

Conversion of convertible notes to convertible preferred shares, including bifurcated
   conversion liability - related party

 

$

 

 

$

354

 

Interest paid

 

$

 

 

$

18

 

 

The accompanying notes are an integral part of these financial statements.

5


 

DESIGN THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

1. Organization

Design Therapeutics, Inc. (the “Company”) was incorporated in Delaware in December 2017 and is based in Carlsbad, California. The Company is a biopharmaceutical company pioneering GeneTACTM molecules, a novel class of disease-modifying small-molecule gene targeted chimera therapeutics that are designed to target the underlying cause of inherited nucleotide repeat expansion diseases. The Company’s lead product candidate is in Friedreich ataxia (“FA”), its second GeneTAC™ program is in myotonic dystrophy type-1 (“DM1”), and it is also advancing its GeneTACTM portfolio to address other serious nucleotide repeat-driven monogenic diseases.

The Company has experienced net losses and negative cash flows from operating activities since inception and expects to incur net losses for the foreseeable future as it advances its research and development programs, conducts clinical trials for any future product candidates and commercializes any such product candidates for which it receives regulatory approval. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of its future product candidates, and on the achievement of sufficient revenue to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital to fund its operations.

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

The accompanying interim condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and following the requirements of the United States Securities and Exchange Commission ("SEC") for interim reporting. The Company's financial statements include all adjustments, consisting of only normal recurring adjustments, which in the opinion of management are necessary to present fairly the Company’s financial position as of the reporting date and results of operations for the periods presented. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the recognition of grant revenue, accruals for research and development expenses and the valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.

The full extent to which the novel coronavirus-2019 (“COVID-19”) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.

Stock Splits

In February 2020, the Company effected a 5-for-1 forward stock split of its issued and outstanding common stock. Further, in March 2021, the Company effected a 1-for-1.63 reverse stock split of its issued and outstanding common stock. The par value and the authorized shares of the common stock were not adjusted as a result of these stock splits. The reverse stock split in March 2021 resulted in an adjustment to the convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying financial statements and notes to the financial statements give retroactive effect to the stock splits for all periods presented.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities at the date of acquisition of three months or less to be cash equivalents. These investments may include money market accounts, money market funds, U.S. Government agency securities, corporate debt securities and commercial paper. The Company’s cash reserves are in a readily available checking account.

6


DESIGN THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS—(Continued)

 

Investment Securities

Investments in securities with maturities at the date of acquisition of more than three months are considered marketable securities. The Company determines the appropriate classification of its investments at the time of acquisition and reevaluates such determination at each balance sheet date. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management strategies. Further, the Company classifies its available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations. The Company’s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for safety of principle, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of other comprehensive income (loss) until realized. Allowances for credit losses are reported on the balance sheet, if any.

The cost of available-for-sale investment securities is adjusted for amortization of premiums and accretion of discounts until the securities mature. Such amortization and accretion is included in other income (expense) on the statements of operations. Realized gains and losses, if any, are also included in other income (expense) on the statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the periods presented, no realized gains or losses were recorded on the sale of investment securities and no impairments to reduce the value of any security was taken. See Note 5 for further discussion.

Leases

At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise the option. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company's leases do not provide an implicit interest rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less ("Short-Term Leases"). For any Short-Term leases, the Company records the rent expense on a straight-line basis and does not record the leases on the condensed balance sheet. The Company had no Short-Term Leases as of September 30, 2021 or December 31, 2020.

After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.

Revenue Recognition

The Company has generated revenue from grants awarded to it by the National Science Foundation (“NSF”), the National Institutes of Health (“NIH”) and the Friedreich’s Ataxia Research Alliance (“FARA”). These grants provide the Company with funding for certain research and development activities on a best-efforts basis and do not require scientific achievement as a performance obligation. The Company has determined that the entities funding these grant awards do not meet the definition of a “customer”, as defined by Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606), and does not consider there to be a transfer of control of goods or services to the entities funding the grant. As such, the Company recognizes revenue from these awards in the period during which the related qualifying services are rendered and costs are incurred in accordance with ASC 730, Research and Development. ASC 730 requires an assessment, at the inception of the grant, to determine whether the agreement is a liability or a contract to perform research and development services for others. Further, these grants are subject to the contribution’s guidance under ASC 958, Not-for-Profit Entities-Revenue Recognition, and as such, the Company determines whether it is obligated to repay the funds received to the grantor regardless of the outcome of the related research and development activities. If it determines there is such a liability, it estimates the obligation and recognize that liability. Alternatively, if the Company is not required to repay the funds, the grant agreement is accounted for as a contract to perform research and

7


DESIGN THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS—(Continued)

 

development services for others, in which case, the grant revenue is recorded as income in the statements of operations as the expenses are incurred.

The Company’s current grant revenue is not deemed refundable, and therefore, no liability is recognized when income is recorded. Grant funding received prior to expenses being incurred are recorded as deferred revenue on the Company’s balance sheets. See Note 8 for further discussion.

Research and Development Expenses

Research and development expenses consist primarily of direct and indirect costs incurred in connection with its discovery efforts, and the preclinical and formulation development of its product candidates. In the future, the Company expects a substantial portion of its research and development expenses will relate to the clinical development of its product candidates. Direct costs include contracted research development and manufacturing, consulting fees, license fees, laboratory supplies and other expenses incurred to sustain research and development programs. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, facilities related expenses, and other indirect expenses. A significant portion of the Company’s research and development expenses have been direct costs, which the Company tracks by stage of development, preclinical or clinical. However, the Company does not track its internal research and development expenses on a program specific basis, unless specific to research grants, because these costs are deployed across multiple projects and, as such, are not separately classified. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company’s research and development efforts and have no alternative future uses.

The Company has entered into various contracts with research and development organizations, vendors and consultants. Payments for these activities are based on the terms of the individual agreements, which may differ from the periods over which materials or services are provided. Payments made in advance of performance are reflected in the accompanying balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. The Company determines accrual estimates through review of the underlying contracts along with discussions with research and other key personnel as to the progress of the research and development activities, invoices received and contracted costs. During the course of a study or trial, the Company adjusts its rate of expense recognition if actual results differ from its estimates. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.

Stock-Based Compensation

Stock options issued pursuant to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) and 2018 Equity Incentive Plan (the “2018 Plan”) and option features associated with the rights to purchase shares pursuant to the Company’s 2021 Employee Stock Purchase Plan (the “ESPP”) are valued using the Black-Scholes option pricing model on the date of grant or subscription period. This option pricing model involves a number of estimates, including the expected lives of the stock options or subscription period, the Company’s anticipated stock volatility and interest rates. The Company recognizes the expense for equity awards on a straight-line basis over the requisite service periods of the awards or the number of shares estimated to be issued pursuant to the ESPP. Forfeitures are recognized as they occur.

Stock-based compensation expense recognized in the Company’s statements of operations during the three and nine months ended September 30, 2021 and 2020, were as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

521

 

 

$

12

 

 

$

1,181

 

 

$

22

 

General and administrative

 

 

722

 

 

 

3

 

 

 

1,952

 

 

 

7

 

Total

 

$

1,243

 

 

$

15

 

 

$

3,133

 

 

$

29

 

 

Recent Accounting Pronouncements

In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting

8


DESIGN THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS—(Continued)

 

for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The ASU provides guidance to clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. ASU 2021-04 is effective for annual periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact that this new guidance will have on its condensed consolidated financial statements and does not currently expect the adoption will have a material impact on its financial statements and related disclosures.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity. The guidance, among other items, clarifies that certain transactions between collaborative participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. The ASU’s amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted for periods beginning after December 15, 2020. The Company has not yet adopted this guidance and does not currently expect the adoption will have a material impact on its financial statements and related disclosures.

3. Net Loss Per Share

Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, restricted common stock subject to repurchase, stock options outstanding under the Company’s equity incentive plans, employee stock purchase rights under the Company’s ESPP, and shares of common stock that are issuable under convertible debt, as applicable. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company's net loss position.

The following table sets forth the outstanding, potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:

 

 

 

September 30,
2021

 

 

September 30,
2020

 

Convertible preferred stock

 

$

 

 

$

13,504,598

 

Stock options

 

 

2,124,238

 

 

 

389,565

 

Shares subject to repurchase

 

 

430,413

 

 

 

564,055

 

Employee stock purchase plan

 

 

15,335

 

 

 

 

Total

 

$

2,569,986

 

 

$

14,458,218

 

 

4. Fair Value Measurements

Accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices in active markets.

Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The carrying value of the Company’s cash, accounts payable and accrued liabilities are considered to be representative of their respective fair values due to the short-term nature of those instruments. The Company’s investment securities, which may include

9


DESIGN THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS—(Continued)

 

money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises, are measured at fair value in accordance with the fair value hierarchy. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis and no transfers between levels have occurred during the periods presented.

The following table summarize the Company’s financial instruments measured at fair value on a recurring basis at September 30, 2021 and December 31, 2020 (in thousands):

 

 

 

Fair Value Measurement at End of Period Using:

 

 

 

 

 

 

Quoted Prices

 

 

 

 

 

 

 

 

 

 

 

 

In Active

 

 

 

 

 

 

 

 

 

 

 

 

Markets

 

 

Significant

 

 

 

 

 

 

 

 

 

For

 

 

Other

 

 

Significant

 

 

 

 

 

 

Identical

 

 

Observable

 

 

Unobservable

 

 

 

 

 

 

Assets

 

 

Inputs

 

 

Inputs

 

 

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

As of September 30, 2021:

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

356,793

 

 

$

356,793

 

 

$

 

 

$

 

Certificates of deposit

 

 

5,987

 

 

 

5,987

 

 

 

 

 

 

 

U.S. Treasury securities

 

 

30,068

 

 

 

30,068

 

 

 

 

 

 

 

Total

 

$

392,848

 

 

$

392,848

 

 

$

 

 

$

 

As of December 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

2,100

 

 

$

2,100

 

 

$

 

 

$

 

Certificates of deposit

 

 

1,754

 

 

 

1,754

 

 

 

 

 

 

 

U.S. Treasury securities

 

 

31,958

 

 

 

31,958

 

 

 

 

 

 

 

Total

 

$

35,812

 

 

$

35,812

 

 

$

 

 

$

 

 

(1)
Included in cash and cash equivalents on the accompanying balance sheets.

 

Interest bearing money market accounts and certificates of deposit are valued at amortized cost, which approximates fair value.

5. Investment Securities

The Company’s investment policy defines allowable investment securities and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. In accordance with the Company’s investment policy, it has invested funds in marketable securities. The cost, gross unrealized holding gains, gross unrealized holding

10


DESIGN THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS—(Continued)

 

losses, allowances for credit losses and fair value of available-for-sale investments by types, maturities and classes of securities at September 30, 2021 and December 31, 2020 consisted of the following (in thousands):

 

 

 

 

 

As of September 30, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Estimated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Allowance

 

 

Fair

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

for Credit

 

 

Market

 

 

 

Maturity

 

Cost

 

 

Gains

 

 

Losses

 

 

Losses

 

 

Value

 

Certificates of deposits

 

Within 1 year

 

$

2,853

 

 

$

 

 

$

(1

)

 

$

 

 

$

2,852

 

U.S. Treasury securities

 

Within 1 year

 

 

10,066

 

 

 

1

 

 

 

 

 

 

 

 

$

10,067

 

Certificates of deposits

 

1 year to 2 years

 

 

3,137

 

 

 

 

 

 

(2

)

 

 

 

 

 

3,135

 

U.S. Treasury securities

 

1 year to 2 years

 

 

20,004

 

 

 

 

 

 

(2

)

 

 

 

 

 

20,002

 

Total

 

 

 

$

36,060

 

 

$

1

 

 

$

(5

)

 

$

 

 

$

36,056

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Estimated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Allowance

 

 

Fair

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

for Credit

 

 

Market

 

 

 

Maturity

 

Cost

 

 

Gains

 

 

Losses

 

 

Losses

 

 

Value

 

Certificates of deposits

 

Within 1 year

 

$

1,750

 

 

$

4

 

 

$

 

 

$

 

 

$

1,754

 

U.S. Treasury securities

 

Within 1 year

 

 

31,806

 

 

 

152

 

 

 

 

 

 

 

 

 

31,958

 

Total

 

 

 

$

33,556

 

 

$

156

 

 

$

 

 

$

 

 

$

33,712

 

 

The Company reviews its investments at each reporting date to identify and evaluate whether a decline in fair value below the amortized cost basis of available-for-sale securities is due to credit-related factors and determines if such unrealized losses are the result of credit losses that require impairment. Factors considered in determining whether an unrealized loss is the result of a credit loss or other factors include the extent to which the fair value is less than the cost basis, any changes to the rating of the security by a rating agency, the financial condition and near-term prospects of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any adverse legal or regulatory events affecting the issuer or issuer’s industry, any significant deterioration in economic condition and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.

At September 30, 2021 there were 19 securities in an unrealized loss position. The Company evaluated the securities individually for other-than-temporary impairment and considered the decline in market value to be primarily attributable to changes in interest rates. Each security remained at a high credit quality rating and the unrealized losses of each security was immaterial. Further, there had been no adverse conditions noted for any of the issuers and Company does not intend to sell any of the securities prior to maturity. As such, the Company has classified the losses as temporary in nature and the Company did not record a reserve for credit losses. At December 31, 2020, there were no securities in an unrealized loss position.

As of September 30, 2021, the Company held 25 domestic certificates of deposit with amortized costs below the Federal Deposit Insurance Corporation (“FDIC”) insured limit. Accrued interest receivable on available-for-sale investment securities, included in prepaids and other current assets on the Company’s balance sheets, was less than $0.1 million at September 30, 2021 and December 31, 2020.

6. Balance Sheet Details

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

 

September 30,
2021

 

 

December 31,
2020

 

Prepaid expenses

 

$

1,421

 

 

$

60

 

Security deposits

 

 

104

 

 

 

47

 

Interest receivable

 

 

47

 

 

 

10

 

Other

 

 

 

 

 

25

 

Total

 

$

1,572

 

 

$

142

 

 

11


DESIGN THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS—(Continued)

 

Property and equipment consisted of the following (in thousands):

 

 

 

September 30,
2021

 

 

December 31,
2020

 

Laboratory equipment

 

$

1,058

 

 

$

76

 

Computer equipment and software

 

 

77

 

 

 

 

Leasehold improvements

 

 

91

 

 

 

 

Construction in progress

 

 

146

 

 

 

 

 

 

 

1,372

 

 

 

76

 

Less accumulated depreciation

 

 

(52

)

 

 

(5

)

Total

 

$

1,320

 

 

$

71

 

 

Accrued liabilities consisted of the following (in thousands):

 

 

 

September 30,
2021

 

 

December 31,
2020

 

Accrued personnel costs

 

$

1,411

 

 

$

565

 

Accrued research and development costs

 

 

652

 

 

 

266

 

Current portion of operating lease liability

 

 

475

 

 

 

 

Accrued other

 

 

751

 

 

 

100

 

Total

 

$

3,289

 

 

$

931

 

 

7. Lease

In May 2019 the Company entered into an agreement, as subsequently amended, to lease laboratory space pursuant to a three-month, automatically renewing lease. Due to the short-term nature of the lease, it was not included as an operating lease right of use asset nor as an operating lease liability on the Company’s balance sheets. The Company terminated the agreement in September 2021.

In February 2021, the Company entered into a lease agreement with Crossing Holdings, LLC to rent approximately 12,370 square feet of laboratory and office space (the “Lease”). The Company’s Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC. The lease commenced in September 2021 with a term of 72 months and an option to extend the lease term for a period of three years; however, it is not reasonably certain the Company will exercise the option to renew when the lease term ends in 2027, and thus, the incremental term was excluded from the calculation of the right-of-use asset or lease liability. Lease payments are subject to annual increases of 3% and the Company is responsible for its share of operating expenses and taxes, which are expensed as incurred. As of September 30, 2021, the remaining lease term for the lease was 5.9 years and the discount rate used to determine the right-of-use asset and corresponding operating lease liability was 7.15%.

Maturities of operating lease liabilities as of September 30, 2021 are as follows (in thousands):

 

 2021 (remaining three months)

 

$

181

 

 2022

 

 

733

 

 2023

 

 

755

 

 2024

 

 

778

 

 2025

 

 

801

 

Thereafter

 

 

1,386

 

Total future minimum lease payments

 

 

4,634

 

Less: Present value adjustment

 

 

(886

)

Operating lease liabilities

 

$

3,748

 

 

Rent expense for the three months ended September 30, 2021 and 2020 was $0.2 million and less than $0.1 million, respectively. Rent expense for the nine months ended September 30, 2021 and 2020 was $0.4 million and $0.1 million, respectively.

8. Grant Revenue

The Company recognizes revenue pursuant to grants, as described further in Note 2, by measuring the progress of the applicable research and development services provided over time, based on the effort the Company expends and costs incurred, relative to the

12


DESIGN THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS—(Continued)

 

estimated total effort and costs to be incurred under the grant. This results in a percentage that the Company multiplies by the grant award amount to determine the amount of grant revenue to be recognized each period. This approach requires the Company to use judgement and make estimates of future expenditures. If the Company’s estimates or judgements change over the course of the term of the grant, it may affect the timing and amount of revenue that it recognizes in the current and future periods.

During the three and nine months ended September 30, 2020, the Company recognized less than $0.1 million and $0.2 million of grant revenue, respectively, from awards by the NSF, NIH and FARA, respectively. No grant revenue was recognized for the three and nine months ended September 30, 2021.

9. Commitments and Contingencies

Notes Payable-Related Party

In January 2019, the Company issued an unsecured promissory note to borrow up to $0.5 million to a co-founder (the “January Note”) for working capital. The January Note bore interest at prime plus 4.5%, was scheduled to mature on or before January 30, 2021 and included a final payment of 3% on the amounts advanced at maturity. In February and March 2019, the Company borrowed an aggregate of $0.2 million under the January Note with interest payable at 10% per annum. The Company recorded an immaterial amount of debt issuance costs associated with the January Note. The debt issuance costs and final payment for the advances were amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the January Note were repaid in full in 2020.

In November 2019, the Company issued an unsecured promissory note to borrow up to $0.5 million to a co-founder (the “November Note”) for working capital. The November Note bore interest at prime plus 4.5% and matured on or before January 1, 2022 and included a final payment of 3% on the amounts advanced at maturity. In December 2019 and January 2020, the Company borrowed a total of $0.4 million under the November Note with interest payable at 9.25% per annum. The final payment on the advances was amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the November Note were repaid in full in 2020.

Convertible Notes

In May and July 2018, the Company issued $0.3 million of convertible notes to a co-founder for cash with a maturity date on or after February 5, 2021, if not converted earlier. In February 2019, the Company issued an additional $0.2 million of convertible notes to consultants for services rendered with a maturity date on or after May 16, 2020, if not converted earlier. The convertible notes bore interest of 8% per annum and were convertible into equity securities sold at the next financing at 80% of the selling price per share of such equity financing. The conversion features of the convertible notes were recorded as a discount to the notes payable at issuance and amortized as interest expense over the loan term using the effective interest rate method.

In February 2020, the outstanding principal and accrued interest of the convertible notes totaling $0.5 million were converted into 301,685 shares of the Company’s Series A convertible preferred stock at $1.65816 per share. See Note 11 for further discussion.

Contingencies

From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that the future expenditures will be made and such expenditures can be reasonably estimated. The Company had no such contingent liabilities as of September 30, 2021 or December 31, 2020.

10. License Agreement

In February 2019, the Company entered into a Human Therapeutics Exclusive License Agreement (the “License Agreement”) with the Wisconsin Alumni Research Foundation (“WARF”). Under the License Agreement, the Company licensed the exclusive, worldwide, royalty-bearing, sublicensable rights to certain WARF patents and the nonexclusive worldwide rights to certain know-how to develop and commercialize products for the prevention, diagnosis and treatment of disease. As consideration for the license, the Company agreed to pay an upfront fee of $250,000, which the Company immediately expensed as research and development expense in its statements of operations as there was no alternative future use for the license. The Company paid $25,000 of the upfront fee upon execution of the agreement and the remaining $225,000 was due upon the earlier of the first anniversary of the License Agreement or the Company receiving a certain level of gross proceeds from an equity financing. At December 31, 2019, the second

13


DESIGN THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS—(Continued)

 

payment of $225,000 was recorded as an accrued liability on the Company’s balance sheet. In February 2020, the Company paid the $225,000 balance upon the initial closing of its Series A preferred stock financing.

Pursuant to the License Agreement, the Company is required to pay $125,000 upon the acceptance of an investigation new drug (“IND”) application in the U.S. and will be required to make further aggregate milestone payments of up to $17.5 million upon achievement of certain other regulatory and commercial milestones. The Company may also be required to pay royalties based on annual net product sales in the low single digits on its or its sublicensees’ net product sales on a country-by-country and product-by-product basis, and is subject to a minimum royalty of $0.1 million per calendar year upon first commercial product sale. Further, the Company may be required to pay sublicense fees in the mid-single digits percentage for fees, royalties or other payments earned from the granting of sublicenses to the WARF patents and know-how. The Company has paid no milestone or royalty payments as of September 30, 2021.

The Company is responsible for reimbursing WARF for costs incurred in connection with prosecuting and maintaining patent rights that are specific to the License Agreement. Expenses recognized in connection with legal patent fees under this License Agreement were less than $0.1 million for the three and nine months ended September 30, 2021 and 2020, respectively, which were recorded as general and administrative expenses in the statements of operations.

The Company may terminate the License Agreement with 90 days written notice or for certain breaches of the agreement. WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.

11. Convertible Preferred Stock and Stockholders’ Deficit

Authorized Shares

In connection with the completion of the Company’s initial public offering (“IPO”) in March 2021, the Company amended its Certificate of Incorporation to authorize 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, respectively.

Public Offering and Related Transaction

In March 2021, the Company completed its IPO selling 13,800,000 shares its common stock at $20.00 per share. Proceeds from the Company’s IPO, net of underwriting discounts and commissions and other offering costs, were $254.3 million. In connection with the IPO, all 41,096,478 shares of convertible preferred stock outstanding at the time of the IPO converted into 25,212,548 shares of the Company’s common stock.

Convertible Preferred Stock

In February and March 2020, the Company issued 21,710,814 shares of Series A convertible preferred stock at $2.0727 per share for net cash proceeds of $ 44.7 million (the “Series A Financing”). In connection with the Series A Financing, the Company issued an additional 301,685 shares of its Series A convertible preferred stock at $1.65816 per share in February 2020 upon the conversion and extinguishment of its convertible notes, as discussed further in Note 8.

In January 2021, the Company issued 19,083,979 shares of Series B convertible preferred stock at $6.55 per share for net cash proceeds of approximately $124.7 million.

All shares of convertible preferred stock outstanding at the Company’s IPO were converted into shares of the Company’s common stock.

Equity Incentive Award Plans

In March 2021, the Company’s board of directors and stockholders adopted the 2021 Plan, which became effective on March 25, 2021, the date of the underwriting agreement related to the Company’s IPO. Commencing with the effectiveness of the 2021 Plan, no further grants can be made under the 2018 Plan.

14


DESIGN THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS—(Continued)

 

Under the 2021 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock awards, performance cash awards and other forms of stock awards to employees, directors and consultants, including employees and consultants of the Company’s affiliates. A total of 6,118,648 new shares of common stock were approved to be initially reserved for issuance under the 2021 Plan. The number of shares reserved under the 2021 Plan also include 881,352 shares of common stock that remained available for issuance under the 2018 Plan at the time the 2021 Plan became effective, and will be increased by the number of shares under the 2018 Plan that are repurchased, forfeited, expired or cancelled on or after the effective date of the 2021 Plan. In addition, the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares of the Company’s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company’s board of directors.

Shares subject to Repurchase

Pursuant to the 2018 Plan, the Company has issued shares of restricted common stock to employees, consultants and members of its board of directors. Additionally, certain stock options granted pursuant to the 2018 Plan provide for the right to elect to exercise unvested options early in exchange for restricted shares of common stock. These restricted shares of common stock generally vest over a four-year period and are subject to repurchase by the Company at the original purchase price or, in certain instances the fair market value if such fair market value is lower than the purchase price, in the event the recipient’s service is terminated either voluntarily or involuntarily prior to vesting.

A summary of the Company’s restricted shares of common stock and unvested stock liability, which is included in accrued expenses and other current liabilities and other long-term liabilities on the Company’s balance sheets, is as follows (in thousands, except share data):

 

 

 

Shares

 

 

Liability

 

Balance at December 31, 2020

 

 

646,953

 

 

$

145

 

Vested shares

 

 

(216,540

)

 

 

(8

)

Balance at September 30, 2021

 

 

430,413

 

 

$

137

 

 

2021 Employee Stock Purchase Plan

In March 2021, the Company’s board of directors and stockholders adopted the 2021 Employee Stock Purchase Plan (the “ESPP”), which became effective on March 25, 2021, the date of the underwriting agreement related to the Company’s IPO. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to 15% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to 85% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase. A total of 600,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 1% of the total number of shares of the Company’s common stock on the last day of the calendar month before the date of each automatic increase and (ii) 1,200,000 shares; provided that before the date of any such increase, the Company’s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii). As of September 30, 2021, no shares of the Company’s common stock have been purchased under the ESPP. 

15


DESIGN THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS—(Continued)

 

12. Related Party Transactions

Lease Agreement

In February 2021, the Company entered into the Lease with Crossing Holdings, LLC to rent laboratory and office space. The Company's Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC.

Expenses recognized by the Company under the Lease during the periods presented were as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

53

 

 

$

 

 

$

53

 

 

$

 

General and administrative

 

 

22

 

 

 

 

 

 

22

 

 

 

 

Total expenses

 

$

75

 

 

$

 

 

$

75

 

 

$

 

As of September 30, 2021, and December 31, 2020, the Company had prepaid expenses of $0.1 million and zero, respectively, and accrued expenses and other current liabilities of less than $0.1 million and zero, respectively, pursuant to its related party lease agreement.

Consulting Agreements

In January 2019, the Company entered into an agreement with the Marlinspike Group, LLC (“Marlinspike Group”) for research support, management, and business consulting services (the “2019 Consulting Agreement”). Further, Marlinspike Group provides the use of approximately 2,120 square feet of its office space in Carlsbad, California to the Company on an as-available basis from time to time pursuant to the agreement. The Company’s Executive Chairperson, co-founder and member of its board of directors is an executive officer of Marlinspike Group and, the Company’s Chief Operating Officer was an executive officer of Marlinspike Group until February 2020.

The term of the 2019 Consulting Agreement was for a one-year period, subject to automatic one-month renewals unless terminated upon 14 days’ written notice. In March 2020, the Consulting Agreement was terminated and replaced with an amended consulting agreement (the “2020 Consulting Agreement”), which provides for the similar services and use of office space for a monthly fee of $20,000. Pursuant to the terms of the 2020 Consulting Agreement, it shall remain in effect until otherwise terminated. Termination may occur at any time upon mutual agreement or unilaterally upon 30 days’ written notice. If the Company unilaterally terminates the 2020 Consulting Agreement for any reason other than cause, it would be subject to a $240,000 termination fee. The Company cannot determine when, or if, such a termination will occur and hence has not recorded a liability for the fee.

Expenses recognized by the Company under the 2020 Consulting Agreement during the periods presented were as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

 

 

$

 

 

$

 

 

$

8

 

General and administrative

 

 

60

 

 

 

60

 

 

 

180

 

 

 

232

 

Total expenses

 

$

60

 

 

$

60

 

 

$

180

 

 

$

240

 

 

In December 2017, the Company entered into a consulting agreement with Aseem Z. Ansari, Ph.D. Dr. Ansari, a co-founder, provides consulting services and advises on certain research and development activities (the “Research Consulting Agreement”). Pursuant to the Research Consulting Agreement, as amended, Dr. Ansari performs these services for a monthly fee of $15,000.

Expenses recognized by the Company under the Research Consulting Agreement during the periods presented were as follows (in thousands):

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

45

 

 

$

 

 

$

135

 

 

$

 

Total expenses

 

$

45

 

 

$

 

 

$

135

 

 

$

 

As of September 30, 2021 and December 31, 2020, the Company had accounts payable of $20,000 pursuant to its related party consulting agreements.

16


DESIGN THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS—(Continued)

 

Convertible Notes and Notes Payable

In May and July 2018, the Company issued a total of $0.3 million of convertible notes to a co-founder for cash with a maturity date on or after February 5, 2021, if not converted earlier. The notes bore interest of 8% per annum and were convertible into equity securities sold at the next financing at 80% of the selling price per share of such equity financing. In February 2020, these notes converted into 171,025 shares of the Company’s convertible preferred stock pursuant to the closing of the Series A preferred stock financing. Further, the Company has issued unsecured promissory notes to this co-founder for working capital. See Note 9 for further discussion.

 

17


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited financial statements and notes thereto included in “Item 1. Financial Statements” of this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December 31, 2020 included in our Prospectus dated March 25, 2021 filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (Securities Act) with the Securities and Exchange Commission (SEC) on March 26, 2021. In addition to historical information, this Quarterly Report contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including but not limited to those set forth under the captions “Special Note Regarding Forward-Looking Statements” and “Risk Factors” in this Quarterly Report, as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Furthermore, past operating results are not necessarily indicative of results that may occur in future periods.

Overview

We are a preclinical-stage biopharmaceutical company pioneering GeneTACTM molecules, which are a novel class of small-molecule gene targeted chimera therapeutics that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Certain nucleotide repeat expansion diseases, such as Friedreich ataxia (FA), can result in reduced expression of specific mRNAs; in other diseases, such as myotonic dystrophy type-1 (DM1), Fuchs endothelial corneal dystrophy (FECD), and Huntington disease, the nucleotide repeat expansions result in the generation of toxic gene products, often associated with pathological nuclear foci. Our GeneTACTM molecules are designed to selectively bind to genetic repeat sequences, modulate gene expression either by restoring or blocking mRNA transcription, and restore cellular health. As a platform, we believe that our GeneTACTM molecules have broad potential applicability across monogenic nucleotide repeat expansion diseases.

In preclinical studies for our lead program, we have observed restoration of frataxin (FXN) levels in cells from FA patients using our FA GeneTACTM molecules. FA GeneTACTM molecules administered to rodents and to non-human primates, at doses that were observed to be well tolerated, achieved biodistribution to brain and heart, the key organs affected by FA, at concentrations that exceeded those observed to restore FXN levels in FA patient cells. Further, and consistent with this favorable target-organ biodistribution, we observed increased endogenous FXN expression in the brain and heart in an animal model of FA after treatment with our FA GeneTACTM molecules. Investigational new drug (IND)-enabling studies for FA GeneTACTM development candidates are underway, in alignment with feedback received from the Food and Drug Administration (FDA) through a pre-IND meeting and from the European Medicines Agency (EMA) through a scientific advice procedure. Subject to receiving regulatory clearance, one of these FA GeneTACTM development candidates will be selected to proceed into clinical trials. We anticipate a first-in-human dosing in FA patients in the first half of 2022, with initial topline clinical data expected in 2022.

In our second GeneTACTM program in DM1, we observed reduced nuclear foci in DM1 patient muscle cells after administration of our DM1 GeneTACTM molecules. Preclinical in vivo studies demonstrated distribution of DM1 GeneTACTM molecules to key target tissues including skeletal muscle and heart, achieving tissue concentrations that reduced nuclear foci and corrected mRNA splicing in our in vitro experiments. We expect to complete IND-enabling studies and seek regulatory clearance for a first-in-human clinical trial in 2023. We continue to make significant progress in advancing our GeneTACTM portfolio in preclinical studies to address other serious nucleotide repeat expansion-driven monogenic diseases, and intend to declare an additional product candidate in 2023.

To date, we have incurred net losses and negative cash flows from operations since our inception and as of September 30, 2021, had an accumulated deficit of $36.4 million. Our net losses have resulted primarily from costs incurred in connection with organizing and staffing our company, business planning, raising capital, developing and optimizing our technology platform, identifying potential product candidates, undertaking research and preclinical studies, engaging in manufacturing for our development programs, and providing general and administrative support for these operations. We do not have any products approved for sale and have not generated any revenue from product sales.

We expect our expenses and operating losses will increase substantially for the foreseeable future as we conduct preclinical studies and clinical trials for our product candidates, nominate additional product candidates from our discovery programs, and as we expand our clinical, regulatory, quality and manufacturing capabilities, incur significant commercialization expenses for marketing, sales, manufacturing and distribution, if we obtain marketing approval for any of our product candidates, and incur additional costs associated with operating as a public company.

We have funded our operations primarily through the sale of our common stock, convertible preferred stock, grant revenue and the issuance of convertible notes and debt. In March 2021, we completed our initial public offering in which we sold 13,800,000 shares of our common stock at $20.00 per share and received net proceeds, after underwriting discount and offering costs, of $254.3 million. In January 2021, we issued 19,083,979 shares of Series B convertible preferred stock at $6.55 per share for net proceeds of

18


 

approximately $124.7 million. Our cash, cash equivalents and investment securities balance as of September 30, 2021, was $393.7 million.

Components of Our Results of Operations

Research and Development Expenses

To date, our research and development expenses have consisted primarily of direct and indirect costs incurred in connection with our discovery efforts, and the preclinical and formulation development of our product candidates. In the future, we expect a substantial portion of our research and development expenses will relate to the clinical development and manufacturing of our product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.

Direct costs include:

external research and development expenses incurred under agreements with contract research organizations, consultants and other vendors that conduct our preclinical and discovery activities;
expenses related to manufacturing our product candidates for preclinical studies;
laboratory supplies; and
license fees.

Indirect costs include:

personnel-related expenses, consisting of employee salaries, payroll taxes, bonuses, benefits and stock-based compensation charges for those individuals involved in research and development efforts; and
facilities expenses which include allocated expenses for amortization of ROU assets, depreciation and other overhead expenses, costs for general laboratory consumables and other indirect expenses.

A significant portion of our research and development expenses have been direct costs, which we track by stage of development, preclinical or clinical. However, we do not track our internal research and development expenses on a program specific basis, unless specific to research grants, because these costs are deployed across multiple projects and, as such, are not separately classified.

We expect that our research and development expenses will substantially increase for the foreseeable future as we continue the development of our FA program, DM1 program and our other discovery programs, in particular as we advance our product candidates into clinical development. As of the date of this Quarterly Report, we cannot reasonably determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical programs of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Preclinical and clinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate’s commercial potential. We will need to raise substantial additional capital in the future. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

Our future research and development expenses may vary significantly based on a wide variety of factors such as:

the number and scope, rate of progress, expense and results of our discovery and preclinical development activities;
the number of trials required for approval;
the number of sites included in the trials;
the countries in which the trials are conducted;
the length of time required to enroll eligible patients;
the number of patients that participate in the trials;
the number of doses that patients receive;

19


 

the drop-out or discontinuation rates of patients;
potential additional safety monitoring requested by regulatory agencies;
the duration of patient participation in the trials and follow-up;
the phase of development of the product candidate;
the efficacy and safety profile of the product candidate;
the timing, receipt, and terms of any approvals from applicable regulatory authorities including FDA and non-U.S. regulators;
maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates;
establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully;
significant and changing government regulation and regulatory guidance;
the impact of any business interruptions to our operations or to those of the third parties with whom we work, particularly in light of the current COVID-19 pandemic environment; and
the extent to which we establish additional strategic collaborations or other arrangements.

A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate.

The process of conducting the necessary preclinical and clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates or any future candidates may be affected by a variety of factors. We may never succeed in achieving regulatory approval for any of our product candidates or any future candidates. Further, a number of factors, including those outside of our control, could adversely impact the timing and duration of our product candidates’ or any future candidates’ development, which could increase our research and development expenses.

General and Administrative

General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses, benefits, and stock-based compensation charges, for personnel in executive and administrative functions. Other significant general and administrative expenses include insurance costs, legal fees relating to intellectual property and corporate matters and professional fees for accounting, tax and consulting services.

We anticipate that our general and administrative expenses will substantially increase in the foreseeable future as we add general and administrative personnel to support our expanded research and development activities and infrastructure and, if any of our product candidates or any future candidates receive marketing approval, commercialization activities, as well as to support our operations generally, including facility-related expenses and patent-related costs. We also expect to incur increased expenses related to accounting, audit, legal, regulatory and tax-related services, director and officer insurance premiums, board of director fees, investor and public relations, and other costs associated with operating as a public company.

Results of Operations

Comparison of the Three Months Ended September 30, 2021 and 2020

The following table summarizes our operating expenses for the three months ended September 30, 2021 and 2020 (in thousands):

 

 

 

Three Months Ended September 30,

 

 

 

 

 

 

2021

 

 

2020

 

 

Change

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

$

8,539

 

 

$

1,914

 

 

$

6,625

 

General and administrative

 

 

2,798

 

 

 

489

 

 

 

2,309

 

Total operating expenses

 

$

11,337

 

 

$

2,403

 

 

$

8,934

 

 

20


 

Research and Development Expenses. The increase of $6.6 million in research and development expenses was due primarily to additional expense to support the advancement of our FA program, including chemistry and manufacturing development costs, and cost incurred on our DM1 program during the three months ended September 30, 2021 which were not incurred in the same period of 2020. Further, we incurred higher personnel and related costs during the three months ended September 30, 2021 as compared to the same period in 2020, as we expanded the number of research and development employees to support our programs. The increased personnel related costs include an additional $0.5 million of non-cash stock-based compensation costs incurred during 2021 as compared to 2020.

The following table summarizes our research and development expenses by direct and indirect costs for the three months ended September 30, 2021 and 2020 (in thousands):

 

 

 

Three Months Ended September 30,

 

 

 

 

 

 

2021

 

 

2020

 

 

Change

 

Direct costs(1)

 

$

5,650

 

 

$

1,348

 

 

$

4,302

 

Indirect costs

 

 

2,889

 

 

 

566

 

 

 

2,323

 

Total research and development expenses

 

$

8,539

 

 

$

1,914

 

 

$

6,625

 

 

(1)
In future periods when clinical trial expenses are incurred, external costs will be broken out between our clinical programs and our preclinical programs.

General and Administrative Expenses. The increase of $2.3 million in general and administrative expenses was due primarily to additional personnel and related costs incurred during the three months ended September 30, 2021 as compared to the same period in 2020, as we increased the number of general and administrative personnel to support our organization, including our expanded research and development team and public company operations. The increased personnel related costs includes an additional $0.7 million of non-cash stock-based compensation costs incurred during 2021 as compared to 2020. Further, we incurred increased costs to operate as a public company during the three months ended September 30, 2021 as compared to the same period in 2020, including insurance expense and professional fees for legal and accounting services.

Comparison of the Nine Months Ended September 30, 2021 and 2020

The following table summarizes our operating expenses for the nine months ended September 30, 2021 and 2020 (in thousands):

 

 

 

Nine Months Ended September 30,

 

 

 

 

 

 

2021

 

 

2020

 

 

Change

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

$

17,441

 

 

$

3,352

 

 

$

14,089

 

General and administrative

 

 

7,263

 

 

 

1,310

 

 

 

5,953

 

Total operating expenses

 

$

24,704

 

 

$

4,662

 

 

$

20,042

 

 

Research and Development Expenses. The increase of $14.1 million in research and development expenses was due primarily to additional expense to support the advancement of our FA program, including chemistry and manufacturing development costs, and costs incurred on our DM1 program during the nine months ended September 30, 2021 which were not incurred in the same period of 2020. Further, we incurred higher personnel and related costs during the nine months ended September 30, 2021 as compared to the same period in 2020, as we expanded the number of research and development employees to support our programs. The increased personnel related costs include an additional $1.2 million of non-cash stock-based compensation costs incurred during 2021 as compared to 2020.

The following table summarizes our research and development expenses by direct and indirect costs for the nine months ended September 30, 2021 and 2020 (in thousands):

 

 

 

Nine Months Ended September 30,

 

 

 

 

 

 

2021

 

 

2020

 

 

Change

 

Direct costs(1)

 

$

10,853

 

 

$

2,292

 

 

$

8,561

 

Indirect costs

 

 

6,588

 

 

 

1,060

 

 

 

5,528

 

Total research and development expenses

 

$

17,441

 

 

$

3,352

 

 

$

14,089

 

 

(1)
In future periods when clinical trial expenses are incurred, external costs will be broken out between our clinical programs and our preclinical programs.

General and Administrative Expenses. The increase of $6.0 million in general and administrative expenses was due primarily to additional personnel and related costs incurred during the nine months ended September 30, 2021 as compared to the same period in

21


 

2020, as we increased the number of general and administrative personnel to support our organization, including our expanded research and development team and public company operations. The increased personnel related costs includes an additional $2.0 million of non-cash stock-based compensation costs incurred during 2021 as compared to 2020. Further, we incurred increased insurance expense and professional fees for legal and accounting services during the nine months ended September 30, 2021 as compared to the same period in 2020.

Liquidity and Capital Resources

We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. Since our inception, we have funded our operations primarily through the sale of our common stock, convertible preferred stock, grant income and the issuance of convertible notes and notes payable. In March 2021, we completed our initial public offering in which we sold 13,800,000 shares of our common stock at $20.00 per share and received net proceeds, after underwriting discount and offering costs, of $254.3 million. In January 2021, we issued 19,083,979 shares of Series B convertible preferred stock at $6.55 per share for net proceeds of approximately $124.7 million.

As of September 30, 2021, we had $357.7 million of cash and cash equivalents, an increase of $355.3 million from the $2.4 million of cash and cash equivalents at December 31, 2020. In addition, we had $36.1 million of available-for-sale investment securities at September 30, 2021, an increase of $2.4 million from the $33.7 million of available-for-sale investment securities held at December 31, 2020. The increase in our cash and cash equivalents balance during the nine months ended September 30, 2021 was primarily due to the proceeds received from our initial public offering of common stock completed in March 2021 and Series B convertible preferred stock offering completed in January 2021. Further detail of the change in our cash and cash equivalents for the nine months ended September 30, 2021 and 2020 is summarized below (in thousands):

 

 

 

Nine Months Ended September 30,

 

 

 

 

 

 

2021

 

 

2020

 

 

Change

 

Net cash (used in) provided by:

 

 

 

 

 

 

 

 

 

Operating activities

 

$

(20,150

)

 

$

(5,825

)

 

$

(14,325

)

Investing activities

 

 

(3,585

)

 

 

(35,559

)

 

 

31,974

 

Financing activities

 

 

379,018

 

 

 

44,531

 

 

 

334,487

 

Net increase in cash and cash equivalents

 

$

355,283

 

 

$

3,147

 

 

$

352,136

 

 

Operating Activities. Net cash used in operating activities was $20.2 million and $5.8 million for the nine months ended September 30, 2021 and 2020, respectively. The increase in our use of cash was primarily due to the $20.0 million increase in the net loss we incurred during the nine months ended September 30, 2021, as compared to the same period in 2020. The higher net loss incurred during the 2021 period was due primarily to the advancement of our research and development programs and higher personnel costs to support these activities and our preparations to become, and operations as, a public company. Partially offsetting the cash impact of the increase in our net loss during the 2021 period was an increase in our accounts payable and accrued expense balances and higher non-cash expenses incurred during the period, including $3.1 million of additional non-cash stock-based compensation.

Investing Activities. Net cash used in investing activities was $3.6 million and $35.6 million for the nine months ended September 30, 2021 and 2020, due primarily to the purchase of investment securities, partially offset by net proceeds received from the maturity of investment securities during the periods presented. We have classified our investments securities as available-for-sale and all investments are made in accordance with our investment policy.

Financing Activities. Net cash provided by financing activities was $379.0 million for the nine months ended September 30, 2021, primarily from the $254.3 million of net proceeds received from our initial public offering in March 2021 and the $124.7 million of net proceeds received from the closing of our Series B convertible preferred stock financing in January 2021. Net cash provided by financing activities during the nine months ended September 30, 2020 was $44.5 million, primarily from the $44.7 million of net proceeds received from our Series A convertible preferred stock financing during the period.

Funding Requirements

Based on our current operating plan, we believe that our existing cash, cash equivalents and investments will be sufficient to fund our planned operating expenses and capital expenditure requirements for at least the next 12 months following the date of this Quarterly Report.

Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on

22


 

assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.

Our future capital requirements will depend on many factors, including:

the scope, rate of progress and costs of our drug discovery, preclinical development activities and clinical trials for any future product candidates;
the number and scope of clinical programs we decide to pursue;
the scope and costs of manufacturing our future product candidates and commercial manufacturing activities;
the emergence of competing therapies and other adverse market developments;
the cost, timing and outcome of seeking FDA, EMA and any other regulatory approvals for any future product candidates;
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
the terms and timing of establishing and maintaining strategic collaborations, licenses and other similar arrangements and the financial terms of such agreements;
our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates;
the costs associated with being a public company;
the timing of any milestone and royalty payments to Wisconsin Alumni Research Foundation (WARF), or other future licensors;
the extent to which we acquire or in-license other product candidates and technologies;
our need and ability to retain key management and hire scientific, technical, business, and medical personnel;
our implementation of additional internal systems and infrastructure, including operational, financial and management information systems;
the costs associated with expanding our facilities or building out our laboratory space;
the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide from the COVID-19 pandemic; and
the cost associated with commercialization activities for any of our future product candidates, if approved.

Until such time, if ever, as we can generate substantial revenues from product sales to support our cost structure, we expect to finance our cash needs through public or private equity offerings, debt financings, or other capital sources which may include strategic collaborations, licensing arrangements or other arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Equity and debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through strategic collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic or otherwise. Because of the numerous risks and uncertainties associated with product development, we cannot predict the timing or amount of increased expenses and cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.

Contractual Obligations and Commitments

In February 2021, we entered into a lease agreement to rent approximately 12,370 square feet of lab and office space with a related party. The delivery date of the space was September 1, 2021, and the lease commenced at that time. The term of the lease is 72 months after commencement with an option to extend the lease term for a period of three years. Annual rent payments will be approximately $0.8 million per year, subject to annual increases of 3%, plus our share of operating expenses and taxes.

23


 

Off-Balance Sheet Arrangements

During the periods presented we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to grant revenue and research and development expenses. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Our critical accounting policies are those that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. For a description of our critical accounting policies, please see Item 1 of Part I, “Notes to Condensed Financial Statements — Note 2 — Basis of Presentation and Summary of Significant Accounting Policies” of this Quarterly Report on Form 10-Q, and Note 2 to our Financial Statements and our Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Prospectus, dated March 25, 2021, filed pursuant to Rule 424(b) under the Securities Act with the Securities and Exchange Commission on March 26, 2021. There have not been any material changes to our critical accounting policies since December 31, 2020.

Recent Accounting Pronouncements

See Item 1 of Part I, “Notes to Condensed Financial Statements — Note 2 — Basis of Presentation and Summary of Significant Accounting Policies” for a discussion of recent accounting pronouncements.

Other Information

Emerging Growth Company Status

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act, as amended (JOBS Act), and we may remain an emerging growth company until as late as December 31, 2026 (the fiscal year-end following the fifth anniversary of the completion of our initial public offering). For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved.

Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

We will remain an emerging growth company until the earliest to occur of: (i) the last day of the fiscal year in which we have at least $1.07 billion in annual revenue; (ii) the date upon which we are deemed to be a “large accelerated filer,” as defined in Rule 12b-2 under the Exchange Act, which would occur if we have been subject to the reporting requirements of the Exchange Act for at least 12 months as of December 31st and the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt securities during the prior three-year period; and (iv) as December 31, 2026 (the last day of the fiscal year ending after the fifth anniversary of our initial public offering).

 

24


 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

The primary objective of our investment activities is to preserve principal and liquidity while at the same time maximizing the income we receive without significantly increasing risk. To achieve this objective, we may invest in certificates of deposit insured by the Federal Deposit Insurance Corporation (FDIC), money market accounts, money market funds, U.S. Treasury notes, and high-quality marketable debt instruments of corporations and government sponsored enterprises with contractual maturity dates of generally less than two years, in accordance with an investment policy approved by our audit committee. Some of the financial instruments that we invest in could be subject to market risk, meaning that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. To minimize this risk, we intend to maintain a portfolio which may include a variety of securities, including money market funds, government debt securities and commercial paper, all with various maturity dates.

Based on our current investment portfolio, we do not believe that a hypothetical 100 basis point increase or decrease in interest rates during any of the periods presented would have had a material impact on our financial statements.

Item 4. Controls and Procedures.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (our principal executive and financial officer), as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As of September 30, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our Chief Executive Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2021.

An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any changes in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

25


 

PART II—OTHER INFORMATION

From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors.

We operate in a dynamic and rapidly changing environment that involves numerous risks and uncertainties. Certain factors may have a material adverse effect on our business, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risks described below, together with the other information contained in this Quarterly Report and in our other public filings. If any of the following risks actually occur, our business, financial condition, results of operations, and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our results of operations and financial condition. We have marked with an asterisk (*) those risk factors that reflect changes from the similarly titled risk factors included in our Prospectus dated March 25, 2021 filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended with the Securities and Exchange Commission.

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it.*

We are an early-stage biopharmaceutical company with a limited operating history that may make it difficult to evaluate the success of our business to date and to assess our future viability. Our operations to date have been limited to business planning, organizing and staffing our company, raising capital, developing and optimizing our technology platform, identifying potential product candidates, undertaking research and preclinical studies for our lead program, establishing and enhancing our intellectual property portfolio, and providing general and administrative support for these operations. All of our product candidates are in preclinical development, and none have been approved for commercial sale or tested in human subjects. We have never generated any revenue from product sales and have incurred net losses each year since we commenced operations, including a net loss of $24.5 million and $8.3 million for the nine months ended September 30, 2021 and the year ended December 31, 2020, respectively. We expect that it will be several years, if ever, before we have a product candidate ready for regulatory approval and commercialization. We expect to incur increasing levels of operating losses over the next several years and for the foreseeable future as we advance our product candidates through clinical development. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ equity and working capital.

To become and remain profitable, we must develop and eventually commercialize a product or products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we succeed in commercializing one or more of our product candidates, we may never generate revenue that is significant or large enough to achieve profitability. In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.

If we are unable to raise additional capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.*

Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially during the next few years. The development of biopharmaceutical product candidates is capital intensive. As our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our

26


 

clinical, regulatory, quality and manufacturing capabilities. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution.

As of September 30, 2021, we had $393.7 million in cash, cash equivalents and investment securities. Based upon our current operating plan, we estimate that our existing cash, cash equivalents and investment securities will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 12 months. However, we believe that our existing cash, cash equivalents and investment securities will not be sufficient to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates.

We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:

the scope, rate of progress and costs of our drug discovery, preclinical development activities, laboratory testing and clinical trials for any future product candidates;
the number and scope of clinical programs we decide to pursue;
the scope and costs of manufacturing our future product candidates and commercial manufacturing activities;
the emergence of competing therapies and other adverse market developments;
the cost, timing and outcome of seeking FDA, EMA and any other regulatory approvals for any future product candidates;
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
the terms and timing of establishing and maintaining strategic collaborations, licenses and other similar arrangements and the financial terms of such agreements;
our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates;
the costs associated with being a public company;
the timing of any milestone and royalty payments to WARF, or other future licensors;
the extent to which we acquire or in-license other product candidates and technologies;
our need and ability to retain key management and hire scientific, technical, medical and business personnel;
our implementation of additional internal systems and infrastructure, including operational, financial and management information systems;
or costs associated with expanding our facilities or building out our laboratory space;
the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide from the COVID-19 pandemic; and
the cost associated with commercialization activities for any of our future product candidates, if approved.

Because we do not expect to generate revenue from product sales for many years, if at all, we will need to obtain substantial additional funding in connection with our continuing operations and expected increases in expenses. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses or other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. The impact of the COVID-19 pandemic on capital markets may affect the availability, amount and type of financing available to us in the future. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, as we can generate substantial revenue from product sales to support our cost structure, we expect to finance our operations through public or private equity offerings, debt financings or other capital sources, which may include strategic collaborations, licensing arrangements or other similar arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, current stockholders will be or could be diluted, and the terms of these

27


 

securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Equity and debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

If we raise funds through strategic collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic or otherwise. Because of the numerous risks and uncertainties associated with product development, we cannot predict the timing or amount of increased expenses and cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.

Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates

We are early in our development efforts and all of our research programs are still in the preclinical or discovery stage. We have no history of conducting clinical trials to test our product candidates in humans.*

We are early in our development efforts and most of our operations to date have been limited to developing our platform technologies and conducting drug discovery and preclinical studies. We are conducting IND-enabling studies for FA GeneTACTM development candidates. We have not yet begun clinical trials for any of our development programs. As a result, we have limited infrastructure, experience conducting clinical trials as a company and regulatory interactions, and cannot be certain that our planned clinical trials will be completed on time, if at all, that our planned development programs would be acceptable to the FDA or other comparable foreign regulatory authorities, or that, if approval is obtained, such product candidates can be successfully commercialized.

Because of the early stage of development of our products candidates, our ability to eventually generate significant revenues from product sales will depend on a number of factors, including:

completion of preclinical studies and clinical trials with favorable results;
acceptance of INDs by the FDA or similar regulatory filing by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates and our proposed design of future clinical trials;
receipt of marketing approvals from applicable regulatory authorities, including new drug applications (NDAs), from the FDA and maintaining such approvals;
market acceptance of any of our approved product candidates;
making arrangements with our third-party manufacturers for, or establishing, commercial manufacturing capabilities;
maintaining an acceptable safety profile of our products following approval; and
maintaining and growing an organization of scientists and business people who can develop our products and technology.

The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our FA and DM1 GeneTACTM candidates, as well as our other product candidates, which may never occur. In the future, we may also become dependent on other product candidates that we may develop or acquire; however, given our early stage of development, it may be several years, if at all, before we have demonstrated the safety and efficacy of a treatment sufficient to warrant approval for commercialization. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.

Preclinical and clinical development involves a lengthy and expensive process with uncertain timelines and outcomes, and results of earlier studies and trials may not be predictive of future trial results. If development of our programs is unsuccessful or delayed, we may be unable to obtain required regulatory approvals and be unable to commercialize our product candidates on a timely basis, if at all.

Clinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure or delay can occur at any time during the drug development process, including due to factors outside of our control. Success in

28


 

nonclinical testing and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in clinical trials, even after promising results in earlier nonclinical studies or clinical trials. These setbacks have been caused by, among other things, nonclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. The results of preclinical, nonclinical and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical and initial clinical trials. Notwithstanding any potential promising results in earlier studies, we cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates.

We may experience delays in initiating our future clinical trials for our product candidates and we cannot be certain that the trials or any other future clinical trials for our product candidates will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be delayed or terminated for a variety of reasons, including delay or failure related to:

the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our planned clinical trials, or the sufficiency of preclinical data to initiate clinical trials;
the size of the study population for further analysis of the study’s primary endpoints;
obtaining regulatory approval to commence a trial;
reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
obtaining institutional review board (IRB), approval at each site;
recruiting suitable patients to participate in a trial;
having patients complete a trial or return for post-treatment follow-up;
clinical sites deviating from trial protocol or dropping out of a trial;
addressing patient safety concerns that arise during the course of a trial;
addressing any conflicts with new or existing laws or regulations;
adding a sufficient number of clinical trial sites; or
manufacturing sufficient quantities of product candidate for use in clinical trials.

We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board (DSMB) for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

Further, conducting clinical trials in foreign countries, as we plan to do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.

Moreover, principal investigators for our planned clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of our product candidates.

If we experience delays in the completion, or termination, of any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenue from any of these product candidates

29


 

will be delayed or not realized at all. In addition, any delays in completing our planned clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.

We have concentrated our research and development efforts on product candidates using our platform technologies, and our future success depends on the successful development of this approach. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates based on our platform technologies in clinical trials or in obtaining marketing approval thereafter, and use of our platform technologies may not ever result in marketable products. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners or establishing our own commercial manufacturing capabilities, which may prevent us from completing our planned clinical trials or commercializing any products on a timely or profitable basis, if at all.

The clinical trial requirements of the FDA, EMA and other comparable foreign regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates.

The biotechnology and biopharmaceutical industries are also rapidly developing, and our competitors may introduce new technologies improving the treatments in the field of expansion repeat driven diseases and small molecules that render our technologies obsolete or less attractive. New technology could emerge at any point in the development cycle of our product candidates.

If we encounter difficulties or delays enrolling patients in our planned clinical trials, our clinical development activities could be delayed or otherwise adversely affected.

We may not be able to initiate or continue our planned clinical trials for our product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, the design of the clinical trial, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.

The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment or retention in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:

the patient eligibility criteria defined in the protocol;
the size of the patient population required for analysis of the trial’s primary endpoints;
the proximity of patients to study sites;
the design of the trial;
our ability to recruit clinical trial investigators with the appropriate competencies and experience;
clinicians’ and patients’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;
our ability to obtain and maintain patient consents; and
the risk that patients enrolled in clinical trials will drop out of the trials before completion.

In addition, our planned clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors.

30


 

Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.

We plan to conduct clinical trials for our product candidates outside the United States and the FDA may not accept data from such trials.

We plan to conduct additional clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of such study data by the FDA is subject to certain conditions. For example, the clinical trial must be conducted in accordance with Good Clinical Practices (GCP) requirements and the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary.

Where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the U.S. population and U.S. medical practice, the clinical trials were performed by clinical investigators of recognized competence, and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, such clinical trials would be subject to the applicable local laws of the foreign jurisdictions where the clinical trials are conducted.

There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States. If the FDA does not accept any such data, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay aspects of our development plan. In addition, the conduct of clinical trials outside the United States could have a significant impact on us. Risks inherent in conducting international clinical trials include:

foreign regulatory requirements that could burden or limit our ability to conduct our clinical trials;
difficulties staffing and managing foreign operations;
compliance with legal requirements applicable to privacy, data protection, information security and other matters;
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
foreign taxes, including value-added tax and withholding of payroll taxes;
administrative burdens of conducting clinical trials under multiple foreign regulatory schema;
foreign exchange fluctuations;
manufacturing, customs, shipment and storage requirements;
impact of the COVID-19 pandemic on our ability to produce our product candidates and conduct clinical trials in foreign countries;
potential liability under the Foreign Corrupt Practices Act of 1977, as amended (FCPA), or comparable foreign regulations;
cultural differences in medical practice and clinical research; and
diminished protection of intellectual property in some countries.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.

31


 

Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.

Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue planned clinical trials, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.

Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt planned clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. Results of our planned clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics.

If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted, or the DSMB could suspend or terminate our future clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.

In addition, if any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:

we may be forced to suspend marketing of that product, or decide to remove the product from the marketplace;
regulatory authorities may withdraw or change their approvals of that product;
regulatory authorities may require additional warnings on the label or limit access of that product to selective specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment;
we may be required to create a medication guide outlining the risks of the product for patients, or to conduct post-marketing studies;
we may be required to change the way the product is administered;
we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or be sued and held liable for harm caused to subjects or patients; and
the product may become less competitive, and our reputation may suffer.

Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenue to us, which would materially and adversely affect our results of operations and business.

Interim, topline and preliminary data from our preclinical studies or planned clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publicly disclose interim, preliminary or topline data from our preclinical studies or planned clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim, topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, such data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. Interim, topline,

32


 

or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary, interim or topline data and final data could significantly harm our business prospects.

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the interim, topline or preliminary data that we report differ from actual results, or if others including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.

The regulatory approval process is lengthy, expensive and uncertain, and we may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our ability to generate revenue, our business and our results of operations.

The development, research, testing, manufacturing, labeling, approval, selling, import, export, marketing, promotion and distribution of drug products are subject to extensive and evolving regulation by federal, state and local governmental authorities in the United States, principally the FDA, and by foreign regulatory authorities, which regulations differ from country to country. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States until we receive regulatory approval of an NDA from the FDA.

Obtaining regulatory approval of an NDA can be a lengthy, expensive and uncertain process. Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or other foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. The number of nonclinical studies and clinical trials that will be required for FDA approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular product candidate.

Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA or other regulatory authorities denying approval of a product candidate for any or all indications. The FDA may also require us to conduct additional studies or trials for our product candidates either prior to or post-approval, such as additional drug-drug interaction studies or safety or efficacy studies or trials, or it may object to elements of our clinical development program such as the number of subjects in our future clinical trials from the United States.

The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates or require us to conduct additional nonclinical or clinical testing or abandon a program for many reasons, including:

the FDA or the applicable foreign regulatory agency’s disagreement with the design or implementation of our planned clinical trials;
negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;
serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;
our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that our product candidates are safe and effective for the proposed indication;
the FDA’s or the applicable foreign regulatory agency’s disagreement with the interpretation of data from nonclinical studies or clinical trials;
our inability to demonstrate the clinical and other benefits of our product candidates outweigh any safety or other perceived risks;

33


 

the FDA’s or the applicable foreign regulatory agency’s requirement for additional nonclinical studies or clinical trials;
the FDA’s or the applicable foreign regulatory agency’s disagreement regarding the formulation, labeling and/or the specifications of our product candidates;
the FDA’s or the applicable foreign regulatory agency’s failure to approve the manufacturing processes or facilities of third-party manufacturers with which we contract; or
the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval.

Of the large number of drugs in development, only a small percentage successfully complete the FDA or other regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.

Even if we eventually complete our planned clinical testing and receive approval of an NDA or foreign marketing application for our product candidates, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials, including Phase 4 clinical trials, and/or in the case of the FDA, the implementation of a Risk Evaluation and Mitigation Strategy (REMS), which may be required to ensure safe use of the drug after approval. The FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or a narrower patient population than we originally requested, and the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.

The COVID-19 pandemic could adversely impact our business and affect our operations, as well as the business or operations of our manufacturers or other third parties with whom we conduct business.

In December 2019, COVID-19 was reported to have surfaced in Wuhan, China. Since then, the virus has spread to most countries across the world, including all 50 states within the United States, resulting in the World Health Organization characterizing COVID-19 as a pandemic. As a result of measures imposed by the governments in affected regions, many commercial activities, businesses and schools have been, were, or may again be suspended as part of quarantines and other measures intended to contain this pandemic. As the COVID-19 pandemic continues to spread around the globe, we may experience disruptions that could severely impact our business and planned clinical trials, including:

delays or difficulties in enrolling and retaining patients in our planned clinical trials, particularly elderly subjects, who are at a higher risk of severe illness or death from COVID-19;
delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;
delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials;
difficulties interpreting data from our clinical trials due to the possible effects of COVID-19 on patients;
changes in local regulations as part of a response to the COVID-19 outbreak which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;
interruptions, difficulties or delays arising in our existing operations and company culture as a result of some of our employees working remotely, including those hired during the COVID-19 pandemic;
diversion of healthcare resources away from the conduct of future clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;
interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;
limitations in resources that would otherwise be focused on the conduct of our business, our preclinical studies or our clinical trials, including because of sickness or the desire to avoid contact with large groups of people or as a result of government-imposed “shelter in place” or similar working restrictions;

34


 

interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;
interruption in global freight and shipping that may affect the transport of clinical trial materials, such as investigational drug product to be used in our clinical trials;
risks relating to potential disruptions of our contracted manufacturing operations as a result of any potential shut downs or other restrictions in operation due to or impact from the COVID-19 pandemic;
changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are to be conducted, or to discontinue the clinical trials altogether, or which may result in unexpected costs;
delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel;
risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; and
refusal of the FDA to accept data from clinical trials in affected geographies outside of their respective jurisdictions.

These and other disruptions in our operations and the global economy could negatively impact our business, operating results and financial condition.

The COVID-19 pandemic and actions taken to reduce its spread continue to rapidly evolve. The extent to which the COVID-19 pandemic may continue to impact the development of our product candidates, reduce the productivity of our employees, disrupt our supply chains, delay our planned preclinical studies and clinical trials, reduce our access to capital or limit our business development activities, will depend on future developments, which are highly uncertain and cannot be predicted with confidence.

In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this “Risk Factors” section.

We may seek orphan drug designation for our product candidates from the FDA and/or from the EMA in the future. However, we may be unsuccessful in obtaining or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.*

We may seek orphan drug designation for our product candidates in the future; however, we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and the European Union (EU), may designate drugs for relatively small patient populations as orphan drugs. Under the U.S. Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EMA’s Committee for Orphan Medicinal Products may grant orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition, provided that the condition is affecting not more than five in 10,000 persons in the EU or if, without incentives, it is unlikely that marketing of the drug in the EU would generate sufficient returns to justify the investment needed to develop the drug, and no satisfactory method of diagnosis, prevention or treatment of the condition exists (or, if such a method exists, the drug must be of significant benefit to patients). There can be no assurance that the FDA or EMA will grant orphan designation for any indication for which we apply, or that we will be able to maintain such designation.

In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. If a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of orphan drug exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug or biologic for that time period, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. The applicable exclusivity period is ten years in Europe, but such exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.

35


 

Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve the same active moiety in a new drug for the same condition if such regulatory authority concludes that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA later determines that the initial request for designation was materially defective.

In addition, orphan drug exclusivity does not prevent the FDA from approving competing drugs for the same or similar indication containing a different active ingredient. In addition, if a subsequent drug is approved for marketing for the same or a similar indication as any of our product candidates that receive marketing approval, we may face increased competition and lose market share regardless of orphan drug exclusivity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.

We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.*

The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of repeat expansion driven diseases, including FA and DM1. Our competitors include larger and better funded pharmaceutical, specialty pharmaceutical and biotechnology companies. Moreover, we may also compete with universities, governmental agencies and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

We are aware of a number of companies targeting FA including (i) Reata Pharmaceuticals evaluating omaveloxolone, a Nrf2 activator, (ii) PTC Therapeutics evaluating vatiquinone, a 15-lipoxygenase inhibitor, (iii) Retrotope evaluating RT001, a deuterated poly-saturated fatty acid, (iv) Minoryx Therapeutics evaluating leriglitazone, a PPAR-gamma agonist and (vi) Larimar Therapeutics evaluating CTI-1601, a cell penetrating peptide FXN recombinant fusion protein. In addition, several companies are in preclinical development for AAV-based gene therapies including PTC Therapeutics, Voyager Therapeutics, Lexeo Therapeutics, Pfizer, StrideBio, and AavantiBio.

With respect to development programs for DM1, (i) AMO Pharma is evaluating tideglusib, a GSK3-ß inhibitor and (ii) Harmony Biosciences is evaluating a histamine 3 receptor for the treatment of excessive daytime sleepiness in DM1. In addition, there are several products currently in preclinical development for the treatment of DM1, including: an antibody linked siRNA by Avidity Biosciences; an AAV-antisense candidate by Audentes Therapeutics; an antibody linked oligonucleotide by Dyne Therapeutics; an miR-23b antisense candidate; gene editing treatments by Vertex Pharmaceuticals; an RNA-targeting AAV-based gene therapy by Locana; an AAV-based RNA degrading gene therapy by Enzerna Biosciences; antisense oligonucleotides by NeuBase Therapeutics; antisense oligonucleotides and siRNA candidates by Triplet Therapeutics; small molecules interacting with RNA by Anima Biotech; small molecule modulators of transcription factors by Syros Pharmaceuticals; and small molecules interacting with RNA by Expansion Therapeutics.

We will also compete more generally with other companies developing alternative scientific and technological approaches to modulate individual genes, including other companies working to develop nuclease-based gene editing technologies, such as Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Precision BioSciences and Sangamo Biosciences.

Many of our competitors, either alone or with their collaborators, have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing

36


 

and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.

Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

Separately, in response to the global COVID-19 pandemic, the FDA and regulatory authorities outside the United States have and may adopt restrictions or other policy measures in response to the COVID-19 pandemic that divert resources and delay their attention to any submissions we may make. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our discovery and development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we believe could be pursued using our platform technologies. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.

We may not be successful in our efforts to identify or discover additional product candidates in the future.

Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:

our inability to design such product candidates with the properties that we desire; or
potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance.

Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable additional candidates for preclinical and clinical development, our opportunities to successfully develop and commercialize therapeutic products will be limited.

37


 

Risks Related to Manufacturing, Commercialization and Reliance on Third Parties

We may rely on third parties to conduct, supervise, and monitor our planned clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.*

We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we are and expect to remain dependent on third parties to conduct our preclinical studies, and any future clinical trials of our product candidates. The timing of the initiation and completion of these studies and trials will therefore be partially controlled by such third parties and may result in delays to our development programs. Nevertheless, we are responsible for ensuring that each of our preclinical studies and planned clinical trials is conducted in accordance with the applicable protocol, legal requirements, and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with Good Laboratory Practice (GLP) and GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GLP and GCP requirements through periodic inspections of preclinical study sites, trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites fail to comply with applicable GLP or GCP requirements, the data generated in our preclinical studies and clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical or clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under current Good Manufacturing Practice (cGMP) regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process.

There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources to our development activities, provide services in a timely manner or perform as contractually required. These risks are heightened as a result of the efforts of government agencies and the CROs themselves to limit the spread of COVID-19, including quarantines and shelter-in-place orders, which have also adversely impacted the supply chain for many research and clinical supplies. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trials unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or any comparable foreign regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit by the FDA or any comparable foreign regulatory authority. Any such delay or rejection could prevent us from commercializing our product candidates.

Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our products.

We contract with third parties for the manufacturing and supply of our product candidates for use in preclinical testing and planned clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity.

We do not have any manufacturing facilities. We rely on third parties for the manufacture of our product candidates for preclinical and clinical testing. We will continue to rely on such third parties for commercial product manufacture, if any of our product candidates are approved. We currently have limited manufacturing arrangements and expect that each of our product candidates will only be covered by single source suppliers for the foreseeable future. This reliance increases the risk that we will not have sufficient quantities of our product candidates or products, if approved, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.

Furthermore, all entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of

38


 

quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA on a timely basis and must adhere to the FDA’s cGMP regulations enforced by the FDA through its facilities inspection program. Comparable foreign regulatory authorities may require compliance with similar requirements. The facilities and quality systems of our third-party contract manufacturers must pass a pre-approval inspection for compliance with the applicable regulations as a condition of marketing approval of our product candidates. We do not have direct control of the manufacturing activities of, and are completely dependent on, our contract manufacturers for compliance with cGMP regulations.

In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, including due to the impact of the COVID-19 pandemic, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third- party, which we may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to or voluntarily change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines and that the product produced is equivalent to that produced in a prior facility. The delays associated with the verification of a new manufacturer and equivalent product could negatively affect our ability to develop product candidates in a timely manner or within budget.

Our or a third-party’s failure to execute on our manufacturing requirements, or to so execute on commercially reasonable terms and timelines in compliance with cGMP requirements, could adversely affect our business in a number of ways, including:

inability to meet our product specifications and quality requirements consistently;
an inability to initiate or continue preclinical studies or clinical trials of our product candidates under development;
delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates, if at all;
loss of the cooperation of future collaborators;
subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;
requirements to cease development or to recall batches of our product candidates; and
in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product or any other future product candidates.

Changes in methods of product candidate manufacturing may result in additional costs or delays.

As product candidates progress through preclinical to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize yield, manufacturing batch size, change drug product dosage form, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue.

39


 

Any approved products may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.

If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. Most of our product candidates target mechanisms for which there are limited or no currently approved products, which may result in slower adoption by physicians, patients and payors. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:

efficacy and potential advantages compared to alternative treatments;
our ability to offer our products for sale at competitive prices;
convenience and ease of administration compared to alternative treatments;
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
the availability of coverage and adequate reimbursement from third-party payor programs, and the willingness of patients to pay out of pocket in the absence of such third-party payor coverage and reimbursement;
the strength of marketing and distribution support; and
the prevalence and severity of any side effects.

We may not be able to successfully commercialize our product candidates, if approved, due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably.

Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process, with uncertain results, that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may not be available, or may be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, by any future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower prices than in the United States.

There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, there is no uniform policy among third-party payors for coverage and reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Therefore, a third-party payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product.

Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor’s determination that use of a product is:

a covered benefit under its health plan;
safe, effective and medically necessary;
appropriate for the specific patient;
cost-effective; and
neither experimental nor investigational.

We cannot be sure that reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded therapeutics and therapeutics administered under the supervision of a physician. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private

40


 

payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.

Reimbursement may impact the demand for, and the price of, any product for which we obtain marketing approval. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement are critical to a new product’s acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available.

For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, the Centers for Medicare & Medicaid Services (CMS) revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment System, which may result in reduced Medicare payments.

We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the successful commercialization of new products. Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved product.

Additionally, we or collaborators may develop companion diagnostic tests for use with our product candidates. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we may seek for our product candidates. While we have not yet developed any companion diagnostic tests for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates.

Outside of the United States, many countries require approval of the sale price of a product before it can be marketed, and the pricing review period only begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some of these countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if such product candidates obtain marketing approval.

If the market opportunities for any of our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.

We are focused initially on the development of treatments for nucleotide expansion repeat diseases. Our projections of addressable patient populations that have the potential to benefit from treatment with our product candidates are based on estimates. If any of our estimates are inaccurate, the market opportunities for any of our product candidates could be significantly diminished and have an adverse material impact on our business.

Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Because we rely on third parties to research and develop and to manufacture our product candidates, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in

41


 

violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.

In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with will likely expect to be granted rights to publish data arising out of such collaboration and any joint research and development programs may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor’s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.

If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved.

We have no sales, marketing or distribution capabilities or experience. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.

There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.

Factors that may inhibit our efforts to commercialize future products on our own include:

our inability to recruit and retain adequate numbers of effective sales and marketing personnel;
the inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing any future products;
the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product portfolios; and
unforeseen costs and expenses associated with creating an independent sales and marketing organization.

If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of this product revenue to us are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or devote the necessary resources and attention to sell and market any future products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.

Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential.

In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory

42


 

approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed.

Risks Related to Our In-Licenses and Other Strategic Agreements

We may not realize the benefits of any acquisitions, in-license or strategic alliances that we enter into.

We have entered into in-license agreements with multiple licensors and in the future may seek and form strategic alliances, create joint ventures or collaborations, or enter into acquisitions or additional licensing arrangements with third parties that we believe will complement or augment our existing technologies and product candidates.

These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management’s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into acquisition or in-license agreements or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, or if there are materially adverse impacts on our or the counterparty’s operations resulting from COVID-19, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction or such other benefits that led us to enter into the arrangement.

We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.

The development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. We may, in the future, decide to collaborate with other biopharmaceutical companies for the development and potential commercialization of those product candidates, including in territories outside the United States or for certain indications. We will face significant competition in seeking appropriate collaborators. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third-party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third-party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of our technologies, product candidates and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators.

Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.

Our product candidates may also require specific technologies to work effectively and efficiently, and rights to those technologies may be held by others. We may be unable to in-license any compositions, methods of use, processes or other third party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our

43


 

competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.

Risks Related to Our Business Operations, Employee Matters and Managing Growth

Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.

We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.

The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:

impairment of our business reputation;
withdrawal of clinical trial participants;
costs due to related litigation;
distraction of management’s attention from our primary business;
substantial monetary awards to patients or other claimants;
the inability to commercialize our product candidates; and
decreased demand for our product candidates, if approved for commercial sale.

We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claims, or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.

We face an inherent risk of product liability as a result of the planned studies and clinical trials of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such

44


 

product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts.

We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.*

Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.

We conduct substantially all of our operations at our leased laboratory and office space in Carlsbad, California and remotely. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.

To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options and restricted stock awards that vest over time. The value to employees of stock awards and restricted stock awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with certain of our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain “key person” insurance policies on the lives of these individuals or the lives of any of our employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.

We expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.*

As of September 30, 2021, we had 33 employees. As we advance our research and development programs, we may be required to further increase the number of our employees and the scope of our operations, particularly in the areas of clinical development, discovery biology, chemistry, product development, general and administrative matters relating to being a public company, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage any future growth, we must:

identify, recruit integrate, maintain and motivate additional qualified personnel;
manage our development efforts effectively, including the initiation and conduct of clinical trials for our product candidates; and
improve our operational, financial and management controls, reporting systems and procedures.

Our future financial performance and our ability to develop, manufacture and commercialize our product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time, to managing these growth activities.

If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. Under legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act (Tax Act), as modified by legislation enacted on March 27, 2020, entitled the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), U.S. federal net operating losses (NOLs), incurred in taxable years beginning after December 31, 2017, can be carried forward indefinitely to offset

45


 

future taxable income, but the deductibility of such U.S. federal NOLs in taxable years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act.

As of December 31, 2020, we had $10.1 million of U.S. federal NOLs and $10.3 million of state NOLs. U.S. federal NOL carryforwards totaling $0.1 million will begin to expire in 2037 unless previously utilized, and U.S. federal NOL carryforwards of $ 10.0 million can be carried forward indefinitely under current law. State NOL carryforwards totaling $10.3 million will begin to expire in 2037, unless previously utilized. As of December 31, 2020, we also had aggregate U.S. federal and state research and development (R&D) credits of approximately $0.1 million and $0.2 million, respectively. U.S. federal R&D credits carryforwards begin to expire in 2038 unless previously utilized. The state R&D credit carryforwards do not expire. Our NOL carryforwards and R&D credits are subject to review and possible adjustment by the U.S. and state tax authorities.

In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50 percentage point change (by value) in its equity ownership over a three-year period, the corporation’s ability to use its pre-change NOL carryforwards, R&D credits and certain other tax attributes to offset its post-change income or taxes may be limited. This could limit the amount of NOLs, R&D credit carryforwards or other applicable tax attributes that we can utilize annually to offset future taxable income or tax liabilities. Subsequent ownership changes and changes to the U.S. tax rules in respect of the utilization of NOLs, R&D credits and other applicable tax attributes carried forward may further affect the limitation in future years. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California imposed limits on the usability of California state NOL carryforwards to offset taxable income in tax years beginning after 2019 and before 2023. As a result, we may be unable to use all or a material portion of our NOL carryforwards and other tax attributes, which could adversely affect our future cash flows. We have not undertaken a Section 382 study, and it is possible that we have previously undergone one or more ownership changes so that our use of net operating losses is subject to limitation. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.

Risks Related to Government Regulation

Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.

Although we do not currently have any products on the market, our operations may be, directly or indirectly through our prescribers, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal civil and criminal false claims laws and the Physician Payments Sunshine Act and regulations. Healthcare providers and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may impact, among other things, our current business operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers and other parties through which we may market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The laws that may affect our ability to operate include:

the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
the U.S. federal false claims, including the False Claims Act, which can be enforced through whistleblower actions, and civil monetary penalties laws, which, among other things, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including

46


 

items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;
the U.S. federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and their covered subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of such individually identifiable health information;
the U.S. Federal Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;
the U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the Affordable Care Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children’s Health Insurance Program to report annually to CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives;
analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives; and
European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers.

Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the delay, reduction, termination or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.

47


 

Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may charge for such product candidates.*

The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval.

In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the Affordable Care Act) was enacted, which includes measures that have significantly changed the way health care is financed by both governmental and private insurers. There have been executive, judicial and congressional challenges to certain aspects of the Affordable Care Act. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the Affordable Care Act or our business. We continue to evaluate the effect that the Affordable Care Act and its possible repeal and replacement has on our business.

In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year through 2030, with the exception of a temporary suspension from May 1, 2020 through December 31, 2021, due to COVID-19 relief legislation, unless Congress takes additional action.

Recently, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. congressional inquiries and legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives.

For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration’s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the United States Department of Health and Human Services (HHS) finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing President Trump’s Most Favored Nation (MFN) executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the MFN model, on August 10, 2021, CMS published a proposed rule that seeks to rescind the MFN Model interim final rule. In July 2021, the Biden administration released an executive order, "Promoting Competition in the American Economy," with multiple provisions aimed at prescription drugs. In response to Biden's executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, Congress is considering drug pricing as part of the budget reconciliation process. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control costs pharmaceutical and biological products. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.

48


 

We expect that the healthcare reform measures that have been adopted, and that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.

Failure or perceived failure to comply with current or future federal, state and foreign laws and regulations and industry standards relating to data privacy and protection, which are changing, could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, adverse publicity, and other adverse effects, which could negatively affect our operating results and business.*

We and our collaborators and third-party providers may process personal data and other sensitive and confidential information, such as proprietary and confidential business data, trade secrets, intellectual property, and data we collect about trial participants in connection with clinical trials, which may subject us and our collaborators and third-party providers to stringent and changing federal, state and foreign data privacy and security laws and regulations. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators and third-party providers. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA.

Additionally, many state legislatures have adopted legislation that regulates how businesses operate online, including measures relating to privacy, data security and data breaches. Laws in all 50 states require businesses to provide notice to customers whose personally identifiable information has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event of a widespread data breach is costly. States are also constantly amending existing laws, requiring attention to frequently changing regulatory requirements. For example, California recently enacted the California Consumer Privacy Act (the CCPA) which became effective on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. In addition, it is anticipated that the California Privacy Rights Act of 2020 (the CPRA), effective January 1, 2023, will expand the CCPA. At this time, we do not collect personal information relating to residents of California but should we begin to do so, the CCPA (and later, the CPRA) will impose new and burdensome privacy compliance obligations on our business and will raise new risks for potential fines and class actions. In addition, data privacy and security laws have been proposed at the federal, state, and local levels in recent years, which could complicate our compliance efforts. In addition, privacy advocates and industry groups have regularly proposed, and may propose in the future, self-regulatory standards that may legally or contractually apply to us. If we fail to follow these obligations, we may incur significant fines, experience a significant increase in costs, or other consequences.

Foreign data protection laws, including the EU General Data Protection Regulation (the EU GDPR) and the United Kingdom's GDPR (the UK GDPR), may also apply to health-related and other personal information obtained from foreign data subjects. For example, the EU GDPR, which came into effect on May 25, 2018, imposes strict requirements for processing the personal data of individuals within the European Economic Area (EEA), including clinical trial data, as well as potential fines for noncompliant companies of up to the greater of €20 million or 4% of annual global revenue. The EU GDPR imposes strict requirements for the collection, use and disclosure of personal data, including stringent requirements relating to obtaining consent, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches and taking certain measures when engaging third-party processors. Additionally, the EU GDPR regulates transfers of personal data subject to the GDPR from the EEA to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between Europe and the United States remains unsettled. Other jurisdictions have enacted or are considering similar cross-border personal data transfer laws and local personal data residency laws, any of which could increase the cost and complexity of doing business. At this time, we do not believe we are subject to the EU GDPR or the UK GDPR, but should this change, the EU GDPR and the UK GDPR will increase our responsibility and potential liability in relation to personal data that we process, and we may be required to put in place additional mechanisms or change our business practices to ensure compliance with European and other foreign data protection rules.

Compliance with U.S. and foreign data privacy and protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in

49


 

certain jurisdictions. Failure by us or our collaborators and third-party providers to comply with U.S. and foreign data privacy and protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. In many jurisdictions, enforcement actions and consequences for noncompliance with data privacy and protection laws are rising. In the United States, these include enforcement actions in response to rules and regulations promulgated under the authority of federal agencies and state attorneys general, legislatures and consumer protection agencies. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose such information. Claims that we have violated individuals’ privacy rights, failed to comply with data privacy or protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, results of operations and prospects.

Risks Related to Our Intellectual Property

If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.*

We rely upon a combination of patents, know-how and confidentiality agreements to protect the intellectual property related to our products and technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market.

Our success depends in large part on our ability to obtain and maintain patent protection for our platform technologies, product candidates and their uses, as well as our ability to operate without infringing the proprietary rights of others. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business. Our pending and future patent applications may not result in patents being issued or provide assurance that issued patents will afford sufficient protection of our product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or product candidates.

Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner, including delays as a result of the COVID-19 pandemic impacting our or our licensors’ operations. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection.

Composition of matter patents for biological and pharmaceutical product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications directed to composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO) or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products “off-label.” Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.

The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, which have increased uncertainties as to the ability to enforce patent rights in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa.

The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. For example, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their

50


 

intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, inventorship, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending patent applications may be challenged in patent offices in the United States and abroad. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. For example, our pending patent applications may be subject to third-party pre-issuance submissions of prior art to the USPTO or our issued patents may be subject to post-grant review (PGR) proceedings, oppositions, derivations, reexaminations, or inter partes review (IPR) proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Any failure to obtain or maintain patent protection with respect to our product candidates or their uses could have a material adverse effect on our business, financial condition, results of operations and prospects.

In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent filing. However, trade secret protection will not protect us from innovations that a competitor develops independently of our proprietary know how. If a competitor independently develops a technology that we protect as a trade secret and files a patent application on that technology, then we may not be able to patent that technology in the future, may require a license from the competitor to use our own know-how, and if the license is not available on commercially-viable terms, then we may not be able to launch our product. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, and this scenario could materially adversely affect our business, financial condition and results of operations.

We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable.

The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. We have pending U.S. and foreign patent applications in our portfolio; however, we cannot predict:

if and when patents may issue based on our patent applications;
the scope of protection of any patent issuing based on our patent applications;
whether the claims of any patent issuing based on our patent applications will provide protection against competitors;
whether or not third parties will find ways to invalidate or circumvent our patent rights;
whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications;
whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose;
whether the patent applications that we own or in-license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries; and/or
whether, as the COVID-19 pandemic continues to spread around the globe, we may experience patent office interruption or delays to our ability to timely secure patent coverage to our product candidates.

51


 

We cannot be certain that the claims in our pending patent applications directed to our product candidates and/or technologies will be considered patentable by the USPTO or by patent offices in foreign countries. There can be no assurance that any such patent applications will issue as granted patents. One aspect of the determination of patentability of our inventions depends on the scope and content of the “prior art,” information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Even if the patents do issue based on our patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our product candidates. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries.

We may not be able to protect our intellectual property rights throughout the world.

Patents are of national or regional effect, and although we currently have an issued patent and pending applications in the United States, filing, prosecuting and defending patents on all of our research programs and product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These competitor products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Various companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights.

Various countries outside the United States have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. As a result, a patent owner may have limited remedies in certain circumstances, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. As such, we do not know the degree of future protection that we will have on our technologies, products and product candidates. While we will endeavor to try to protect our technologies, products and product candidates with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time consuming, expensive and unpredictable.

Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.*

As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These

52


 

include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Further, because of a lower evidentiary standard in these USPTO post-grant proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third -party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates and other proprietary technologies we may develop or (ii) invent any of the inventions claimed in our or our licensor’s patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the 2013 case Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.

Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse, including due to the effect of the COVID-19 pandemic on us or our patent maintenance vendors, can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected.

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed;

53


 

we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;
we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;
others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;
it is possible that noncompliance with the USPTO and foreign governmental patent agencies requirement for a number of procedural, documentary, fee payment and other provisions during the patent process can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;
it is possible that our pending patent applications will not lead to issued patents;
issued patents that we own or have exclusively licensed may be revoked, modified, or held invalid or unenforceable, as a result of legal challenges by our competitors;
our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
we may not develop additional proprietary technologies that are patentable;
we cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or in-license will result in issued patents with claims that directed to our product candidates or uses thereof in the United States or in other foreign countries;
there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns;
countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates;
the claims of any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties;
if enforced, a court may not hold that our patents are valid, enforceable and infringed;
we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose;
we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property;
we may fail to adequately protect and police our trademarks and trade secrets; and
the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications.

Should any of these or similar events occur, they could significantly harm our business, results of operations and prospects.

Our technology licensed from various third parties may be subject to retained rights.*

We are currently party to a license agreement with WARF pursuant to which we acquired an exclusive license to certain patents relating to compounds and methods for modulating gene expression, compounds and methods for modulating FA expression and next generation synthetic transcription factors. WARF retains, and our future licensors may also retain, certain rights under the relevant agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.

In addition, the United States federal government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole Act. The federal government retains a “nonexclusive, nontransferable, irrevocable, paid-up license” for its own benefit. The Bayh-Dole Act also provides federal agencies with “march-in

54


 

rights.” March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a “nonexclusive, partially exclusive, or exclusive license” to a “responsible applicant or applicants.” If the patent owner refuses to do so, the government may grant the license itself. We sometimes collaborate with academic institutions to accelerate our preclinical research or development. While it is our policy to avoid engaging our university partners in projects in which there is a risk that federal funds may be commingled, we cannot be sure that any co-developed intellectual property will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we co-own or license in technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.

We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.

Because our development programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these third-party proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.

While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our product candidates, there may be times when the filing and prosecution activities for patents and patent applications relating to our product candidates are controlled by our future licensors or collaboration partners. If any of our future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our future licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.

We may enter into license agreements in the future with others to advance our existing or future research or allow commercialization of our existing or future product candidates. These licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future.

In addition, subject to the terms of any such license agreements, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. In such an event, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our future licensors fail to prosecute, maintain, enforce, and defend such patents or patent applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our future product candidates that are subject of such licensed rights could be adversely affected.

Our future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our future licensors are not the sole and exclusive owners of the patents we in-license. If other third parties have ownership rights to our future in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.

It is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial

55


 

basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.

Disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement, including:

the scope of rights granted under the license agreement and other interpretation-related issues;
whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
our right to sublicense patents and other rights to third parties;
our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
our right to transfer or assign the license;
the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners; and
the priority of invention of patented technology.

In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.

In spite of our best efforts, our future licensors might conclude that we materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.

From time to time, we may be required to license technologies relating to our therapeutic research programs from additional third parties to further develop or commercialize our product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our product candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations.

Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that:

collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;
collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities, or the ongoing COVID-19 pandemic;
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;
a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;
we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;

56


 

collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;
disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our future product candidates or that results in costly litigation or arbitration that diverts management attention and resources;
collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable future product candidates;
collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and
a collaborator’s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.

We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.

As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. There can be no assurance that our operations do not, or will not in the future, infringe existing or future third-party patents. Identification of third-party patent rights that may be relevant to our operations is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction.

Numerous U.S. and foreign patents and pending patent applications exist in our market that are owned by third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our products. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the U.S. can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products. As such, there may be applications of others now pending or recently revived patents of which we are unaware. These patent applications may later result in issued patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to make, use or sell our products.

The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.

We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, including our research programs, product candidates, their respective methods of use, manufacture and formulations thereof, and could result in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.

If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.

Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed or

57


 

misappropriated their intellectual property. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates. We cannot be certain that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. Third parties may assert infringement claims against us based on existing or future intellectual property rights. In the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. If we are found to infringe a third party’s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate or product. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our investigational products or force us to cease some of our business operations, which could materially harm our business.

We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our product candidates, might assert are infringed by our future product candidates, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our product candidate. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. The pharmaceutical and biotechnology industries have produced a considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.

We may choose to challenge the enforceability or validity of claims in a third party’s U.S. patent by requesting that the USPTO review the patent claims in an ex-parte re-exam, inter partes review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party’s patent in patent opposition proceedings in the European Patent Office (EPO), or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.

58


 

If we are found to infringe a third-party’s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third-party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, and could divert the time and attention of our technical personnel and management, cause development delays, and/or require us to develop non-infringing technology, which may not be possible on a cost-effective basis, any of which could materially harm our business. In the event of a successful claim of infringement against us, we may have to pay substantial monetary damages, including treble damages and attorneys’ fees for willful infringement, pay royalties and other fees, redesign our infringing drug or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.

We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.

Competitors or other third parties may infringe our patents, trademarks or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent’s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party’s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. §271(e)(1). An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.

Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.

Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.

Because of the expense and uncertainty of litigation, we may conclude that even if a third-party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we

59


 

can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, in-license needed technology or other product candidates, or enter into development partnerships that would help us bring our product candidates to market.

We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

As is common in the pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.

While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.

We may rely on trade secrets and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.*

In addition to seeking patents for some of our technology and product candidates, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Elements of our product candidate, including processes for their preparation and manufacture, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a security incident) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Trade secrets and know-how can be difficult to protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We and any third parties with whom we share facilities enter into written agreements that include confidentiality and intellectual property obligations to protect each party’s property, potential trade secrets, proprietary know-how, and information. We further seek to protect our potential trade secrets, proprietary know-how, and information in part, by entering into non-disclosure and confidentiality agreements with parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. We cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and

60


 

others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would be harmed.

We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

Our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.

In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.

Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

Patent rights are of limited duration. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its first effective filing date. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. Upon issuance in the United States, the term of a patent can be increased by patent term adjustment, which is based on certain delays caused by the USPTO, but this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. The term of a United States patent may also be shortened if the patent is terminally disclaimed over an earlier-filed patent. A patent term extension (PTE) based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the PTE does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous PTEs in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain PTE or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially.

61


 

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Although these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.

Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.

Risks Related to the Securities Market and Ownership of Our Common Stock

An active trading market for our common stock may not be sustained, which may make it difficult for you to sell your shares.*

Prior to our initial public offering in March 2021, there had been no public market for our common stock. The trading market for our common stock on The Nasdaq Global Select Market has been limited and an active trading market for our shares may not be sustained. If an active market for our common stock is not sustained, it may be difficult for you to sell your shares at a price that is attractive to you, or at all.

The price of our common stock could be subject to volatility related or unrelated to our operations.*

Our stock price may be volatile. The stock market in general and the market for biotechnology and pharmaceutical companies, in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your shares at a price that is attractive to you, or at all. The market price for our common stock may be influenced by numerous factors, many of which are beyond our control, including:

overall performance of the equity markets;
our operating performance and the performance of other similar companies;
the published opinions and third-party valuations by banking and market analysts;
results from our future clinical trials with our future product candidates or of our competitors;
adverse results or delays in preclinical studies;
failure to commercialize our product candidates;
unanticipated serious safety concerns related to the use of our product candidates;

62


 

changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock;
any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority’s review of such filings, including without limitation the FDA’s issuance of a “refusal to file” letter or a request for additional information;
regulatory or legal developments in the United States and other countries;
changes in the structure of healthcare payment systems;
the level of expenses related to future product candidates or clinical development programs;
our failure to achieve product development goals in the timeframe we announce;
announcements of acquisitions, strategic alliances or significant agreements by us or by our competitors;
recruitment or departure of key personnel;
the economy as a whole and market conditions in our industry;
trading activity by our principal stockholders;
the size of our market float;
political uncertainty and/or instability in the United States;
the ongoing and future impact of the COVID-19 pandemic and actions taken to slow its spread; and
any other factors discussed in this report.

In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many biopharmaceutical companies. Stock prices of many biopharmaceutical companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. The trading prices for common stock of other biopharmaceutical companies have also been highly volatile as a result of the COVID-19 pandemic. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.*

Certain of our executive officers, directors and large stockholders own a significant percentage of our outstanding capital stock. As a result of their share ownership, these stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.

If there are substantial sales of shares of our common stock, the market price of our common stock could decline.*

The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our directors, executive officers and significant stockholders, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. We and our officers, directors, and holders of substantially all of our capital stock, stock options and other securities convertible into, exercisable or exchangeable for our capital stock outstanding immediately prior to the closing of our initial public offering previously agreed with the underwriters for our initial public offering, subject to certain exceptions, not to dispose of or hedge any of our common stock or securities convertible into or exchangeable for shares of common stock for a period of 180 days following the date of the final prospectus for our initial public offering, except with the prior written consent of Goldman Sachs & Co. LLC, SVB Leerink LLC and Piper Sandler & Co. on behalf of the underwriters. We refer to such period as the lock-up period. When the lock-up period expired on September 22, 2021, we and our securityholders subject to a lock-up agreement or market stand-off agreement became able to sell our shares in the public market. The market price of the shares of our common stock could decline as a result of the sale of a substantial number of our shares of common stock in the public market.

63


 

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.*

Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner, we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.

Pursuant to our 2021 Plan, our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares of our common stock reserved for issuance under our 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 5% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase; or (ii) a lesser number of shares determined by our board of directors prior to the applicable January 1st. In addition, our 2021 Employee Stock Purchase Plan ("ESPP") authorizes the issuance of 600,000 shares of our common stock under purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of our common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year by the lesser of 1% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year and 1,200,000 shares, subject to the ability of our Board of Directors to take action to reduce the size of the increase in any given year. Increases in the number of shares available for future grant or purchase may result in additional dilution, which could cause our stock price to fall.

We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.

We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.

We are an “emerging growth company”, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.*

We are an “emerging growth company” as defined in the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:

not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;
not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;
reduced disclosure obligations regarding executive compensation; and
not being required to hold a non-binding advisory vote on executive compensation or obtain stockholder approval of any golden parachute payments not previously approved.

In addition, as an “emerging growth company” the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies, unless we later irrevocably elect not to avail ourselves of this exemption. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (i) December 31, 2026 (the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering), (ii) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (iii) the date upon which we are deemed to be a “large accelerated filer”, which means we have been subject to the reporting requirements of the Exchange Act for at least 12 months as of December 31st, and the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th and (iv) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

64


 

We incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to public company reporting and compliance initiatives.*

As a public company listed on the Nasdaq Global Select Market, we incur significant expenses for director and officer insurance, legal services, accounting services and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC, and the Nasdaq Global Select Market have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the Dodd-Frank Act) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as “say on pay” and proxy access. Recent legislation permits smaller “emerging growth companies” to implement many of these requirements over a longer period and up to five years from the pricing of our initial public offering. We intend to continue to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costlier. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance and we are required to incur substantial costs to maintain our current levels of such coverage.

If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.*

As a public company, we are subject to requirements of the Sarbanes-Oxley Act, the regulations of the Nasdaq Global Market, the rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting and financial compliance costs, make some activities more difficult, time-consuming and costly and place significant strain on our personnel, systems and resources. Company responsibilities required by the Sarbanes-Oxley Act include, among other things, that we maintain corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. We are continuing to develop and refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers. We are also continuing to improve our internal control over financial reporting. In order to develop, maintain, and improve the effectiveness of our internal controls and procedures, and internal control over financial reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight.

Our current controls and any new controls that we develop may become inadequate because of changes in conditions in our business. Further, weaknesses in our disclosure controls and internal control over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to implement and maintain effective internal control over financial reporting could also adversely affect the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting that we will eventually be required to include in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the trading price of our common stock. In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on the Nasdaq Global Select Market. We are not currently required to make a formal assessment of the effectiveness of our internal control over financial reporting under the SEC rules that implement Section 404 of the Sarbanes-Oxley Act. As a public company, we will be required to provide an annual management report on the effectiveness of our internal control over financial reporting commencing with our second annual report on Form 10-K.

If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Any failure to maintain effective disclosure controls and internal control over financial reporting could have a material and adverse effect on our business, results of operations and financial condition and could cause a decline in the trading price of our common stock.

65


 

Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations.

Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results of operations or the way in which such financial condition and results of operations are reported. We intend to invest resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from business activities to compliance activities. See the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Recent Accounting Pronouncements.

Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.

New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the CARES Act modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.

Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.

As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.

Our internal information technology systems or data, or those of our third-party CROs or other contractors or consultants, may fail or suffer security incidents, loss or leakage of data, and other disruptions, which could result in a material disruption of our product candidates’ development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.*

We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we rely on a number of third-party contractors who have access to our confidential information.

Despite the implementation of security measures, given their size and complexity and the increasing amounts of confidential information that they maintain, our internal information technology systems and those of our third -party CROs and other contractors and consultants are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures. We may also suffer a security incident, which are an evolving and increasing threat, from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, including traditional hackers, sophisticated nation-states, and state-sponsored actors. These threats include but are not limited to the deployment of harmful malware, ransomware, denial-of-service attacks, social

66


 

engineering, software bugs, supply-chain attacks and other means to affect service reliability or misuse, disclose, access, acquire, lose, or damage data or information systems. To the extent that any disruption or security incident were to or has resulted in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage and the further development and commercialization of our product candidates could be delayed.

We cannot assure you that our data protection efforts and our investment in information technology will prevent such disruptions or incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or security incidents could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, require us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. Furthermore, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from claims related to our data security obligations.

We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Our corporate headquarters and research facility are located in the county of San Diego, California, which in the past has experienced severe earthquakes and fires. If these earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us from using all or a significant portion of our headquarters or research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our clinical trials, our development plans and business.

We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.

U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, Trade Laws), prohibit, among other things, companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies, and clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.*

We, and the third parties with whom we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous

67


 

materials by us or the third parties with whom we share our facilities or contract with, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations may also result in substantial fines, penalties or other sanctions.

Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.*

Our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law (DGCL) may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may make the acquisition of our company more difficult, including the following:

a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our board of directors;
the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;
the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;
a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;
the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors or our chief executive officer, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors;
the requirement for the affirmative vote of holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend the provisions of our amended and restated certificate of incorporation relating to the management of our business or our amended and restated bylaws, which may inhibit the ability of an acquirer to affect such amendments to facilitate an unsolicited takeover attempt; and
advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of us.

In addition, as a Delaware corporation, we are subject to Section 203 of the DGCL. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision.

These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company.

The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction.

68


 

Our amended and restated certificate of incorporation provides that the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, and the federal district courts of the United States of America will be the exclusive forums for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against our company and our directors, officers and employees.*

Our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws; (v) any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any action asserting a claim against us or any of our directors, officers or other employees, governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.

In addition, our amended and restated certificate of incorporation will provide that, to the fullest extent permitted by law, the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, unless we consent in writing to the selection of an alternative forum.

These exclusive-forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.

We could be subject to securities class action litigation.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

General Risk Factors

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.*

We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

69


 

If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.*

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If only very few securities analysts commence coverage of us, or if industry analysts cease coverage of us, the trading price for our common stock would be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.

70


 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Use of Proceeds

On March 25, 2021, we commenced our initial public offering pursuant to a registration statement on Form S-1 (File No. 333-253954) that was declared effective by the SEC on March 25, 2021, for 12,000,000 shares of our common stock for sale to the public at a price of $20.00 per share. In addition, in March 2021, the underwriters exercised their over-allotment option to purchase 1,800,000 additional shares of our common stock in the initial public offering at the public offering price of $20.00 per share, such that the aggregate offering price of our initial public offering was $276.0 million. The net offering proceeds to us, after deducting underwriting discounts and commissions and offering costs, were $254.3 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates. The underwriters for our initial public offering were Goldman Sachs & Co. LLC, SVB Leerink LLC and Piper Sandler & Co.

The net proceeds from our initial public offering are being held in cash, cash equivalents and investments securities, primarily in money market funds invested in U.S. government agency securities and U.S. Treasury securities. These investments are made pursuant to our investment policy and we may further invest these funds in high-quality marketable debt instruments of corporations and government sponsored enterprises with contractual maturity dates of generally less than two years until needed to fund our operations. There has been no material change in the use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on March 26, 2021 and through September 30, 2021, we had used approximately $10.9 million of the net proceeds received from our initial public offering to support our operations.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

71


 

Item 6. Exhibits.

 

Exhibit

Number

 

Description

    3.1

 

Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed March 30, 2021).

    3.2

 

Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed March 30, 2021).

    4.1

 

Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended, filed March 22, 2021).

    4.2

 

Amended and Restated Investors’ Rights Agreement, by and between the Registrant and certain of its stockholders, dated January 25, 2021 (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, filed March 5, 2021).

  31.1

 

Certification of Principal Executive and Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

  32.1

 

Certification of Principal Executive and Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

 

INLINE XBRL Instance Document

101.SCH

 

INLINE XBRL Taxonomy Extension Schema Document

101.CAL

 

INLINE XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

 

INLINE XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

 

INLINE XBRL Taxonomy Extension Label Linkbase Document

101.PRE

 

INLINE XBRL Taxonomy Extension Presentation Linkbase Document

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

72


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Design Therapeutics, Inc.

 

 

 

 

Date: November 9, 2021

 

By:

/s/ João Siffert, M.D.

 

 

 

João Siffert, M.D.

 

 

 

President and Chief Executive Officer

 

 

 

(Principal Executive and Financial Officer)

 

 

 

 

 

73


EX-31.1 2 dsgn-ex31_1.htm EX-31.1 EX-31.1

 

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, João Siffert, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Design Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(c)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 9, 2021

 

By:

/s/ João Siffert, M.D.

 

 

 

João Siffert, M.D.

 

 

 

President and Chief Executive Officer

 

 

 

(Principal Executive and Financial Officer)

 

 


EX-32.1 3 dsgn-ex32_1.htm EX-32.1 EX-32.1

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Design Therapeutics, Inc. (the “Company”) for the quarterly period ended September 30, 2021, to which this Certification is attached, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

The undersigned have executed this Certification effective as of November 9, 2021.

 

 

 

By:

/s/ João Siffert, M.D.

 

 

 

João Siffert, M.D.

 

 

 

President and Chief Executive Officer

 

 

 

(Principal Executive and Financial Officer)

 

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 


EX-101.LAB 4 dsgn-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Non-cash lease expense Operating Lease, Right-of-Use Asset, Amortization Expense Other income, net related party expense amount Interest Expense, Related Party Research and development expenses related party amount Related Party Transaction, Expenses from Transactions with Related Party General and administrative expenses related party amount Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party Accrued expenses and other current liabilities (including related party amounts of $10 and $0, respectively) Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Accounts payable and other liabilities related-party Increase Decrease In Accounts Payable And Other Liabilities Related Parties Increase Decrease In Accounts Payable And Other Liabilities Related Parties Accrued expenses and other current liabilities, related party amounts Accrued expenses and other current liabilities Related Parties, Current Accrued expenses and other current liabilities Related Parties, Current Option to renew lease term ends, year Lessee, Operating Lease, Term of expiration year Lessee, Operating Lease, Term of expiration year Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Shares Subject to Repurchase Shares subject to repurchase [Member] Shares subject to repurchase. Employee Stock Purchase Plan Employee Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Stock Options Share-based Payment Arrangement, Option [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities [Axis] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Initial public offering of common shares, net of $21,728 of issuance costs Short Term Lease Liability Short term lease liability. Stockholders' Equity Note, Stock Split, Conversion Ratio Percentage of number of shares that may be issued in accordance with plan Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Initial recognition of operating lease right-of-use asset and operating lease liability. Purchases of property and equipment included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Prepaid expenses Leases Lessee, Leases [Policy Text Block] Short-term leases Prepaid Expenses Related Party Current Prepaid expenses related party current. Other income, net related party expense amount Other income, net (including related party expense amounts of $0, $0, $0, and $30, respectively) Unrealized gain (loss) on available-for-sale securities Net cash used in investing activities Initial recognition of operating lease right-of-use asset and operating lease liability Initial Recognition Of Operating Lease Right Of Use Asset And Operating Lease Liability General and administrative (including related party amounts of $82, $60, $202 and $232, respectively) Research and development (including related party amounts of $98, $0, $188 and $8, respectively) Exercises of stock options and vesting of restricted stock, Shares Exercises of stock options and vesting of restricted stock Current portion of operating lease liability Operating Lease, Liability, Current Construction in Progress Construction in Progress [Member] Leasehold Improvements Leasehold Improvements [Member] Lease commencement date Lease Commencement Date Lease commencement date. Operating lease liabilities Operating lease right-of-use asset discount rate Lessee, Operating Lease, Discount Rate Operating lease remaining lease term Lessee, Operating Lease, Remaining Lease Term Lease agreement termination date Lease Agreement Termination Date Lease agreement termination date. Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Table] 2021 (remaining three months) Operating lease liabilities Less: Present value adjustment Total future minimum lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Operating Lease, Liability Summary of Maturities of Operating Lease Liabilities Common stock, $0.0001 par value; 200,000,000 and 60,000,000 shares authorized, 55,654,833 and 16,604,774 shares issued, 55,224,420 and 15,957,821 shares outstanding at September 30, 2021 and December 31, 2020, respectively Lease Lessee, Operating Leases [Text Block] Convertible preferred stock, $0.0001 par value; no shares and 22,500,000 shares authorized, no shares and 22,012,499 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively; liquidation preference of zero and $45,625 as of September 30, 2021 and December 31, 2020, respectively Commitments and contingencies (See Note 9) Accounts Payable and Other Accrued Liabilities, Current Leases [Abstract] Right-of-use asset Operating Lease, Right-of-Use Asset Operating lease liability, net Operating Lease, Liability, Noncurrent Marketable Securities, Current, Total Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Other Nonoperating Income (Expense), Total Payments to Acquire Investments, Total Research and Development Expense, Total Entity Central Index Key Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Current Fiscal Year End Date Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Lease Agreement Lease Agreements [Member] Summary of Expenses Recognized under Various Agreements Initial public offering of common shares, net of $21,728 of issuance costs, Shares Conversion ratio of forward/reverse stock split Short-term leases Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Shell Company Entity Shell Company Entity Small Business Unrealized gain (loss) on investments Comprehensive Income Net Of Tax Comprehensive loss Stock issued during period value stock options exercised and vesting of early exercised common stock options. Stock Issued During Period Value Stock Options Exercised And Vesting Of Early Exercised Common Stock Options Vesting of restricted stock Stock issued during period shares stock options exercised and vesting of early exercised common stock options. Stock Issued During Period Shares Stock Options Exercised And Vesting Of Early Exercised Common Stock Options Vesting of restricted stock, Shares Temporary equity stock issued during period shares new issues. Temporary Equity Stock Issued During Period Shares New Issues Issuance of Series A and Series B convertible preferred stock, net of issuance costs, Shares Temporary equity converted into shares of common stock, shares. Temporary Equity Converted Into Shares Of Common Stock Shares Preferred stock converted into shares of common stock, Shares Temporary equity converted into shares of common stock, value. Temporary Equity Converted Into Shares Of Common Stock Value Preferred stock converted into shares of common stock Conversion of convertible debt and interest classified as temporary equity during period, shares. Temporary Equity Conversion Of Convertible Debt And Interest Shares Conversion of convertible debt and interest to Series A convertible preferred stock, Shares Conversion of convertible debt and interest classified as temporary equity during the period. Temporary Equity Conversion Of Convertible Debt And Interest Conversion of convertible debt and interest to Series A convertible preferred stock Temporary equity settlement of bifurcated conversion. Temporary Equity Settlement Of Bifurcated Conversion Settlement of bifurcated conversion liability Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Statement Equity Components [Axis] Equity Components Equity Component [Domain] Equity Component Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid-in Capital Accumulated Other Comprehensive Income [Member] Accumulated Other Comprehensive Income Retained Earnings [Member] Accumulated Deficit Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Class of Stock Convertible Preferred Stock [Member] Convertible Preferred Stock Statement [Line Items] Statement [Line Items] Shares Outstanding Ending Balance, Shares Beginning Balance, Shares Temporary Equity Stock Issued During Period Value New Issues Issuance of Series A and Series B convertible preferred stock, net of issuance costs Stock Issued During Period Value Conversion Of Convertible Securities Preferred stock converted into shares of common stock Stock Issued During Period Shares Conversion Of Convertible Securities Preferred stock converted into shares of common stock, Shares Stock Issued During Period Value New Issues Stock Issued During Period Shares New Issues Initial public offering of common shares Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Stock-based compensation Preferred stock issuance cost. Preferred Stock Issuance Cost Preferred stock issuance costs Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Sale of Stock I P O [Member] Initial Public Offering Series B convertible preferred stock. Series B Convertible Preferred Stock [Member] Series B Convertible Preferred Stock Series A convertible preferred stock. Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Stock issuance costs Paid in kind interest related party. Paid In Kind Interest Related Party Non-cash interest expense—related party Increase (decrease) in prepaid expense and other assets related party. Increase Decrease In Prepaid Expense And Other Assets Related Party Prepaid expense and other assets—related party Proceeds from notes payable related party. Proceeds From Notes Payable Related Party Proceeds from the issuance of notes payable, net of issuance costs—related party Repayments of notes payable related party. Repayments Of Notes Payable Related Party Repayment of notes payable—related party Conversion of stock amount converted related party. Conversion Of Stock Amount Converted Related Party Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability - related party Statement Of Cash Flows [Abstract] Net Cash Provided By Used In Operating Activities [Abstract] Cash flows from operating activities Profit Loss Net loss Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Reconciliation of net loss to net cash used in operating activities: Depreciation Depreciation Share Based Compensation Stock-based compensation Accretion Amortization Of Discounts And Premiums Investments Amortization of premiums on investment securities, net Paid In Kind Interest Non-cash interest expense Increase Decrease In Operating Capital [Abstract] Change in operating assets and liabilities: Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expense and other assets Increase Decrease In Deferred Revenue Total current assets Property Plant And Equipment Net Property and equipment, net Total Deferred Costs Deferred offering costs Assets Total assets Liabilities And Stockholders Equity [Abstract] Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit) Liabilities Current [Abstract] Current liabilities: Accounts Payable Current Accounts payable (including related party amounts of $20 and $20, respectively) Accrued Liabilities Current Accrued expenses Total Liabilities Current Total current liabilities Other Liabilities Noncurrent Other long-term liabilities Liabilities Total liabilities Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Revenue from Contract with Customer, Excluding Assessed Tax, Total Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total Deferred Costs, Noncurrent, Total Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised, Total Convertible Debt, Total Share-based Payment Arrangement, Noncash Expense, Total Prepaid Expense, Current, Total Depreciation, Total Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Earnings Per Share, Basic and Diluted, Total Accounts Payable, Total Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance Debt Securities, Available-for-sale, Allowance for Credit Loss, Total Accounts Payable, Current, Total Other Liabilities, Noncurrent, Total Common Stock, Shares, Issued, Total Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance General and Administrative Expense, Total Employee-related Liabilities, Current, Total Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total Contractual Obligation, Total Debt Securities, Available-for-sale, Current, Total Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Payments to Acquire Property, Plant, and Equipment, Total Increase (Decrease) in Prepaid Expense and Other Assets, Total Investments, Fair Value Disclosure, Total Commitments And Contingencies Temporary Equity Carrying Amount Attributable To Parent Ending Balance Beginning Balance Stockholders Equity [Abstract] Stockholders’ equity (deficit): Common Stock Value Additional Paid In Capital Common Stock Additional paid-in capital Retained Earnings Accumulated Deficit Accumulated deficit Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated other comprehensive income Stockholders Equity Ending Balance Beginning Balance Total stockholders’ equity (deficit) Liabilities And Stockholders Equity Total liabilities, convertible preferred stock and stockholders’ equity (deficit) Prepaid expense and other current assets related party current. Prepaid Expense And Other Current Assets Related Party Current Prepaid expense and other current assets, related party amounts Accounts Payable Related Parties Current Accounts payable, related party amounts Temporary Equity Par Or Stated Value Per Share Convertible preferred stock, par value Temporary Equity Shares Authorized Convertible preferred stock, authorized Temporary Equity Shares Issued Convertible preferred stock, issued Temporary Equity Shares Outstanding Ending Balance, Shares Beginning Balance, Shares Convertible preferred stock, outstanding Temporary Equity Liquidation Preference Convertible preferred stock, liquidation preference Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Income Statement [Abstract] Revenue From Contract With Customer [Abstract] Revenue: Revenue From Contract With Customer Excluding Assessed Tax Grant revenue Type Of Revenue [Extensible List] Revenue, Product and Service [Extensible List] Operating Expenses [Abstract] Operating expenses: Research And Development Expense General And Administrative Expense Operating Expenses Total operating expenses Operating Income Loss Loss from operations Other Nonoperating Income Expense Net Income Loss Net loss Net loss Earnings Per Share Basic And Diluted Net loss per share, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Weighted-average shares of common stock outstanding, basic and diluted Other (expense) income, net related party expenses amount. Other Expense Income Net Related Party Expense Amount Statement Of Income And Comprehensive Income [Abstract] Debt securities, Maturity Debt Securities Available For Sale [Table] Debt Securities Available For Sale [Table] Investment Type [Axis] Investment Type Investment Type Categorization [Member] Investments Extinguishment Of Debt [Axis] Extinguishment of Debt Extinguishment Of Debt Type [Domain] Extinguishment of Debt, Type Within 1 year. Within One Year [Member] Within 1 Year 1 year to 2 years. One Year To Two Years [Member] 1 Year to 2 Years Schedule Of Available For Sale Securities [Line Items] Schedule Of Available For Sale Securities [Line Items] Available For Sale Debt Securities Amortized Cost Basis Debt securities, Amortized Cost Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Debt securities, Unrealized Gains Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Debt securities, Unrealized Losses Debt Securities Available For Sale Allowance For Credit Loss Debt securities, Allowance for Credit Losses Available For Sale Securities Debt Securities Current Debt securities, Estimated Fair Value Range [Axis] Statistical Measurement Number of common stock purchased Area of office. Area Of Office Area of office space Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Related Party Marlinspike Group, LLC. Marlinspike Group L L C [Member] Marlinspike Group, LLC Statement Geographical [Axis] Geographical Segment Geographical [Domain] Geographical CANADA Carlsbad, California Investments Debt And Equity Securities [Abstract] Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Investment Securities Balance sheet component. Balance Sheet Component [Abstract] Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Details The entire disclosure of grant revenue. Grant Revenue [Text Block] Grant Revenue Disaggregation Of Revenue [Abstract] Commitments And Contingencies Disclosure [Abstract] Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure of license agreement. Disclosure Of License Agreement [Text Block] License Agreement License agreement. License Agreement [Abstract] Equity [Abstract] Stockholders Equity Note Disclosure [Text Block] Convertible Preferred Stock and Stockholders' Deficit Related Party Transactions [Abstract] APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Unsecured Debt, Total Deferred revenue Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net Cash Provided By Used In Investing Activities [Abstract] Cash flows from investing activities Payments To Acquire Investments Purchases of investment securities Proceeds From Sale And Maturity Of Available For Sale Securities Proceeds from maturities of investment securities Payments To Acquire Property Plant And Equipment Purchases of property and equipment Net Cash Provided By Used In Investing Activities Net Cash Provided By Used In Financing Activities [Abstract] Cash flows from financing activities Proceeds From Issuance Initial Public Offering Proceeds from initial public offering, net of issuance costs Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Security12b Title Title of 12(b) Security Entity File Number Entity File Number Security Exchange Name Security Exchange Name Entity Incorporation State Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address Address Line1 Entity Address, Address Line One Entity Address Address Line2 Entity Address, Address Line Two Entity Address City Or Town Entity Address, City or Town Entity Address State Or Province Entity Address, State or Province Entity Address Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Statement Of Financial Position [Abstract] Assets [Abstract] Assets Assets Current [Abstract] Current assets: Cash And Cash Equivalents At Carrying Value Cash and cash equivalents Marketable Securities Current Investment securities Prepaid Expense And Other Assets Current Prepaid expense and other current assets (including related party amounts of $60 and $0, respectively) Total Assets Current Related Party Transactions Disclosure [Text Block] Related Party Transactions Disclosure of accounting policy for basis of presentation and use of estimates. Basis Of Presentation And Use Of Estimates Policy [Text Block] Basis of Presentation and Use of Estimates Stock splits policy. Stock Splits Policy [Text Block] Stock Splits Cash And Cash Equivalents Policy [Text Block] Cash and Cash Equivalents Investment Policy [Text Block] Investment Securities Revenue Recognition Policy [Text Block] Revenue Recognition Research And Development Expense Policy Research and Development Expenses Compensation Related Costs Policy [Text Block] Stock-Based Compensation New Accounting Pronouncements Policy Policy [Text Block] Recent Accounting Pronouncements Share Based Compensation Allocation And Classification In Financial Statements [Abstract] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Summary of Stock-based Compensation Expense Fair Value Assets Measured On Recurring Basis [Text Block] Summary of Company's Financial Instruments Measured at Fair Value on a Recurring Basis Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Disclosure - Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Detail) Organization Consolidation And Presentation Of Financial Statements [Abstract] Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block] Summary of Prepaid Expenses and Other Current Assets Property Plant And Equipment [Text Block] Summary of Property and Equipment Schedule Of Accrued Liabilities Table [Text Block] Summary of Accrued Liabilities Lessee Operating Lease Liability Maturity Table [Text Block] Schedule of restricted shares of common stock and unvested stock liability. Schedule Of Restricted Shares Of Common Stock And Unvested Stock Liability Table [Text Block] Summary of Restricted Shares of Common Stock and Unvested Stock Liability Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Axis] Related Party Transaction Related Party Transaction [Domain] Related Party Transaction Research consulting agreements. Research Consulting Agreements [Member] Research Consulting Agreements Related Party Transaction [Line Items] Related Party Transaction [Line Items] Schedule Of Related Party Transactions Table [Text Block] Stockholders Equity Note Stock Split Stock split of issued and outstanding common stock Stockholders Equity Reverse Stock Split Reverse stock split of issued and outstanding common stock Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Income Statement Location Research And Development Expense [Member] Research and Development General And Administrative Expense [Member] General and Administrative General and Administrative Expenses Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Allocated Share Based Compensation Expense Stock-based compensation expense Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Antidilutive securities excluded from calculation of diluted net loss per share Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV Fair Value Inputs Level1 [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value Inputs Level2 [Member] Significant Other Observable Inputs (Level 2) Fair Value Inputs Level3 [Member] Significant Unobservable Inputs (Level 3) Cash And Cash Equivalents [Axis] Cash and Cash Equivalents Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Cash and Cash Equivalents Money Market Funds [Member] Money market funds Certificates Of Deposit [Member] Certificates of deposit Certificates of Deposit U S Treasury Securities [Member] U.S. Treasury securities U.S. Treasury Securities Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Lessee Operating Lease Term Of Contract Lease term Lessee Operating Lease Existence Of Option To Extend Lessee, Operating Lease, Existence of Option to Extend [true false] Lessee Operating Lease Option To Extend Lease term, option to extend period Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee Operating Lease Liability Payments Due After Year Four Thereafter Operating Lease Liabilities Payments Due [Abstract] Lessee Operating Lease Liability Payments Remainder Of Fiscal Year Lessee Operating Lease Liability Payments Due Next Twelve Months 2022 Lessee Operating Lease Liability Payments Due Year Two 2023 Lessee Operating Lease Liability Payments Due Year Three 2024 Lessee Operating Lease Liability Payments Due Year Four 2025 Lessee Operating Lease Liability Payments Due Operating Lease Cost Rent expense Collaborative arrangements upfront payment. Collaborative Arrangements Upfront Payment Payment for upfront fee Upfront payment upon execution of agreement. Upfront Payment Upon Execution Of Agreement Upfront payment upon execution of agreement Upfront payment within one year. Upfront Payment Within One Year Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Proceeds From Issuance Of Common Stock Proceeds from sale of common stock Convertible Preferred Stock Shares Issued Upon Conversion Convertible preferred stock, shares issued upon conversion Common Stock Capital Shares Reserved For Future Issuance Common stock reserved for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Common stock remained available for issuance Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms Common stock issuance, description and terms Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Vesting period Liabilities and stockholders equity. Liabilities And Stockholders Equity [Line Items] Liabilities And Stockholders Equity [Line Items] Liabilities and stockholders equity. Liabilities And Stockholders Equity [Table] Liabilities And Stockholders Equity [Table] Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares Ending Balance Beginning Balance 2019 Consulting Agreement. Two Thousand Nineteen Consulting Agreement [Member] 2019 Consulting Agreement 2020 Consulting Agreement. Two Thousand Twenty Consulting Agreement [Member] 2020 Consulting Agreement Consulting agreements. Consulting Agreements [Member] Consulting Agreements Co-founder. Co Founder [Member] Aseem Z. Ansari, Ph.D. Convertible Notes Payable [Member] Convertible Notes and Notes Payable May note. May Note [Member] May Note July note. July Note [Member] Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Other comprehensive gain (loss): Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Proceeds From Issuance Of Convertible Preferred Stock Proceeds from issuance of convertible preferred stock, net of issuance costs Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Proceeds from the exercise of stock options and vesting of restricted stock Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Net increase in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Supplemental Cash Flow Information [Abstract] Supplemental disclosures Conversion Of Stock Amount Converted1 Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability Interest Paid Net Interest paid Accounting Policies [Abstract] Nature Of Operations Organization Basis Of Presentation And Significant Accounting Policies [Text Block] Basis of Presentation and Summary of Significant Accounting Policies Earnings Per Share [Abstract] Earnings Per Share [Text Block] Net Loss Per Share Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares Vested shares Unvested stock liability. Unvested Stock Liability Ending Balance, Unvested stock liability Beginning Balance, Unvested stock liability Unvested stock liability vested shares value. Unvested Stock Liability Vested Shares Value Vested shares, Unvested stock liability Share based compensation arrangement by share based payment award maximum percentage of eligible earnings withheld to participate in offering. Share Based Compensation Arrangement By Share Based Payment Award Maximum Percentage Of Eligible Earnings Withheld To Participate In Offering Maximum percentage of eligible earnings withheld to participate in offering Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent Price of common stock purchased Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award July Note Series A Preferred Stock [Member] Series A Preferred Stock Monthly fee for consultancy services. Monthly Fee For Consultancy Services Monthly fee for consultancy services Termination fee. Termination Fee Termination fee Costs And Expenses Total expenses Related party transaction monthly fee for services. Related Party Transaction Monthly Fee For Services Monthly fee for services Accounts Payable Current And Noncurrent Accounts payable Conversion Of Stock Shares Converted1 Convertible preferred stock converted Investments Fair Value Disclosure Investments, fair value disclosure Debt securities, available-for-sale, maturity. Debt Securities Available For Sale Maturity Range [Member] Statistical Measurement Maximum [Member] Maximum Minimum [Member] Minimum [Member] Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions Number of available-for-sale investment securities in continuous unrealized loss position, less than 12 months Number of domestic certificates of deposit held. Number Of Domestic Certificates Of Deposit Held Number of domestic certificates of deposit held Accrued interest receivable on available-for-sale investment securities. Accrued Interest Receivable On Available For Sale Investment Securities Accrued interest receivable on available-for-sale investment securities Prepaid Expense And Other Assets Current [Abstract] Prepaid Expense Current Prepaid expenses Deposits Assets Current Security deposits Interest Receivable Current Interest receivable Other Assets Current Other Property Plant And Equipment [Abstract] Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Long-Lived Tangible Asset Equipment [Member] Laboratory Equipment Computer equipment and software. Computer Equipment And Software [Member] Computer Equipment and Software Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property Plant And Equipment Gross Property and equipment Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Less accumulated depreciation Accrued research and development expense current. Accrued Research And Development Expense Current Accrued research and development costs Accrued Liabilities Current [Abstract] Employee Related Liabilities Current Accrued personnel costs Other Accrued Liabilities Current Accrued other Disaggregation Of Revenue [Table] Disaggregation Of Revenue [Table] Product Or Service [Axis] Product and Service Products And Services [Domain] Product and Service Grant [Member] Grant Disaggregation Of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Revenue From Contract With Customer Including Assessed Tax Recognized grant revenue Debt instrument periodic payment terms balloon payment to be paid, percentage. Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid Percentage Percentage of final payment on advanced at maturity Commitments and contingencies disclosure. Commitments And Contingencies Disclosure [Line Items] Commitments And Contingencies Disclosure [Line Items] Commitments and contingencies disclosure. Commitments And Contingencies Disclosure [Table] Commitments And Contingencies Disclosure [Table] Debt Instrument [Axis] Debt Instrument Debt Instrument Name [Domain] Debt Instrument, Name Unsecured promissory note. Unsecured Promissory Note [Member] Unsecured Promissory Note February and March 2019 draws. February And March2019 Draws [Member] February and March 2019 Draws Short Term Debt Type [Axis] Short-term Debt, Type Short Term Debt Type [Domain] Short-term Debt, Type January note. January Note [Member] January Note Variable Rate [Axis] Variable Rate Variable Rate [Domain] Variable Rate Prime Rate [Member] Prime Plus Jan 2020 and Dec 2019 draws. Jan2020 And Dec2019 Draws [Member] Jan 2020 and Dec 2019 Draws November note. November Note [Member] November Note May 2018 note. May2018 Note [Member] May 2018 Note July 2018 note. July2018 Note [Member] July 2018 Note February 2019 note. February2019 Note [Member] February 2019 Note Convertible notes issued in May and July 2018. Convertible Notes Issued In May And July2018 [Member] Convertible Notes Issued in May and July 2018 Upfront payment within first anniversary of license agreement Schedule of license agreement. Schedule Of License Agreement [Line Items] Schedule Of License Agreement [Line Items] Schedule of license agreement. Schedule Of License Agreement [Table] Schedule Of License Agreement [Table] Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Collaborative Arrangement and Arrangement Other than Collaborative License agreement. License Agreement [Member] License Agreement Initial closing of series A preferred stock. Initial Closing Of Series A Preferred Stock [Member] Initial Closing of Series A Preferred Stock Investigation new drug. Investigation New Drug [Member] Investigation New Drug (IND) Expected milestone payment on achieving certain regulatory and commercial milestones. Expected Milestone Payment On Achieving Certain Regulatory And Commercial Milestones Expected milestone payment on achieving certain regulatory and commercial milestones Expected royalty payments upon first commercial product sale. Expected Royalty Payments Upon First Commercial Product Sale Expected royalty payments upon first commercial product sale Contractual Obligation Milestone payment Royalty Expense Royalty payments Legal patent fees. Legal Patent Fees Legal patent fees Notice period for termination of agreement. Notice Period For Termination Of Agreement Written notice period for termination of agreement Notice period description. Notice Period Description Termination period Description Convertible preferred stock and stockholders’ deficit. Convertible Preferred Stock And Stockholders Deficit [Line Items] Convertible Preferred Stock And Stockholders Deficit [Line Items] Convertible preferred stock and stockholders’ deficit. Convertible Preferred Stock And Stockholders Deficit [Table] Convertible Preferred Stock And Stockholders Deficit [Table] Plan Name [Axis] Plan Name Plan Name [Domain] Plan Name Two thousand twenty one equity incentive award plan. Two Thousand Twenty One Equity Incentive Award Plan [Member] 2021 Equity Incentive Award Plan Two thousand eighteen equity incentive plan. Two Thousand Eighteen Equity Incentive Plan [Member] 2018 Equity Incentive Plan Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Award Type Restricted Stock [Member] Restricted Shares Two thousand twenty one employee stock purchase plan. Two Thousand Twenty One Employee Stock Purchase Plan [Member] 2021 Employee Stock Purchase Plan Preferred Stock Shares Authorized Preferred stock, authorized Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Counterparty Name Crossing Holdings LLC. Crossing Holdings L L C [Member] Crossing Holdings, LLC Unsecured Debt Borrowings Debt Instrument Face Amount Notes issued Debt Instrument Basis Spread On Variable Rate1 Debt instrument variable interest rate Debt Instrument Maturity Date Description Maturity description Debt Instrument Interest Rate Stated Percentage Debt instrument interest rate Percentage of selling price per share that can convertible into equity securities sold. Percentage Of Selling Price Per Share That Can Convertible Into Equity Securities Sold Percentage of selling price per share that can convertible into equity securities sold Convertible Debt Convertible notes issued Debt Conversion Original Debt Amount1 Converted amount Debt Conversion Converted Instrument Shares Issued1 Converted shares Share Price Share price Area of leased property. Area Of Leased Property Area of lease space Percentage of annual increase in lease payments. Percentage Of Annual Increase In Lease Payments Percentage of annual increase in lease payments EX-101.SCH 5 dsgn-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Lease - Summary of Maturities of Operating Lease Liabilities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Statements of Operations (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Condensed Statements of Convertible Preferred stock and Stockholders' Equity (Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100090 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Investment Securities link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Lease link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Grant Revenue link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - License Agreement link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Investment Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Details) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Investment Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Balance Sheet Details - Summary of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Balance Sheet Details - Summary of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Lease - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Lease - Summary of Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Grant Revenue - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - License Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Summary of Restricted Shares of Common Stock and Unvested Stock Liability (Details) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Related Party Transactions - Summary of Expenses Recognized under Consulting Agreement (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 6 dsgn-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 7 dsgn-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.CAL 8 dsgn-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT XML 9 dsgn-20210930_htm.xml IDEA: XBRL DOCUMENT 0001807120 us-gaap:LeaseAgreementsMember 2021-07-01 2021-09-30 0001807120 dsgn:UnsecuredPromissoryNoteMember dsgn:JanuaryNoteMember 2019-02-28 0001807120 dsgn:UnsecuredPromissoryNoteMember dsgn:NovemberNoteMember 2021-01-01 2021-09-30 0001807120 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001807120 dsgn:CoFounderMember dsgn:MayNoteMember 2021-01-01 2021-09-30 0001807120 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001807120 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001807120 dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember 2021-01-01 2021-09-30 0001807120 us-gaap:RetainedEarningsMember 2021-06-30 0001807120 us-gaap:GrantMember 2020-01-01 2020-09-30 0001807120 dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember 2021-03-25 2021-03-25 0001807120 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001807120 dsgn:InvestigationNewDrugMember srt:MinimumMember dsgn:LicenseAgreementMember 2021-09-30 0001807120 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001807120 us-gaap:CertificatesOfDepositMember 2020-12-31 0001807120 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001807120 2021-07-01 2021-09-30 0001807120 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001807120 dsgn:ResearchConsultingAgreementsMember 2021-07-01 2021-09-30 0001807120 dsgn:SeriesAConvertiblePreferredStockMember 2020-02-01 2020-02-29 0001807120 us-gaap:LeaseholdImprovementsMember 2021-09-30 0001807120 2020-09-30 0001807120 srt:MaximumMember us-gaap:GeneralAndAdministrativeExpenseMember dsgn:LicenseAgreementMember 2020-01-01 2020-09-30 0001807120 us-gaap:GrantMember 2021-07-01 2021-09-30 0001807120 us-gaap:RestrictedStockMember 2020-12-31 0001807120 us-gaap:ConvertiblePreferredStockMember 2020-12-31 0001807120 us-gaap:USTreasurySecuritiesMember 2021-09-30 0001807120 2021-06-30 0001807120 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001807120 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001807120 dsgn:SeriesAConvertiblePreferredStockMember 2020-03-01 2020-03-31 0001807120 2020-02-01 2020-02-29 0001807120 dsgn:CoFounderMember us-gaap:ConvertibleNotesPayableMember 2018-07-31 0001807120 us-gaap:RetainedEarningsMember 2020-12-31 0001807120 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001807120 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001807120 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001807120 2021-03-01 2021-03-31 0001807120 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001807120 2020-06-30 0001807120 us-gaap:IPOMember 2021-01-01 2021-09-30 0001807120 us-gaap:MoneyMarketFundsMember 2020-12-31 0001807120 srt:MaximumMember dsgn:UnsecuredPromissoryNoteMember dsgn:JanuaryNoteMember 2019-01-31 0001807120 srt:MaximumMember us-gaap:GeneralAndAdministrativeExpenseMember dsgn:LicenseAgreementMember 2020-07-01 2020-09-30 0001807120 dsgn:ConsultingAgreementsMember 2020-12-31 0001807120 dsgn:UnsecuredPromissoryNoteMember dsgn:JanuaryNoteMember 2019-01-31 0001807120 us-gaap:IPOMember 2021-03-01 2021-03-31 0001807120 dsgn:WithinOneYearMember us-gaap:CertificatesOfDepositMember 2021-01-01 2021-09-30 0001807120 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001807120 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001807120 dsgn:WithinOneYearMember us-gaap:USTreasurySecuritiesMember 2021-01-01 2021-09-30 0001807120 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001807120 dsgn:InvestigationNewDrugMember dsgn:LicenseAgreementMember 2021-09-30 0001807120 dsgn:CoFounderMember us-gaap:ConvertibleNotesPayableMember us-gaap:SeriesAPreferredStockMember 2020-02-01 2020-02-29 0001807120 us-gaap:LeaseAgreementsMember 2020-12-31 0001807120 us-gaap:CommonStockMember 2021-06-30 0001807120 us-gaap:LeaseAgreementsMember 2021-01-01 2021-09-30 0001807120 dsgn:SeriesBConvertiblePreferredStockMember 2021-01-31 0001807120 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-09-30 0001807120 2021-09-30 0001807120 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001807120 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001807120 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001807120 srt:MaximumMember 2020-07-01 2020-09-30 0001807120 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001807120 dsgn:ComputerEquipmentAndSoftwareMember 2021-09-30 0001807120 dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2021-03-25 2021-03-25 0001807120 dsgn:CrossingHoldingsLLCMember 2021-09-30 0001807120 dsgn:InvestigationNewDrugMember dsgn:LicenseAgreementMember 2021-01-01 2021-09-30 0001807120 dsgn:OneYearToTwoYearsMember us-gaap:USTreasurySecuritiesMember 2021-01-01 2021-09-30 0001807120 dsgn:TwoThousandTwentyConsultingAgreementMember dsgn:MarlinspikeGroupLLCMember 2020-03-01 2020-03-31 0001807120 dsgn:UnsecuredPromissoryNoteMember dsgn:NovemberNoteMember 2019-12-31 0001807120 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001807120 dsgn:TwoThousandEighteenEquityIncentivePlanMember 2021-03-25 0001807120 dsgn:InitialClosingOfSeriesAPreferredStockMember dsgn:LicenseAgreementMember 2020-02-01 2020-02-29 0001807120 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0001807120 dsgn:ConsultingAgreementsMember 2021-09-30 0001807120 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001807120 dsgn:May2018NoteMember 2021-01-01 2021-09-30 0001807120 dsgn:July2018NoteMember 2021-01-01 2021-09-30 0001807120 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001807120 srt:MaximumMember us-gaap:GeneralAndAdministrativeExpenseMember dsgn:LicenseAgreementMember 2021-01-01 2021-09-30 0001807120 2021-01-01 2021-09-30 0001807120 us-gaap:ConvertiblePreferredStockMember 2020-09-30 0001807120 srt:MaximumMember us-gaap:GeneralAndAdministrativeExpenseMember dsgn:LicenseAgreementMember 2021-07-01 2021-09-30 0001807120 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001807120 dsgn:WithinOneYearMember us-gaap:CertificatesOfDepositMember 2020-01-01 2020-12-31 0001807120 srt:MaximumMember 2020-12-31 0001807120 dsgn:LicenseAgreementMember 2019-01-01 2019-12-31 0001807120 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001807120 dsgn:ConsultingAgreementsMember dsgn:MarlinspikeGroupLLCMember 2020-01-01 2020-09-30 0001807120 country:CA dsgn:TwoThousandNineteenConsultingAgreementMember dsgn:MarlinspikeGroupLLCMember 2019-01-01 2019-01-31 0001807120 dsgn:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-09-30 0001807120 dsgn:OneYearToTwoYearsMember us-gaap:CertificatesOfDepositMember 2021-09-30 0001807120 dsgn:UnsecuredPromissoryNoteMember dsgn:JanuaryNoteMember 2019-03-31 0001807120 dsgn:LicenseAgreementMember 2021-01-01 2021-09-30 0001807120 srt:MaximumMember 2021-09-30 0001807120 dsgn:ConsultingAgreementsMember dsgn:MarlinspikeGroupLLCMember 2021-07-01 2021-09-30 0001807120 2020-07-01 2020-09-30 0001807120 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001807120 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001807120 dsgn:ConsultingAgreementsMember dsgn:MarlinspikeGroupLLCMember 2021-01-01 2021-09-30 0001807120 dsgn:OneYearToTwoYearsMember us-gaap:USTreasurySecuritiesMember 2021-09-30 0001807120 dsgn:UnsecuredPromissoryNoteMember dsgn:FebruaryAndMarch2019DrawsMember dsgn:JanuaryNoteMember 2021-09-30 0001807120 dsgn:SeriesAConvertiblePreferredStockMember 2020-01-01 2020-09-30 0001807120 us-gaap:EquipmentMember 2020-12-31 0001807120 dsgn:ConsultingAgreementsMember 2021-01-01 2021-09-30 0001807120 us-gaap:EquipmentMember 2021-09-30 0001807120 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001807120 us-gaap:LeaseAgreementsMember 2021-09-30 0001807120 dsgn:UnsecuredPromissoryNoteMember dsgn:NovemberNoteMember 2019-11-30 0001807120 dsgn:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-01-31 0001807120 dsgn:CrossingHoldingsLLCMember 2021-02-01 2021-02-28 0001807120 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001807120 us-gaap:RestrictedStockMember 2021-09-30 0001807120 us-gaap:CommonStockMember 2020-06-30 0001807120 us-gaap:ResearchAndDevelopmentExpenseMember dsgn:LicenseAgreementMember 2019-02-01 2019-02-28 0001807120 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001807120 us-gaap:RetainedEarningsMember 2020-09-30 0001807120 dsgn:ConsultingAgreementsMember dsgn:MarlinspikeGroupLLCMember 2020-07-01 2020-09-30 0001807120 2021-09-01 2021-09-30 0001807120 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-09-30 0001807120 us-gaap:GrantMember srt:MaximumMember 2020-07-01 2020-09-30 0001807120 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001807120 dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2021-01-01 2021-09-30 0001807120 2019-12-31 0001807120 dsgn:February2019NoteMember 2021-01-01 2021-09-30 0001807120 dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember 2021-03-25 0001807120 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001807120 us-gaap:ConstructionInProgressMember 2021-09-30 0001807120 us-gaap:GrantMember 2021-01-01 2021-09-30 0001807120 2020-01-01 2020-09-30 0001807120 us-gaap:RetainedEarningsMember 2020-06-30 0001807120 us-gaap:CommonStockMember 2021-09-30 0001807120 2020-12-31 0001807120 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001807120 dsgn:LicenseAgreementMember 2019-02-01 2019-02-28 0001807120 us-gaap:RetainedEarningsMember 2019-12-31 0001807120 dsgn:UnsecuredPromissoryNoteMember dsgn:JanuaryNoteMember 2021-01-01 2021-09-30 0001807120 us-gaap:IPOMember 2021-03-31 0001807120 us-gaap:EmployeeStockMember 2021-01-01 2021-09-30 0001807120 dsgn:InvestigationNewDrugMember srt:MaximumMember dsgn:LicenseAgreementMember 2021-09-30 0001807120 dsgn:SeriesAConvertiblePreferredStockMember 2020-03-31 0001807120 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001807120 dsgn:ConsultingAgreementsMember dsgn:CoFounderMember 2017-12-01 2017-12-31 0001807120 dsgn:CoFounderMember dsgn:JulyNoteMember 2021-01-01 2021-09-30 0001807120 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001807120 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001807120 dsgn:SharesSubjectToRepurchaseMember 2020-01-01 2020-09-30 0001807120 dsgn:CrossingHoldingsLLCMember 2021-01-01 2021-09-30 0001807120 2019-02-28 0001807120 dsgn:SeriesAConvertiblePreferredStockMember 2020-02-29 0001807120 2021-11-05 0001807120 dsgn:UnsecuredPromissoryNoteMember dsgn:NovemberNoteMember 2020-01-31 0001807120 dsgn:WithinOneYearMember us-gaap:CertificatesOfDepositMember 2021-09-30 0001807120 dsgn:WithinOneYearMember us-gaap:USTreasurySecuritiesMember 2020-01-01 2020-12-31 0001807120 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001807120 dsgn:OneYearToTwoYearsMember us-gaap:CertificatesOfDepositMember 2021-01-01 2021-09-30 0001807120 dsgn:WithinOneYearMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001807120 us-gaap:CommonStockMember 2019-12-31 0001807120 dsgn:ConvertibleNotesIssuedInMayAndJuly2018Member 2021-09-30 0001807120 dsgn:CoFounderMember us-gaap:ConvertibleNotesPayableMember 2018-05-31 0001807120 dsgn:ResearchConsultingAgreementsMember 2021-01-01 2021-09-30 0001807120 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-09-30 0001807120 us-gaap:CommonStockMember 2020-12-31 0001807120 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001807120 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001807120 dsgn:UnsecuredPromissoryNoteMember dsgn:Jan2020AndDec2019DrawsMember dsgn:NovemberNoteMember 2021-09-30 0001807120 us-gaap:MoneyMarketFundsMember 2021-09-30 0001807120 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001807120 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001807120 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001807120 dsgn:SharesSubjectToRepurchaseMember 2021-01-01 2021-09-30 0001807120 srt:MaximumMember us-gaap:LeaseAgreementsMember 2021-09-30 0001807120 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001807120 us-gaap:CommonStockMember us-gaap:IPOMember 2021-03-31 0001807120 dsgn:WithinOneYearMember us-gaap:USTreasurySecuritiesMember 2021-09-30 0001807120 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0001807120 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001807120 dsgn:WithinOneYearMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001807120 srt:MaximumMember dsgn:UnsecuredPromissoryNoteMember dsgn:NovemberNoteMember 2019-11-30 0001807120 us-gaap:RetainedEarningsMember 2021-09-30 0001807120 us-gaap:RestrictedStockMember dsgn:TwoThousandEighteenEquityIncentivePlanMember us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001807120 dsgn:UnsecuredPromissoryNoteMember dsgn:JanuaryNoteMember us-gaap:PrimeRateMember 2019-01-01 2019-01-31 0001807120 us-gaap:CommonStockMember 2020-09-30 0001807120 dsgn:UnsecuredPromissoryNoteMember dsgn:NovemberNoteMember us-gaap:PrimeRateMember 2019-11-01 2019-11-30 0001807120 dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2021-03-25 0001807120 us-gaap:ConvertiblePreferredStockMember 2020-06-30 0001807120 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001807120 us-gaap:CertificatesOfDepositMember 2021-09-30 0001807120 dsgn:CrossingHoldingsLLCMember 2021-02-28 0001807120 us-gaap:FairValueInputsLevel1Member 2020-12-31 pure utr:sqft dsgn:Security shares iso4217:USD shares iso4217:USD http://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned http://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned --12-31 0.613497 false http://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned 0001807120 http://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned Q3 10-Q true 2021-09-30 2021 false 001-40288 Design Therapeutics, Inc. DE 82-3929248 6005 Hidden Valley Road Suite 110 Carlsbad CA 92011 858 293-4900 Common Stock, $0.0001 par value per share DSGN NASDAQ Yes Yes Non-accelerated Filer false true true false 55662501 357662000 2379000 36056000 33712000 60000 0 1572000 142000 395290000 36233000 1320000 71000 3743000 212000 400353000 36516000 20000 20000 2216000 1399000 10000 0 3289000 931000 5505000 2330000 3273000 11000 145000 8789000 2475000 0.0001 0.0001 0 22500000 0 0 22012499 22012499 0 45625000 45356000 0.0001 0.0001 200000000 60000000 55654833 16604774 55224420 15957821 6000 1000 427953000 451000 -36391000 -11923000 -4000 156000 391564000 -11315000 400353000 36516000 20000 193000 98000 0 188000 8000 8539000 1914000 17441000 3352000 82000 60000 202000 232000 2798000 489000 7263000 1310000 11337000 2403000 24704000 4662000 -11337000 -2383000 -24704000 -4469000 0 0 0 30000 19000 63000 236000 44000 -11318000 -2320000 -24468000 -4425000 -0.21 -0.09 -0.57 -0.17 55155030 25701737 42759656 25606779 -11318000 -2320000 -24468000 -4425000 8000 -42000 -160000 152000 -11310000 -2362000 -24628000 -4273000 55114729 6000 426680000 -12000 -25073000 401601000 109691 30000 30000 1243000 1243000 8000 8000 -11318000 -11318000 55224420 6000 427953000 -4000 -36391000 391564000 22012499 45356000 15957821 1000 451000 156000 -11923000 -11315000 288000 19083979 124712000 -41096478 -170068000 25212548 4000 170064000 170068000 21728000 13800000 1000 254270000 254271000 254051 35000 35000 3133000 3133000 -160000 -160000 -24468000 -24468000 55224420 6000 427953000 -4000 -36391000 391564000 22012499 45356000 15782575 1000 14000 194000 -5748000 -5539000 104771 15000 15000 -42000 -42000 -2320000 -2320000 22012499 45356000 15887346 1000 29000 152000 -8068000 -7886000 15640133 1000 -3643000 -3642000 270000 21710814 44731000 301685 500000 125000 247213 29000 29000 152000 152000 -4425000 -4425000 22012499 45356000 15887346 1000 29000 152000 -8068000 -7886000 -24468000 -4425000 47000 1000 3133000 29000 103000 69000 12000 26000 5000 1158000 71000 60000 -193000 2444000 708000 10000 -1843000 -20150000 -5825000 36356000 55589000 33955000 20092000 1184000 62000 -3585000 -35559000 254271000 124712000 44731000 35000 200000 400000 379018000 44531000 355283000 3147000 2379000 77000 357662000 3224000 3786000 112000 271000 354000 18000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Organization</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc. (the “Company”) was incorporated in Delaware in December 2017 and is based in Carlsbad, California. The Company is a biopharmaceutical company pioneering GeneTAC</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules, a novel class of disease-modifying small-molecule gene targeted chimera therapeutics that are designed to target the underlying cause of inherited nucleotide repeat expansion diseases. The Company’s lead product candidate is in Friedreich ataxia (“FA”), its second GeneTAC™ program is in myotonic dystrophy type-1 (“DM1”), and it is also advancing its GeneTAC</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> portfolio to address other serious nucleotide repeat-driven monogenic diseases.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has experienced net losses and negative cash flows from operating activities since inception and expects to incur net losses for the foreseeable future as it advances its research and development programs, conducts clinical trials for any future product candidates and commercializes any such product candidates for which it receives regulatory approval. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of its future product candidates, and on the achievement of sufficient revenue to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital to fund its operations.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Basis of Presentation and Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation and Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying interim condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and following the requirements of the United States Securities and Exchange Commission ("SEC") for interim reporting. The Company's financial statements include all adjustments, consisting of only normal recurring adjustments, which in the opinion of management are necessary to present fairly the Company’s financial position as of the reporting date and results of operations for the periods presented. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the recognition of grant revenue, accruals for research and development expenses and the valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The full extent to which the novel coronavirus-2019 (“COVID-19”) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Splits</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-for-1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> forward stock split of its issued and outstanding common stock. Further, in March 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1-for-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bf0d5ab7-4e9e-4dd9-9ef2-d77e47167a9f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.63</span></span></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split of its issued and outstanding common stock. The par value and the authorized shares of the common stock were not adjusted as a result of these stock splits. The reverse stock split in March 2021 resulted in an adjustment to the convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying financial statements and notes to the financial statements give retroactive effect to the stock splits for all periods presented.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with maturities at the date of acquisition of three months or less to be cash equivalents. These investments may include money market accounts, money market funds, U.S. Government agency securities, corporate debt securities and commercial paper. The Company’s cash reserves are in a readily available checking account.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investment Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments in securities with maturities at the date of acquisition of more than three months are considered marketable securities. The Company determines the appropriate classification of its investments at the time of acquisition and reevaluates such determination at each balance sheet date. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management strategies. Further, the Company classifies its</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company’s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for safety of principle, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of other comprehensive income (loss) until realized. Allowances for credit losses are reported on the balance sheet, if any.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost of available-for-sale investment securities is adjusted for amortization of premiums and accretion of discounts until the securities mature. Such amortization and accretion is included in other income (expense) on the statements of operations. Realized gains and losses, if any, are also included in other income (expense) on the statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the periods presented, no realized gains or losses were recorded on the sale of investment securities and no impairments to reduce the value of any security was taken. See Note 5 for further discussion.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise the option. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company's leases do not provide an implicit interest rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less ("Short-Term Leases"). For any Short-Term leases, the Company records the rent expense on a straight-line basis and does not record the leases on the condensed balance sheet. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Short-Term Leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021 or December 31, 2020.</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has generated revenue from grants awarded to it by the National Science Foundation (“NSF”), the National Institutes of Health (“NIH”) and the Friedreich’s Ataxia Research Alliance (“FARA”). These grants provide the Company with funding for certain research and development activities on a best-efforts basis and do not require scientific achievement as a performance obligation. The Company has determined that the entities funding these grant awards do not meet the definition of a “customer”, as defined by Accounting Standards Codification (“ASC”) 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and does not consider there to be a transfer of control of goods or services to the entities funding the grant. As such, the Company recognizes revenue from these awards in the period during which the related qualifying services are rendered and costs are incurred in accordance with ASC 730, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. ASC 730 requires an assessment, at the inception of the grant, to determine whether the agreement is a liability or a contract to perform research and development services for others. Further, these grants are subject to the contribution’s guidance under ASC 958, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Not-for-Profit Entities-Revenue Recognition</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and as such, the Company determines whether it is obligated to repay the funds received to the grantor regardless of the outcome of the related research and development activities. If it determines there is such a liability, it estimates the obligation and recognize that liability. Alternatively, if the Company is not required to repay the funds, the grant agreement is accounted for as a contract to perform research and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">development services for others, in which case, the grant revenue is recorded as income in the statements of operations as the expenses are incurred.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s current grant revenue is not deemed refundable, and therefore, no liability is recognized when income is recorded. Grant funding received prior to expenses being incurred are recorded as deferred revenue on the Company’s balance sheets. See Note 8 for further discussion.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist primarily of direct and indirect costs incurred in connection with its discovery efforts, and the preclinical and formulation development of its product candidates. In the future, the Company expects a substantial portion of its research and development expenses will relate to the clinical development of its product candidates. Direct costs include contracted research development and manufacturing, consulting fees, license fees, laboratory supplies and other expenses incurred to sustain research and development programs. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, facilities related expenses, and other indirect expenses. A significant portion of the Company’s research and development expenses have been direct costs, which the Company tracks by stage of development, preclinical or clinical. However, the Company does not track its internal research and development expenses on a program specific basis, unless specific to research grants, because these costs are deployed across multiple projects and, as such, are not separately classified. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company’s research and development efforts and have no alternative future uses.</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into various contracts with research and development organizations, vendors and consultants. Payments for these activities are based on the terms of the individual agreements, which may differ from the periods over which materials or services are provided. Payments made in advance of performance are reflected in the accompanying balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. The Company determines accrual estimates through review of the underlying contracts along with discussions with research and other key personnel as to the progress of the research and development activities, invoices received and contracted costs. During the course of a study or trial, the Company adjusts its rate of expense recognition if actual results differ from its estimates. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options issued pursuant to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) and 2018 Equity Incentive Plan (the “2018 Plan”) and option features associated with the rights to purchase shares pursuant to the Company’s 2021 Employee Stock Purchase Plan (the “ESPP”) are valued using the Black-Scholes option pricing model on the date of grant or subscription period. This option pricing model involves a number of estimates, including the expected lives of the stock options or subscription period, the Company’s anticipated stock volatility and interest rates. The Company recognizes the expense for equity awards on a straight-line basis over the requisite service periods of the awards or the number of shares estimated to be issued pursuant to the ESPP. Forfeitures are recognized as they occur.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense recognized in the Company’s statements of operations during the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three and nine months ended September 30, 2021 and 2020, were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.418%;"/> <td style="width:1.067%;"/> <td style="width:1.531%;"/> <td style="width:10.52%;"/> <td style="width:0.872%;"/> <td style="width:1.039%;"/> <td style="width:1.531%;"/> <td style="width:9.695%;"/> <td style="width:0.872%;"/> <td style="width:1.039%;"/> <td style="width:1.531%;"/> <td style="width:8.786%;"/> <td style="width:0.872%;"/> <td style="width:1.039%;"/> <td style="width:1.531%;"/> <td style="width:8.786%;"/> <td style="width:0.872%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">521</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,181</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">722</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,952</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,243</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,133</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-04, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The ASU provides guidance to clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. ASU 2021-04 is effective for annual periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact that this new guidance will have on its condensed consolidated financial statements and does not currently expect the adoption will have a material impact on its financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, the FASB issued ASU 2020-06, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The guidance, among other items, clarifies that certain transactions between collaborative participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. The ASU’s amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted for periods beginning after December 15, 2020. The Company has not yet adopted this guidance and does not currently expect the adoption will have a material impact on its financial statements and related disclosures.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation and Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying interim condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and following the requirements of the United States Securities and Exchange Commission ("SEC") for interim reporting. The Company's financial statements include all adjustments, consisting of only normal recurring adjustments, which in the opinion of management are necessary to present fairly the Company’s financial position as of the reporting date and results of operations for the periods presented. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the recognition of grant revenue, accruals for research and development expenses and the valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The full extent to which the novel coronavirus-2019 (“COVID-19”) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Splits</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-for-1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> forward stock split of its issued and outstanding common stock. Further, in March 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1-for-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bf0d5ab7-4e9e-4dd9-9ef2-d77e47167a9f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.63</span></span></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split of its issued and outstanding common stock. The par value and the authorized shares of the common stock were not adjusted as a result of these stock splits. The reverse stock split in March 2021 resulted in an adjustment to the convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying financial statements and notes to the financial statements give retroactive effect to the stock splits for all periods presented.</span> 5-for-1 5 1-for-1.63 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with maturities at the date of acquisition of three months or less to be cash equivalents. These investments may include money market accounts, money market funds, U.S. Government agency securities, corporate debt securities and commercial paper. The Company’s cash reserves are in a readily available checking account.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investment Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments in securities with maturities at the date of acquisition of more than three months are considered marketable securities. The Company determines the appropriate classification of its investments at the time of acquisition and reevaluates such determination at each balance sheet date. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management strategies. Further, the Company classifies its</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company’s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for safety of principle, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of other comprehensive income (loss) until realized. Allowances for credit losses are reported on the balance sheet, if any.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost of available-for-sale investment securities is adjusted for amortization of premiums and accretion of discounts until the securities mature. Such amortization and accretion is included in other income (expense) on the statements of operations. Realized gains and losses, if any, are also included in other income (expense) on the statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the periods presented, no realized gains or losses were recorded on the sale of investment securities and no impairments to reduce the value of any security was taken. See Note 5 for further discussion.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise the option. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company's leases do not provide an implicit interest rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less ("Short-Term Leases"). For any Short-Term leases, the Company records the rent expense on a straight-line basis and does not record the leases on the condensed balance sheet. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Short-Term Leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021 or December 31, 2020.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span> 0 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has generated revenue from grants awarded to it by the National Science Foundation (“NSF”), the National Institutes of Health (“NIH”) and the Friedreich’s Ataxia Research Alliance (“FARA”). These grants provide the Company with funding for certain research and development activities on a best-efforts basis and do not require scientific achievement as a performance obligation. The Company has determined that the entities funding these grant awards do not meet the definition of a “customer”, as defined by Accounting Standards Codification (“ASC”) 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and does not consider there to be a transfer of control of goods or services to the entities funding the grant. As such, the Company recognizes revenue from these awards in the period during which the related qualifying services are rendered and costs are incurred in accordance with ASC 730, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. ASC 730 requires an assessment, at the inception of the grant, to determine whether the agreement is a liability or a contract to perform research and development services for others. Further, these grants are subject to the contribution’s guidance under ASC 958, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Not-for-Profit Entities-Revenue Recognition</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and as such, the Company determines whether it is obligated to repay the funds received to the grantor regardless of the outcome of the related research and development activities. If it determines there is such a liability, it estimates the obligation and recognize that liability. Alternatively, if the Company is not required to repay the funds, the grant agreement is accounted for as a contract to perform research and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">development services for others, in which case, the grant revenue is recorded as income in the statements of operations as the expenses are incurred.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s current grant revenue is not deemed refundable, and therefore, no liability is recognized when income is recorded. Grant funding received prior to expenses being incurred are recorded as deferred revenue on the Company’s balance sheets. See Note 8 for further discussion.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist primarily of direct and indirect costs incurred in connection with its discovery efforts, and the preclinical and formulation development of its product candidates. In the future, the Company expects a substantial portion of its research and development expenses will relate to the clinical development of its product candidates. Direct costs include contracted research development and manufacturing, consulting fees, license fees, laboratory supplies and other expenses incurred to sustain research and development programs. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, facilities related expenses, and other indirect expenses. A significant portion of the Company’s research and development expenses have been direct costs, which the Company tracks by stage of development, preclinical or clinical. However, the Company does not track its internal research and development expenses on a program specific basis, unless specific to research grants, because these costs are deployed across multiple projects and, as such, are not separately classified. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company’s research and development efforts and have no alternative future uses.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into various contracts with research and development organizations, vendors and consultants. Payments for these activities are based on the terms of the individual agreements, which may differ from the periods over which materials or services are provided. Payments made in advance of performance are reflected in the accompanying balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. The Company determines accrual estimates through review of the underlying contracts along with discussions with research and other key personnel as to the progress of the research and development activities, invoices received and contracted costs. During the course of a study or trial, the Company adjusts its rate of expense recognition if actual results differ from its estimates. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options issued pursuant to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) and 2018 Equity Incentive Plan (the “2018 Plan”) and option features associated with the rights to purchase shares pursuant to the Company’s 2021 Employee Stock Purchase Plan (the “ESPP”) are valued using the Black-Scholes option pricing model on the date of grant or subscription period. This option pricing model involves a number of estimates, including the expected lives of the stock options or subscription period, the Company’s anticipated stock volatility and interest rates. The Company recognizes the expense for equity awards on a straight-line basis over the requisite service periods of the awards or the number of shares estimated to be issued pursuant to the ESPP. Forfeitures are recognized as they occur.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense recognized in the Company’s statements of operations during the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three and nine months ended September 30, 2021 and 2020, were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.418%;"/> <td style="width:1.067%;"/> <td style="width:1.531%;"/> <td style="width:10.52%;"/> <td style="width:0.872%;"/> <td style="width:1.039%;"/> <td style="width:1.531%;"/> <td style="width:9.695%;"/> <td style="width:0.872%;"/> <td style="width:1.039%;"/> <td style="width:1.531%;"/> <td style="width:8.786%;"/> <td style="width:0.872%;"/> <td style="width:1.039%;"/> <td style="width:1.531%;"/> <td style="width:8.786%;"/> <td style="width:0.872%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">521</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,181</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">722</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,952</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,243</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,133</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense recognized in the Company’s statements of operations during the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three and nine months ended September 30, 2021 and 2020, were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.418%;"/> <td style="width:1.067%;"/> <td style="width:1.531%;"/> <td style="width:10.52%;"/> <td style="width:0.872%;"/> <td style="width:1.039%;"/> <td style="width:1.531%;"/> <td style="width:9.695%;"/> <td style="width:0.872%;"/> <td style="width:1.039%;"/> <td style="width:1.531%;"/> <td style="width:8.786%;"/> <td style="width:0.872%;"/> <td style="width:1.039%;"/> <td style="width:1.531%;"/> <td style="width:8.786%;"/> <td style="width:0.872%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">521</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,181</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">722</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,952</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,243</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,133</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 521000 12000 1181000 22000 722000 3000 1952000 7000 1243000 15000 3133000 29000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-04, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The ASU provides guidance to clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. ASU 2021-04 is effective for annual periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact that this new guidance will have on its condensed consolidated financial statements and does not currently expect the adoption will have a material impact on its financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, the FASB issued ASU 2020-06, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The guidance, among other items, clarifies that certain transactions between collaborative participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. The ASU’s amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted for periods beginning after December 15, 2020. The Company has not yet adopted this guidance and does not currently expect the adoption will have a material impact on its financial statements and related disclosures.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, restricted common stock subject to repurchase, stock options outstanding under the Company’s equity incentive plans, employee stock purchase rights under the Company’s ESPP, and shares of common stock that are issuable under convertible debt, as applicable. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company's net loss position.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the outstanding, potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.874%;"/> <td style="width:1.985%;"/> <td style="width:1.531%;"/> <td style="width:16.291%;"/> <td style="width:0.751%;"/> <td style="width:1.985%;"/> <td style="width:1.531%;"/> <td style="width:16.3%;"/> <td style="width:0.751%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,<br/>2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,<br/>2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Convertible preferred stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,504,598</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,124,238</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">389,565</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares subject to repurchase</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">430,413</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">564,055</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee stock purchase plan</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,335</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,569,986</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,458,218</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the outstanding, potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.874%;"/> <td style="width:1.985%;"/> <td style="width:1.531%;"/> <td style="width:16.291%;"/> <td style="width:0.751%;"/> <td style="width:1.985%;"/> <td style="width:1.531%;"/> <td style="width:16.3%;"/> <td style="width:0.751%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,<br/>2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,<br/>2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Convertible preferred stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,504,598</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,124,238</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">389,565</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares subject to repurchase</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">430,413</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">564,055</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee stock purchase plan</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,335</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,569,986</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,458,218</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 13504598 2124238 389565 430413 564055 15335 2569986 14458218 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1: Observable inputs such as quoted prices in active markets.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</span></p><p style="margin-left:4.533%;text-indent:-10.154%;padding-left:8.8%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying value of the Company’s cash, accounts payable and accrued liabilities are considered to be representative of their respective fair values due to the short-term nature of those instruments. The Company’s investment securities, which may include</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises, are measured at fair value in accordance with the fair value hierarchy. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis and no transfers between levels have occurred during the periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarize the Company’s financial instruments measured at fair value on a recurring basis at </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021 and December 31, 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.051%;"/> <td style="width:1.062%;"/> <td style="width:1.722%;"/> <td style="width:9.456%;"/> <td style="width:0.866%;"/> <td style="width:1.062%;"/> <td style="width:1.722%;"/> <td style="width:9.456%;"/> <td style="width:0.866%;"/> <td style="width:1.062%;"/> <td style="width:1.774%;"/> <td style="width:9.476%;"/> <td style="width:0.866%;"/> <td style="width:1.072%;"/> <td style="width:1.825%;"/> <td style="width:9.796%;"/> <td style="width:0.866%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurement at End of Period Using:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Quoted Prices</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">In Active</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Markets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">For</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Identical</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Observable</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Inputs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Inputs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 1)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 2)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 3)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of September 30, 2021:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">356,793</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">356,793</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,987</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,987</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">392,848</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">392,848</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,958</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,958</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,812</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,812</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="margin-left:5.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:10.0pt;font-family:Times New Roman;transform-origin:top left;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.25in;">(1)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Included in cash and cash equivalents on the accompanying balance sheets.</span></div></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest bearing money market accounts and certificates of deposit are valued at amortized cost, which approximates fair value.</span></p> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarize the Company’s financial instruments measured at fair value on a recurring basis at </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021 and December 31, 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.051%;"/> <td style="width:1.062%;"/> <td style="width:1.722%;"/> <td style="width:9.456%;"/> <td style="width:0.866%;"/> <td style="width:1.062%;"/> <td style="width:1.722%;"/> <td style="width:9.456%;"/> <td style="width:0.866%;"/> <td style="width:1.062%;"/> <td style="width:1.774%;"/> <td style="width:9.476%;"/> <td style="width:0.866%;"/> <td style="width:1.072%;"/> <td style="width:1.825%;"/> <td style="width:9.796%;"/> <td style="width:0.866%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurement at End of Period Using:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Quoted Prices</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">In Active</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Markets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">For</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Identical</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Observable</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Inputs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Inputs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 1)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 2)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 3)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of September 30, 2021:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">356,793</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">356,793</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,987</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,987</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,068</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">392,848</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">392,848</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,958</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,958</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,812</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,812</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="margin-left:5.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.25in;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:10.0pt;font-family:Times New Roman;transform-origin:top left;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.25in;">(1)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Included in cash and cash equivalents on the accompanying balance sheets.</span></div></div> 356793000 356793000 5987000 5987000 30068000 30068000 392848000 392848000 2100000 2100000 1754000 1754000 31958000 31958000 35812000 35812000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Investment Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s investment policy defines allowable investment securities and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. In accordance with the Company’s investment policy, it has invested funds in marketable securities. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cost, gross unrealized holding gains, gross unrealized holding </span></span><span style=""/></p><div style="font-size:11.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">losses, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">allowances for credit losses and fair value of available-for-sale investments by types, maturities and classes of securities at September 30, 2021 and December 31, 2020 consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:21.338%;"/> <td style="width:1.262%;"/> <td style="width:10.975%;"/> <td style="width:1.262%;"/> <td style="width:1.521%;"/> <td style="width:9.75%;"/> <td style="width:0.742%;"/> <td style="width:1.262%;"/> <td style="width:1.521%;"/> <td style="width:9.76%;"/> <td style="width:0.742%;"/> <td style="width:1.262%;"/> <td style="width:1.521%;"/> <td style="width:9.602%;"/> <td style="width:0.937%;"/> <td style="width:1.262%;"/> <td style="width:1.521%;"/> <td style="width:9.75%;"/> <td style="width:0.742%;"/> <td style="width:1.262%;"/> <td style="width:1.521%;"/> <td style="width:9.741%;"/> <td style="width:0.742%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of September 30, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Allowance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">for Credit</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Market</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maturity</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,853</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,852</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,066</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,067</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 year to 2 years</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,137</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,135</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 year to 2 years</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,004</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,002</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,060</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,056</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Allowance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">for Credit</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Market</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maturity</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,750</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,806</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,958</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,556</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">156</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,712</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews its investments at each reporting date to identify and evaluate whether a decline in fair value below the amortized cost basis of available-for-sale securities is due to credit-related factors and determines if such unrealized losses are the result of credit losses that require impairment. Factors considered in determining whether an unrealized loss is the result of a credit loss or other factors include the extent to which the fair value is less than the cost basis, any changes to the rating of the security by a rating agency, the financial condition and near-term prospects of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any adverse legal or regulatory events affecting the issuer or issuer’s industry, any significant deterioration in economic condition and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At September 30, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> securities in an unrealized loss position. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluated the securities individually for other-than-temporary impairment and considered the decline in market value to be primarily attributable to changes in interest rates. Each security remained at a high credit quality rating and the unrealized losses of each security was immaterial. Further, there had been no adverse conditions noted for any of the issuers and Company does not intend to sell any of the securities prior to maturity. As such, the Company has classified the losses as temporary in nature</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and the Company did not record a reserve for credit losses. At December 31, 2020, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> securities in an unrealized loss position.</span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of September 30, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company held </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> domestic certificates of deposit with amortized costs below the Federal Deposit Insurance Corporation (“FDIC”) insured limit. Accrued interest receivable on available-for-sale investment securities, included in prepaids and other current assets on the Company’s balance sheets, was less than</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">at September 30, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and December 31, 2020.</span> <span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cost, gross unrealized holding gains, gross unrealized holding </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">losses, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">allowances for credit losses and fair value of available-for-sale investments by types, maturities and classes of securities at September 30, 2021 and December 31, 2020 consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:21.338%;"/> <td style="width:1.262%;"/> <td style="width:10.975%;"/> <td style="width:1.262%;"/> <td style="width:1.521%;"/> <td style="width:9.75%;"/> <td style="width:0.742%;"/> <td style="width:1.262%;"/> <td style="width:1.521%;"/> <td style="width:9.76%;"/> <td style="width:0.742%;"/> <td style="width:1.262%;"/> <td style="width:1.521%;"/> <td style="width:9.602%;"/> <td style="width:0.937%;"/> <td style="width:1.262%;"/> <td style="width:1.521%;"/> <td style="width:9.75%;"/> <td style="width:0.742%;"/> <td style="width:1.262%;"/> <td style="width:1.521%;"/> <td style="width:9.741%;"/> <td style="width:0.742%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of September 30, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Allowance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">for Credit</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Market</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maturity</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,853</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,852</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,066</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,067</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 year to 2 years</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,137</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,135</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 year to 2 years</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,004</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,002</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,060</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,056</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Allowance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">for Credit</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Market</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maturity</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,750</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,806</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,958</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,556</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">156</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,712</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> Within 1 year 2853000 1000 2852000 Within 1 year 10066000 1000 10067000 1 year to 2 years 3137000 2000 3135000 1 year to 2 years 20004000 2000 20002000 36060000 1000 5000 36056000 Within 1 year 1750000 4000 1754000 Within 1 year 31806000 152000 31958000 33556000 156000 33712000 19 0 25 100000 100000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Balance Sheet Details</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.298%;"/> <td style="width:1.671%;"/> <td style="width:2.4%;"/> <td style="width:17.358%;"/> <td style="width:1.034%;"/> <td style="width:1.684%;"/> <td style="width:2.4%;"/> <td style="width:17.12%;"/> <td style="width:1.034%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,<br/>2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,421</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Security deposits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest receivable</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,572</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.257%;"/> <td style="width:1.737%;"/> <td style="width:2.36%;"/> <td style="width:16.916%;"/> <td style="width:1.485%;"/> <td style="width:1.737%;"/> <td style="width:2.36%;"/> <td style="width:16.664%;"/> <td style="width:1.485%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,<br/>2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,058</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,372</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,320</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.485%;"/> <td style="width:1.764%;"/> <td style="width:2.374%;"/> <td style="width:17.23%;"/> <td style="width:1.008%;"/> <td style="width:1.764%;"/> <td style="width:2.374%;"/> <td style="width:16.992%;"/> <td style="width:1.008%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,<br/>2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued personnel costs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,411</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">565</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">652</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current portion of operating lease liability</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">475</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">751</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,289</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">931</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.298%;"/> <td style="width:1.671%;"/> <td style="width:2.4%;"/> <td style="width:17.358%;"/> <td style="width:1.034%;"/> <td style="width:1.684%;"/> <td style="width:2.4%;"/> <td style="width:17.12%;"/> <td style="width:1.034%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,<br/>2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,421</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Security deposits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest receivable</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,572</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 1421000 60000 104000 47000 47000 10000 25000 1572000 142000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.257%;"/> <td style="width:1.737%;"/> <td style="width:2.36%;"/> <td style="width:16.916%;"/> <td style="width:1.485%;"/> <td style="width:1.737%;"/> <td style="width:2.36%;"/> <td style="width:16.664%;"/> <td style="width:1.485%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,<br/>2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,058</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">146</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,372</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,320</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 1058000 76000 77000 91000 146000 1372000 76000 52000 5000 1320000 71000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.485%;"/> <td style="width:1.764%;"/> <td style="width:2.374%;"/> <td style="width:17.23%;"/> <td style="width:1.008%;"/> <td style="width:1.764%;"/> <td style="width:2.374%;"/> <td style="width:16.992%;"/> <td style="width:1.008%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30,<br/>2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued personnel costs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,411</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">565</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">652</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current portion of operating lease liability</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">475</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">751</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,289</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">931</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 1411000 565000 652000 266000 475000 751000 100000 3289000 931000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Lease</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2019 the Company entered into an agreement, as subsequently amended, to lease laboratory space pursuant to a three-month, automatically renewing lease. Due to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the short-term nature of the lease, it was not included as an operating lease right of use asset nor as an operating lease liability on the Company’s balance sheets. The Company terminated the agreement in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 2021</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company entered into a lease agreement with Crossing Holdings, LLC to rent approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,370</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of laboratory and office space (the “Lease”). The Company’s Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC. The lease commenced in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 2021</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> with a term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> months and an </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option to extend</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the lease term for a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">; however, it is not reasonably certain the Company will exercise the option to renew when the lease term ends in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2027</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and thus, the incremental term was excluded from the calculation of the right-of-use asset or lease liability. Lease payments are subject to annual increases of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and the Company is responsible for its share of operating expenses and taxes, which are expensed as incurred. As of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the remaining lease term for the lease was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years and the discount rate used to determine the right-of-use asset and corresponding operating lease liability was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.15</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maturities of operating lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021 are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.993%;"/> <td style="width:1.939%;"/> <td style="width:1.533%;"/> <td style="width:15.594%;"/> <td style="width:0.942%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 2021 (remaining three months)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">181</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">733</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">755</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 2024</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">778</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 2025</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">801</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,386</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future minimum lease payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,634</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Present value adjustment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">886</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,748</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rent expense for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three months ended September 30, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, resp</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ectively.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rent expense for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">nine months ended September 30, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p> 2021-09 12370 2021-09 P72M true three years 2027 0.03 P5Y10M24D 0.0715 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maturities of operating lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021 are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.993%;"/> <td style="width:1.939%;"/> <td style="width:1.533%;"/> <td style="width:15.594%;"/> <td style="width:0.942%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 2021 (remaining three months)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">181</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">733</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">755</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 2024</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">778</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 2025</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">801</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,386</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future minimum lease payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,634</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Present value adjustment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">886</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,748</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 181000 733000 755000 778000 801000 1386000 4634000 886000 3748000 200000 100000 400000 100000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Grant Revenue</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue pursuant to grants, as described further in Note 2, by measuring the progress of the applicable research and development services provided over time, based on the effort the Company expends and costs incurred, relative to the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">estimated total effort and costs to be incurred under the grant. This results in a percentage that the Company multiplies by the grant award amount to determine the amount of grant revenue to be recognized each period. This approach requires the Company to use judgement and make estimates of future expenditures. If the Company’s estimates or judgements change over the course of the term of the grant, it may affect the timing and amount of revenue that it recognizes in the current and future periods.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the three and nine months ended September 30, 2020, the Company recognized less t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">han $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of grant revenue, respectively, from awards by the NSF, NIH and FARA, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> grant revenue was recognized for the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three and nine months ended September 30, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 100000 200000 0 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Notes Payable-Related Party</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2019, the Company issued an unsecured promissory note to borrow up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to a co-founder (the “January Note”) for working capital. The January Note bore interest at prime plus </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, was scheduled to mature </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or before January 30, 2021</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and included a final payment of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the amounts advanced at maturity. In February and March 2019, the Company borrowed an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the January Note with interest payable at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum. The Company recorded an immaterial amount of debt issuance costs associated with the January Note. The debt issuance costs and final payment for the advances were amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the January Note were repaid in full in 2020.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2019, the Company issued an unsecured promissory note to borrow up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to a co-founder (the “November Note”) for working capital. The November Note bore interest at prime plus </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and matured </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or before January 1, 2022</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and included a final payment of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the amounts advanced at maturity. In December 2019 and January 2020, the Company borrowed a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the November Note with interest payable at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.25</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum. The final payment on the advances was amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the November Note were repaid in full in 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Convertible Notes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May and July 2018, the Company issued $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of convertible notes to a co-founder for cash with a maturity date </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or after February 5, 2021, if not converted earlier</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In February 2019, the Company issued an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of convertible notes to consultants for services rendered with a maturity date </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or after May 16, 2020, if not converted earlier</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The convertible notes bore interest of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum and were convertible into equity securities sold at the next financing at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the selling price per share of such equity financing. The conversion features of the convertible notes were recorded as a discount to the notes payable at issuance and amortized as interest expense over the loan term using the effective interest rate method.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, the outstanding principal and accrued interest of the convertible notes totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">301,685</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company’s Series A convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.65816</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. See Note 11 for further discussion.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingencies</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that the future expenditures will be made and such expenditures can be reasonably estimated. The Company had no such contingent liabilities as of September 30, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or December 31, 2020.</span></p> 500000 0.045 on or before January 30, 2021 0.03 200000 0.10 0.10 500000 0.045 on or before January 1, 2022 0.03 400000 0.0925 0.0925 300000 on or after February 5, 2021, if not converted earlier on or after February 5, 2021, if not converted earlier 200000 on or after May 16, 2020, if not converted earlier 0.08 0.80 500000 301685 1.65816 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2019, the Company entered into a Human Therapeutics Exclusive License Agreement (the “License Agreement”) with the Wisconsin Alumni Research Foundation (“WARF”). Under the License Agreement, the Company licensed the exclusive, worldwide, royalty-bearing, sublicensable rights to certain WARF patents and the nonexclusive worldwide rights to certain know-how to develop and commercialize products for the prevention, diagnosis and treatment of disease. As consideration for the license, the Company agreed to pay an upfront fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which the Company immediately expensed as research and development expense in its statements of operations as there was no alternative future use for the license. The Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the upfront fee upon execution of the agreement and the remaining $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">due upon the earlier of the first anniversary of the License Agreement or the Company receiving a certain level of gross proceeds from an equity financing. At December 31, 2019, the second</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">payment </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was recorded as an accrued liability on the Company’s balance sheet. In February 2020, the Company paid the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> balance upon the initial closing of its Series A preferred stock financing.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the License Agreement, the Company is required to pay $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> upon the acceptance of an investigation new drug (“IND”) application in the U.S. and will be required to make further aggregate milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon achievement of certain other regulatory and commercial milestones. The Company may also be required to pay royalties based on annual net product sales in the low single digits on its or its sublicensees’ net product sales on a country-by-country and product-by-product basis, and is subject to a minimum royalty of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per calendar year upon first commercial product sale. Further, the Company may be required to pay sublicense fees in the mid-single digits percentage for fees, royalties or other payments earned from the granting of sublicenses to the WARF patents and know-how. The Company has paid </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> milestone or royalty payments as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is responsible for reimbursing WARF for costs incurred in connection with prosecuting and maintaining patent rights that are specific to the License Agreement. Expenses recognized in connection with legal patent fees under this License Agreement were less th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the three and nine months ended September 30, 2021 and 2020, respectively, which were recorded as general and administrative expenses in the statements of operations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may terminate the License Agreement with </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days written notice or for certain breaches of the agreement. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/></span></p> 250000 25000 225000 225000 225000 125000 17500000 100000 0 0 100000 100000 100000 100000 P90D WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries. <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Convertible Preferred Stock and Stockholders’ Deficit</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Authorized Shares</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the completion of the Company’s initial public offering (“IPO”) in March 2021, the Company amended its Certificate of Incorporation to authorize </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200,000,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0001</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0001</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Public Offering and Related Transaction</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Company completed its IPO selling </span><span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,800,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares its common stock at </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.00</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. Proceeds from the Company’s IPO, net of underwriting discounts and commissions and other offering costs, were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">254.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In connection with the IPO, all </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,096,478</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of convertible preferred stock outstanding at the time of the IPO converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,212,548</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company’s common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February and March 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,710,814</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series A convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0727</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for net cash proceeds of $ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the “Series A Financing”). In connection with the Series A Financing, the Company issued an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">301,685</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its Series A convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.65816</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share in February 2020 upon the conversion and extinguishment of its convertible notes, as discussed further in Note 8.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,083,979</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B convertible preferred stock at </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.55</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for net cash proceeds of approximately </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All shares of convertible preferred stock outstanding at the Company’s IPO were converted into shares of the Company’s common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Incentive Award Plans</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Company’s board of directors and stockholders adopted the 2021 Plan, which became effective on March 25, 2021, the date of the underwriting agreement related to the Company’s IPO. Commencing with the effectiveness of the 2021 Plan, no further grants can be made under the 2018 Plan.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the 2021 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock awards, performance cash awards and other forms of stock awards to employees, directors and consultants, including employees and consultants of the Company’s affiliates. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,118,648</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> new shares of common stock were approved to be initially reserved for issuance under the 2021 Plan. The number of shares reserved under the 2021 Plan also include </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">881,352</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock that remained available for issuance under the 2018 Plan at the time the 2021 Plan became effective, and will be increased by the number of shares under the 2018 Plan that are repurchased, forfeited, expired or cancelled on or after the effective date of the 2021 Plan. In addition, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the total number of shares of the Company’s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company’s board of directors.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Shares subject to Repurchase</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the 2018 Plan, the Company has issued shares of restricted common stock to employees, consultants and members of its board of directors. Additionally, certain stock options granted pursuant to the 2018 Plan provide for the right to elect to exercise unvested options early in exchange for restricted shares of common stock. These restricted shares of common stock generally vest over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four-year</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period and are subject to repurchase by the Company at the original purchase price or, in certain instances the fair market value if such fair market value is lower than the purchase price, in the event the recipient’s service is terminated either voluntarily or involuntarily prior to vesting.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company’s restricted shares of common stock and unvested stock liability, which is included in accrued expenses and other current liabilities and other long-term liabilities on the Company’s balance sheets, is as follows (in thousands, except share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.675%;"/> <td style="width:1.71%;"/> <td style="width:1.034%;"/> <td style="width:17.82%;"/> <td style="width:1.512%;"/> <td style="width:1.71%;"/> <td style="width:2.413%;"/> <td style="width:16.614%;"/> <td style="width:1.512%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Liability</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">646,953</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">216,540</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at September 30, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">430,413</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Company’s board of directors and stockholders adopted the 2021 Employee Stock Purchase Plan (the “ESPP”), which became effective on March 25, 2021, the date of the underwriting agreement related to the Company’s IPO. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">600,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the total number of shares of the Company’s common stock on the last day of the calendar month before the date of each automatic increase and (ii) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,200,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares; provided that before the date of any such increase, the Company’s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii). As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 30, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company’s common stock have been purchased under the ESPP.</span></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 200000000 0.0001 10000000 0.0001 13800000 20.00 254300000 41096478 25212548 21710814 21710814 2.0727 2.0727 44700000 44700000 301685 1.65816 19083979 6.55 124700000 6118648 881352 the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares of the Company’s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company’s board of directors. 0.05 P4Y <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company’s restricted shares of common stock and unvested stock liability, which is included in accrued expenses and other current liabilities and other long-term liabilities on the Company’s balance sheets, is as follows (in thousands, except share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.675%;"/> <td style="width:1.71%;"/> <td style="width:1.034%;"/> <td style="width:17.82%;"/> <td style="width:1.512%;"/> <td style="width:1.71%;"/> <td style="width:2.413%;"/> <td style="width:16.614%;"/> <td style="width:1.512%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Liability</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">646,953</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">216,540</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at September 30, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">430,413</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 646953 145000 216540 8000 430413 137000 0.15 0.85 600000 the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 1% of the total number of shares of the Company’s common stock on the last day of the calendar month before the date of each automatic increase and (ii) 1,200,000 shares; provided that before the date of any such increase, the Company’s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii). As of September 30, 2021, no shares of the Company’s common stock have been purchased under the ESPP. 0.01 1200000 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Related Party Transactions</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lease Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company entered into the Lease with Crossing Holdings, LLC to rent laboratory and office space. The Company's Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the Lease during the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.688%;"/> <td style="width:1.401%;"/> <td style="width:1.531%;"/> <td style="width:10.9%;"/> <td style="width:0.751%;"/> <td style="width:1.401%;"/> <td style="width:1.531%;"/> <td style="width:10.891%;"/> <td style="width:0.751%;"/> <td style="width:1.401%;"/> <td style="width:1.531%;"/> <td style="width:10.9%;"/> <td style="width:0.751%;"/> <td style="width:1.401%;"/> <td style="width:1.531%;"/> <td style="width:10.891%;"/> <td style="width:0.751%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of September 30, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and December 31, 2020, the Company had prepaid expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, and accrued expenses and other current liabilities of less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, pursuant to its related party lease agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Consulting Agreements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2019, the Company entered into an agreement with the Marlinspike Group, LLC (“Marlinspike Group”) for research support, management, and business consulting services (the “2019 Consulting Agreement”). Further, Marlinspike Group provides the use of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,120</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of its office space in Carlsbad, California to the Company on an as-available basis from time to time pursuant to the agreement. The Company’s Executive Chairperson, co-founder and member of its board of directors is an executive officer of Marlinspike Group and, the Company’s Chief Operating Officer was an executive officer of Marlinspike Group until February 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of the 2019 Consulting Agreement was for a one-year period, subject to automatic one-month renewals unless terminated upon 14 days’ written notice. In March 2020, the Consulting Agreement was terminated and replaced with an amended consulting agreement (the “2020 Consulting Agreement”), which provides for the similar services and use of office space for a monthly fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Pursuant to the terms of the 2020 Consulting Agreement, it shall remain in effect until otherwise terminated. Termination may occur at any time upon mutual agreement or unilaterally upon 30 days’ written notice. If the Company unilaterally terminates the 2020 Consulting Agreement for any reason other than cause, it would be subject to a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">240,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> termination fee. The Company cannot determine when, or if, such a termination will occur and hence has not recorded a liability for the fee.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the 2020 Consulting Agreement during the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:36.568%;"/> <td style="width:2.709%;"/> <td style="width:2.931%;"/> <td style="width:10.158%;"/> <td style="width:1.058%;"/> <td style="width:1.15%;"/> <td style="width:2.143%;"/> <td style="width:11.364%;"/> <td style="width:1.03%;"/> <td style="width:1.113%;"/> <td style="width:2.115%;"/> <td style="width:11.132%;"/> <td style="width:1.039%;"/> <td style="width:1.132%;"/> <td style="width:2.115%;"/> <td style="width:11.215%;"/> <td style="width:1.03%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">232</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">240</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2017, the Company entered into a consulting agreement with Aseem Z. Ansari, Ph.D. Dr. Ansari, a co-founder, provides consulting services and advises on certain research and development activities (the “Research Consulting Agreement”). Pursuant to the Research Consulting Agreement, as amended, Dr. Ansari performs these services for a monthly fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the Research Consulting Agreement during the periods presented were as follows (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.56%;"/> <td style="width:1.308%;"/> <td style="width:1.53%;"/> <td style="width:10.842%;"/> <td style="width:0.909%;"/> <td style="width:1.326%;"/> <td style="width:1.53%;"/> <td style="width:10.851%;"/> <td style="width:0.909%;"/> <td style="width:1.326%;"/> <td style="width:1.53%;"/> <td style="width:10.851%;"/> <td style="width:0.909%;"/> <td style="width:1.326%;"/> <td style="width:1.53%;"/> <td style="width:10.851%;"/> <td style="width:0.909%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of September 30, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and December 31, 2020, the Company had accounts payable of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> pursuant to its related party consulting agreements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Convertible Notes and Notes Payable</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May and July 2018, the Company issued a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of convertible notes to a co-founder for cash with a maturity date </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or after February 5, 2021, if not converted earlier</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The notes bore interest of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum and were convertible into equity securities sold at the next financing at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the selling price per share of such equity financing. In February 2020, these notes converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">171,025</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company’s convertible preferred stock pursuant to the closing of the Series A preferred stock financing. Further, the Company has issued unsecured promissory notes to this co-founder for working capital. See Note 9 for further discussion.</span></p> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the Lease during the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.688%;"/> <td style="width:1.401%;"/> <td style="width:1.531%;"/> <td style="width:10.9%;"/> <td style="width:0.751%;"/> <td style="width:1.401%;"/> <td style="width:1.531%;"/> <td style="width:10.891%;"/> <td style="width:0.751%;"/> <td style="width:1.401%;"/> <td style="width:1.531%;"/> <td style="width:10.9%;"/> <td style="width:0.751%;"/> <td style="width:1.401%;"/> <td style="width:1.531%;"/> <td style="width:10.891%;"/> <td style="width:0.751%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 53000 53000 22000 22000 75000 75000 100000 0 100000 0 2120 20000 240000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the 2020 Consulting Agreement during the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:36.568%;"/> <td style="width:2.709%;"/> <td style="width:2.931%;"/> <td style="width:10.158%;"/> <td style="width:1.058%;"/> <td style="width:1.15%;"/> <td style="width:2.143%;"/> <td style="width:11.364%;"/> <td style="width:1.03%;"/> <td style="width:1.113%;"/> <td style="width:2.115%;"/> <td style="width:11.132%;"/> <td style="width:1.039%;"/> <td style="width:1.132%;"/> <td style="width:2.115%;"/> <td style="width:11.215%;"/> <td style="width:1.03%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">232</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">240</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 8000 60000 60000 180000 232000 60000 60000 180000 240000 15000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the Research Consulting Agreement during the periods presented were as follows (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.56%;"/> <td style="width:1.308%;"/> <td style="width:1.53%;"/> <td style="width:10.842%;"/> <td style="width:0.909%;"/> <td style="width:1.326%;"/> <td style="width:1.53%;"/> <td style="width:10.851%;"/> <td style="width:0.909%;"/> <td style="width:1.326%;"/> <td style="width:1.53%;"/> <td style="width:10.851%;"/> <td style="width:0.909%;"/> <td style="width:1.326%;"/> <td style="width:1.53%;"/> <td style="width:10.851%;"/> <td style="width:0.909%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Nine Months Ended September 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 45000 135000 45000 135000 20000 20000 300000 300000 on or after February 5, 2021, if not converted earlier on or after February 5, 2021, if not converted earlier 0.08 0.80 171025 XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2021
Nov. 05, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Trading Symbol DSGN  
Entity Registrant Name Design Therapeutics, Inc.  
Entity Central Index Key 0001807120  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Shell Company false  
Entity Small Business false  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Common Stock, Shares Outstanding   55,662,501
Title of 12(b) Security Common Stock, $0.0001 par value per share  
Entity File Number 001-40288  
Security Exchange Name NASDAQ  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 82-3929248  
Entity Address, Address Line One 6005 Hidden Valley Road  
Entity Address, Address Line Two Suite 110  
Entity Address, City or Town Carlsbad  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92011  
City Area Code 858  
Local Phone Number 293-4900  
Document Transition Report false  
Document Quarterly Report true  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 357,662 $ 2,379
Investment securities 36,056 33,712
Prepaid expense and other current assets (including related party amounts of $60 and $0, respectively) 1,572 142
Total current assets 395,290 36,233
Property and equipment, net 1,320 71
Right-of-use asset 3,743  
Deferred offering costs   212
Total assets 400,353 36,516
Current liabilities:    
Accounts payable (including related party amounts of $20 and $20, respectively) 2,216 1,399
Accrued expenses and other current liabilities (including related party amounts of $10 and $0, respectively) 3,289 931
Total current liabilities 5,505 2,330
Operating lease liability, net 3,273  
Other long-term liabilities 11 145
Total liabilities 8,789 2,475
Commitments and contingencies (See Note 9)
Convertible preferred stock, $0.0001 par value; no shares and 22,500,000 shares authorized, no shares and 22,012,499 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively; liquidation preference of zero and $45,625 as of September 30, 2021 and December 31, 2020, respectively   45,356
Stockholders’ equity (deficit):    
Common stock, $0.0001 par value; 200,000,000 and 60,000,000 shares authorized, 55,654,833 and 16,604,774 shares issued, 55,224,420 and 15,957,821 shares outstanding at September 30, 2021 and December 31, 2020, respectively 6 1
Additional paid-in capital 427,953 451
Accumulated deficit (36,391) (11,923)
Accumulated other comprehensive income (4) 156
Total stockholders’ equity (deficit) 391,564 (11,315)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit) $ 400,353 $ 36,516
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Statement Of Financial Position [Abstract]    
Prepaid expense and other current assets, related party amounts $ 60 $ 0
Accounts payable, related party amounts 20 20
Accrued expenses and other current liabilities, related party amounts $ 10 $ 0
Convertible preferred stock, par value $ 0.0001 $ 0.0001
Convertible preferred stock, authorized 0 22,500,000
Convertible preferred stock, issued 0 22,012,499
Convertible preferred stock, outstanding 0 22,012,499
Convertible preferred stock, liquidation preference $ 0 $ 45,625
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 200,000,000 60,000,000
Common stock, shares issued 55,654,833 16,604,774
Common stock, shares outstanding 55,224,420 15,957,821
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue:        
Grant revenue   $ 20   $ 193
Revenue, Product and Service [Extensible List] us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Operating expenses:        
Research and development (including related party amounts of $98, $0, $188 and $8, respectively) $ 8,539 $ 1,914 $ 17,441 $ 3,352
General and administrative (including related party amounts of $82, $60, $202 and $232, respectively) 2,798 489 7,263 1,310
Total operating expenses 11,337 2,403 24,704 4,662
Loss from operations (11,337) (2,383) (24,704) (4,469)
Other income, net (including related party expense amounts of $0, $0, $0, and $30, respectively) 19 63 236 44
Net loss $ (11,318) $ (2,320) $ (24,468) $ (4,425)
Net loss per share, basic and diluted $ (0.21) $ (0.09) $ (0.57) $ (0.17)
Weighted-average shares of common stock outstanding, basic and diluted 55,155,030 25,701,737 42,759,656 25,606,779
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statements of Operations (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Research and development expenses related party amount $ 98 $ 0 $ 188 $ 8
General and administrative expenses related party amount 82 60 202 232
Other income, net related party expense amount $ 0 $ 0 $ 0 $ 30
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement Of Income And Comprehensive Income [Abstract]        
Net loss $ (11,318) $ (2,320) $ (24,468) $ (4,425)
Other comprehensive gain (loss):        
Unrealized gain (loss) on available-for-sale securities 8 (42) (160) 152
Comprehensive loss $ (11,310) $ (2,362) $ (24,628) $ (4,273)
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Beginning Balance at Dec. 31, 2019 $ (3,642)   $ 1 $ (3,643)
Beginning Balance, Shares at Dec. 31, 2019     15,640,133      
Issuance of Series A and Series B convertible preferred stock, net of issuance costs   $ 44,731        
Issuance of Series A and Series B convertible preferred stock, net of issuance costs, Shares   21,710,814        
Conversion of convertible debt and interest to Series A convertible preferred stock   $ 500        
Conversion of convertible debt and interest to Series A convertible preferred stock, Shares   301,685        
Settlement of bifurcated conversion liability   $ 125        
Exercises of stock options and vesting of restricted stock, Shares     247,213      
Stock-based compensation 29     29    
Unrealized gain (loss) on investments 152       152  
Net loss (4,425)         (4,425)
Ending Balance at Sep. 30, 2020 (7,886)   $ 1 29 152 (8,068)
Ending Balance, Shares at Sep. 30, 2020   22,012,499        
Ending Balance at Sep. 30, 2020   $ 45,356        
Ending Balance, Shares at Sep. 30, 2020     15,887,346      
Beginning Balance at Jun. 30, 2020 (5,539)   $ 1 14 194 (5,748)
Beginning Balance, Shares at Jun. 30, 2020   22,012,499        
Beginning Balance at Jun. 30, 2020   $ 45,356        
Beginning Balance, Shares at Jun. 30, 2020     15,782,575      
Exercises of stock options and vesting of restricted stock, Shares     104,771      
Stock-based compensation 15     15    
Unrealized gain (loss) on investments (42)       (42)  
Net loss (2,320)         (2,320)
Ending Balance at Sep. 30, 2020 (7,886)   $ 1 29 152 (8,068)
Ending Balance, Shares at Sep. 30, 2020   22,012,499        
Ending Balance at Sep. 30, 2020   $ 45,356        
Ending Balance, Shares at Sep. 30, 2020     15,887,346      
Beginning Balance at Dec. 31, 2020 $ (11,315)   $ 1 451 156 (11,923)
Beginning Balance, Shares at Dec. 31, 2020 22,012,499 22,012,499        
Beginning Balance at Dec. 31, 2020 $ 45,356 $ 45,356        
Beginning Balance, Shares at Dec. 31, 2020     15,957,821      
Issuance of Series A and Series B convertible preferred stock, net of issuance costs   $ 124,712        
Issuance of Series A and Series B convertible preferred stock, net of issuance costs, Shares   19,083,979        
Preferred stock converted into shares of common stock 170,068   $ 4 170,064    
Preferred stock converted into shares of common stock, Shares   (41,096,478)        
Preferred stock converted into shares of common stock   $ (170,068)        
Preferred stock converted into shares of common stock, Shares     25,212,548      
Initial public offering of common shares, net of $21,728 of issuance costs 254,271   $ 1 254,270    
Initial public offering of common shares, net of $21,728 of issuance costs, Shares     13,800,000      
Exercises of stock options and vesting of restricted stock 35     35    
Exercises of stock options and vesting of restricted stock, Shares     254,051      
Stock-based compensation 3,133     3,133    
Unrealized gain (loss) on investments (160)       (160)  
Net loss (24,468)         (24,468)
Ending Balance at Sep. 30, 2021 $ 391,564   $ 6 427,953 (4) (36,391)
Ending Balance, Shares at Sep. 30, 2021 0          
Ending Balance, Shares at Sep. 30, 2021     55,224,420      
Beginning Balance at Jun. 30, 2021 $ 401,601   $ 6 426,680 (12) (25,073)
Beginning Balance, Shares at Jun. 30, 2021     55,114,729      
Exercises of stock options and vesting of restricted stock 30     30    
Exercises of stock options and vesting of restricted stock, Shares     109,691      
Stock-based compensation 1,243     1,243    
Unrealized gain (loss) on investments 8       8  
Net loss (11,318)         (11,318)
Ending Balance at Sep. 30, 2021 $ 391,564   $ 6 $ 427,953 $ (4) $ (36,391)
Ending Balance, Shares at Sep. 30, 2021 0          
Ending Balance, Shares at Sep. 30, 2021     55,224,420      
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statements of Convertible Preferred stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Series B Convertible Preferred Stock    
Preferred stock issuance costs $ 288  
Series A Convertible Preferred Stock    
Preferred stock issuance costs   $ 270
Initial Public Offering    
Stock issuance costs $ 21,728  
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities    
Net loss $ (24,468) $ (4,425)
Reconciliation of net loss to net cash used in operating activities:    
Depreciation 47 1
Stock-based compensation 3,133 29
Amortization of premiums on investment securities, net (103) (69)
Non-cash interest expense   12
Non-cash interest expense—related party   26
Non-cash lease expense 5  
Change in operating assets and liabilities:    
Prepaid expense and other assets (1,158) (71)
Prepaid expense and other assets—related party (60)  
Deferred revenue   (193)
Accounts payable and other liabilities 2,444 708
Accounts payable and other liabilities related-party 10 (1,843)
Net cash used in operating activities (20,150) (5,825)
Cash flows from investing activities    
Purchases of investment securities (36,356) (55,589)
Proceeds from maturities of investment securities 33,955 20,092
Purchases of property and equipment (1,184) (62)
Net cash used in investing activities (3,585) (35,559)
Cash flows from financing activities    
Proceeds from initial public offering, net of issuance costs 254,271
Proceeds from issuance of convertible preferred stock, net of issuance costs 124,712 44,731
Proceeds from the exercise of stock options and vesting of restricted stock 35
Proceeds from the issuance of notes payable, net of issuance costs—related party 200
Repayment of notes payable—related party (400)
Net cash provided by financing activities 379,018 44,531
Net increase in cash and cash equivalents 355,283 3,147
Cash and cash equivalents at beginning of period 2,379 77
Cash and cash equivalents at end of period 357,662 3,224
Supplemental disclosures    
Initial recognition of operating lease right-of-use asset and operating lease liability 3,786  
Purchases of property and equipment included in accounts payable and accrued expenses $ 112  
Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability   271
Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability - related party   354
Interest paid   $ 18
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Organization
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Organization

1. Organization

Design Therapeutics, Inc. (the “Company”) was incorporated in Delaware in December 2017 and is based in Carlsbad, California. The Company is a biopharmaceutical company pioneering GeneTACTM molecules, a novel class of disease-modifying small-molecule gene targeted chimera therapeutics that are designed to target the underlying cause of inherited nucleotide repeat expansion diseases. The Company’s lead product candidate is in Friedreich ataxia (“FA”), its second GeneTAC™ program is in myotonic dystrophy type-1 (“DM1”), and it is also advancing its GeneTACTM portfolio to address other serious nucleotide repeat-driven monogenic diseases.

The Company has experienced net losses and negative cash flows from operating activities since inception and expects to incur net losses for the foreseeable future as it advances its research and development programs, conducts clinical trials for any future product candidates and commercializes any such product candidates for which it receives regulatory approval. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of its future product candidates, and on the achievement of sufficient revenue to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital to fund its operations.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

The accompanying interim condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and following the requirements of the United States Securities and Exchange Commission ("SEC") for interim reporting. The Company's financial statements include all adjustments, consisting of only normal recurring adjustments, which in the opinion of management are necessary to present fairly the Company’s financial position as of the reporting date and results of operations for the periods presented. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the recognition of grant revenue, accruals for research and development expenses and the valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.

The full extent to which the novel coronavirus-2019 (“COVID-19”) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.

Stock Splits

In February 2020, the Company effected a 5-for-1 forward stock split of its issued and outstanding common stock. Further, in March 2021, the Company effected a 1-for-1.63 reverse stock split of its issued and outstanding common stock. The par value and the authorized shares of the common stock were not adjusted as a result of these stock splits. The reverse stock split in March 2021 resulted in an adjustment to the convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying financial statements and notes to the financial statements give retroactive effect to the stock splits for all periods presented.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities at the date of acquisition of three months or less to be cash equivalents. These investments may include money market accounts, money market funds, U.S. Government agency securities, corporate debt securities and commercial paper. The Company’s cash reserves are in a readily available checking account.

Investment Securities

Investments in securities with maturities at the date of acquisition of more than three months are considered marketable securities. The Company determines the appropriate classification of its investments at the time of acquisition and reevaluates such determination at each balance sheet date. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management strategies. Further, the Company classifies its available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations. The Company’s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for safety of principle, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of other comprehensive income (loss) until realized. Allowances for credit losses are reported on the balance sheet, if any.

The cost of available-for-sale investment securities is adjusted for amortization of premiums and accretion of discounts until the securities mature. Such amortization and accretion is included in other income (expense) on the statements of operations. Realized gains and losses, if any, are also included in other income (expense) on the statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the periods presented, no realized gains or losses were recorded on the sale of investment securities and no impairments to reduce the value of any security was taken. See Note 5 for further discussion.

Leases

At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise the option. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company's leases do not provide an implicit interest rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less ("Short-Term Leases"). For any Short-Term leases, the Company records the rent expense on a straight-line basis and does not record the leases on the condensed balance sheet. The Company had no Short-Term Leases as of September 30, 2021 or December 31, 2020.

After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.

Revenue Recognition

The Company has generated revenue from grants awarded to it by the National Science Foundation (“NSF”), the National Institutes of Health (“NIH”) and the Friedreich’s Ataxia Research Alliance (“FARA”). These grants provide the Company with funding for certain research and development activities on a best-efforts basis and do not require scientific achievement as a performance obligation. The Company has determined that the entities funding these grant awards do not meet the definition of a “customer”, as defined by Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606), and does not consider there to be a transfer of control of goods or services to the entities funding the grant. As such, the Company recognizes revenue from these awards in the period during which the related qualifying services are rendered and costs are incurred in accordance with ASC 730, Research and Development. ASC 730 requires an assessment, at the inception of the grant, to determine whether the agreement is a liability or a contract to perform research and development services for others. Further, these grants are subject to the contribution’s guidance under ASC 958, Not-for-Profit Entities-Revenue Recognition, and as such, the Company determines whether it is obligated to repay the funds received to the grantor regardless of the outcome of the related research and development activities. If it determines there is such a liability, it estimates the obligation and recognize that liability. Alternatively, if the Company is not required to repay the funds, the grant agreement is accounted for as a contract to perform research and

development services for others, in which case, the grant revenue is recorded as income in the statements of operations as the expenses are incurred.

The Company’s current grant revenue is not deemed refundable, and therefore, no liability is recognized when income is recorded. Grant funding received prior to expenses being incurred are recorded as deferred revenue on the Company’s balance sheets. See Note 8 for further discussion.

Research and Development Expenses

Research and development expenses consist primarily of direct and indirect costs incurred in connection with its discovery efforts, and the preclinical and formulation development of its product candidates. In the future, the Company expects a substantial portion of its research and development expenses will relate to the clinical development of its product candidates. Direct costs include contracted research development and manufacturing, consulting fees, license fees, laboratory supplies and other expenses incurred to sustain research and development programs. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, facilities related expenses, and other indirect expenses. A significant portion of the Company’s research and development expenses have been direct costs, which the Company tracks by stage of development, preclinical or clinical. However, the Company does not track its internal research and development expenses on a program specific basis, unless specific to research grants, because these costs are deployed across multiple projects and, as such, are not separately classified. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company’s research and development efforts and have no alternative future uses.

The Company has entered into various contracts with research and development organizations, vendors and consultants. Payments for these activities are based on the terms of the individual agreements, which may differ from the periods over which materials or services are provided. Payments made in advance of performance are reflected in the accompanying balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. The Company determines accrual estimates through review of the underlying contracts along with discussions with research and other key personnel as to the progress of the research and development activities, invoices received and contracted costs. During the course of a study or trial, the Company adjusts its rate of expense recognition if actual results differ from its estimates. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.

Stock-Based Compensation

Stock options issued pursuant to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) and 2018 Equity Incentive Plan (the “2018 Plan”) and option features associated with the rights to purchase shares pursuant to the Company’s 2021 Employee Stock Purchase Plan (the “ESPP”) are valued using the Black-Scholes option pricing model on the date of grant or subscription period. This option pricing model involves a number of estimates, including the expected lives of the stock options or subscription period, the Company’s anticipated stock volatility and interest rates. The Company recognizes the expense for equity awards on a straight-line basis over the requisite service periods of the awards or the number of shares estimated to be issued pursuant to the ESPP. Forfeitures are recognized as they occur.

Stock-based compensation expense recognized in the Company’s statements of operations during the three and nine months ended September 30, 2021 and 2020, were as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

521

 

 

$

12

 

 

$

1,181

 

 

$

22

 

General and administrative

 

 

722

 

 

 

3

 

 

 

1,952

 

 

 

7

 

Total

 

$

1,243

 

 

$

15

 

 

$

3,133

 

 

$

29

 

 

Recent Accounting Pronouncements

In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting

for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The ASU provides guidance to clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. ASU 2021-04 is effective for annual periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact that this new guidance will have on its condensed consolidated financial statements and does not currently expect the adoption will have a material impact on its financial statements and related disclosures.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity. The guidance, among other items, clarifies that certain transactions between collaborative participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. The ASU’s amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted for periods beginning after December 15, 2020. The Company has not yet adopted this guidance and does not currently expect the adoption will have a material impact on its financial statements and related disclosures.

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss Per Share
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Net Loss Per Share

3. Net Loss Per Share

Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, restricted common stock subject to repurchase, stock options outstanding under the Company’s equity incentive plans, employee stock purchase rights under the Company’s ESPP, and shares of common stock that are issuable under convertible debt, as applicable. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company's net loss position.

The following table sets forth the outstanding, potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:

 

 

 

September 30,
2021

 

 

September 30,
2020

 

Convertible preferred stock

 

$

 

 

$

13,504,598

 

Stock options

 

 

2,124,238

 

 

 

389,565

 

Shares subject to repurchase

 

 

430,413

 

 

 

564,055

 

Employee stock purchase plan

 

 

15,335

 

 

 

 

Total

 

$

2,569,986

 

 

$

14,458,218

 

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

4. Fair Value Measurements

Accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices in active markets.

Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The carrying value of the Company’s cash, accounts payable and accrued liabilities are considered to be representative of their respective fair values due to the short-term nature of those instruments. The Company’s investment securities, which may include

money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises, are measured at fair value in accordance with the fair value hierarchy. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis and no transfers between levels have occurred during the periods presented.

The following table summarize the Company’s financial instruments measured at fair value on a recurring basis at September 30, 2021 and December 31, 2020 (in thousands):

 

 

 

Fair Value Measurement at End of Period Using:

 

 

 

 

 

 

Quoted Prices

 

 

 

 

 

 

 

 

 

 

 

 

In Active

 

 

 

 

 

 

 

 

 

 

 

 

Markets

 

 

Significant

 

 

 

 

 

 

 

 

 

For

 

 

Other

 

 

Significant

 

 

 

 

 

 

Identical

 

 

Observable

 

 

Unobservable

 

 

 

 

 

 

Assets

 

 

Inputs

 

 

Inputs

 

 

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

As of September 30, 2021:

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

356,793

 

 

$

356,793

 

 

$

 

 

$

 

Certificates of deposit

 

 

5,987

 

 

 

5,987

 

 

 

 

 

 

 

U.S. Treasury securities

 

 

30,068

 

 

 

30,068

 

 

 

 

 

 

 

Total

 

$

392,848

 

 

$

392,848

 

 

$

 

 

$

 

As of December 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

2,100

 

 

$

2,100

 

 

$

 

 

$

 

Certificates of deposit

 

 

1,754

 

 

 

1,754

 

 

 

 

 

 

 

U.S. Treasury securities

 

 

31,958

 

 

 

31,958

 

 

 

 

 

 

 

Total

 

$

35,812

 

 

$

35,812

 

 

$

 

 

$

 

 

(1)
Included in cash and cash equivalents on the accompanying balance sheets.

 

Interest bearing money market accounts and certificates of deposit are valued at amortized cost, which approximates fair value.

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Investment Securities
9 Months Ended
Sep. 30, 2021
Investments Debt And Equity Securities [Abstract]  
Investment Securities

5. Investment Securities

The Company’s investment policy defines allowable investment securities and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. In accordance with the Company’s investment policy, it has invested funds in marketable securities. The cost, gross unrealized holding gains, gross unrealized holding

losses, allowances for credit losses and fair value of available-for-sale investments by types, maturities and classes of securities at September 30, 2021 and December 31, 2020 consisted of the following (in thousands):

 

 

 

 

 

As of September 30, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Estimated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Allowance

 

 

Fair

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

for Credit

 

 

Market

 

 

 

Maturity

 

Cost

 

 

Gains

 

 

Losses

 

 

Losses

 

 

Value

 

Certificates of deposits

 

Within 1 year

 

$

2,853

 

 

$

 

 

$

(1

)

 

$

 

 

$

2,852

 

U.S. Treasury securities

 

Within 1 year

 

 

10,066

 

 

 

1

 

 

 

 

 

 

 

 

$

10,067

 

Certificates of deposits

 

1 year to 2 years

 

 

3,137

 

 

 

 

 

 

(2

)

 

 

 

 

 

3,135

 

U.S. Treasury securities

 

1 year to 2 years

 

 

20,004

 

 

 

 

 

 

(2

)

 

 

 

 

 

20,002

 

Total

 

 

 

$

36,060

 

 

$

1

 

 

$

(5

)

 

$

 

 

$

36,056

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Estimated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Allowance

 

 

Fair

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

for Credit

 

 

Market

 

 

 

Maturity

 

Cost

 

 

Gains

 

 

Losses

 

 

Losses

 

 

Value

 

Certificates of deposits

 

Within 1 year

 

$

1,750

 

 

$

4

 

 

$

 

 

$

 

 

$

1,754

 

U.S. Treasury securities

 

Within 1 year

 

 

31,806

 

 

 

152

 

 

 

 

 

 

 

 

 

31,958

 

Total

 

 

 

$

33,556

 

 

$

156

 

 

$

 

 

$

 

 

$

33,712

 

 

The Company reviews its investments at each reporting date to identify and evaluate whether a decline in fair value below the amortized cost basis of available-for-sale securities is due to credit-related factors and determines if such unrealized losses are the result of credit losses that require impairment. Factors considered in determining whether an unrealized loss is the result of a credit loss or other factors include the extent to which the fair value is less than the cost basis, any changes to the rating of the security by a rating agency, the financial condition and near-term prospects of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any adverse legal or regulatory events affecting the issuer or issuer’s industry, any significant deterioration in economic condition and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.

At September 30, 2021 there were 19 securities in an unrealized loss position. The Company evaluated the securities individually for other-than-temporary impairment and considered the decline in market value to be primarily attributable to changes in interest rates. Each security remained at a high credit quality rating and the unrealized losses of each security was immaterial. Further, there had been no adverse conditions noted for any of the issuers and Company does not intend to sell any of the securities prior to maturity. As such, the Company has classified the losses as temporary in nature and the Company did not record a reserve for credit losses. At December 31, 2020, there were no securities in an unrealized loss position.

As of September 30, 2021, the Company held 25 domestic certificates of deposit with amortized costs below the Federal Deposit Insurance Corporation (“FDIC”) insured limit. Accrued interest receivable on available-for-sale investment securities, included in prepaids and other current assets on the Company’s balance sheets, was less than $0.1 million at September 30, 2021 and December 31, 2020.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Details
9 Months Ended
Sep. 30, 2021
Balance Sheet Component [Abstract]  
Balance Sheet Details

6. Balance Sheet Details

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

 

September 30,
2021

 

 

December 31,
2020

 

Prepaid expenses

 

$

1,421

 

 

$

60

 

Security deposits

 

 

104

 

 

 

47

 

Interest receivable

 

 

47

 

 

 

10

 

Other

 

 

 

 

 

25

 

Total

 

$

1,572

 

 

$

142

 

 

Property and equipment consisted of the following (in thousands):

 

 

 

September 30,
2021

 

 

December 31,
2020

 

Laboratory equipment

 

$

1,058

 

 

$

76

 

Computer equipment and software

 

 

77

 

 

 

 

Leasehold improvements

 

 

91

 

 

 

 

Construction in progress

 

 

146

 

 

 

 

 

 

 

1,372

 

 

 

76

 

Less accumulated depreciation

 

 

(52

)

 

 

(5

)

Total

 

$

1,320

 

 

$

71

 

 

Accrued liabilities consisted of the following (in thousands):

 

 

 

September 30,
2021

 

 

December 31,
2020

 

Accrued personnel costs

 

$

1,411

 

 

$

565

 

Accrued research and development costs

 

 

652

 

 

 

266

 

Current portion of operating lease liability

 

 

475

 

 

 

 

Accrued other

 

 

751

 

 

 

100

 

Total

 

$

3,289

 

 

$

931

 

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Lease
9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Lease

7. Lease

In May 2019 the Company entered into an agreement, as subsequently amended, to lease laboratory space pursuant to a three-month, automatically renewing lease. Due to the short-term nature of the lease, it was not included as an operating lease right of use asset nor as an operating lease liability on the Company’s balance sheets. The Company terminated the agreement in September 2021.

In February 2021, the Company entered into a lease agreement with Crossing Holdings, LLC to rent approximately 12,370 square feet of laboratory and office space (the “Lease”). The Company’s Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC. The lease commenced in September 2021 with a term of 72 months and an option to extend the lease term for a period of three years; however, it is not reasonably certain the Company will exercise the option to renew when the lease term ends in 2027, and thus, the incremental term was excluded from the calculation of the right-of-use asset or lease liability. Lease payments are subject to annual increases of 3% and the Company is responsible for its share of operating expenses and taxes, which are expensed as incurred. As of September 30, 2021, the remaining lease term for the lease was 5.9 years and the discount rate used to determine the right-of-use asset and corresponding operating lease liability was 7.15%.

Maturities of operating lease liabilities as of September 30, 2021 are as follows (in thousands):

 

 2021 (remaining three months)

 

$

181

 

 2022

 

 

733

 

 2023

 

 

755

 

 2024

 

 

778

 

 2025

 

 

801

 

Thereafter

 

 

1,386

 

Total future minimum lease payments

 

 

4,634

 

Less: Present value adjustment

 

 

(886

)

Operating lease liabilities

 

$

3,748

 

 

Rent expense for the three months ended September 30, 2021 and 2020 was $0.2 million and less than $0.1 million, respectively. Rent expense for the nine months ended September 30, 2021 and 2020 was $0.4 million and $0.1 million, respectively.

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Grant Revenue
9 Months Ended
Sep. 30, 2021
Disaggregation Of Revenue [Abstract]  
Grant Revenue

8. Grant Revenue

The Company recognizes revenue pursuant to grants, as described further in Note 2, by measuring the progress of the applicable research and development services provided over time, based on the effort the Company expends and costs incurred, relative to the

estimated total effort and costs to be incurred under the grant. This results in a percentage that the Company multiplies by the grant award amount to determine the amount of grant revenue to be recognized each period. This approach requires the Company to use judgement and make estimates of future expenditures. If the Company’s estimates or judgements change over the course of the term of the grant, it may affect the timing and amount of revenue that it recognizes in the current and future periods.

During the three and nine months ended September 30, 2020, the Company recognized less than $0.1 million and $0.2 million of grant revenue, respectively, from awards by the NSF, NIH and FARA, respectively. No grant revenue was recognized for the three and nine months ended September 30, 2021.

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

9. Commitments and Contingencies

Notes Payable-Related Party

In January 2019, the Company issued an unsecured promissory note to borrow up to $0.5 million to a co-founder (the “January Note”) for working capital. The January Note bore interest at prime plus 4.5%, was scheduled to mature on or before January 30, 2021 and included a final payment of 3% on the amounts advanced at maturity. In February and March 2019, the Company borrowed an aggregate of $0.2 million under the January Note with interest payable at 10% per annum. The Company recorded an immaterial amount of debt issuance costs associated with the January Note. The debt issuance costs and final payment for the advances were amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the January Note were repaid in full in 2020.

In November 2019, the Company issued an unsecured promissory note to borrow up to $0.5 million to a co-founder (the “November Note”) for working capital. The November Note bore interest at prime plus 4.5% and matured on or before January 1, 2022 and included a final payment of 3% on the amounts advanced at maturity. In December 2019 and January 2020, the Company borrowed a total of $0.4 million under the November Note with interest payable at 9.25% per annum. The final payment on the advances was amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the November Note were repaid in full in 2020.

Convertible Notes

In May and July 2018, the Company issued $0.3 million of convertible notes to a co-founder for cash with a maturity date on or after February 5, 2021, if not converted earlier. In February 2019, the Company issued an additional $0.2 million of convertible notes to consultants for services rendered with a maturity date on or after May 16, 2020, if not converted earlier. The convertible notes bore interest of 8% per annum and were convertible into equity securities sold at the next financing at 80% of the selling price per share of such equity financing. The conversion features of the convertible notes were recorded as a discount to the notes payable at issuance and amortized as interest expense over the loan term using the effective interest rate method.

In February 2020, the outstanding principal and accrued interest of the convertible notes totaling $0.5 million were converted into 301,685 shares of the Company’s Series A convertible preferred stock at $1.65816 per share. See Note 11 for further discussion.

Contingencies

From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that the future expenditures will be made and such expenditures can be reasonably estimated. The Company had no such contingent liabilities as of September 30, 2021 or December 31, 2020.

XML 28 R19.htm IDEA: XBRL DOCUMENT v3.21.2
License Agreement
9 Months Ended
Sep. 30, 2021
License Agreement [Abstract]  
License Agreement

10. License Agreement

In February 2019, the Company entered into a Human Therapeutics Exclusive License Agreement (the “License Agreement”) with the Wisconsin Alumni Research Foundation (“WARF”). Under the License Agreement, the Company licensed the exclusive, worldwide, royalty-bearing, sublicensable rights to certain WARF patents and the nonexclusive worldwide rights to certain know-how to develop and commercialize products for the prevention, diagnosis and treatment of disease. As consideration for the license, the Company agreed to pay an upfront fee of $250,000, which the Company immediately expensed as research and development expense in its statements of operations as there was no alternative future use for the license. The Company paid $25,000 of the upfront fee upon execution of the agreement and the remaining $225,000 was due upon the earlier of the first anniversary of the License Agreement or the Company receiving a certain level of gross proceeds from an equity financing. At December 31, 2019, the second

payment of $225,000 was recorded as an accrued liability on the Company’s balance sheet. In February 2020, the Company paid the $225,000 balance upon the initial closing of its Series A preferred stock financing.

Pursuant to the License Agreement, the Company is required to pay $125,000 upon the acceptance of an investigation new drug (“IND”) application in the U.S. and will be required to make further aggregate milestone payments of up to $17.5 million upon achievement of certain other regulatory and commercial milestones. The Company may also be required to pay royalties based on annual net product sales in the low single digits on its or its sublicensees’ net product sales on a country-by-country and product-by-product basis, and is subject to a minimum royalty of $0.1 million per calendar year upon first commercial product sale. Further, the Company may be required to pay sublicense fees in the mid-single digits percentage for fees, royalties or other payments earned from the granting of sublicenses to the WARF patents and know-how. The Company has paid no milestone or royalty payments as of September 30, 2021.

The Company is responsible for reimbursing WARF for costs incurred in connection with prosecuting and maintaining patent rights that are specific to the License Agreement. Expenses recognized in connection with legal patent fees under this License Agreement were less than $0.1 million for the three and nine months ended September 30, 2021 and 2020, respectively, which were recorded as general and administrative expenses in the statements of operations.

The Company may terminate the License Agreement with 90 days written notice or for certain breaches of the agreement. WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.

XML 29 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Convertible Preferred Stock and Stockholders' Deficit
9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Convertible Preferred Stock and Stockholders' Deficit

11. Convertible Preferred Stock and Stockholders’ Deficit

Authorized Shares

In connection with the completion of the Company’s initial public offering (“IPO”) in March 2021, the Company amended its Certificate of Incorporation to authorize 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, respectively.

Public Offering and Related Transaction

In March 2021, the Company completed its IPO selling 13,800,000 shares its common stock at $20.00 per share. Proceeds from the Company’s IPO, net of underwriting discounts and commissions and other offering costs, were $254.3 million. In connection with the IPO, all 41,096,478 shares of convertible preferred stock outstanding at the time of the IPO converted into 25,212,548 shares of the Company’s common stock.

Convertible Preferred Stock

In February and March 2020, the Company issued 21,710,814 shares of Series A convertible preferred stock at $2.0727 per share for net cash proceeds of $ 44.7 million (the “Series A Financing”). In connection with the Series A Financing, the Company issued an additional 301,685 shares of its Series A convertible preferred stock at $1.65816 per share in February 2020 upon the conversion and extinguishment of its convertible notes, as discussed further in Note 8.

In January 2021, the Company issued 19,083,979 shares of Series B convertible preferred stock at $6.55 per share for net cash proceeds of approximately $124.7 million.

All shares of convertible preferred stock outstanding at the Company’s IPO were converted into shares of the Company’s common stock.

Equity Incentive Award Plans

In March 2021, the Company’s board of directors and stockholders adopted the 2021 Plan, which became effective on March 25, 2021, the date of the underwriting agreement related to the Company’s IPO. Commencing with the effectiveness of the 2021 Plan, no further grants can be made under the 2018 Plan.

Under the 2021 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock awards, performance cash awards and other forms of stock awards to employees, directors and consultants, including employees and consultants of the Company’s affiliates. A total of 6,118,648 new shares of common stock were approved to be initially reserved for issuance under the 2021 Plan. The number of shares reserved under the 2021 Plan also include 881,352 shares of common stock that remained available for issuance under the 2018 Plan at the time the 2021 Plan became effective, and will be increased by the number of shares under the 2018 Plan that are repurchased, forfeited, expired or cancelled on or after the effective date of the 2021 Plan. In addition, the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares of the Company’s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company’s board of directors.

Shares subject to Repurchase

Pursuant to the 2018 Plan, the Company has issued shares of restricted common stock to employees, consultants and members of its board of directors. Additionally, certain stock options granted pursuant to the 2018 Plan provide for the right to elect to exercise unvested options early in exchange for restricted shares of common stock. These restricted shares of common stock generally vest over a four-year period and are subject to repurchase by the Company at the original purchase price or, in certain instances the fair market value if such fair market value is lower than the purchase price, in the event the recipient’s service is terminated either voluntarily or involuntarily prior to vesting.

A summary of the Company’s restricted shares of common stock and unvested stock liability, which is included in accrued expenses and other current liabilities and other long-term liabilities on the Company’s balance sheets, is as follows (in thousands, except share data):

 

 

 

Shares

 

 

Liability

 

Balance at December 31, 2020

 

 

646,953

 

 

$

145

 

Vested shares

 

 

(216,540

)

 

 

(8

)

Balance at September 30, 2021

 

 

430,413

 

 

$

137

 

 

2021 Employee Stock Purchase Plan

In March 2021, the Company’s board of directors and stockholders adopted the 2021 Employee Stock Purchase Plan (the “ESPP”), which became effective on March 25, 2021, the date of the underwriting agreement related to the Company’s IPO. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to 15% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to 85% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase. A total of 600,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 1% of the total number of shares of the Company’s common stock on the last day of the calendar month before the date of each automatic increase and (ii) 1,200,000 shares; provided that before the date of any such increase, the Company’s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii). As of September 30, 2021, no shares of the Company’s common stock have been purchased under the ESPP. 

XML 30 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions
9 Months Ended
Sep. 30, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

12. Related Party Transactions

Lease Agreement

In February 2021, the Company entered into the Lease with Crossing Holdings, LLC to rent laboratory and office space. The Company's Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC.

Expenses recognized by the Company under the Lease during the periods presented were as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

53

 

 

$

 

 

$

53

 

 

$

 

General and administrative

 

 

22

 

 

 

 

 

 

22

 

 

 

 

Total expenses

 

$

75

 

 

$

 

 

$

75

 

 

$

 

As of September 30, 2021, and December 31, 2020, the Company had prepaid expenses of $0.1 million and zero, respectively, and accrued expenses and other current liabilities of less than $0.1 million and zero, respectively, pursuant to its related party lease agreement.

Consulting Agreements

In January 2019, the Company entered into an agreement with the Marlinspike Group, LLC (“Marlinspike Group”) for research support, management, and business consulting services (the “2019 Consulting Agreement”). Further, Marlinspike Group provides the use of approximately 2,120 square feet of its office space in Carlsbad, California to the Company on an as-available basis from time to time pursuant to the agreement. The Company’s Executive Chairperson, co-founder and member of its board of directors is an executive officer of Marlinspike Group and, the Company’s Chief Operating Officer was an executive officer of Marlinspike Group until February 2020.

The term of the 2019 Consulting Agreement was for a one-year period, subject to automatic one-month renewals unless terminated upon 14 days’ written notice. In March 2020, the Consulting Agreement was terminated and replaced with an amended consulting agreement (the “2020 Consulting Agreement”), which provides for the similar services and use of office space for a monthly fee of $20,000. Pursuant to the terms of the 2020 Consulting Agreement, it shall remain in effect until otherwise terminated. Termination may occur at any time upon mutual agreement or unilaterally upon 30 days’ written notice. If the Company unilaterally terminates the 2020 Consulting Agreement for any reason other than cause, it would be subject to a $240,000 termination fee. The Company cannot determine when, or if, such a termination will occur and hence has not recorded a liability for the fee.

Expenses recognized by the Company under the 2020 Consulting Agreement during the periods presented were as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

 

 

$

 

 

$

 

 

$

8

 

General and administrative

 

 

60

 

 

 

60

 

 

 

180

 

 

 

232

 

Total expenses

 

$

60

 

 

$

60

 

 

$

180

 

 

$

240

 

 

In December 2017, the Company entered into a consulting agreement with Aseem Z. Ansari, Ph.D. Dr. Ansari, a co-founder, provides consulting services and advises on certain research and development activities (the “Research Consulting Agreement”). Pursuant to the Research Consulting Agreement, as amended, Dr. Ansari performs these services for a monthly fee of $15,000.

Expenses recognized by the Company under the Research Consulting Agreement during the periods presented were as follows (in thousands):

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

45

 

 

$

 

 

$

135

 

 

$

 

Total expenses

 

$

45

 

 

$

 

 

$

135

 

 

$

 

As of September 30, 2021 and December 31, 2020, the Company had accounts payable of $20,000 pursuant to its related party consulting agreements.

Convertible Notes and Notes Payable

In May and July 2018, the Company issued a total of $0.3 million of convertible notes to a co-founder for cash with a maturity date on or after February 5, 2021, if not converted earlier. The notes bore interest of 8% per annum and were convertible into equity securities sold at the next financing at 80% of the selling price per share of such equity financing. In February 2020, these notes converted into 171,025 shares of the Company’s convertible preferred stock pursuant to the closing of the Series A preferred stock financing. Further, the Company has issued unsecured promissory notes to this co-founder for working capital. See Note 9 for further discussion.

XML 31 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation and Use of Estimates

Basis of Presentation and Use of Estimates

The accompanying interim condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and following the requirements of the United States Securities and Exchange Commission ("SEC") for interim reporting. The Company's financial statements include all adjustments, consisting of only normal recurring adjustments, which in the opinion of management are necessary to present fairly the Company’s financial position as of the reporting date and results of operations for the periods presented. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the recognition of grant revenue, accruals for research and development expenses and the valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.

The full extent to which the novel coronavirus-2019 (“COVID-19”) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.

Stock Splits

Stock Splits

In February 2020, the Company effected a 5-for-1 forward stock split of its issued and outstanding common stock. Further, in March 2021, the Company effected a 1-for-1.63 reverse stock split of its issued and outstanding common stock. The par value and the authorized shares of the common stock were not adjusted as a result of these stock splits. The reverse stock split in March 2021 resulted in an adjustment to the convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying financial statements and notes to the financial statements give retroactive effect to the stock splits for all periods presented.
Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities at the date of acquisition of three months or less to be cash equivalents. These investments may include money market accounts, money market funds, U.S. Government agency securities, corporate debt securities and commercial paper. The Company’s cash reserves are in a readily available checking account.

Investment Securities

Investment Securities

Investments in securities with maturities at the date of acquisition of more than three months are considered marketable securities. The Company determines the appropriate classification of its investments at the time of acquisition and reevaluates such determination at each balance sheet date. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management strategies. Further, the Company classifies its available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations. The Company’s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for safety of principle, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of other comprehensive income (loss) until realized. Allowances for credit losses are reported on the balance sheet, if any.

The cost of available-for-sale investment securities is adjusted for amortization of premiums and accretion of discounts until the securities mature. Such amortization and accretion is included in other income (expense) on the statements of operations. Realized gains and losses, if any, are also included in other income (expense) on the statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the periods presented, no realized gains or losses were recorded on the sale of investment securities and no impairments to reduce the value of any security was taken. See Note 5 for further discussion.

Leases

Leases

At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise the option. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company's leases do not provide an implicit interest rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less ("Short-Term Leases"). For any Short-Term leases, the Company records the rent expense on a straight-line basis and does not record the leases on the condensed balance sheet. The Company had no Short-Term Leases as of September 30, 2021 or December 31, 2020.

After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.
Revenue Recognition

Revenue Recognition

The Company has generated revenue from grants awarded to it by the National Science Foundation (“NSF”), the National Institutes of Health (“NIH”) and the Friedreich’s Ataxia Research Alliance (“FARA”). These grants provide the Company with funding for certain research and development activities on a best-efforts basis and do not require scientific achievement as a performance obligation. The Company has determined that the entities funding these grant awards do not meet the definition of a “customer”, as defined by Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606), and does not consider there to be a transfer of control of goods or services to the entities funding the grant. As such, the Company recognizes revenue from these awards in the period during which the related qualifying services are rendered and costs are incurred in accordance with ASC 730, Research and Development. ASC 730 requires an assessment, at the inception of the grant, to determine whether the agreement is a liability or a contract to perform research and development services for others. Further, these grants are subject to the contribution’s guidance under ASC 958, Not-for-Profit Entities-Revenue Recognition, and as such, the Company determines whether it is obligated to repay the funds received to the grantor regardless of the outcome of the related research and development activities. If it determines there is such a liability, it estimates the obligation and recognize that liability. Alternatively, if the Company is not required to repay the funds, the grant agreement is accounted for as a contract to perform research and

development services for others, in which case, the grant revenue is recorded as income in the statements of operations as the expenses are incurred.

The Company’s current grant revenue is not deemed refundable, and therefore, no liability is recognized when income is recorded. Grant funding received prior to expenses being incurred are recorded as deferred revenue on the Company’s balance sheets. See Note 8 for further discussion.

Research and Development Expenses

Research and Development Expenses

Research and development expenses consist primarily of direct and indirect costs incurred in connection with its discovery efforts, and the preclinical and formulation development of its product candidates. In the future, the Company expects a substantial portion of its research and development expenses will relate to the clinical development of its product candidates. Direct costs include contracted research development and manufacturing, consulting fees, license fees, laboratory supplies and other expenses incurred to sustain research and development programs. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, facilities related expenses, and other indirect expenses. A significant portion of the Company’s research and development expenses have been direct costs, which the Company tracks by stage of development, preclinical or clinical. However, the Company does not track its internal research and development expenses on a program specific basis, unless specific to research grants, because these costs are deployed across multiple projects and, as such, are not separately classified. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company’s research and development efforts and have no alternative future uses.

The Company has entered into various contracts with research and development organizations, vendors and consultants. Payments for these activities are based on the terms of the individual agreements, which may differ from the periods over which materials or services are provided. Payments made in advance of performance are reflected in the accompanying balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. The Company determines accrual estimates through review of the underlying contracts along with discussions with research and other key personnel as to the progress of the research and development activities, invoices received and contracted costs. During the course of a study or trial, the Company adjusts its rate of expense recognition if actual results differ from its estimates. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.
Stock-Based Compensation

Stock-Based Compensation

Stock options issued pursuant to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) and 2018 Equity Incentive Plan (the “2018 Plan”) and option features associated with the rights to purchase shares pursuant to the Company’s 2021 Employee Stock Purchase Plan (the “ESPP”) are valued using the Black-Scholes option pricing model on the date of grant or subscription period. This option pricing model involves a number of estimates, including the expected lives of the stock options or subscription period, the Company’s anticipated stock volatility and interest rates. The Company recognizes the expense for equity awards on a straight-line basis over the requisite service periods of the awards or the number of shares estimated to be issued pursuant to the ESPP. Forfeitures are recognized as they occur.

Stock-based compensation expense recognized in the Company’s statements of operations during the three and nine months ended September 30, 2021 and 2020, were as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

521

 

 

$

12

 

 

$

1,181

 

 

$

22

 

General and administrative

 

 

722

 

 

 

3

 

 

 

1,952

 

 

 

7

 

Total

 

$

1,243

 

 

$

15

 

 

$

3,133

 

 

$

29

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting

for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The ASU provides guidance to clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. ASU 2021-04 is effective for annual periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact that this new guidance will have on its condensed consolidated financial statements and does not currently expect the adoption will have a material impact on its financial statements and related disclosures.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity. The guidance, among other items, clarifies that certain transactions between collaborative participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. The ASU’s amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted for periods beginning after December 15, 2020. The Company has not yet adopted this guidance and does not currently expect the adoption will have a material impact on its financial statements and related disclosures.
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2021
Share Based Compensation Allocation And Classification In Financial Statements [Abstract]  
Summary of Stock-based Compensation Expense

Stock-based compensation expense recognized in the Company’s statements of operations during the three and nine months ended September 30, 2021 and 2020, were as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

521

 

 

$

12

 

 

$

1,181

 

 

$

22

 

General and administrative

 

 

722

 

 

 

3

 

 

 

1,952

 

 

 

7

 

Total

 

$

1,243

 

 

$

15

 

 

$

3,133

 

 

$

29

 

XML 33 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss Per Share (Tables)
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share

The following table sets forth the outstanding, potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:

 

 

 

September 30,
2021

 

 

September 30,
2020

 

Convertible preferred stock

 

$

 

 

$

13,504,598

 

Stock options

 

 

2,124,238

 

 

 

389,565

 

Shares subject to repurchase

 

 

430,413

 

 

 

564,055

 

Employee stock purchase plan

 

 

15,335

 

 

 

 

Total

 

$

2,569,986

 

 

$

14,458,218

 

XML 34 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Summary of Company's Financial Instruments Measured at Fair Value on a Recurring Basis

The following table summarize the Company’s financial instruments measured at fair value on a recurring basis at September 30, 2021 and December 31, 2020 (in thousands):

 

 

 

Fair Value Measurement at End of Period Using:

 

 

 

 

 

 

Quoted Prices

 

 

 

 

 

 

 

 

 

 

 

 

In Active

 

 

 

 

 

 

 

 

 

 

 

 

Markets

 

 

Significant

 

 

 

 

 

 

 

 

 

For

 

 

Other

 

 

Significant

 

 

 

 

 

 

Identical

 

 

Observable

 

 

Unobservable

 

 

 

 

 

 

Assets

 

 

Inputs

 

 

Inputs

 

 

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

As of September 30, 2021:

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

356,793

 

 

$

356,793

 

 

$

 

 

$

 

Certificates of deposit

 

 

5,987

 

 

 

5,987

 

 

 

 

 

 

 

U.S. Treasury securities

 

 

30,068

 

 

 

30,068

 

 

 

 

 

 

 

Total

 

$

392,848

 

 

$

392,848

 

 

$

 

 

$

 

As of December 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

2,100

 

 

$

2,100

 

 

$

 

 

$

 

Certificates of deposit

 

 

1,754

 

 

 

1,754

 

 

 

 

 

 

 

U.S. Treasury securities

 

 

31,958

 

 

 

31,958

 

 

 

 

 

 

 

Total

 

$

35,812

 

 

$

35,812

 

 

$

 

 

$

 

 

(1)
Included in cash and cash equivalents on the accompanying balance sheets.
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Investment Securities (Tables)
9 Months Ended
Sep. 30, 2021
Investments Debt And Equity Securities [Abstract]  
Disclosure - Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Detail) The cost, gross unrealized holding gains, gross unrealized holding

losses, allowances for credit losses and fair value of available-for-sale investments by types, maturities and classes of securities at September 30, 2021 and December 31, 2020 consisted of the following (in thousands):

 

 

 

 

 

As of September 30, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Estimated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Allowance

 

 

Fair

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

for Credit

 

 

Market

 

 

 

Maturity

 

Cost

 

 

Gains

 

 

Losses

 

 

Losses

 

 

Value

 

Certificates of deposits

 

Within 1 year

 

$

2,853

 

 

$

 

 

$

(1

)

 

$

 

 

$

2,852

 

U.S. Treasury securities

 

Within 1 year

 

 

10,066

 

 

 

1

 

 

 

 

 

 

 

 

$

10,067

 

Certificates of deposits

 

1 year to 2 years

 

 

3,137

 

 

 

 

 

 

(2

)

 

 

 

 

 

3,135

 

U.S. Treasury securities

 

1 year to 2 years

 

 

20,004

 

 

 

 

 

 

(2

)

 

 

 

 

 

20,002

 

Total

 

 

 

$

36,060

 

 

$

1

 

 

$

(5

)

 

$

 

 

$

36,056

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Estimated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Allowance

 

 

Fair

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

for Credit

 

 

Market

 

 

 

Maturity

 

Cost

 

 

Gains

 

 

Losses

 

 

Losses

 

 

Value

 

Certificates of deposits

 

Within 1 year

 

$

1,750

 

 

$

4

 

 

$

 

 

$

 

 

$

1,754

 

U.S. Treasury securities

 

Within 1 year

 

 

31,806

 

 

 

152

 

 

 

 

 

 

 

 

 

31,958

 

Total

 

 

 

$

33,556

 

 

$

156

 

 

$

 

 

$

 

 

$

33,712

 

XML 36 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Details (Tables)
9 Months Ended
Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Summary of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

 

September 30,
2021

 

 

December 31,
2020

 

Prepaid expenses

 

$

1,421

 

 

$

60

 

Security deposits

 

 

104

 

 

 

47

 

Interest receivable

 

 

47

 

 

 

10

 

Other

 

 

 

 

 

25

 

Total

 

$

1,572

 

 

$

142

 

Summary of Property and Equipment

Property and equipment consisted of the following (in thousands):

 

 

 

September 30,
2021

 

 

December 31,
2020

 

Laboratory equipment

 

$

1,058

 

 

$

76

 

Computer equipment and software

 

 

77

 

 

 

 

Leasehold improvements

 

 

91

 

 

 

 

Construction in progress

 

 

146

 

 

 

 

 

 

 

1,372

 

 

 

76

 

Less accumulated depreciation

 

 

(52

)

 

 

(5

)

Total

 

$

1,320

 

 

$

71

 

Summary of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

 

September 30,
2021

 

 

December 31,
2020

 

Accrued personnel costs

 

$

1,411

 

 

$

565

 

Accrued research and development costs

 

 

652

 

 

 

266

 

Current portion of operating lease liability

 

 

475

 

 

 

 

Accrued other

 

 

751

 

 

 

100

 

Total

 

$

3,289

 

 

$

931

 

XML 37 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Lease (Tables)
9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Summary of Maturities of Operating Lease Liabilities

Maturities of operating lease liabilities as of September 30, 2021 are as follows (in thousands):

 

 2021 (remaining three months)

 

$

181

 

 2022

 

 

733

 

 2023

 

 

755

 

 2024

 

 

778

 

 2025

 

 

801

 

Thereafter

 

 

1,386

 

Total future minimum lease payments

 

 

4,634

 

Less: Present value adjustment

 

 

(886

)

Operating lease liabilities

 

$

3,748

 

XML 38 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Convertible Preferred Stock and Stockholders' Deficit (Tables)
9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Summary of Restricted Shares of Common Stock and Unvested Stock Liability

A summary of the Company’s restricted shares of common stock and unvested stock liability, which is included in accrued expenses and other current liabilities and other long-term liabilities on the Company’s balance sheets, is as follows (in thousands, except share data):

 

 

 

Shares

 

 

Liability

 

Balance at December 31, 2020

 

 

646,953

 

 

$

145

 

Vested shares

 

 

(216,540

)

 

 

(8

)

Balance at September 30, 2021

 

 

430,413

 

 

$

137

 

XML 39 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions (Tables)
9 Months Ended
Sep. 30, 2021
Consulting Agreements  
Related Party Transaction [Line Items]  
Summary of Expenses Recognized under Various Agreements

Expenses recognized by the Company under the 2020 Consulting Agreement during the periods presented were as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

 

 

$

 

 

$

 

 

$

8

 

General and administrative

 

 

60

 

 

 

60

 

 

 

180

 

 

 

232

 

Total expenses

 

$

60

 

 

$

60

 

 

$

180

 

 

$

240

 

Research Consulting Agreements  
Related Party Transaction [Line Items]  
Summary of Expenses Recognized under Various Agreements

Expenses recognized by the Company under the Research Consulting Agreement during the periods presented were as follows (in thousands):

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

45

 

 

$

 

 

$

135

 

 

$

 

Total expenses

 

$

45

 

 

$

 

 

$

135

 

 

$

 

Lease Agreement  
Related Party Transaction [Line Items]  
Summary of Expenses Recognized under Various Agreements

Expenses recognized by the Company under the Lease during the periods presented were as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

53

 

 

$

 

 

$

53

 

 

$

 

General and administrative

 

 

22

 

 

 

 

 

 

22

 

 

 

 

Total expenses

 

$

75

 

 

$

 

 

$

75

 

 

$

 

XML 40 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)
1 Months Ended 9 Months Ended
Mar. 31, 2021
Feb. 29, 2020
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Accounting Policies [Abstract]        
Stock split of issued and outstanding common stock     5-for-1  
Reverse stock split of issued and outstanding common stock     1-for-1.63  
Conversion ratio of forward/reverse stock split 0.613497 5    
Short-term leases     $ 0 $ 0
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Summary of Significant Accounting Policies - Summary of Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation expense $ 1,243 $ 15 $ 3,133 $ 29
Research and Development        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation expense 521 12 1,181 22
General and Administrative        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock-based compensation expense $ 722 $ 3 $ 1,952 $ 7
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss Per Share - Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details) - shares
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from calculation of diluted net loss per share 2,569,986 14,458,218
Convertible Preferred Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from calculation of diluted net loss per share   13,504,598
Stock Options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from calculation of diluted net loss per share 2,124,238 389,565
Shares Subject to Repurchase    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from calculation of diluted net loss per share 430,413 564,055
Employee Stock Purchase Plan    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from calculation of diluted net loss per share 15,335  
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Investments, fair value disclosure $ 392,848 $ 35,812
Money market funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Investments, fair value disclosure 356,793 2,100
Certificates of deposit    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Investments, fair value disclosure 5,987 1,754
U.S. Treasury securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Investments, fair value disclosure 30,068 31,958
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Investments, fair value disclosure 392,848 35,812
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Investments, fair value disclosure 356,793 2,100
Quoted Prices in Active Markets for Identical Assets (Level 1) | Certificates of deposit    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Investments, fair value disclosure 5,987 1,754
Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Treasury securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Investments, fair value disclosure $ 30,068 $ 31,958
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]    
Debt securities, Amortized Cost $ 36,060 $ 33,556
Debt securities, Unrealized Gains 1 156
Debt securities, Unrealized Losses (5)  
Debt securities, Estimated Fair Value $ 36,056 $ 33,712
Certificates of deposit | Within 1 Year    
Schedule Of Available For Sale Securities [Line Items]    
Debt securities, Maturity Within 1 year Within 1 year
Debt securities, Amortized Cost $ 2,853 $ 1,750
Debt securities, Unrealized Gains   4
Debt securities, Unrealized Losses (1)  
Debt securities, Estimated Fair Value $ 2,852 $ 1,754
Certificates of deposit | 1 Year to 2 Years    
Schedule Of Available For Sale Securities [Line Items]    
Debt securities, Maturity 1 year to 2 years  
Debt securities, Amortized Cost $ 3,137  
Debt securities, Unrealized Losses (2)  
Debt securities, Estimated Fair Value $ 3,135  
U.S. Treasury securities | Within 1 Year    
Schedule Of Available For Sale Securities [Line Items]    
Debt securities, Maturity Within 1 year Within 1 year
Debt securities, Amortized Cost $ 10,066 $ 31,806
Debt securities, Unrealized Gains 1 152
Debt securities, Estimated Fair Value $ 10,067 $ 31,958
U.S. Treasury securities | 1 Year to 2 Years    
Schedule Of Available For Sale Securities [Line Items]    
Debt securities, Maturity 1 year to 2 years  
Debt securities, Amortized Cost $ 20,004  
Debt securities, Unrealized Losses (2)  
Debt securities, Estimated Fair Value $ 20,002  
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Investment Securities - Additional Information (Details)
Sep. 30, 2021
USD ($)
Security
Dec. 31, 2020
USD ($)
Security
Schedule Of Available For Sale Securities [Line Items]    
Number of available-for-sale investment securities in continuous unrealized loss position, less than 12 months 19 0
Number of domestic certificates of deposit held 25  
Maximum    
Schedule Of Available For Sale Securities [Line Items]    
Accrued interest receivable on available-for-sale investment securities | $ $ 100,000 $ 100,000
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Prepaid Expense And Other Assets Current [Abstract]    
Prepaid expenses $ 1,421 $ 60
Security deposits 104 47
Interest receivable 47 10
Other   25
Total $ 1,572 $ 142
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Details - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Property Plant And Equipment [Line Items]    
Property and equipment $ 1,372 $ 76
Less accumulated depreciation (52) (5)
Total 1,320 71
Laboratory Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment 1,058 $ 76
Computer Equipment and Software    
Property Plant And Equipment [Line Items]    
Property and equipment 77  
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Property and equipment 91  
Construction in Progress    
Property Plant And Equipment [Line Items]    
Property and equipment $ 146  
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Details - Summary of Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Accrued Liabilities Current [Abstract]    
Accrued personnel costs $ 1,411 $ 565
Accrued research and development costs 652 266
Current portion of operating lease liability 475  
Accrued other 751 100
Total $ 3,289 $ 931
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Lease - Additional Information (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2021
Feb. 28, 2021
ft²
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Lessee, Lease, Description [Line Items]            
Lease agreement termination date 2021-09          
Rent expense     $ 200,000   $ 400,000 $ 100,000
Maximum            
Lessee, Lease, Description [Line Items]            
Rent expense       $ 100,000    
Crossing Holdings, LLC            
Lessee, Lease, Description [Line Items]            
Area of lease space | ft²   12,370        
Lease commencement date         2021-09  
Lease term   72 months        
Option to renew lease term ends, year         2027  
Lessee, Operating Lease, Existence of Option to Extend [true false]   true        
Lease term, option to extend period         three years  
Percentage of annual increase in lease payments   3.00%        
Operating lease remaining lease term 5 years 10 months 24 days   5 years 10 months 24 days   5 years 10 months 24 days  
Operating lease right-of-use asset discount rate 7.15%   7.15%   7.15%  
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Lease - Summary of Maturities of Operating Lease Liabilities (Details)
$ in Thousands
Sep. 30, 2021
USD ($)
Operating Lease Liabilities Payments Due [Abstract]  
2021 (remaining three months) $ 181
2022 733
2023 755
2024 778
2025 801
Thereafter 1,386
Total future minimum lease payments 4,634
Less: Present value adjustment (886)
Operating lease liabilities $ 3,748
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Grant Revenue - Additional Information (Details) - Grant - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Disaggregation Of Revenue [Line Items]        
Recognized grant revenue $ 0   $ 0 $ 200,000
Maximum        
Disaggregation Of Revenue [Line Items]        
Recognized grant revenue   $ 100,000    
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 9 Months Ended
Feb. 29, 2020
Nov. 30, 2019
Jan. 31, 2019
Sep. 30, 2021
Jan. 31, 2020
Dec. 31, 2019
Mar. 31, 2019
Feb. 28, 2019
Commitments And Contingencies Disclosure [Line Items]                
Debt instrument interest rate               8.00%
Convertible notes issued               $ 0.2
Percentage of selling price per share that can convertible into equity securities sold               80.00%
Converted amount $ 0.5              
Series A Convertible Preferred Stock                
Commitments And Contingencies Disclosure [Line Items]                
Converted shares 301,685              
Share price $ 1.65816              
May 2018 Note                
Commitments And Contingencies Disclosure [Line Items]                
Maturity description       on or after February 5, 2021, if not converted earlier        
July 2018 Note                
Commitments And Contingencies Disclosure [Line Items]                
Maturity description       on or after February 5, 2021, if not converted earlier        
February 2019 Note                
Commitments And Contingencies Disclosure [Line Items]                
Maturity description       on or after May 16, 2020, if not converted earlier        
Unsecured Promissory Note | January Note                
Commitments And Contingencies Disclosure [Line Items]                
Maturity description       on or before January 30, 2021        
Percentage of final payment on advanced at maturity     3.00%          
Debt instrument interest rate             10.00% 10.00%
Unsecured Promissory Note | January Note | Maximum                
Commitments And Contingencies Disclosure [Line Items]                
Notes issued     $ 0.5          
Unsecured Promissory Note | January Note | Prime Plus                
Commitments And Contingencies Disclosure [Line Items]                
Debt instrument variable interest rate     4.50%          
Unsecured Promissory Note | November Note                
Commitments And Contingencies Disclosure [Line Items]                
Maturity description       on or before January 1, 2022        
Percentage of final payment on advanced at maturity   3.00%            
Debt instrument interest rate         9.25% 9.25%    
Unsecured Promissory Note | November Note | Maximum                
Commitments And Contingencies Disclosure [Line Items]                
Notes issued   $ 0.5            
Unsecured Promissory Note | November Note | Prime Plus                
Commitments And Contingencies Disclosure [Line Items]                
Debt instrument variable interest rate   4.50%            
Unsecured Promissory Note | February and March 2019 Draws | January Note                
Commitments And Contingencies Disclosure [Line Items]                
Borrowings       $ 0.2        
Unsecured Promissory Note | Jan 2020 and Dec 2019 Draws | November Note                
Commitments And Contingencies Disclosure [Line Items]                
Borrowings       0.4        
Convertible Notes Issued in May and July 2018                
Commitments And Contingencies Disclosure [Line Items]                
Convertible notes issued       $ 0.3        
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.21.2
License Agreement - Additional Information (Details) - License Agreement - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 29, 2020
Feb. 28, 2019
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2019
Schedule Of License Agreement [Line Items]              
Payment for upfront fee             $ 225,000
Upfront payment upon execution of agreement   $ 25,000          
Upfront payment within first anniversary of license agreement   225,000          
Written notice period for termination of agreement         90 days    
Termination period Description         WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.    
Investigation New Drug (IND)              
Schedule Of License Agreement [Line Items]              
Expected milestone payment on achieving certain regulatory and commercial milestones     $ 125,000   $ 125,000    
Milestone payment     0   0    
Royalty payments         0    
Investigation New Drug (IND) | Maximum              
Schedule Of License Agreement [Line Items]              
Expected milestone payment on achieving certain regulatory and commercial milestones     17,500,000   17,500,000    
Investigation New Drug (IND) | Minimum [Member]              
Schedule Of License Agreement [Line Items]              
Expected royalty payments upon first commercial product sale     100,000   100,000    
Initial Closing of Series A Preferred Stock              
Schedule Of License Agreement [Line Items]              
Payment for upfront fee $ 225,000            
Research and Development              
Schedule Of License Agreement [Line Items]              
Payment for upfront fee   $ 250,000          
General and Administrative Expenses | Maximum              
Schedule Of License Agreement [Line Items]              
Legal patent fees     $ 100,000 $ 100,000 $ 100,000 $ 100,000  
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 9 Months Ended
Mar. 25, 2021
Mar. 31, 2021
Jan. 31, 2021
Mar. 31, 2020
Feb. 29, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Convertible Preferred Stock And Stockholders Deficit [Line Items]                
Common stock, shares authorized           200,000,000   60,000,000
Common stock, par value           $ 0.0001   $ 0.0001
Convertible preferred stock, issued           0   22,012,499
Convertible preferred stock, par value           $ 0.0001   $ 0.0001
Proceeds from issuance of convertible preferred stock, net of issuance costs           $ 124,712 $ 44,731  
2021 Equity Incentive Award Plan                
Convertible Preferred Stock And Stockholders Deficit [Line Items]                
Common stock reserved for issuance 6,118,648              
Common stock issuance, description and terms           the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares of the Company’s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company’s board of directors.    
Percentage of number of shares that may be issued in accordance with plan 5.00%              
2018 Equity Incentive Plan                
Convertible Preferred Stock And Stockholders Deficit [Line Items]                
Common stock remained available for issuance 881,352              
2021 Employee Stock Purchase Plan                
Convertible Preferred Stock And Stockholders Deficit [Line Items]                
Common stock reserved for issuance 600,000              
Common stock remained available for issuance 1,200,000              
Common stock issuance, description and terms           the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 1% of the total number of shares of the Company’s common stock on the last day of the calendar month before the date of each automatic increase and (ii) 1,200,000 shares; provided that before the date of any such increase, the Company’s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii). As of September 30, 2021, no shares of the Company’s common stock have been purchased under the ESPP.    
Percentage of number of shares that may be issued in accordance with plan 1.00%              
Maximum percentage of eligible earnings withheld to participate in offering 15.00%              
Price of common stock purchased 85.00%              
Number of common stock purchased           0    
Series A Convertible Preferred Stock                
Convertible Preferred Stock And Stockholders Deficit [Line Items]                
Share price         $ 1.65816      
Convertible preferred stock, issued       21,710,814 21,710,814      
Convertible preferred stock, par value       $ 2.0727 $ 2.0727      
Proceeds from issuance of convertible preferred stock, net of issuance costs       $ 44,700 $ 44,700      
Converted shares         301,685      
Series B Convertible Preferred Stock                
Convertible Preferred Stock And Stockholders Deficit [Line Items]                
Convertible preferred stock, issued     19,083,979          
Convertible preferred stock, par value     $ 6.55          
Proceeds from issuance of convertible preferred stock, net of issuance costs     $ 124,700          
Common Stock                
Convertible Preferred Stock And Stockholders Deficit [Line Items]                
Initial public offering of common shares           13,800,000    
Common Stock | 2018 Equity Incentive Plan | Restricted Shares                
Convertible Preferred Stock And Stockholders Deficit [Line Items]                
Vesting period           4 years    
Initial Public Offering                
Convertible Preferred Stock And Stockholders Deficit [Line Items]                
Common stock, shares authorized   200,000,000            
Common stock, par value   $ 0.0001            
Preferred stock, authorized   10,000,000            
Preferred stock, par value   $ 0.0001            
Initial public offering of common shares   13,800,000            
Share price   $ 20.00            
Proceeds from sale of common stock   $ 254,300            
Convertible preferred stock, shares issued upon conversion   41,096,478            
Initial Public Offering | Common Stock                
Convertible Preferred Stock And Stockholders Deficit [Line Items]                
Convertible preferred stock, shares issued upon conversion   25,212,548            
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Convertible Preferred Stock and Stockholders' Deficit - Summary of Restricted Shares of Common Stock and Unvested Stock Liability (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2021
USD ($)
shares
Liabilities And Stockholders Equity [Line Items]  
Beginning Balance, Unvested stock liability | $ $ 145
Vested shares, Unvested stock liability | $ (8)
Ending Balance, Unvested stock liability | $ $ 137
Restricted Shares  
Liabilities And Stockholders Equity [Line Items]  
Beginning Balance | shares 646,953
Vested shares | shares (216,540)
Ending Balance | shares 430,413
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions - Additional Information (Details)
1 Months Ended 9 Months Ended
Mar. 31, 2020
USD ($)
Feb. 29, 2020
shares
Jan. 31, 2019
ft²
Dec. 31, 2017
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Feb. 28, 2019
USD ($)
Jul. 31, 2018
USD ($)
May 31, 2018
USD ($)
Related Party Transaction [Line Items]                  
Accrued expenses and other current liabilities, related party amounts         $ 10,000 $ 0      
Convertible notes issued             $ 200,000    
Debt instrument interest rate             8.00%    
Percentage of selling price per share that can convertible into equity securities sold             80.00%    
Lease Agreement                  
Related Party Transaction [Line Items]                  
Prepaid expenses         100,000 0      
Accrued expenses and other current liabilities, related party amounts           0      
Lease Agreement | Maximum                  
Related Party Transaction [Line Items]                  
Accrued expenses and other current liabilities, related party amounts         100,000        
Consulting Agreements                  
Related Party Transaction [Line Items]                  
Accounts payable         $ 20,000 $ 20,000      
Marlinspike Group, LLC | 2020 Consulting Agreement                  
Related Party Transaction [Line Items]                  
Monthly fee for consultancy services $ 20,000                
Termination fee $ 240,000                
Marlinspike Group, LLC | Carlsbad, California | 2019 Consulting Agreement                  
Related Party Transaction [Line Items]                  
Area of office space | ft²     2,120            
Aseem Z. Ansari, Ph.D. | Convertible Notes and Notes Payable                  
Related Party Transaction [Line Items]                  
Convertible notes issued               $ 300,000 $ 300,000
Debt instrument interest rate                 8.00%
Percentage of selling price per share that can convertible into equity securities sold                 80.00%
Aseem Z. Ansari, Ph.D. | Convertible Notes and Notes Payable | Series A Preferred Stock                  
Related Party Transaction [Line Items]                  
Convertible preferred stock converted | shares   171,025              
Aseem Z. Ansari, Ph.D. | May Note                  
Related Party Transaction [Line Items]                  
Maturity description         on or after February 5, 2021, if not converted earlier        
Aseem Z. Ansari, Ph.D. | July Note                  
Related Party Transaction [Line Items]                  
Maturity description         on or after February 5, 2021, if not converted earlier        
Aseem Z. Ansari, Ph.D. | Consulting Agreements                  
Related Party Transaction [Line Items]                  
Monthly fee for services       $ 15,000          
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions - Summary of Expenses Recognized under Consulting Agreement (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Related Party Transaction [Line Items]        
Research and development (including related party amounts of $98, $0, $188 and $8, respectively) $ 8,539 $ 1,914 $ 17,441 $ 3,352
General and administrative (including related party amounts of $82, $60, $202 and $232, respectively) 2,798 489 7,263 1,310
Lease Agreement        
Related Party Transaction [Line Items]        
Research and development (including related party amounts of $98, $0, $188 and $8, respectively) 53   53  
General and administrative (including related party amounts of $82, $60, $202 and $232, respectively) 22   22  
Total expenses 75   75  
Research Consulting Agreements        
Related Party Transaction [Line Items]        
Research and development (including related party amounts of $98, $0, $188 and $8, respectively) 45   135  
Total expenses 45   135  
Marlinspike Group, LLC | Consulting Agreements        
Related Party Transaction [Line Items]        
Research and development (including related party amounts of $98, $0, $188 and $8, respectively)       8
General and administrative (including related party amounts of $82, $60, $202 and $232, respectively) 60 60 180 232
Total expenses $ 60 $ 60 $ 180 $ 240
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 192 315 1 false 59 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Balance Sheets Sheet http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 100030 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100040 - Statement - Condensed Statements of Operations Sheet http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations Condensed Statements of Operations Statements 4 false false R5.htm 100050 - Statement - Condensed Statements of Operations (Parenthetical) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsParenthetical Condensed Statements of Operations (Parenthetical) Statements 5 false false R6.htm 100060 - Statement - Condensed Statements of Comprehensive Loss (Unaudited) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited Condensed Statements of Comprehensive Loss (Unaudited) Statements 6 false false R7.htm 100070 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Statements 7 false false R8.htm 100080 - Statement - Condensed Statements of Convertible Preferred stock and Stockholders' Equity (Deficit) (Parenthetical) Sheet http://www.designtx.com/20210930/taxonomy/role/StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical Condensed Statements of Convertible Preferred stock and Stockholders' Equity (Deficit) (Parenthetical) Statements 8 false false R9.htm 100090 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (Unaudited) Statements 9 false false R10.htm 100100 - Disclosure - Organization Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureOrganization Organization Notes 10 false false R11.htm 100110 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 11 false false R12.htm 100120 - Disclosure - Net Loss Per Share Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShare Net Loss Per Share Notes 12 false false R13.htm 100130 - Disclosure - Fair Value Measurements Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 100140 - Disclosure - Investment Securities Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureInvestmentSecurities Investment Securities Notes 14 false false R15.htm 100150 - Disclosure - Balance Sheet Details Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetails Balance Sheet Details Notes 15 false false R16.htm 100160 - Disclosure - Lease Sheet http://www.designtx.com/20210930/taxonomy/role/DisclosureLease Lease Notes 16 false false R17.htm 100170 - Disclosure - Grant Revenue Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureGrantRevenue Grant Revenue Notes 17 false false R18.htm 100180 - Disclosure - Commitments and Contingencies Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 100190 - Disclosure - License Agreement Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreement License Agreement Notes 19 false false R20.htm 100200 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficit Convertible Preferred Stock and Stockholders' Deficit Notes 20 false false R21.htm 100210 - Disclosure - Related Party Transactions Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactions Related Party Transactions Notes 21 false false R22.htm 100220 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies 22 false false R23.htm 100230 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies 23 false false R24.htm 100240 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShare 24 false false R25.htm 100250 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurements 25 false false R26.htm 100260 - Disclosure - Investment Securities (Tables) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureInvestmentSecuritiesTables Investment Securities (Tables) Tables http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureInvestmentSecurities 26 false false R27.htm 100270 - Disclosure - Balance Sheet Details (Tables) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetails 27 false false R28.htm 100280 - Disclosure - Lease (Tables) Sheet http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseTables Lease (Tables) Tables http://www.designtx.com/20210930/taxonomy/role/DisclosureLease 28 false false R29.htm 100290 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit (Tables) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitTables Convertible Preferred Stock and Stockholders' Deficit (Tables) Tables http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficit 29 false false R30.htm 100300 - Disclosure - Related Party Transactions (Tables) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactions 30 false false R31.htm 100310 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) Details 31 false false R32.htm 100320 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Stock-based Compensation Expense (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationExpenseDetails Basis of Presentation and Summary of Significant Accounting Policies - Summary of Stock-based Compensation Expense (Details) Details 32 false false R33.htm 100330 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails Net Loss Per Share - Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details) Details 33 false false R34.htm 100340 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) Details 34 false false R35.htm 100350 - Disclosure - Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Details) Details 35 false false R36.htm 100360 - Disclosure - Investment Securities - Additional Information (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails Investment Securities - Additional Information (Details) Details 36 false false R37.htm 100370 - Disclosure - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details) Details 37 false false R38.htm 100380 - Disclosure - Balance Sheet Details - Summary of Property and Equipment (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails Balance Sheet Details - Summary of Property and Equipment (Details) Details 38 false false R39.htm 100390 - Disclosure - Balance Sheet Details - Summary of Accrued Liabilities (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails Balance Sheet Details - Summary of Accrued Liabilities (Details) Details 39 false false R40.htm 100400 - Disclosure - Lease - Additional Information (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails Lease - Additional Information (Details) Details 40 false false R41.htm 100410 - Disclosure - Lease - Summary of Maturities of Operating Lease Liabilities (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails Lease - Summary of Maturities of Operating Lease Liabilities (Details) Details 41 false false R42.htm 100420 - Disclosure - Grant Revenue - Additional Information (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails Grant Revenue - Additional Information (Details) Details 42 false false R43.htm 100430 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 43 false false R44.htm 100440 - Disclosure - License Agreement - Additional Information (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails License Agreement - Additional Information (Details) Details 44 false false R45.htm 100450 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details) Details 45 false false R46.htm 100460 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Summary of Restricted Shares of Common Stock and Unvested Stock Liability (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails Convertible Preferred Stock and Stockholders' Deficit - Summary of Restricted Shares of Common Stock and Unvested Stock Liability (Details) Details 46 false false R47.htm 100470 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 47 false false R48.htm 100480 - Disclosure - Related Party Transactions - Summary of Expenses Recognized under Consulting Agreement (Details) Sheet http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails Related Party Transactions - Summary of Expenses Recognized under Consulting Agreement (Details) Details 48 false false All Reports Book All Reports dsgn-20210930.htm dsgn-20210930.xsd dsgn-20210930_cal.xml dsgn-20210930_def.xml dsgn-20210930_lab.xml dsgn-20210930_pre.xml dsgn-ex31_1.htm dsgn-ex32_1.htm http://xbrl.sec.gov/country/2021 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dsgn-20210930.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 192, "dts": { "calculationLink": { "local": [ "dsgn-20210930_cal.xml" ] }, "definitionLink": { "local": [ "dsgn-20210930_def.xml" ] }, "inline": { "local": [ "dsgn-20210930.htm" ] }, "labelLink": { "local": [ "dsgn-20210930_lab.xml" ] }, "presentationLink": { "local": [ "dsgn-20210930_pre.xml" ] }, "schema": { "local": [ "dsgn-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 419, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 11, "http://www.designtx.com/20210930": 2, "http://xbrl.sec.gov/dei/2021": 4, "total": 17 }, "keyCustom": 52, "keyStandard": 263, "memberCustom": 30, "memberStandard": 26, "nsprefix": "dsgn", "nsuri": "http://www.designtx.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Organization", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureOrganization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Net Loss Per Share", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Fair Value Measurements", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Investment Securities", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureInvestmentSecurities", "shortName": "Investment Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Balance Sheet Details", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetails", "shortName": "Balance Sheet Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Lease", "role": "http://www.designtx.com/20210930/taxonomy/role/DisclosureLease", "shortName": "Lease", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "dsgn:GrantRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Grant Revenue", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureGrantRevenue", "shortName": "Grant Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "dsgn:GrantRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Commitments and Contingencies", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "dsgn:DisclosureOfLicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - License Agreement", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreement", "shortName": "License Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "dsgn:DisclosureOfLicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Balance Sheets", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficit", "shortName": "Convertible Preferred Stock and Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Related Party Transactions", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "dsgn:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "dsgn:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CompensationRelatedCostsPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CompensationRelatedCostsPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Net Loss Per Share (Tables)", "role": "http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Investment Securities (Tables)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureInvestmentSecuritiesTables", "shortName": "Investment Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Balance Sheet Details (Tables)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables", "shortName": "Balance Sheet Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Lease (Tables)", "role": "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseTables", "shortName": "Lease (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "dsgn:ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit (Tables)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitTables", "shortName": "Convertible Preferred Stock and Stockholders' Deficit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "dsgn:ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "dsgn:PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Balance Sheets (Parenthetical)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "dsgn:PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_6ea53d07-5102-416e-8959-ac0d1bfade36", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Related Party Transactions (Tables)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_6ea53d07-5102-416e-8959-ac0d1bfade36", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "span", "p", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "span", "p", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:CompensationRelatedCostsPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_f41e658f-59cf-410c-a078-6d988ba3f10d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Stock-based Compensation Expense (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationExpenseDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Summary of Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:CompensationRelatedCostsPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_f41e658f-59cf-410c-a078-6d988ba3f10d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails", "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv", "shortName": "Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "U_Security", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Investment Securities - Additional Information (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails", "shortName": "Investment Securities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "U_Security", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Balance Sheet Details - Summary of Property and Equipment (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails", "shortName": "Balance Sheet Details - Summary of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Balance Sheet Details - Summary of Accrued Liabilities (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails", "shortName": "Balance Sheet Details - Summary of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_49f150e1-174d-4cac-acd2-073f0f64eb39", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Statements of Operations", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations", "shortName": "Condensed Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_49f150e1-174d-4cac-acd2-073f0f64eb39", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe95d703-cf14-4bc3-814c-fb117ea1df54", "decimals": null, "first": true, "lang": "en-US", "name": "dsgn:LeaseAgreementTerminationDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Lease - Additional Information (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails", "shortName": "Lease - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe95d703-cf14-4bc3-814c-fb117ea1df54", "decimals": null, "first": true, "lang": "en-US", "name": "dsgn:LeaseAgreementTerminationDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Lease - Summary of Maturities of Operating Lease Liabilities (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "shortName": "Lease - Summary of Maturities of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "span", "p", "dsgn:GrantRevenueTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_e375eb88-e98b-49a8-a42b-4a2ef1330a2a", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Grant Revenue - Additional Information (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "shortName": "Grant Revenue - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "span", "p", "dsgn:GrantRevenueTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_e375eb88-e98b-49a8-a42b-4a2ef1330a2a", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_5806369b-7be2-49fa-b372-f0457c3b2935", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_be9d3f8f-8aa1-44d7-974a-d3d0beff5e71", "decimals": "-5", "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "dsgn:DisclosureOfLicenseAgreementTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_11f43495-dcaa-4af7-a4c5-27c169921908", "decimals": "0", "first": true, "lang": null, "name": "dsgn:CollaborativeArrangementsUpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - License Agreement - Additional Information (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "shortName": "License Agreement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "dsgn:DisclosureOfLicenseAgreementTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_11f43495-dcaa-4af7-a4c5-27c169921908", "decimals": "0", "first": true, "lang": null, "name": "dsgn:CollaborativeArrangementsUpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "shortName": "Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a18514e6-260a-42bb-93f3-84f6142ce2e3", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dsgn:ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_8f2caff5-c001-4c87-88fc-b332d34980bf", "decimals": "-3", "first": true, "lang": null, "name": "dsgn:UnvestedStockLiability", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Summary of Restricted Shares of Common Stock and Unvested Stock Liability (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails", "shortName": "Convertible Preferred Stock and Stockholders' Deficit - Summary of Restricted Shares of Common Stock and Unvested Stock Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "dsgn:ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_8f2caff5-c001-4c87-88fc-b332d34980bf", "decimals": "-3", "first": true, "lang": null, "name": "dsgn:UnvestedStockLiability", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_fe7cd7d3-1ef9-447e-b7fb-a2d0055c1260", "decimals": "-3", "first": true, "lang": null, "name": "dsgn:AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_c3df21b2-6aba-46c8-b892-b3a3ba06aecd", "decimals": "-5", "lang": null, "name": "dsgn:PrepaidExpensesRelatedPartyCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_f41e658f-59cf-410c-a078-6d988ba3f10d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Related Party Transactions - Summary of Expenses Recognized under Consulting Agreement (Details)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails", "shortName": "Related Party Transactions - Summary of Expenses Recognized under Consulting Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_b435ece2-a007-4860-9af4-d480e4a80e9f", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_f41e658f-59cf-410c-a078-6d988ba3f10d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Statements of Operations (Parenthetical)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsParenthetical", "shortName": "Condensed Statements of Operations (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_f41e658f-59cf-410c-a078-6d988ba3f10d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_f41e658f-59cf-410c-a078-6d988ba3f10d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Statements of Comprehensive Loss (Unaudited)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited", "shortName": "Condensed Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_f41e658f-59cf-410c-a078-6d988ba3f10d", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_2e1fd091-1469-4ba8-9151-7c033a29bb3e", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_2e1fd091-1469-4ba8-9151-7c033a29bb3e", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_9d6db5aa-c9a0-4aee-a89b-8bfabcbb7841", "decimals": "-3", "first": true, "lang": null, "name": "dsgn:PreferredStockIssuanceCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - Condensed Statements of Convertible Preferred stock and Stockholders' Equity (Deficit) (Parenthetical)", "role": "http://www.designtx.com/20210930/taxonomy/role/StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "shortName": "Condensed Statements of Convertible Preferred stock and Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_9d6db5aa-c9a0-4aee-a89b-8bfabcbb7841", "decimals": "-3", "first": true, "lang": null, "name": "dsgn:PreferredStockIssuanceCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100090 - Statement - Condensed Statements of Cash Flows (Unaudited)", "role": "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "dsgn-20210930.htm", "contextRef": "C_a186face-cc40-40df-98d2-6057bc0adff6", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } } }, "segmentCount": 59, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA", "terseLabel": "Carlsbad, California" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "verboseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current liabilities Related Parties, Current", "label": "Accrued expenses and other current liabilities Related Parties, Current", "terseLabel": "Accrued expenses and other current liabilities, related party amounts" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued interest receivable on available-for-sale investment securities.", "label": "Accrued Interest Receivable On Available For Sale Investment Securities", "terseLabel": "Accrued interest receivable on available-for-sale investment securities" } } }, "localname": "AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_AccruedResearchAndDevelopmentExpenseCurrent": { "auth_ref": [], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development expense current.", "label": "Accrued Research And Development Expense Current", "terseLabel": "Accrued research and development costs" } } }, "localname": "AccruedResearchAndDevelopmentExpenseCurrent", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_AreaOfLeasedProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of leased property.", "label": "Area Of Leased Property", "terseLabel": "Area of lease space" } } }, "localname": "AreaOfLeasedProperty", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "dsgn_AreaOfOffice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of office.", "label": "Area Of Office", "terseLabel": "Area of office space" } } }, "localname": "AreaOfOffice", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "dsgn_BalanceSheetComponentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Balance sheet component.", "label": "Balance Sheet Component [Abstract]" } } }, "localname": "BalanceSheetComponentAbstract", "nsuri": "http://www.designtx.com/20210930", "xbrltype": "stringItemType" }, "dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of presentation and use of estimates.", "label": "Basis Of Presentation And Use Of Estimates Policy [Text Block]", "terseLabel": "Basis of Presentation and Use of Estimates" } } }, "localname": "BasisOfPresentationAndUseOfEstimatesPolicyTextBlock", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dsgn_CoFounderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Co-founder.", "label": "Co Founder [Member]", "terseLabel": "Aseem Z. Ansari, Ph.D." } } }, "localname": "CoFounderMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_CollaborativeArrangementsUpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative arrangements upfront payment.", "label": "Collaborative Arrangements Upfront Payment", "terseLabel": "Payment for upfront fee" } } }, "localname": "CollaborativeArrangementsUpfrontPayment", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_CommitmentsAndContingenciesDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies disclosure.", "label": "Commitments And Contingencies Disclosure [Line Items]", "terseLabel": "Commitments And Contingencies Disclosure [Line Items]" } } }, "localname": "CommitmentsAndContingenciesDisclosureLineItems", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dsgn_CommitmentsAndContingenciesDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies disclosure.", "label": "Commitments And Contingencies Disclosure [Table]", "terseLabel": "Commitments And Contingencies Disclosure [Table]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTable", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dsgn_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer equipment and software.", "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer Equipment and Software" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "dsgn_ConsultingAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting agreements.", "label": "Consulting Agreements [Member]", "terseLabel": "Consulting Agreements" } } }, "localname": "ConsultingAgreementsMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "domainItemType" }, "dsgn_ConversionOfStockAmountConvertedRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Conversion of stock amount converted related party.", "label": "Conversion Of Stock Amount Converted Related Party", "terseLabel": "Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability - related party" } } }, "localname": "ConversionOfStockAmountConvertedRelatedParty", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible notes issued in May and July 2018.", "label": "Convertible Notes Issued In May And July2018 [Member]", "terseLabel": "Convertible Notes Issued in May and July 2018" } } }, "localname": "ConvertibleNotesIssuedInMayAndJuly2018Member", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock and stockholders\u2019 deficit.", "label": "Convertible Preferred Stock And Stockholders Deficit [Line Items]", "terseLabel": "Convertible Preferred Stock And Stockholders Deficit [Line Items]" } } }, "localname": "ConvertiblePreferredStockAndStockholdersDeficitLineItems", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock and stockholders\u2019 deficit.", "label": "Convertible Preferred Stock And Stockholders Deficit [Table]", "terseLabel": "Convertible Preferred Stock And Stockholders Deficit [Table]" } } }, "localname": "ConvertiblePreferredStockAndStockholdersDeficitTable", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dsgn_CrossingHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Crossing Holdings LLC.", "label": "Crossing Holdings L L C [Member]", "terseLabel": "Crossing Holdings, LLC" } } }, "localname": "CrossingHoldingsLLCMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument periodic payment terms balloon payment to be paid, percentage.", "label": "Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid Percentage", "terseLabel": "Percentage of final payment on advanced at maturity" } } }, "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dsgn_DebtSecuritiesAvailableForSaleMaturity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt securities, available-for-sale, maturity.", "label": "Debt Securities Available For Sale Maturity", "terseLabel": "Debt securities, Maturity" } } }, "localname": "DebtSecuritiesAvailableForSaleMaturity", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "stringItemType" }, "dsgn_DisclosureOfLicenseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of license agreement.", "label": "Disclosure Of License Agreement [Text Block]", "terseLabel": "License Agreement" } } }, "localname": "DisclosureOfLicenseAgreementTextBlock", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureLicenseAgreement" ], "xbrltype": "textBlockItemType" }, "dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Expected milestone payment on achieving certain regulatory and commercial milestones.", "label": "Expected Milestone Payment On Achieving Certain Regulatory And Commercial Milestones", "terseLabel": "Expected milestone payment on achieving certain regulatory and commercial milestones" } } }, "localname": "ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Expected royalty payments upon first commercial product sale.", "label": "Expected Royalty Payments Upon First Commercial Product Sale", "terseLabel": "Expected royalty payments upon first commercial product sale" } } }, "localname": "ExpectedRoyaltyPaymentsUponFirstCommercialProductSale", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_February2019NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "February 2019 note.", "label": "February2019 Note [Member]", "terseLabel": "February 2019 Note" } } }, "localname": "February2019NoteMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_FebruaryAndMarch2019DrawsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "February and March 2019 draws.", "label": "February And March2019 Draws [Member]", "terseLabel": "February and March 2019 Draws" } } }, "localname": "FebruaryAndMarch2019DrawsMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_GrantRevenueTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of grant revenue.", "label": "Grant Revenue [Text Block]", "terseLabel": "Grant Revenue" } } }, "localname": "GrantRevenueTextBlock", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureGrantRevenue" ], "xbrltype": "textBlockItemType" }, "dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties": { "auth_ref": [], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Accounts Payable And Other Liabilities Related Parties", "label": "Increase Decrease In Accounts Payable And Other Liabilities Related Parties", "terseLabel": "Accounts payable and other liabilities related-party" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dsgn_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsRelatedParty": { "auth_ref": [], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in prepaid expense and other assets related party.", "label": "Increase Decrease In Prepaid Expense And Other Assets Related Party", "negatedLabel": "Prepaid expense and other assets\u2014related party" } } }, "localname": "IncreaseDecreaseInPrepaidExpenseAndOtherAssetsRelatedParty", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dsgn_InitialClosingOfSeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial closing of series A preferred stock.", "label": "Initial Closing Of Series A Preferred Stock [Member]", "terseLabel": "Initial Closing of Series A Preferred Stock" } } }, "localname": "InitialClosingOfSeriesAPreferredStockMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial recognition of operating lease right-of-use asset and operating lease liability.", "label": "Initial Recognition Of Operating Lease Right Of Use Asset And Operating Lease Liability", "terseLabel": "Initial recognition of operating lease right-of-use asset and operating lease liability" } } }, "localname": "InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dsgn_InvestigationNewDrugMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investigation new drug.", "label": "Investigation New Drug [Member]", "terseLabel": "Investigation New Drug (IND)" } } }, "localname": "InvestigationNewDrugMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_Jan2020AndDec2019DrawsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jan 2020 and Dec 2019 draws.", "label": "Jan2020 And Dec2019 Draws [Member]", "terseLabel": "Jan 2020 and Dec 2019 Draws" } } }, "localname": "Jan2020AndDec2019DrawsMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_JanuaryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "January note.", "label": "January Note [Member]", "terseLabel": "January Note" } } }, "localname": "JanuaryNoteMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_July2018NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "July 2018 note.", "label": "July2018 Note [Member]", "terseLabel": "July 2018 Note" } } }, "localname": "July2018NoteMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_JulyNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "July note.", "label": "July Note [Member]", "terseLabel": "July Note" } } }, "localname": "JulyNoteMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_LeaseAgreementTerminationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease agreement termination date.", "label": "Lease Agreement Termination Date", "terseLabel": "Lease agreement termination date" } } }, "localname": "LeaseAgreementTerminationDate", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "dsgn_LeaseCommencementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease commencement date.", "label": "Lease Commencement Date", "terseLabel": "Lease commencement date" } } }, "localname": "LeaseCommencementDate", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "dsgn_LegalPatentFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Legal patent fees.", "label": "Legal Patent Fees", "terseLabel": "Legal patent fees" } } }, "localname": "LegalPatentFees", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_LesseeOperatingLeaseTermOfExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Term of expiration year", "label": "Lessee, Operating Lease, Term of expiration year", "terseLabel": "Option to renew lease term ends, year" } } }, "localname": "LesseeOperatingLeaseTermOfExpirationYear", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "dsgn_LiabilitiesAndStockholdersEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liabilities and stockholders equity.", "label": "Liabilities And Stockholders Equity [Line Items]", "terseLabel": "Liabilities And Stockholders Equity [Line Items]" } } }, "localname": "LiabilitiesAndStockholdersEquityLineItems", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" ], "xbrltype": "stringItemType" }, "dsgn_LiabilitiesAndStockholdersEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liabilities and stockholders equity.", "label": "Liabilities And Stockholders Equity [Table]", "terseLabel": "Liabilities And Stockholders Equity [Table]" } } }, "localname": "LiabilitiesAndStockholdersEquityTable", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" ], "xbrltype": "stringItemType" }, "dsgn_LicenseAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "License Agreement [Abstract]" } } }, "localname": "LicenseAgreementAbstract", "nsuri": "http://www.designtx.com/20210930", "xbrltype": "stringItemType" }, "dsgn_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "License Agreement [Member]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_MarlinspikeGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marlinspike Group, LLC.", "label": "Marlinspike Group L L C [Member]", "terseLabel": "Marlinspike Group, LLC" } } }, "localname": "MarlinspikeGroupLLCMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails" ], "xbrltype": "domainItemType" }, "dsgn_May2018NoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May 2018 note.", "label": "May2018 Note [Member]", "terseLabel": "May 2018 Note" } } }, "localname": "May2018NoteMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_MayNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May note.", "label": "May Note [Member]", "terseLabel": "May Note" } } }, "localname": "MayNoteMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_MonthlyFeeForConsultancyServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Monthly fee for consultancy services.", "label": "Monthly Fee For Consultancy Services", "terseLabel": "Monthly fee for consultancy services" } } }, "localname": "MonthlyFeeForConsultancyServices", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_NoticePeriodDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notice period description.", "label": "Notice Period Description", "terseLabel": "Termination period Description" } } }, "localname": "NoticePeriodDescription", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dsgn_NoticePeriodForTerminationOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notice period for termination of agreement.", "label": "Notice Period For Termination Of Agreement", "terseLabel": "Written notice period for termination of agreement" } } }, "localname": "NoticePeriodForTerminationOfAgreement", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dsgn_NovemberNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "November note.", "label": "November Note [Member]", "terseLabel": "November Note" } } }, "localname": "NovemberNoteMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_NumberOfDomesticCertificatesOfDepositHeld": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of domestic certificates of deposit held.", "label": "Number Of Domestic Certificates Of Deposit Held", "terseLabel": "Number of domestic certificates of deposit held" } } }, "localname": "NumberOfDomesticCertificatesOfDepositHeld", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "dsgn_OneYearToTwoYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1 year to 2 years.", "label": "One Year To Two Years [Member]", "terseLabel": "1 Year to 2 Years" } } }, "localname": "OneYearToTwoYearsMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "domainItemType" }, "dsgn_OtherExpenseIncomeNetRelatedPartyExpenseAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other (expense) income, net related party expenses amount.", "label": "Other Expense Income Net Related Party Expense Amount", "terseLabel": "Other income, net related party expense amount" } } }, "localname": "OtherExpenseIncomeNetRelatedPartyExpenseAmount", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsParenthetical" ], "xbrltype": "monetaryItemType" }, "dsgn_PaidInKindInterestRelatedParty": { "auth_ref": [], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Paid in kind interest related party.", "label": "Paid In Kind Interest Related Party", "terseLabel": "Non-cash interest expense\u2014related party" } } }, "localname": "PaidInKindInterestRelatedParty", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dsgn_PercentageOfAnnualIncreaseInLeasePayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of annual increase in lease payments.", "label": "Percentage Of Annual Increase In Lease Payments", "terseLabel": "Percentage of annual increase in lease payments" } } }, "localname": "PercentageOfAnnualIncreaseInLeasePayments", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of selling price per share that can convertible into equity securities sold.", "label": "Percentage Of Selling Price Per Share That Can Convertible Into Equity Securities Sold", "terseLabel": "Percentage of selling price per share that can convertible into equity securities sold" } } }, "localname": "PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dsgn_PreferredStockIssuanceCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred stock issuance cost.", "label": "Preferred Stock Issuance Cost", "terseLabel": "Preferred stock issuance costs" } } }, "localname": "PreferredStockIssuanceCost", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "dsgn_PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid expense and other current assets related party current.", "label": "Prepaid Expense And Other Current Assets Related Party Current", "terseLabel": "Prepaid expense and other current assets, related party amounts" } } }, "localname": "PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "dsgn_PrepaidExpensesRelatedPartyCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid expenses related party current.", "label": "Prepaid Expenses Related Party Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpensesRelatedPartyCurrent", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_ProceedsFromNotesPayableRelatedParty": { "auth_ref": [], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from notes payable related party.", "label": "Proceeds From Notes Payable Related Party", "terseLabel": "Proceeds from the issuance of notes payable, net of issuance costs\u2014related party" } } }, "localname": "ProceedsFromNotesPayableRelatedParty", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dsgn_RelatedPartyTransactionMonthlyFeeForServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related party transaction monthly fee for services.", "label": "Related Party Transaction Monthly Fee For Services", "terseLabel": "Monthly fee for services" } } }, "localname": "RelatedPartyTransactionMonthlyFeeForServices", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_RepaymentsOfNotesPayableRelatedParty": { "auth_ref": [], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments of notes payable related party.", "label": "Repayments Of Notes Payable Related Party", "negatedLabel": "Repayment of notes payable\u2014related party" } } }, "localname": "RepaymentsOfNotesPayableRelatedParty", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "dsgn_ResearchConsultingAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research consulting agreements.", "label": "Research Consulting Agreements [Member]", "terseLabel": "Research Consulting Agreements" } } }, "localname": "ResearchConsultingAgreementsMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "domainItemType" }, "dsgn_ScheduleOfLicenseAgreementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of license agreement.", "label": "Schedule Of License Agreement [Line Items]", "terseLabel": "Schedule Of License Agreement [Line Items]" } } }, "localname": "ScheduleOfLicenseAgreementLineItems", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dsgn_ScheduleOfLicenseAgreementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of license agreement.", "label": "Schedule Of License Agreement [Table]", "terseLabel": "Schedule Of License Agreement [Table]" } } }, "localname": "ScheduleOfLicenseAgreementTable", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of restricted shares of common stock and unvested stock liability.", "label": "Schedule Of Restricted Shares Of Common Stock And Unvested Stock Liability Table [Text Block]", "terseLabel": "Summary of Restricted Shares of Common Stock and Unvested Stock Liability" } } }, "localname": "ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "dsgn_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A convertible preferred stock.", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "dsgn_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B convertible preferred stock.", "label": "Series B Convertible Preferred Stock [Member]", "terseLabel": "Series B Convertible Preferred Stock" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award maximum percentage of eligible earnings withheld to participate in offering.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Percentage Of Eligible Earnings Withheld To Participate In Offering", "terseLabel": "Maximum percentage of eligible earnings withheld to participate in offering" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dsgn_SharesSubjectToRepurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares subject to repurchase.", "label": "Shares subject to repurchase [Member]", "terseLabel": "Shares Subject to Repurchase" } } }, "localname": "SharesSubjectToRepurchaseMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "dsgn_ShortTermLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Short term lease liability.", "label": "Short Term Lease Liability", "terseLabel": "Short-term leases" } } }, "localname": "ShortTermLeaseLiability", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options exercised and vesting of early exercised common stock options.", "label": "Stock Issued During Period Shares Stock Options Exercised And Vesting Of Early Exercised Common Stock Options", "terseLabel": "Vesting of restricted stock, Shares", "verboseLabel": "Exercises of stock options and vesting of restricted stock, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value stock options exercised and vesting of early exercised common stock options.", "label": "Stock Issued During Period Value Stock Options Exercised And Vesting Of Early Exercised Common Stock Options", "terseLabel": "Vesting of restricted stock", "verboseLabel": "Exercises of stock options and vesting of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dsgn_StockSplitsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock splits policy.", "label": "Stock Splits Policy [Text Block]", "terseLabel": "Stock Splits" } } }, "localname": "StockSplitsPolicyTextBlock", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of convertible debt and interest classified as temporary equity during the period.", "label": "Temporary Equity Conversion Of Convertible Debt And Interest", "terseLabel": "Conversion of convertible debt and interest to Series A convertible preferred stock" } } }, "localname": "TemporaryEquityConversionOfConvertibleDebtAndInterest", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of convertible debt and interest classified as temporary equity during period, shares.", "label": "Temporary Equity Conversion Of Convertible Debt And Interest Shares", "terseLabel": "Conversion of convertible debt and interest to Series A convertible preferred stock, Shares" } } }, "localname": "TemporaryEquityConversionOfConvertibleDebtAndInterestShares", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity converted into shares of common stock, shares.", "label": "Temporary Equity Converted Into Shares Of Common Stock Shares", "terseLabel": "Preferred stock converted into shares of common stock, Shares" } } }, "localname": "TemporaryEquityConvertedIntoSharesOfCommonStockShares", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity converted into shares of common stock, value.", "label": "Temporary Equity Converted Into Shares Of Common Stock Value", "terseLabel": "Preferred stock converted into shares of common stock" } } }, "localname": "TemporaryEquityConvertedIntoSharesOfCommonStockValue", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dsgn_TemporaryEquitySettlementOfBifurcatedConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity settlement of bifurcated conversion.", "label": "Temporary Equity Settlement Of Bifurcated Conversion", "terseLabel": "Settlement of bifurcated conversion liability" } } }, "localname": "TemporaryEquitySettlementOfBifurcatedConversion", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period shares new issues.", "label": "Temporary Equity Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of Series A and Series B convertible preferred stock, net of issuance costs, Shares" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "dsgn_TerminationFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Termination fee.", "label": "Termination Fee", "terseLabel": "Termination fee" } } }, "localname": "TerminationFee", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_TwoThousandEighteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand eighteen equity incentive plan.", "label": "Two Thousand Eighteen Equity Incentive Plan [Member]", "terseLabel": "2018 Equity Incentive Plan" } } }, "localname": "TwoThousandEighteenEquityIncentivePlanMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_TwoThousandNineteenConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Consulting Agreement.", "label": "Two Thousand Nineteen Consulting Agreement [Member]", "terseLabel": "2019 Consulting Agreement" } } }, "localname": "TwoThousandNineteenConsultingAgreementMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_TwoThousandTwentyConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Consulting Agreement.", "label": "Two Thousand Twenty Consulting Agreement [Member]", "terseLabel": "2020 Consulting Agreement" } } }, "localname": "TwoThousandTwentyConsultingAgreementMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one employee stock purchase plan.", "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]", "terseLabel": "2021 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one equity incentive award plan.", "label": "Two Thousand Twenty One Equity Incentive Award Plan [Member]", "terseLabel": "2021 Equity Incentive Award Plan" } } }, "localname": "TwoThousandTwentyOneEquityIncentiveAwardPlanMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_UnsecuredPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note.", "label": "Unsecured Promissory Note [Member]", "terseLabel": "Unsecured Promissory Note" } } }, "localname": "UnsecuredPromissoryNoteMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dsgn_UnvestedStockLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unvested stock liability.", "label": "Unvested Stock Liability", "periodEndLabel": "Ending Balance, Unvested stock liability", "periodStartLabel": "Beginning Balance, Unvested stock liability" } } }, "localname": "UnvestedStockLiability", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_UnvestedStockLiabilityVestedSharesValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unvested stock liability vested shares value.", "label": "Unvested Stock Liability Vested Shares Value", "negatedLabel": "Vested shares, Unvested stock liability" } } }, "localname": "UnvestedStockLiabilityVestedSharesValue", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_UpfrontPaymentUponExecutionOfAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront payment upon execution of agreement.", "label": "Upfront Payment Upon Execution Of Agreement", "terseLabel": "Upfront payment upon execution of agreement" } } }, "localname": "UpfrontPaymentUponExecutionOfAgreement", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_UpfrontPaymentWithinOneYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront payment within one year.", "label": "Upfront Payment Within One Year", "terseLabel": "Upfront payment within first anniversary of license agreement" } } }, "localname": "UpfrontPaymentWithinOneYear", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dsgn_WithinOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Within 1 year.", "label": "Within One Year [Member]", "terseLabel": "Within 1 Year" } } }, "localname": "WithinOneYearMember", "nsuri": "http://www.designtx.com/20210930", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r51", "r53", "r103", "r104", "r201", "r223" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r200", "r222", "r262", "r263", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r394", "r397", "r432", "r433" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r200", "r222", "r262", "r263", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r394", "r397", "r432", "r433" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r149", "r244", "r245", "r350", "r393", "r395" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r149", "r244", "r245", "r350", "r393", "r395" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r200", "r222", "r252", "r262", "r263", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r394", "r397", "r432", "r433" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r200", "r222", "r252", "r262", "r263", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r394", "r397", "r432", "r433" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r52", "r53", "r103", "r104", "r201", "r223" ], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r150", "r151", "r244", "r246", "r396", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r150", "r151", "r244", "r246", "r396", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities (including related party amounts of $10 and $0, respectively)" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r35", "r338" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable (including related party amounts of $20 and $20, respectively)", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r371", "r389" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable Current And Noncurrent", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Total" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r35", "r101", "r332", "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Related Parties Current", "terseLabel": "Accounts payable, related party amounts" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r87" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion Amortization Of Discounts And Premiums Investments", "negatedLabel": "Amortization of premiums on investment securities, net" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r33", "r177" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less accumulated depreciation", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r25", "r57", "r58", "r59", "r384", "r402", "r403" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive income", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r59", "r65", "r66", "r67", "r107", "r108", "r109", "r294", "r398", "r399", "r444" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r23" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r107", "r108", "r109", "r277", "r278", "r279", "r299" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r264", "r266", "r282", "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r236", "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs", "terseLabel": "Stock issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Reconciliation of net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r266", "r273", "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities excluded from calculation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r100", "r138", "r141", "r147", "r162", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r290", "r295", "r306", "r336", "r338", "r367", "r382" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r50", "r100", "r162", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r290", "r295", "r306", "r336", "r338" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r158" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Debt securities, Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r159" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Debt securities, Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r156", "r164" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Debt securities, Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r155", "r164" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Available For Sale Securities Debt Securities Current", "terseLabel": "Debt securities, Estimated Fair Value", "totalLabel": "Debt Securities, Available-for-sale, Current, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r267", "r275" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r91", "r92", "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "verboseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r31", "r88" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash And Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r12", "r89" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash And Cash Equivalents Policy [Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r82", "r88", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r82", "r307" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates Of Deposit [Member]", "terseLabel": "Certificates of deposit", "verboseLabel": "Certificates of Deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r97", "r100", "r119", "r120", "r121", "r123", "r125", "r131", "r132", "r133", "r162", "r186", "r190", "r191", "r192", "r195", "r196", "r220", "r221", "r225", "r229", "r306", "r440" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.designtx.com/20210930/taxonomy/role/StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r45", "r184", "r372", "r388" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (See Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r181", "r182", "r183", "r185", "r422" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Common stock reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r107", "r108", "r299" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r236" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22", "r338" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.0001 par value; 200,000,000 and 60,000,000 shares authorized, 55,654,833 and 16,604,774 shares issued, 55,224,420 and 15,957,821 shares outstanding at September 30, 2021 and December 31, 2020, respectively", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs Policy [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r61", "r63", "r64", "r69", "r374", "r391" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "terseLabel": "Milestone payment", "totalLabel": "Contractual Obligation, Total" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r91", "r92", "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion Of Stock Amount Converted1", "terseLabel": "Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r91", "r92", "r93" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion Of Stock Shares Converted1", "terseLabel": "Convertible preferred stock converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r18", "r369", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "terseLabel": "Convertible notes issued", "totalLabel": "Convertible Debt, Total" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r16", "r368", "r380", "r404" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]", "terseLabel": "Convertible Notes and Notes Payable" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r220", "r221", "r225" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r20", "r21", "r232", "r237", "r238" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock Shares Issued Upon Conversion", "terseLabel": "Convertible preferred stock, shares issued upon conversion" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r71" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs And Expenses", "totalLabel": "Total expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r91", "r93" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion Converted Instrument Shares Issued1", "terseLabel": "Converted shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r91", "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion Original Debt Amount1", "terseLabel": "Converted amount" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r17", "r18", "r99", "r105", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r315", "r368", "r369", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Debt instrument variable interest rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r197", "r214", "r215", "r314", "r315", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument Face Amount", "terseLabel": "Notes issued" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r41", "r198" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "terseLabel": "Debt instrument interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument Maturity Date Description", "terseLabel": "Maturity description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r43", "r99", "r105", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r315" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r157", "r164", "r166", "r167" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale Allowance For Credit Loss", "periodEndLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance", "terseLabel": "Debt securities, Allowance for Credit Losses", "totalLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Total" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions", "terseLabel": "Number of available-for-sale investment securities in continuous unrealized loss position, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale [Table]", "terseLabel": "Debt Securities Available For Sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCosts": { "auth_ref": [ "r15", "r366", "r381" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.", "label": "Deferred Costs", "terseLabel": "Deferred offering costs", "totalLabel": "Deferred Costs, Noncurrent, Total" } } }, "localname": "DeferredCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]", "terseLabel": "Summary of Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits Assets Current", "terseLabel": "Security deposits" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r86", "r175" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation", "totalLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disaggregation Of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation Of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share, basic and diluted", "totalLabel": "Earnings Per Share, Basic and Diluted, Total" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r126", "r127", "r128", "r129" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued personnel costs", "totalLabel": "Employee-related Liabilities, Current, Total" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r65", "r66", "r67", "r107", "r108", "r109", "r111", "r116", "r118", "r130", "r163", "r236", "r239", "r277", "r278", "r279", "r285", "r286", "r299", "r308", "r309", "r310", "r311", "r312", "r313", "r398", "r399", "r400", "r444" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment Of Debt [Axis]", "terseLabel": "Extinguishment of Debt" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished.", "label": "Extinguishment Of Debt Type [Domain]", "terseLabel": "Extinguishment of Debt, Type" } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r301", "r302", "r303", "r305" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value Assets Measured On Recurring Basis [Text Block]", "terseLabel": "Summary of Company's Financial Instruments Measured at Fair Value on a Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r206", "r214", "r215", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r261", "r302", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r206", "r253", "r254", "r259", "r261", "r302", "r339" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r206", "r214", "r215", "r253", "r254", "r259", "r261", "r302", "r340" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r206", "r214", "r215", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r261", "r302", "r341" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r206", "r214", "r215", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r261", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r170", "r171", "r173", "r174", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r170", "r172" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative (including related party amounts of $82, $60, $202 and $232, respectively)", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative", "verboseLabel": "General and Administrative Expenses" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant [Member]", "terseLabel": "Grant" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "Initial Public Offering" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r179", "r180" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "auth_ref": [ "r85" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "terseLabel": "Accounts payable and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r85" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r85" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expense and other assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense, Related Party", "terseLabel": "Other income, net related party expense amount" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r80", "r83", "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest Receivable Current", "terseLabel": "Interest receivable" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r161", "r392" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment Policy [Text Block]", "terseLabel": "Investment Securities" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Debt And Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments Fair Value Disclosure", "terseLabel": "Investments, fair value disclosure", "totalLabel": "Investments, Fair Value Disclosure, Total" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r160", "r365", "r377", "r420", "r441" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]", "terseLabel": "Investment Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureInvestmentSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseAgreementsMember": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.", "label": "Lease Agreements [Member]", "terseLabel": "Lease Agreement" } } }, "localname": "LeaseAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Operating lease right-of-use asset discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee Operating Lease Existence Of Option To Extend", "terseLabel": "Lessee, Operating Lease, Existence of Option to Extend [true false]" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Summary of Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r325" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r325" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r325" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r325" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r325" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r325" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "2021 (remaining three months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r325" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: Present value adjustment" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Operating Lease Option To Extend", "terseLabel": "Lease term, option to extend period" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Operating lease remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Term Of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lease" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLease" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r37", "r100", "r142", "r162", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r291", "r295", "r296", "r306", "r336", "r337" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r28", "r100", "r162", "r306", "r338", "r370", "r386" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities, convertible preferred stock and stockholders\u2019 equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities, Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r40", "r100", "r162", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r291", "r295", "r296", "r306", "r336", "r337", "r338" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r3", "r38" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities Current", "terseLabel": "Investment securities", "totalLabel": "Marketable Securities, Current, Total" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r134", "r135" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature Of Operations", "terseLabel": "Organization" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureOrganization" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r82" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r82" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r82", "r84", "r87" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r60", "r62", "r67", "r68", "r87", "r100", "r110", "r112", "r113", "r114", "r115", "r117", "r118", "r122", "r138", "r140", "r143", "r146", "r148", "r162", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r300", "r306", "r373", "r390" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r138", "r140", "r143", "r146", "r148" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r324", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities Payments Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r318" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "totalLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r318" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liability", "verboseLabel": "Short-term leases" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r318" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, net" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r317" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r86" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r10", "r39" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r49", "r338" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets Current", "terseLabel": "Other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "Other comprehensive gain (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r55", "r57" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Unrealized gain (loss) on available-for-sale securities", "verboseLabel": "Unrealized gain (loss) on investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other long-term liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "terseLabel": "Other income, net (including related party expense amounts of $0, $0, $0, and $30, respectively)", "totalLabel": "Other Nonoperating Income (Expense), Total" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r86" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid In Kind Interest", "terseLabel": "Non-cash interest expense" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r78" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments To Acquire Investments", "negatedLabel": "Purchases of investment securities", "totalLabel": "Payments to Acquire Investments, Total" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r77" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r267", "r275" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21", "r220" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r29", "r30" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expense and other current assets (including related party amounts of $60 and $0, respectively)", "totalLabel": "Total" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense And Other Assets Current [Abstract]" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r168", "r169" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense Current", "terseLabel": "Prepaid expenses", "totalLabel": "Prepaid Expense, Current, Total" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Plus" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r79" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds From Issuance Initial Public Offering", "terseLabel": "Proceeds from initial public offering, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r79" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds From Issuance Of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r79", "r276" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options", "terseLabel": "Proceeds from the exercise of stock options and vesting of restricted stock", "totalLabel": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised, Total" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r75", "r76", "r154" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds From Sale And Maturity Of Available For Sale Securities", "terseLabel": "Proceeds from maturities of investment securities", "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r60", "r62", "r67", "r81", "r100", "r110", "r117", "r118", "r138", "r140", "r143", "r146", "r148", "r162", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r289", "r292", "r293", "r297", "r298", "r300", "r306", "r375" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r33", "r178" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r32", "r176" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property and equipment", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r13", "r14", "r178", "r338", "r378", "r387" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r13", "r178" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Summary of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r13", "r176" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r260", "r330", "r331" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r260", "r330", "r331", "r333" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r330" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Research and development expenses related party amount" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party", "terseLabel": "General and administrative expenses related party amount" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r260", "r330", "r333", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r328", "r329", "r331", "r334", "r335" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r284", "r349", "r434" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development (including related party amounts of $98, $0, $188 and $8, respectively)", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Shares" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r239", "r280", "r338", "r385", "r401", "r403" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r107", "r108", "r109", "r111", "r116", "r118", "r163", "r277", "r278", "r279", "r285", "r286", "r299", "r398", "r400" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r136", "r137", "r139", "r144", "r145", "r149", "r150", "r152", "r243", "r244", "r350" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Grant revenue", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r136", "r137", "r139", "r144", "r145", "r149", "r150", "r152", "r243", "r244", "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue From Contract With Customer Including Assessed Tax", "terseLabel": "Recognized grant revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition Policy [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty payments" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Summary of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Available For Sale Securities [Line Items]", "terseLabel": "Schedule Of Available For Sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]", "terseLabel": "Disclosure - Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Detail)" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureInvestmentSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r266", "r272", "r281" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r266", "r272", "r281" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r33", "r178" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule Of Related Party Transactions Table [Text Block]", "terseLabel": "Summary of Expenses Recognized under Various Agreements" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r85" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Allocation And Classification In Financial Statements [Abstract]" } } }, "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Common stock remained available for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Percentage of number of shares that may be issued in accordance with plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms", "terseLabel": "Common stock issuance, description and terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "auth_ref": [ "r265", "r275" ], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award", "terseLabel": "Number of common stock purchased" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r265", "r269" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares", "negatedLabel": "Vested shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent", "terseLabel": "Price of common stock purchased" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short Term Debt Type [Axis]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short Term Debt Type [Domain]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r20", "r21", "r22", "r97", "r100", "r119", "r120", "r121", "r123", "r125", "r131", "r132", "r133", "r162", "r186", "r190", "r191", "r192", "r195", "r196", "r220", "r221", "r225", "r229", "r236", "r306", "r440" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.designtx.com/20210930/taxonomy/role/StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r48", "r65", "r66", "r67", "r107", "r108", "r109", "r111", "r116", "r118", "r130", "r163", "r236", "r239", "r277", "r278", "r279", "r285", "r286", "r299", "r308", "r309", "r310", "r311", "r312", "r313", "r398", "r399", "r400", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.designtx.com/20210930/taxonomy/role/StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Income And Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r107", "r108", "r109", "r130", "r350" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.designtx.com/20210930/taxonomy/role/StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r47", "r208", "r236", "r237", "r239" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period Shares Conversion Of Convertible Securities", "terseLabel": "Preferred stock converted into shares of common stock, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r21", "r22", "r236", "r239" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Initial public offering of common shares, net of $21,728 of issuance costs, Shares", "verboseLabel": "Initial public offering of common shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r48", "r236", "r239" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period Value Conversion Of Convertible Securities", "terseLabel": "Preferred stock converted into shares of common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r21", "r22", "r236", "r239" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Initial public offering of common shares, net of $21,728 of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r26", "r27", "r100", "r153", "r162", "r306", "r338" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r98", "r221", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r239", "r242" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Convertible Preferred Stock and Stockholders' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplit": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.", "label": "Stockholders Equity Note Stock Split", "terseLabel": "Stock split of issued and outstanding common stock" } } }, "localname": "StockholdersEquityNoteStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Conversion ratio of forward/reverse stock split" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders Equity Reverse Stock Split", "terseLabel": "Reverse stock split of issued and outstanding common stock" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r186", "r190", "r191", "r192", "r195", "r196" ], "calculation": { "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Carrying Amount Attributable To Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Convertible preferred stock, $0.0001 par value; no shares and 22,500,000 shares authorized, no shares and 22,012,499 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively; liquidation preference of zero and $45,625 as of September 30, 2021 and December 31, 2020, respectively" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Liquidation Preference", "terseLabel": "Convertible preferred stock, liquidation preference" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r11", "r219" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity Par Or Stated Value Per Share", "terseLabel": "Convertible preferred stock, par value" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Authorized", "terseLabel": "Convertible preferred stock, authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Issued", "terseLabel": "Convertible preferred stock, issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares", "terseLabel": "Convertible preferred stock, outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical", "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity Stock Issued During Period Value New Issues", "terseLabel": "Issuance of Series A and Series B convertible preferred stock, net of issuance costs" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRevenueExtensibleList": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Type Of Revenue [Extensible List]", "terseLabel": "Revenue, Product and Service [Extensible List]" } } }, "localname": "TypeOfRevenueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r102", "r253", "r261", "r376" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U S Treasury Securities [Member]", "terseLabel": "U.S. Treasury securities", "verboseLabel": "U.S. Treasury Securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.designtx.com/20210930/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" ], "xbrltype": "domainItemType" }, "us-gaap_UnsecuredDebt": { "auth_ref": [ "r18", "r369", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Unsecured Debt", "terseLabel": "Borrowings", "totalLabel": "Unsecured Debt, Total" } } }, "localname": "UnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted-average shares of common stock outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.designtx.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r335": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r365": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r377": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r435": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r436": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r437": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r438": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r439": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r441": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r442": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r443": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 65 0000950170-21-003753-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-21-003753-xbrl.zip M4$L#!!0 ( !&":5-0Z9U/NO," )SV* 1 9'-G;BTR,#(Q,#DS,"YH M=&WLO=EVVTB6*/K>7X'K.MTK5*1(((';L>?SE?W\]&62?8U67H^&O3]@N M?9+%H1^%'AT_^]V^__#^$9,]?'K[.7LQX/#[=>_KTRY-3L^J\M/Q./O)_YSA3?#DX3 .!F?9RW)HA[ZT@^QH]L@=>$>_F^T/!MD[ MO*O.WL4Z5I]CV,4E_^V7XS' N QK']]LO#>7\3NJ/KTE!ECGG[%:YZT%^U] M==4@E/-K\<_F2DYI_K3]\<*EXZ67JO;2\>*EY8476+Q:/ 4@CF%K<78]@/W/ M[UR./SM;SR__>N7Z"_O#7V>7EE^_M2[#U\#SQN.>73X<#5_#L5>E7WY;&%=/ MQV>G\2E<2(;ME>>/&B^_Z?PQ3\>5'=9I5)TTJ()OH0CEA.<+BY Z7GPZ_+W[ M:?3YVG4T$6P.HKISB].MG;- Z8_-!<3RA;>J*Q'DK/B>UC17C&[(0)\^3)TX_1I_#J.P[IT M@TABQE7!(^JON8D<3U\T_/-^=%D.*[.ED-B^N,%:-35^"HD MX,LE4 CUI^&%%PJQ+C\-QU\;9H+74R/F>YB,JV_"RSR%7Y_\]F_9+\?1!O@W M^V5F/R'K;_)//M7[\^ M&0-0G[:\X2DN^W2Z[B]N%,Z:E4+Y.:O'9X/XZY-0UJ<#>X8$$Y\]^>V7\NL> M7AZK]F,90APV'\\I*BO#KT]>?M16Y<+D!6%2Y40FJXE-*2?P=53")LL"0&MH M3^ I4VS:PS=]D][%SW#8\<7\[/\HZ_%T U_'[V*"K7VT3.?)^DB\EY1(&A(Q M.G"24U4X3VV 9SWY[7JT_0LR5EOYX_UA> X/'HQ.41SL5T!YGR)^1#!6UH_? MC][&"FGQY:AZ,SX&.70P.CF%5VQP\H6MAC'\\O0"*)9#QEGI-!6,*,TED04W MQ/*@B$IYU%IQ;S2]#V0,+:+T@<3(#)'.,F(4T V"Q<-IB@,G$T'OD_WYPVG.9. MP,TFP[*]XX"))>><9SNJJMZ.BC%%01;Y(FTM*":"4<&I\$1%#BP&0$^L#)2XO! J JA<$>^\@XLT:U($6!E#"I4G MV("CQ#)GB4]"YU(SS?VC(9=H4-851$83B0S!$!,3)Z$ S"U87EAS!6VNPOKU:!R;;X].!R52^E3Q M?H<$PRYOP^M4) %J,-<6GDD%\'E;4*)"H$E*Q6UN+IS$*2CC3[(0?7EB!R"Z M03%"2,$K 6<$YG; M0%Q2E@0NF/:YH2KPV^-=\L8&E2PQ%AB4]"P0(VU.BJ XU1Y4:J%7A'= '2GD M@-@Q%8)()34\U$BBO0?$$RJWZ@+>[0/I!R3_EP/[Z6[(EN! XHT$60PHO(!O M1%TX$&0Z!])+@'A):2&5I7#N]Q!D2;*8*YV(,AYHCE%/@'%HD@>CM;,B,1HZ M(\@N0D; WG,:"D)=L 9D!4N@(BGEDL>/0W 01:/[07PZ?'90<37&!R"T/KZ MG_$*VMWL^"BH_IH6C-.;L0N3&!O"EKM M!7F+7*)^:\\L'.&[. &%][:ZBK%W.C55\2I16#,:-"I @6D9!&TAQPT4&!1 M5"<7.%QP#Z24 "]%(]C\A0Q ^Q:0TL-.:"$23;F,3IB.(F5**O@"9 (W%B 3 M/,BPZ"V)14H>Q*4.[@)2SEPCK1"#ERA'X25\=U4INA%B_EW<#"%I2J!Y #L% MA0H0L@#EQ&D!"*FCS75*6JCB'FJ/3MR#(0*J"! *'* &540G0'HA> #1HJE+ MJU)[;+ J*I 1,7H/"HH)1$L0Q5;R/,%6I/7Y3=390WB;$HY@X@:E?Y,20&]X ME;L_H&IJ4'YJ4$BI0?X&?Q -@IF80)D!G9+[1"\PC7?QU)XUY_,F;9AI/+UH MN%81P FH$NO??D&/TE[=^$Q@R:SQ,.VA]^#7)W5Y)2!]/!X7]>E!.7;YXM5\=/>&;M MGP$>]A6405^.7\43!X\(Y0ER2O3&SK#W90G' 8SSW6[^B]/ES[TM]G;SM_MZ3) MG#;<:KZ/,> 7JM^_M0P8Y#*;KS/_;0[1L'"I(8*>/Z+]9?;W["%/+YSB\D,% MQ3 )D/HD ;,% T):XB3:$R*%Z"@%>[?HZJ$^CVY\.*R!H!H1U9Q=0]4?AO!T MT.0#,*V3LJY'56,W7'. -W[NT?&H&K^/U0F^ ,KHA4?_'SN5!YK@6G%@1$5U'@>T?Q M>O2YN6^51[]BE%L!SV /SS-LP50A#>IJ G1-5X!2"Y8%K.XH+S3G1K.N(LR! MK5&UQ7_0B/X,MCTJ9Q?X_H>C]Q6P_DEU=H1G"CI.O([YWUP0V;+ZAQU,XE_/ MYA__!CM"E?OL#U2X+[[+_*+#X>ED7#=7L'5RELN('0CT[BT1CVCG?^,?*--7R1 MII>;V"^^HO'\.(_4!SBYX!WQ$BQFR<"ZU[GVH&5*, B%9M;XKA[I_#!;IRLZ M.4;#JT(#3?W1L''2/LHC+'2PG 9%G()E)1.*&.?!OG;) 9UJ$[CHZA%B'.TU M&/T+#/3]E]'[X]&DML/P_@NL=O9F&-L#/@_+?;%5P%L?Y7D&HX*4!25!(Y<- M2A#'@D62Y"F@UT3)KI[G#4GR71S;S\YF31V3!.[P>NJ>(RK M?8ZM$KLMW++0E GA%>&YH!B*-L0FH,.D:9XG7>1:T:Z=%G++ \SDB]4IFI&7 M*/!P^#G6X_)38SN\CE^>5Y-/J[(JVYCB0CQOX;E_ -,>+KB\[_M,W.8[?$[[ M#/SS53DL3R8GV^+!,"H5DH5 3.(6;%&;$X?Q)2EUR)4&_F[RKB'7]K&"59T6 M!\9L&\ N(Z>V6K/^/X MY608>H_Q79#D9KE5ZT62[0C<1F-X(5T@K"@XD0X6U@(>X!7 *D^6,=[9($QG M[/<.^&$*Z;GB3A"P.# OS("&X64@B?.D%29UTXS=B) L:Y3"O$F-,WOA,(\ M#K'>;Y.NQYA!\[;)(*IB> B_-\64AQL[=SCA9B5^TMQQP[T@3N62R.0#L=)8 M8C@SG!HF4H?]WM4(MCH^0T_-&/079+=-K.FO9^?QQ O93IA??@CZ/Z9.K(=& MUZ,W8/BAD-P0:8L<_@?L?V/1K^TCIJUI:?*UY[#<5K->V>950971P&F,MICU MZ"V@J*8D2)<7!6A.1JFNH>@RUX#]>@/7P(V1_R$=';<*__X>AZ"]#X >]\-) M.2SK,9:/?HX/$P#>C(L\BD)%IS6)1H.68[#J4G+X9'E,3 AJN>TBBFX^I+&A MM%#05WAN-.&8CB_!&B,V@1H3I-#2V:!,<%T[K[E#"X,35^4;J*+CJO3CM2DK MZW&;""$%)M2!_J& 7FC$7'WGB&>.2I82<['['LBK"N5YVL2#*9/K.1].I9)P M1J1H2H-99'@^DA1,,^93RHN\LZDM:TJ&[(Q6:*B2 6.R!4^@%7*AB(U.$0WL M2XK@N0YK#^1M+"YVHVK0CB+F34,7(92H7]G!6UN&P^&!/2W'=K#FQ/N5L0X5 M

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

]'8SNXY/;MXRI=D=4]3#L"TUZ?V:@^ MPZG(%>>*<"=S(BT-1$=K"&-4&*7S$'*["F_#ZC47>+T=;K[MY.[YP5;R@QZF M/4RW ::]W-JHW#+:!Q'R@DC#X7\XQ6HHKHEQPAK+9*'2O8*W:Y1;^0X7HA=; M6V\[]UV:UYY,-3J-34[4,#1]44ZQN&DG&\9QGQS0+1':0[:#D.U5E,VJ*)Y: M$;PA!:=@)AB4DF$:8+5UB63!', M:N+@:Q9N!>LEVR,QR/M@]MJ8P#N\EXP2F6!1$_K$>G]55X1H#]..P+17239K M;P=C"Q?A[; <6W+'B"Y$(('ZI*+EEL8K*LE=[.TWH)#8<3G\]$>T=6PXXYOT MH8Y-J& U(8*=0O81@D?&'7J8]C#=!IANGQ3KCF#ZC[]\Y93)G@2VSG;L@[EK M)HWG,<6JBB$;)?B ?2_\J.YG7'1-9/1U9#_(&?1B?E-BOB^4^D%HK3^,#AU& M+WPZ= ;;)WP>EZ?4)A,8UX3EH2#2B9P8ZQ@)R@\$TXO\B>]RA?PIC"9N$+=+&>H.>=QQ MW-:ZSZ]7I#:J2#'!"N92(%1Q0:1VE%CA.=$AQ>1=C(&%U55/KT2#DI3N"+71 MZ/+U^-TK4/TY].?0R^M>7O?R>K4E688+FGL0T)03&6R3(J:(" PDN'%>F2O] MYN]>-;ZJNS:W=239HG\%H>F>L".0FGH_Y-,3P:;H;I[C%G5-VB?N)T<]14R# M !L;5$OWU]_:("E1A"1*X 91>R.GQS8E/ BLS%HKJRH?6&Q632",8/<#[(J@ M1?Y ET:P:PY'\?IM:_O5FPYCH^G'D/0%7L/5* -[4E2Q:P% F.N%N2)0D2W0 MC1'FV@)%G$9<15!Y$,+U,.%+][Z=(8Y3AU>W0"YH2SF+P*.3()R68 E/H+)( MP7G/A5I+?]TH:^,&_M?7Z-^9\]KQ%/>O=.>KTS'W:R.R?4.V'O)$7=PS M7?1:*B.U@&RD*KI8?G*,$4A.<9\B$93Z+>S&.AW9.^;6HBX.),7SP]+ 0]*= M'9(NKE(M1V\TJV7/>3MO^,+SWSJ4\'J&N:#1E$Y,U$;(PI- H<>"EC:"2 M%EDYFZ5[U/8B-L5O;BQS,P.]N1V"?L.E=Y)WMW?61?MVUK5/)ZN2NL1BR,!L M.PA0AP2.R Q)6,:C]MH2]A@MK\4)^^:#G9RW8F)");?DV%FI'^CCQG*G8L13 M#"4B"L"\E"4BXAF<< :T5[DH#+/!==,*X-.-Y:T>W%/DKR;L]Z@TM!&@>!>0-">5DD.0D0*1%%A!2)ARV<]3Z- M)%O>U> Z5()>'1AC3X MD\EU)\3/G/WB%4M=ZHW(5H@LQCR[[4CH.%=>1XBI MS6V7QH!3A('7PMJ4K#/K9^*;'$-L*:J18TDDWFT/EQX0642V;\BBI.WV9#WR M1'WF(+(CY5^Y2)I+1=R$2$$Y&3@376SCMR1I;,SYEV]PD1[ZM?O^OL,2W'=_ MA_D^S%4>3=O!RA]VWN_'HQG.FZ]'21'32C#%N&2G<8F*CI08A(%208 PS("U MW@*QQ#-!N:>ZDZWVI_/F;Z.4]Z_FL]#M%;_&F?,#8PC$%#'M Z;]4[)ZQ EG MSO=U+XDWN=O>4:ZJ>*;SV1LHG'*!=[GUR@:._MT3&_1/Z@>U:>6"6\Z9A2A) M:#>@ FRB! BA6@2N?&:DDTUK2[UW3M0[WJW2KI+?< SPGA 0&J,B8Z B5V0# M5.3=SJ2S,@4J'%C-& BK(SB3-63#0LZ4)I,ZR5+?MB*+"O*V4 7P7GQPIQC7 M^>B//KO D[Y*#KLQ.NH'^A@7[;:[BU+)FZ# !I= \!+>.$8"1.4RYYJF8%+' MF>R=!$)FK+%6'HD&S= 3,Z#:5H$^JNU.U39'E803'+QQ$80D"IRE$:3T@;'$ M;/1K[6L>F63?47:]T%T=/"#-]^K(8:#I$]^[G.^^%IH48/(.SB>Q?*47/_^A M&,G$, W!^!(0$V; :<^ 2:Y]",0RG>L]^3B<7UQ,EA?%.!_//#[Y3YT?^V,/ MSD>WX'S(OB3GLJ5Q"B*5A8)UV?5XPSDXDYPR.1LN=;WV;>5D,GN39N'NJ59O M+/S#:4JC5_-E&ED<*O3TT>HWS^#_MI'%I0HVY9$)(@0.7@= M/:B468PB.4Y,%[<\9^GBFR;=C_NYM>I==I<7KN M%NG3,ZGR8XJK9S4G^> B+8J3OYQ/IV[1W#S[XSG5\:N?O_0=B?+1.,*@;+K; M.06VW80'4?YH=991F$1M%V=K3_,=BZW+1_K,D5NO9A1MMC\]/BM M>CW?[?->*#0)B7L)GK$$PI8%X[,N:\Y2QXNG<4TZ:5!^SPM73M0<7"W/YXOR M#>(GWM>L'KSO8G?/>]L3C_;,M]69)LV>_?=LWDM/N_ZFHTX.A>KY;I_W-*9% M2$90T"VQBZPLN. 9<$NI%(1P*[?!=X_TM+6;!3:6I,!'^C9^Y5.'^P#'>/B. M9X(,C!D.A*1<'(]I<%0R,(0%&7.2.712W/)9QSMNFJO'T]L7N-L'(2R3D)SQ M()(G8*V-4/B;4&)-)-T,E_CL%SNY6C;+0ER3V9NMD'>/%]<^L+G7GM#@+&2B M'0@>*5B3(D2:(LW&1>?TUMA\HT5UG\F_L*9(H-)S"B&UDT +=8!1FH/Q0JM( M@]2RDTF@':^IS\@4H6PL/CL2M+]+:[(R_/4LQH]8C=QR=)HNE^G"I\6(D_&( M$497SWJ9PLW?TM7?DD^GD/TTFDX*_M&M/.!ZHYUF(;7C&@>_A*,N(M%ZN56M MVXJR%34AE,6LK*6&&>F"W()\_/(1\==CAMA,GRQQ>8 (D) MD%5H\*Y#'02['V!7!"WR![HT@EUSD/DA[KH+XLU[;!1QWH#5KOS;]ZF0A.H) M0MM2TOEL?_*JJ94D)\,@::9!."[!2>I!ZRPBL8PXF;NX\KW&=17B/VE.M7?9 M)2X(A-#V*VA;)QIO!1BJOA:M=IG$M;&4CUQA76>X7J>W]C;%=2_2[TAA)DJ]!.I2(7)&BL-)[X%[ MYXCA,=NX5B#S2*+KV,U4O[UL+Q.I+1$Q9 9>M/D[2A=U+0S5)HPID[FBOILI M 6M.UTF^IY1C)<78\"_/LZO9X?:#UDJP9B210$*)2H7,&3SE"A0IW)6$,]K1 MK=!:)QY&U5@1,=9:]-+#/LFQW0LZD]2H$,KK='$VXA)82]HV9R&QG(40;JW% M>B=TUEV:=]M C(EQT?]>>MQ><%JV*HF8!4CM3.$G3MN!L,5OG N",>,*K6V% MT[IS,RK'5NJQ85^>KU.SF]T06R<5 WB37\N)-F):":;]NQ\8E+X$37T.6@%C MBI>0)"KP66H0M*U9XY9EM5:)]\@P9G70V4F^%*9*#8P,$%/$M ^8HFCM-@M8 M&&NIC!!)VVS&!0..J/)A'24^^I28'9X39%W@IMNBI>8'EOYY>M1)(S>$P8BB\CV M#5D4N=VVB6(\!Q8H4"T\".,(^!@C&*%DE,Z*S- MQ']8)+A]W]'V/82KBZMIF_P^NJG9Q:.P6B07,:T$T_X%,/4PS ^#SP\KSIA- M=@RX;FN6 K%@G6\/!+2A-IO(V=I5R":'"+^FI2MN$X_<8C:9O6GN9X6A50NRON?IUDS>9M&DUGY<\(#S+HBCD<@Z\M#:?'QVTI2/NJHF4\G M-*_2\B2?N7?=AHQ?+G:N9[VRME#VYI]BSOK)LQ[/WO!L M"*VY;U*(-MB]#?H7C@Q*[W-1;N.\@&3: DRA)!@CBXKK)+2.@I"L.DF5V9;> M?[4'0%>UFB@-?4ZUP4[X77/)V7SIIJ/F6_KAXSEL+7*^$:883/4#?0RC=GNY MYA5QS 00- H0BC#P5D?00H= 1!2*KX51FQR;W!U!G]>L.H9N\>0&,W2JOXYASYELZ3/.KUH'Z54\6<^R^U/- M5NQ?7#JHP,\Q(I-/%$)FJ3W:T> #$T -EY)Z*J3LI,'I+Q])_V 6MW0X) @9 M\QIZK#SL_[V+ @>M*6B-FJR!"H\*CPK?V=@?0C@E-(&5+H#@A(!-*8*SP0CE M)'5J+4]VDZ.=)U%XKL:25I1BZT]5EN]KZ=,C.;+\N+W*+\=:&Z\G7>+%:-;A?+ MT3R/EN>I2:,\F;E9F*PR@-PR791OW3SOQ"*4[9=)5HVY/\'M_,-IZZ5[DZZ) M$UPNW^&%F_[;O6]^>C;ZKYI\'M?Y-IW*%ZW_7N1>'IT>_^W5Z.SO1[\>O#[Z M[>SX\'0\.GYUV,T2W1J8J\#J(Z'\,;],"]?&(4VE.!^>O'IY].KTZ.7H].S@ M[.@?1Z_.3D+%-/O+HY'5QBK/CDU>G=3M#K73]PV161'!^U;A9;,:C M]"ZD]A[R_%HPXZCX[,V?HENZ'Q'DC4#^;>:N8CM^OE( GU3S5I']YWH1N*OE M_';+U/[>$KZ](#^MG@Y3]WY^M7R1)^]2_.G?D[@\+Y]@!=3-"XHYI^ZR22^: M5(*[0KJWWWFU=;]^[V?W+X#?3IK):C?Z_L7MZS]S#7S]ZX1Y;I3Y0S:_^;#AW,CKC\ 3(R-2;=(<;W,2Z(MH_\Y9EZ5DN28R\L\P31]K=8]^Q\ MD=+H'^4YY\WHJ$ 4/QW@6W?Z7-^,WD?*0[,@2^X[2[XJWQ-)<@BK$4/T:DR! M&#^U^# 4GQZ*#R.,HL+T:\FA6:HT"S)AWYF0X)+KUY)#LU1I%F3"OC,AQH0] M6W)HEBK-@DS8=R;$F+ _2PY;-O2FLNS7]#;-KM(+;+'PY 68WZQ)>S7^O<>5 MKP@V\@?R![HT@MT#L"N"%OD#71K![AG8%4&+_($NC6#W8@#,71"'/PGX.RWQ MR6NA20$F[^!\$LM7>O'S'RD*S:Q.D(SV(+11X%76(+(T7$A')',/OHGED5)K M++A(RIO0I,$JJ2"83$SVD94G//@FQDG%K=) 17FIR,Z RUE!^>LDN)XH%HD;(B8UN/T&_:2>VR:=D\BBGKL=-T-6^ :0EY"3'N%:3T<@ES_-:[_ M+C#K,>KGVX#&D)521("QV8%@@H#7QH&CDG*F@BV;DOMM0(7-5))$@6H10007 MP(7(@&B>258B>6[OMP&]21CX>3&_."QOUGZ(_SM9GA]>-07XM#AZ%Z97<3)[ M<] TJ?Q_[&J$;IL M+NI+Q6Y,K(X8MI73.LA451&W 7UE0)AN0)3J*\)B5J07A'P4KJ M@7(5J4R."TYKV051V]7THR%23E^N@[&J87:9968-8X( ) M0G7H[:YC302['V!7!"WR![HT@MTSL"N"%OD#71K![AG8%4&+_($NC6#7?**U MIP4.]9QX_9J:Y!;A?#7[*Z:W:3J_;*?7C7Z8S&[.HD>+-'7+%%_B>&%ATQ,Q+023/MWA# H\3#!JC8 M4H$J-BQV0$P1TSY@BBJV4Q7SE H9C 8NDRQ[,2_ ^N@ABE0V6C;J&-=K;38Z M4MZZBNFQ$!1E;%CT@)@BIGW %&5LIS*6&?7>Q "9$E5DC/$B8\X625(Q2)V< M2ZZ;^ZAMRQ@?<\E0Q896'HHI=3OJ<9MF:>&FJXPZ%R\FLTFS;*M*WR9,JKMF M3FY<*-$\!!K+!D#RXI..2Z DL:QY5$'I+2;5G:9I\<4W-V8JM'KPB9&>]J+_ MR[Q;IW/O0\Z3T)204)PK>4N+?V8-G@L+3BF=O#9"L35E[S#GKB;_5)B35Y]_ M2L8,9T$!L]P4+@PEBN24@ GE/\Z44-*I+>;DU>2?C/2-0/%@U+5("1SH"DJ_^5W:A:VPQLLEE]0*6Z$:&Q_DJ1 M5SV^7S ?W_Y3+(=$A,9 8Z RUV8#5.;=9D,JGI*5"6R*N1VGE\ )Z4$Z)XP* MRONPIE%J:KG'Z4@CVA(31&1<9 7:[(!JC+NVU9P4E.)"K@*1L0TFAP MSGJ@9?.;A8H\Z_5"[0VN)YY"EXNWJJXZIZ,8[ D1H3$J,@8JJ3+K MS*PFQD+TC+?U@Q0,XPPRBX+ZS(.FZ\U\-KB/?0IEIF-.NQKMB&+0PVS7[\LT MQC$HWV&^L_G234?SM6$HF!)>BUIOA"G&2OU 'Z.D'1?V:.&M=F!-TB X8V"R MIA (D20I&LCZ++A-;OP_#)NZ343K)BXJ@1'7NZSFP9"H'WR#9JC"#"BZ5:"/ MHKOC1NLZ<\[;(@8ABNB2#(93"\9&SZ*VAA/2Q67^=D27C079Z8!5)/M^T V: MH0HSH.96@3YJ[DXU-RJF6W6>O>"R:*8FHE X@DRD:7,0=9*RYX4"(: MV<4=_'9$5XR5VFFK*"3[2KI+X:U[UWSQR[QI1GDQO[B]>9_/-KQQQZK["K/D M$-EM(=N_B*8>TOEA\$UHHE7>)5N\B=H$)8KRX#W1X+BU1AD?(N>=7NOP1>^8,1V,0653O^AAF^.J=@TXJ1=XF C 0 M2@2PPG/03C.1B:7"K0U@?U1>P+;4FXVYJ:"2L**UA>+=*]/T6&(0613O^AAF M^.+MBV9S&1T0XQ4(PB(X80D0RC6S*G-/.^D$L'WQ[C+78+A$5H\_HGH/1V,0 M653O^AAF^.KM!!."&P&1B]S.:71@%!6KG 6G!?6.K(UI>52FPK;46XR%JJ"] M7D5KJX?BO87& 7>-."#K">Q[LCQ/B]%DM=K'HUE:?GDNUDWG@?V:CR6L M(XGY"#GZ0KR:*["L95+GC#*V\&A8R\O>Y,;RN)7\U-S.$NQ\Y@7.#JK/M[@6 M+/,BT%$25@0ZF.(G[92K[&2V08=(0A?GZ>A;^^=;+ND@@F1 @S(@!,G@6))@ M??$NDK/U=GTBZ@;'/>A;]WUK/\9)&:F(UT%"7#7FD$Z!BYJ"Y$9F13UUI)/V M9=OV+]X_!^M@%-1&Z=Z5[YEV??:SG13Z#^Z$Z&.ASMX6ZIBLB1(E2-;2'30#F@'5 MMRKT47UW>TYEA,F&!BJ!+/.>+!RIFP/D8A'-\*+ >ISW MZ0MMAV=-#%EV;X-Z5A2&+!BR]#-DT2IIY6F 8-M;(Z8I^!*H@$\\9ZX<]VIM M<.8F.1M;#%G8F#.<*CYH?L6(!2,6C%@P8JG K!BQ[/J013MC4A:0N&JCCZC MT!*V9"VC44HE&]9;G&R0Y[+-B*7M;H*'+(,F6 Q9,&3!D 5#E@K,BB'+CD.6 MX(D+6BH@JBU+59R#IYE!]B8*FH7(<6V<:>;0'?_BE^+]T884:V0+9 -T:8*X*Y(E"1 M+="-$>:J8:X(5&0+=&.$N;:ZL\$=&-5SIG=;<3:Z3,5(YVZ1QB/OFDE8M1^. MD^G5,D74@EX3TZ=GXNPYD^V9>)Q?^6G"N\8GO6O@35@%E]> MR\FG%X_EQQ1/EVZ9FI-\<)$690&\G$^G;M&L7OSA6I+ MA@2?6Y]XZ?C4:5)H2 Q8*H"_GG6$ 0L&++T+6)CC*M@8P<6H0"1MP9MH2BSB M2R1"WE4/$H(HQ7F:Z=L&Q2>?;D 0O%@&6H1/M@'=KCLHVPR_66 M[?=_5R].$5Q!T;U)UWE'S6B>"]%<7,S;CSP/_QS-KY;-TLUBX8W.DI*P1_:V MXM#.BG;['(WNAQ'Z%U(.*F:3RG!E=08M78F_B#$E9E,4M%9'7]&@<1PPV: MGM :-5D#%;LF(Z!B[U2QN=,J%2N#4MZ!L.WH3>$2$.HY8405">YD\/4.%)O) ML29TK'E7YRVH$7M#3VB-FJR!BEV3$5"Q=ZK8-F5J3$[ 4ME9"QL4&*O;; Y% M@J4Y92^Z2.38@6(+-M;2CI7L:H8V:L3>T!-:HR9KH&+79 14[!T7MXJ\.A47 M.K.R7U9%?6EP0*W/+&C&6&9=9#+L9H^MB!IKW575"&K$T[=!*?]U!:/5CU]" MX\\#!6/S[\RZ_LX?J;G&Y(CK)[>?Z<5D63YP*!_T[#R-7 CSB_)YWQ=F&N\6;CIZ-(MEFT*Q?(\-6F4)S,W"Y/R]TV;1W51OG7SO!.+ MT#TS2:'?>[B=?T@PNBP"<$V'IT>_^W5Z.SO1[\>O#[Z[>SX\'0\.GYUV,T2W1J8JU#K(Z'\T9+2(IVG M63-YF_YH^TA5BO?AR:N71Z].CUZ.3L\.SH[^3TM&[GJ)6^?YC,BBC.KYH2F#<_(H8;8?C;S%W%-BV[ M4@"?5.)6@?SM;[GY8.T'>.&NEO/;'5+[>TNT]H+\M'HZ3-W[^=7R19Z\2_&G M?T_B\KQ\@A50-R\(;8;[99->-*G$_3MCG5-(_MS!];JMX\YF>4V4??(YD#[V/?4Z$>. YY+G5#SUG MP)]'L;H^SP;X?"7KWGQ7TOU&51:?6?_?=,Y@=L3G#Q"2V?(QZ$88UX/I!A3? M :(?6C.K;;1FWFB 7"]\_0EBZ&^Q[MGY(J71/\ISSIO148$HCD[39=F_^+08 M<3+>64W8-XTFZYO1^TAP:!9DR7UGR5?E>R))#F$U8D!>C2DP(-^NU&QE5@I* MS9:EAI&V63?JR7Z3&)H%F1"9D!%<= MUDE:QU2"%(4'D7,&IW2 1$-@5$9O0^RB@6'A_.-9F%^D7]K*A$]:3)^^_-!$ MFM\MQ 3^L8OTUTHR*1US:G9?CEG1LJJ; S><.,D[F>>Y1>%G8\XJ:$YA1^%OR;A]SIP'HT#%XD&H:5H1Q6UTR:I\B&J$(7KHBGC%H6_Z#Z3 MJ/N]H< M3X?\OCP;3-'X#LN=+,_38O1)3['1&S>9C7YH$S=^?%%AD=UP0[GM M)A+V+VK8=?2,,-<+?-.&YU4W6UK3.\@5A?]U'-X]=NL0#LM3X]WSZQ&\]G(O763Z:H% M=)XOH'%MZ^@4KA:3Y21A.5)EY-;99*2O%<>B#79O@_X)TJ N!HGF)BJ:@2;* M0;"8P"GLQ. M/Y#SP6+2E(=>EC_.WKQ.B\D\ODK+DWSFWGW['>-7KA8K2"?:H *\HG6R;^R% MQJC(&"CG%=F@?W)>CT(//PV).4L9UR6\D-&!,%Z"XXE!)B1+KZW7;"T-:9.Z MH]U'&]^4T<0P[ACR4<339SX/SYI[(9IH@]W; ,7#%R^'+@8'X25)$-20H,@ ME( SQ)9(Q)8 QBB>D^RB<*H?@4M9RABY8.2"UMQ[U40;[-X&_8M9?2.O[ 8JP>AV"\RYR=IXL4&%CKKHZ MK4)]JVP]8IR"<0K&*1BG8)RR;W&*Y,Y9U_8VEHZ!$%2!,52 RSX1YIA+3G>1 MHO-T<8H8*]95:1(*7&4+$@,5#%0P4,% !0.5?0M44I(EM& 22&X#%9(-.*M\ M"51,9LH1:=UZ+O$&"4-/%JB(,=,S:U$ M"YM_9];U=_[\Q/5:?.CZR>UG>C%9E@\1\OSU*11GLS<+$S*WS=+MTP7Y5LWSSNQ"-TS MDSS[;WX/M_,/&8"7[DVZ)MZB2.4[O'#3?[OWS4_/1O^%ZWRWW_GIG,K/I_%[ MD7MY='K\MU>CL[\?_7KP^NBWL^/#T_'H^-5A-TMT:V"NHK*/A/)'";Q644;1 MM3\*-CDM%BG^T2SGX9]_-)5"?WCRZN71J].CEZ/3LX.SHW\?0\AS6P>^BSR6G#WX>:\T3?9ZNGF-;[WB2WU00% \\119P M'@+Y"3].\2_^\*^2_"&;D^="/?2["C>)AWS9/%?FH? M$#Q=X\U1/9AN$$)T@.B3M9Y'#T:6Z"W&]6"*+($>C!@_'<8WF^/K/?#7,A.0 M3I"@D:"1/!#C>C&N!U-D"?1@Q+A.C.O!%%D"/1@QKA/C>C!%EMB]!S]!AL^W MV.P@A*N+JZE;IHAT@W2#=(,>7(T'(\;($L@2>QB4G,V7;HI$LQNBP0RF:DR! MG+]=SE?(^=5P_N''4A]D_NKI!I,P^N9-=X$..D[7"%QX7(-L@V@_7@2MAF-?83B0:)!HD&/;@:#T:,D260 M)?8P'#EM^^"=E]>E17/;E0UY![,F]MP4* $]S)K8J*%_+WR]$K%X?=L^=;22 MC;H[PO?-QK7PV5;2,K;8T7^H7(GJ@^I3!S-5HCZ'\XN+^0RE9[C2@XJ"!S#[ MQFJOW206:/#,95#L5 ^F2#6[]^!*J.:3 7)(.$@X2#@#]>!*" <;@R#=(-T, MWX,KH9NC?UU-EN^1:?#V>L]-@:3?0]+'^X-MISJU\Q";NH^H^V;:/M(8WAP@ M\^T7\QUWC$M8>X?I9>*T%ZE:94+>5<-T 4N!2&LA00UWW$M1H^^1-R/W)_O]=271R% M(R-1)!!7Q+4R[:1D-^+Y/;!6([3_:_*NO'#V\\*%=NK6:!+_\NSG/ZRDRCN5 M@7L20#B?P0N>P(4@E2:$*,F>C4)YYX+)KRG_Y=GA'U+30)PBX(G,("358%DB MP)U+-F5N5/#/1C-W4:"Z:N"-G7^R_D1@&0@R(ZS[B6@UA]FD7B4KX:"5TDG)O@P)EM 'AI2JJYE11PLB= MYHQFX3M1PCN37ZX[YWPBA;^=OGPV:HIKE)?PNXH(_*N"J% 'D:\1U^'@6@U= MH@[NE0Y:SH,/G()Q)H)(+( 5P8&766AAC/!\70<9YR2H!('1!"+2"-9("<2D ME)E6Q/"GTD'!U%@9@FJ(K(VX#@?7:D@3U;!'EXL_W!IKH%HM":-*V2+.@DH0 M/%EPV0IP-%C#M? LN_M:+9+EV@<*DB5:]JPQ@4M%M2F3@DA1=K34=*G537&3 M\M-719LRU.N>\-^&*=>#-0P*_L ='@4?!;\:P52]AQB4 V%%!*>C@E0" M ,6*W L7[PM^M#(*H0E$0TJ0$"4'3Z,#S07+T2C*I7AJP6=R3#1'T>\)!Z+H MH^COE<.CZ._7F7=05(00("?'RCXZ*S"F_%%)(E2B+.:@[LNJ+9OE2,N.6[/R M=,&X+/MH+\%(&P6/@9G8Z3[Z:V?>A(X5H2BG.V3M[L>PW 7P9HUO5.MZ@U2+ MR.W[U&>;:@CBZ%U:A$E3_G:>RX,YE7]%D[,4U,2UBT[A4S+297!9&!#M M4:Y+RH*QTH;,DF#6WI[(QJ: N#J./6Z:JQ1?7BTFLS>OTV(RC]>UJJL'3ZZ/ M?FX/A>+!+/Y^?0)TDH_<8OK^PR.'\XN+^>SNBQY9X4J)'2O;U:$N@/B00QNNRP^"AW74D*KDH M?UA+%A$B9*&< RZ3 "%( ,\=A:@=YTR6O\CQ6[8FO[OI5>IV9[)IT@GOJL82 M.:4*3D%$$=':$<6M"6Y-]MC]$5%$M'9$D:*1HO?8_1%11+1V1/'T:(>G1XD' M[WTDH!PS()SF8!++0'UBQE#'C0OW3X^RH$E)DZ&]QP9!20!'M $5K3'>\4P) MGAXAISQMG=*],C&L5MH%QZS6)7A7%FKAC(O+-&M6@*"1@G.,@4B!VK:70##Z,>4ZM[U=#^+_ M7#7+BV+%YFQ^$..D_0QN^MI-XO'LT%U.EFZZZBRPNJT]O'-9^VOZU]6D*8B< MIL7;24C7R1J_IC!_,UN]RRIOHY.T"UI<&-NN#Y9H$%?$M4^XXIX&]S2X%!!7 MQ+5WN")U(W7C4D!<$=?>X8K'43L\CLHB"1DY :\3!^&$!A-R@*R(,TH8)Q5Y M3/T/'DRB'.C# L-"H%V0S6^S NRT/#N.WKC);-3RS:P=5K1B "RMJT.T M$=$J$,6]*_:HV&/W1T01T=H118I&BAZ8^V-A3R^8!Q%%1&M'%-41U7&/W1\1 M141K1Q0I&BEZC]T?$45$:T<4*1HI>H_='Q%%1&M'%%/5=IBJIIRR2FL-Q/H M0C$-3E()1@;G U61Y7P_54T+G=I*@9[%,])$)!1!'1VA'%?0GN2_;8_1%11+1V1'%? MLL-]"4\B<.H))%E^^+)?SK)$"^S: KC/[5T+B0>-RZ0O=@__C5SU\]T&_5B(FQ8&27+2)1.OO! M-6B%&JS0$[FMAK$'MQ='O7ZT7AO'&/.6@M:VZ#7AQ<*9>A#<2Y:(U%2MM87> M2*^7\_#/\_FT.$5S]*^KR?)])PV=%:HUZ@1:H0]60+5&M4:U?IQ:JQ"9HI1! M2.5?POL,3B59-)@XXC5E1JZIM2H/1>E)D6=FVA1]#D85\;;&6YN=8MFJ)U)K MP?382HZ:C6J!5NB#%5"S4;/W^[I[Z+GX7#$;M7) 32YQ!"<2K+ >N#&)!),D5U>[)HQ*NQMQ2#$T&2:L8FF!H@J$)AB95A"8#$G_MDB8Y M*J!4*Q"LG50MBZ1[$41RCCINQ5I[@*1#U)$#3=F"$+H\76X8NW$\71I"1 M)Y GT(41Y I K@?2H9RB[#NBR+R]=V$$&7D">0)=&$&N .1Z($6>0!=&D&L% MN1Y(D2?0A1'D6D&N!U+D"71A!+E6D.N!%'D"71A![C0/Z/87;C3=8Y.!+@7# MBL"O.FGTSH"/ERG@J_D>Y,DG\-1ML_Y.&D-3,03"?P5N:(!#)57":);[6-KP#83QTB\7[HH<'%P69Y<%RN9CXJZ7STW0V M?UU4<;;LIN^9''/95:O2P7)/79R^E=$H: !T;,05<<588Y=-5$O8D)Q/D'F[ M"9>&03NR!!AE3#G/G<[Q?JQA>"31^;)Q;SND">E*U.&H!TZBT)H%X8/>]H@2 M*L=6ZK%A734406*HCA@0UWW$M1K"Q%WW?BFA%XEFXB%Z6E0MNPQ.*P(D)B%< MXC['M4X;&RGA=CIMH XB7R.N \*U&KI$'=PK'11.9J5D!!-R L'*MM!(%4!1 M:7WB@AFWMB-,W.3R?P%$L )$,A2LLKF(H4PA9Y\)I4\U5D.B$B)C(ZX#PK4: MPD0EW"\EC#P30A5(5;9X0L6B:K1L"[G6W&5MC-'ZOA(&KZU,64.2[2@JDLB)C(ZY#PK4:PD0EQ $)]>BTE[FH@>AS*E'T>\*!GQ7]SFJE/WRANQ:X MH;*-"J=OH&XAO7V?';-FU=8];IJK537U/(].TV)2'OYKRR$KE-MY(>57Y;18 MI-:.A1?&HUE:MD_^T\#9EEDII(X>"&N38[3@9;LDVH)-'Z4NFR^1Y=IDW*BB ME\Y!L(Z <"E!V8UY,#X['[S71GRX%(Q-<8W7M^"N./?6%H?SIIO"$V;,%VFV M2F^\CH:+=TUNW3(4+!KLZE+'A@,1K0+1_NT1!J0+BC#'=5LY0-ID$5?^997A M0 D7S.D40UHK50R",1-=>9+EN;Q&TQ* >P:)>I4)2533^(DNW"_@OU6'%%]> M+2:S-Z^+4L_C=85!^Y2B?:DKS>=%[7^Q^R.BB&CMB")%(T7OL?LCHHAH M[8@B12-%]\']MS6C6O?ZT]JJV[JK\N?);#D?7>=PM\5687YQ,9]= M/POK)&M2&\2U.ES[ETQ<#2$-O82>F$QBH@)HH X$]\6I!)6@M,N"\4@"62NA M?VSQSN$MJ1\73K\9"I(/5X2^2H$^O:G4>;AXYUN*ZP4=$ZO&0G^Y\A,)KJY% MAUUUAJ(\B"LJ>F7D,G1%UX$S%G@1JDC8@P>@N!MT]_@P"@30',AO..&.AL^V\OO2YU#KN.8IGRJ-GSY MT/+K-(7RU.7DT1U%F!PSRL928-PR6!9!7!'7/N&*JK=#U>/:Y6@S@TQMV;'3 MG,!YI2$9Z6V(,4N^3=5;[L/6HNMI-ESR=TE$FN#52C/AL:8@;F6 AB&X;""MP.1'NCT3KDC=2-VX%!!7Q+5W MN.)ITRY/FQ)SV:8(C!D!P@L%GG@/D;),6#22TK7R!D>-RN7#00B"@" Q@S61 M@2)2^T!MJ$>06#J$7]L'YV5(6Z]S, RWJDJ]V=O9O]9QEB,LDTE+Q0J="@NF(T$J;1+DG.3U\>K%Z9TB2<.R0D*(B<& M5C,.AA@K%)=:BG2?1P_B_UPURXOBD\W9_"#&2?L9W/2UF\3CV:&[G"S=] [7 MWIT/V V-,CK6#&<$8O\!;&@R,$3Q" 4;FNRQ^R.BB&CMB")%(T4/S/VQ8+$7 MS(.((J*U(XH7"3L\ //,9^^C!":,!*&)!TLY@ZP=BYYZJ5C<>GGBJZX&F_.Q M(05$0G "[) 8 A%%1&M'%%5LE] 2;N 1G%,F1"2(9VW:Y MX>=%;.-K;U2P(;$#(HJ(UHXH*M@.%2PS)Q,1$9+1%D0,&:QB'AQ1/%,17?)V MV^6#W2H8DV+,-.[$!L41B"@B6CNB>-N&MVU[[/Z(*"):.Z)(T4C1>^S^B"@B M6CNB>!JTR].@[*W6QD)F1( 05(!--H+CQ$9C"EAPU2,N0EP1US[ABH>]NYP01X+3 M@EK0Q8(@6.9M&E][A.NSXR9Z8=<.>[\G>7TUV/:K]5>K!T^NCY!N#Y?BP2S^ M?GV2=)*/W&+Z_L,C=P;@WKSHT>/CQ)C(K@Z'D5^JXQ?$%7'M$ZZXE\2])"X% MQ!5Q[1VNN)79X5:&9$X9B65;8J0!D30'Z]M2)NYX$#)2QM?J<+^GBNEK6YE5 MTDJW.YE-DUVXQ*W,4/D%<45<^X0K;F5P*X-+ 7%%7'N'*U(W4CT= MKG@*M<-3J!BUS=$0"#(X$#%9L%$*R)'FR'-FSJWUTOF>ZBD\A4)^><*:JP_K M"JNM=L$QJW4)WI6%V@Y)NTRSQK6+"2L7ZU!I1+0*1'&SBBT]]MC]$5%$M'9$ MD:*1H@?F_E@5U0OF0401T=H1175$==QC]T=$$=':$46*1HK>8_='1!'1VA'% MQ(<=)CX(&14E08(7E(((*8'7WH*0@2LG2-39=S%$Z"#^SU6SO"A6;,[F!S%. MVL_@IJ_=)![/#MWE9.FFJ\X"JUO3PSN7IK^F?UU-FH+(:5J\G81TG33Q:PKS M-[/5NZSR)[I)?QA3SK'?[)#(!1%%1&M'%/PKJQ,;9/&.[9!+07$ M%7'M$ZZX8\,=VY=*L7C2-# *UHFR8R/$EI]\AJ2#4I9)P:CNHA0+=VP#8<%J M_/FS.S:+V.\.>]S7]ZA9R8-F M95*.;_\I<.+:0B/LJ1%07"K 'L4%Q077UE;JU]!:%3 A(HJZOH_8HZZCKN/: M0B,,S0@H+A5@C^*"XH)K"XTP-".@N%2 /8H+B@NN+33"T(R XE(!]B@N*"ZX MMM (0S,"BDL%V&,5!U9Q?*&*0X<,,(H%US7% M((_ ]5/^8\^9;/DOSJ_\-&$86)L)\.ZB=_V='K9NWR*,(:\TM$4]MNB)\%1# M<7^JV8:H7*A<.U^J=;'E$U2+P$!R_^OFK%P.M/K67 ZR"7H\HJ7WB';1% M/;;HB0Q7P^$#W<&CCC\^>9!'YR7/()TM.JZH .<(@Q2H2CD*H7GH1,>7\_#/ M\_FT.$5S]*^KR?+]MU_X?T7.%:HX*@?:HI^V0!5'%4<5[T+%I2%&,>%!<5(4 M67L%5A6!]EQ2ZS7CT:SMQA5Q)$I/BFPS R)'#J9]C37>VNP4RW8M8V]+*BZ8 M'EO)4A7!7G7JZ)T!)?_[:I9N9Y,09/T>DQ B6@^M8Q+SHY.8O92&MW786K653=Q$ ML)($2(JD*(D1SJ7[2-YIB IT2"TSN"#\\"<=SEY$>WZT->S='$Y7[C% M^^L,YJ[;L3(V)I2-A;6[G-6&W("((J*#B-TV+/M! >R; +)@6-&X )G%(H!4 M<3 T&4C!*4Z$T3*I+0C@H5LLWA?=.[@HR"P/ELO%Q%\MG9^FL_GKHGZS93<= MT>28RZZ:FPZ0;VIA\*V,6D'HT9D1T7U#%*.)'4835+D8"4G .0T@$HU@E E MB!*L[*Z9#VL-5(TEED63(6K%0$1FP 3:=E&-07J5F$IBV^-,J!QKP\922XP5 MAD0&B.A^(5H-/>+^>4\4+U#K!6$2@K(.!*$&'#<&+,]9"*Y]V2)WHGC;Z8+1 M53.L 7()LC,B6CNBU9 CZMV>Z)WD+@9N-4A',P@KBG914VR7O4N42^V,7!N1 M(:2D20B05K6-JVW[&M4.NO),$^DSM>ZI]*ZKAD\#)!.D9T2T=D2K84<4O#T1 M/$$-%]$F8)$*$%0D,$YI((9Z'30QGJ_U/HZ$4L)LAB"\;.=(93"2*,B*>&>B MM)+GIQ(\BXJ'_(R(]A;1:N@1%>]KBE>-F88^BR#[X$UF! A)"42V"IR3!+C1 MBE''A*%KDY.\8XSHY" 0U/:.W^L&*M#4!#1 M*A!%<=Z-.*/[5^'^B"@B6CNB2-%(T0-S?ZPUZ07S(**(:.V(HCJB.NZQ^R.B MB&CMB")%(T7OL?LCHHAH[8AB??8.Z[.)=!_)^K9GE1K-BS MU;O\[J97J9OA&C@N>%#,@H@BHK4CBAL4W*#LL?LCHHAH[8@B12-%[['[(Z*( M:.V(XAG23D>J)F.B-& -,R!B%&"9I4 XY=%:XCU/]\^0A,U4DD2!:A%!!!? MAE J;Y;5: G99GQ]%TWC2CEFQF;]/-\L>B MM)H4&W&M#E?"EA^TR,N0EP1US[ABMJ)VHE+ M 7%%7'N'*U(W4CT=KDC=2-VX%!!7Q+5WN/8O;ZX:[O[AUE@#S>HC MVA-I> :;,@=!4YNAQP2XG)P743ANXOVL/F<5LX))D*9]C=(>G.(6O&5"F?)^ M,83[67TGR_.T:)/U%ND\S9K)VW0\"_.+]#$#Z._S:9S,WOS-36:_S)OF9':: MPM5BLIRDYF Q:U7!A460=<0>&R%ZD[3[X6M^ M.6L7L=\=]KBM[U&?D@?-RJ0UA488FA%07"K 'L4%Q077%AIA:$9 <:D >Q07%!=< M6VB$H1D!Q:4"[%%<4%QP;:$1AF8$%)<*L,12!>!>:A"B_&1B)N S(SDEJI,F]XLX7J7E==5& M6Z#1;>4%&W-&=CD$9W!*5(W/;EA:CU8N)/QZ!ZZ?DQYXSV9)?G%_Y:<(0L#83]"\2 M'%"LY7TR.5C?QDT"A*+%PB9),%FE$G@Q'0.['VMQEZRTD8,J,1<(J26X*,L? M-3>$,F^"%/=CK;-T<3E?N,7[HW]=39;O5R./FY.K9;-TL[;OQB?A5[-Z]&[< M=?SJYZ_'6VQ<]19D_= M%N^+FA]<%&26!\OE8N*OEJXX MQ]G\=='TV?+;CUF^UB=+CKE4J/1#5Y'A.IA0:R],@)'2+I-7 M,M&,:@.14P7":P&>F@ NQ:RX\5*RM>25$#G+3&5(LKUL2IR )2H!*3&6#"1$ MK\W]2*GK$P\JQ\;H,1<8!R'OH"UZ:HN>R' U'(XG'JCCG]=Q';AVP7LPMAWC M%(T%KQ,#[:E.(9D@W5K2R$8ZOIR'?Y[/I\4IFNM#CTZ.-"BJ."H'VJ*?MD 5 M1Q5'%>_DWD(Z9;4,(+W7(+278',N/W%J5=11,!7NJWC426LK*-C8/E,G4S;O MCH+ARL?$/;%A+?5S2RK.,/T I0-MT5-;H(RCC*.,=R'CTA@6"%/@!%$@I!-@ M%6%@(I%EEZTY,6MCO9+S/%!>]N$Z.A#>,;!:.TA>4L%2B)JHI]J,RPH&<:%V M]$D[T!;UV )U''4JN#+,EIU^]KR-&+(!HZ@%S[5-)6+P/J\=%O@0 M0HR"0>1*@[!ME*&B!DU<4)PY%LE:DN-CHHQO*18U8Z(,!AP#9M@->U"@,3%B MJ^):(18^-P;S#(3/L@UTNMMF\I'>-;/O8JJD> M2'<3[17\VD?^\HP]0Q?NIPLCR,@3R!/HP@AR!2#7 VF%IT>(*#+O/I("@HP\ M@3R!+HP@5P!R/9 B3Z +(\BU@EP/I,@3Z,((V8&VJ1^7M,1(CHWE-[-23S MG__QKO")0/?OL_LCHON%:#7LL6$-#W(\\! MM!HI_<( 3LXSL=R"YDF"2$J ]\*!=XP9:8BR,:X-._<\!T\82,,-")D)6.L< M).>$CMY0)^@3S)]0HJ#%^2['G",9(**(*.X'4?'ZHW@Y14(9ST"H:9M#,@\N M" %19">MU#*EM9'3&RE>W9,:!L@ER,Z(:.V(5D..J'==Z=V]ET*3 DS>P?DD MEJ_TXN<_9&8FDJ A*,9 *%=PR])!9)R:H"R1D57K)FL'L)_^9]^7,Q(D(EH[ MHM5P"4K.4TF.22$)3B0$F\M^Q1$-1G(/+#OM(Z 9K@@1M3# \N7:O?5_;6:(Y$DN!"F7;87,&+)44RG,Y=\QZS],N MM+VKN7-(>SMLC?ZHDLA[[?#OVN&&R3:JE;P!O 7V]GUV3)I5V_BX::Y6!93S M/#I-BTEY^*"ED!7*[72!\JMR6BQ2:\U""^/1+"W;)_]IX&3KI J"N$*VUGH0 M1$EPA3+!,Q*9RCX(MI:N&*0VC@0&0;=D:T($$ZR Y$W9@S%&N3"W9!N;XAJO M;\%=4>ZM+0[GS;*;*=V:?)%FJ_3&ZP"X>-?DUBU#P:)Y\GD;=0M$?P=$(:[; MP;5_FX8!*454*(ZQ#)ROG"+]]]2/'EU6(R>_.Z:/<\7N>^EX^\ M>JAY9.8[HV--R=A0L?L)2,@ZF5^GS6K?IADF(L>9=Y;TC>SP)>V!]>(_H&W%% M7/N$*_93V4T_%5P*U2T%Q!5Q[1.N2-U(W;@4$%?$M7>X(G4C=>-20%P1U][A MBM2-U(U+ 7%%7'N'*U(W4CT=KDC=2-W]60K=3]7;4?'8GM<''J[* MQ)HV/W">/RD:B\DO1VX61Y.6C%*S'"WGWU1>AD6@=6@1(EH%HICMO,-L9^*3 MTB9D4%H&$-90L(D:,-X$P8D0AINNZWH^4NI)/OQ(DR\+GQ[,XO$-FY[>E/(\ MJKJ'$SI61F(=_I ( Q%%1&M'%$5MAZ(FO%"2B@!)$@M"6PHFF79$19&H+)GW MNQ*U3@IX)/ERQP,DBTK( BMV>L'3B"@B6CNB>/"-\X[WV/T1442T=D21HI&B M]]C]$5%$M'9$D:*1HO?8_1%11+1V1)&BD:+WV/T1442T=D21HI&B]]C]$5%$ MM'9$D:*1HOO@_@,;LK3G=3*G:;F^_:'#>.I(U^?W\%P[NSVQU1T) @2(+VS$2H;7E&\7;;/I9Z3YQ/$[A:G"X5 M-23+MO;7GP1(5K%TL66II")+.1'3EE0L$GP2>/*"1.:4<$7W$-U#7 J(*^(Z M.5R1NI&Z<2D@KHCKY'!%ZD;JQJ6 N"*ND\,5J1NI&Y<"XHJX3@Y7I&ZD;EP* MB"OB.CES%+!CRWZ<1/D?4S?%XI,[AN)*+E>%:K#SRKAT"B(Z"D11 M/^-)T6<\_1%11'3LB")%(T7OV?3'DQ&38!Y$%!$=.Z)XUG*'9RUUR&,9AC') MJV.:3_\/V%&U-]]-54JJB-/ESH+@+TWAZ) M:GZY^N1U>7Y>+H9?>F!W2@K3']N-[-,A#[^+3Z2H?8>1\PNSJ(7;>\<#4V-2*(CKZ'!%=8UG,G$I(*Z( MZ^1P1>I&ZM[CI8#G0B;$18@KXCHE7%%WHN[$I8"X(JZ3PQ6I&ZD;EP+BBKA. M#E<\G[W+7KB4RC2Q,6%4"_A/&A*A&269R64J121E+*^>SY8F,I1R2113*6$Z MUX1'FA*5**E%'(LPB?OSVR;ES_V_JT/-2Z<&,0\P^BT,>+ MU^*B:,3%O\O_B/G2;*5_ M+LVQ?>Z^L@SBBKA."5=T:-"AP:6 N"*ND\,5J1NI&Y<"XHJX3@Y7C$7M,!85 MJAN' MQD9$1X$H.JYX2O<93W]$%!$=.Z)(T4C1>S;]\4C/))@'$45$QXXH:D?4CL]X M^B.BB.C8$46*1HI^QM,?$45$QXXH4C12]#.>_H@H(CIV1#%/;8=Y:HK)G"8Q M)5D4I82E+"?2QC&A:2@3RPU-:'8U3RU5EFH;4A)FD20L"2W)$\I)1*7,LCPV MF3MGN9FG]KXY,Y5+/ZO,F5G4Q6=SO%#EN5GGM/RCG.MB\>GOHEC\6M;U^\6) M4RJ^;B4_+4HHMK3=)TI!1!'1L2.*G@EZ)L]X M^B.BB.C8$47/9(>>B:9Y1+,X(XI231A+,\(9S0C5*K&YM=(DZ39.T*!G@I2" MW7/V_.@,+,I@#FL7CYV-22D_ -K'MZ1B1,99)SGI)("DY8Q#01D5)$V%3; MB--86GWUC$C(C+$JB0F7PA"FW>61DD3DBL69MHE*Q-4S(N],TQX*<><_[GZP MHX89 C]]\X0'FS&:[+X]RM[IIM',W)]1EJCET,X8OP30SD [X[9N;EIPR9@A MDH=@9XB,$QY201)FJ,ZH5%30;9Q%13MCR&Z277T@":.ZG2YE'.#QM]X MP)^>W;='EI4*J>96,T+C*"/,&D9D%.<;R;76Z?:1)/S7K:C^I!Z4P!BE,1/N.AL#_:P M::I"+AL!D^.T_ "Z>]%LI?H62V9QDJ)&WT==\@2GH5%<6 AS/Q#=&V-JS\%' M6VB'ME F+,\R38F64A.6B9SD&9,DDC97P@J1)]?9+&9HZ2#7H!0F(86)J-O1,#;&+E!?7]MZ MT%:$.4V(4"PC+-4&?N(AX8)&THC<&J&VHJ^;4OUQ5LYA4M1M^&([I<%16Z.> M0"E,00JHK5%;H[9^F+:6><1R%DK"4YL2QA/PKJG*2)9%C,=1I)BZU@Y$9R;+ M98(8F42, M&J6S,'TJYWJW?;=04TQ#4Z 4QB %U->HKW>BKT1R%)0R.IBE,11?:J9<)S33-&Z+7$7 MRR2;<8[Y?_O)JM^L# '_NG,S_L?;P/S3TS+:FF-_P$*(PON8"*-_ZR>91'? MKKW8C>EET<" %0ST],P$0JGR',;K3F,%B[*!+XD*_@S\"*_SJ1+SX$)435#: MH#DSM0ELL1 +5<#?ZT8TYAS>NC[8BD0B^KQ$\N)O[ IN9ZL:+Q?BDVF9EP@+ M[_!2S+^(R_K5B^#/8YKS]_ $<)W?>5)),!=^%+DW1R?'?W\7G/[CZ./AAZ/? M3X]?G\R"XW>OM[-$'PU,;XVM">6?2M1G_[3S\DL]4IQ?OW_WYNC=R=&;X.3T M\/3HMZ-WIR?!^[N?B@4HP7)9BX6N M?T8,[X7A[PNQU'!K/5( GU2E>=.]?THW,#> EV+9E+U+Y9X+UMG+\)6_G,S% M9;EL7MKBJ]&OOA2Z.8,1>*"Z+X XY^*B-B]K [8;<&K_SNUA:7_O%U>KRGTN MZD(6XU21Q][QIZD";Q=RX* M#W*6/N& V/?>_OJ OE')C_OIL_M*?GR,BXN/,7+\W!$%_-PG?WV1OGCT4-(= M2_[V0(Q$+COS$NXBW7?PGL%O<,E9'1P!0GJS=.7.HH9W*B<[-9D_ZFI$K8): M96\076D5BEIE@EJ%AC1"U3$9U8%B&:]8D FGSH1/6?H=E]RC&=%=:.^N5O1] M&FO\B"V]H_CG6'8P7HOZ+/"[0H&MRO.@O#"5:-S.MVJK!Z \O12^)P >P=X#L$<$+?('3FD$>_M@;\_ ?+PP[1Z9EO?+3'AG MFF!>UO9>;S^#H..%4 M91DQ$4L)B\.8B)#E))4LRW64<9K$U[JS1CRU,#JB% L)"[4E.=>4I&&2214* M;>VU6B,?JM(6S?9;LU(V8[L]%CRBU31NTGO*0[XC%PIJ]WV>Z*C=4;N/0[LS M9:WB+",VI1EA*J&$TS0ADE&EXB@/&;O68NP^O=%[#-^/PL38M7F- M8$\#[!%!B_R!4QK!GL3VWQ#$[A[WLD>'9TZC 5;C(J'QF*AO#-Q,M08JNH!C MX2K$="283H_Y]RK49K@2+ H-L3K-"Y3D,IQ38VTH8LN)5R M_2S# -M^,0%BBIA. 5/46#O56'&6:0'ZA\@\C@C3''YBC!.F+)[_V_"X3\Y$97YQ%/EZP)!; ML63B613'6[)FD")&2!&(+"([-611K>U4K?$HC2/)+>%:,<*2S)!<2 7_$5F8 MBC"VX59R-A]1K6VM83ORPZ[]=-SUWC%)')Z7@.?_KM(RX=;GQ?*\#AQA+#Z; MNG%5^X/:J&7ETS!G+EL3 V)C4<2(Z4@PG9Y9,QX2VO^3,HG282*D!C,K3UQ? M.4ZX237)-(U%F#)%DZT$$PZ5JHQ[[I#7W]LW1:T G*8^7.@/'<,?K]C]!T[5 M?&O;)-Q6J&$?.6T\$Q3/R4Y;T2"FJ+S'Q"?[K[QMRI*8,DUX%BG":)H3F6A! M4JLC&7,ME8ZV$3+9H?).MQ52V4=*&\_\?-ICL!B3V5&YLG)!_'%8UZ>U@G4> MF*\N@FHPRCDN6P.1'2&R:,O=GWG^ZS^^TC!BN!SV9SD@LHCLU)"='H7OE;]K MI-0VLH;H.$L("XVKZ,05X2+7/+2**D6W4M9)%/IX\7]!E,>=H;N=0#3%] !, M#T!7]%%=T=Y2K,Q<-$8'%Z)J+C%D-!;EBYB.!-/IF3+C(9^'>:.X!$:R!!!3 MQ'0*F$Z/JO?*ZU222ADI3K*8NG2GB!+.PI2(B&=:)CJ2@C_$Z]0UP'C=Y?S8 M&K ?G/VZG>ST%+=2)^]XXD[H*)ABY7[.C:@-;H..4]LBLB-$%JV9G5HS>18F M&8_!D%'&U6L+#1\/V^KY3^JV/(C^X]WMO?:W-8UZ89 MYI$=M=RY%1-G6ST3D#A&2!R(+"([-62GI^S&H[\PYV?:KNJ/A0FP:\T/B._U MF5A\,E<:TCC#J@[$0@?S0LAB_I#F-!CB>=RV$L\D#KQKS8TPCQ?F$8&*;('3 M&&$>F_WXC:T.NJ6M#HI;'=\5]8?*7(A"]WL ]O\.%JMQN MS!O3_GN\Z,C]C;&FJHSN]F(.%_J]8WB_5[.E(CRS*.&X.S,9K7_/8CS[*YH) M*Q]$%M7Z^!AF_]6ZT&G.8I82DV6NT5 8$BX3062DDI2E-.+)]52+>QQ7W*%: MS[;5DVA_Z6T\L_21B_3<>"82(S7CB=3@TZU:2[T93;^E&A-,2C0A-0^%@Q M>=J*!C%%Y3TF/L&Z!I@K@1[X Q90'W +*O/9+)9X('1D&@61'2&RJ+'QC PN M!T06D9TLLDCA&#']1H^Y/*$FB5*26)?C)B0GN1:4<*&S1$61BN,'%5"Z?1^\ MM\<_MN;XW6.C-4P<^.G;*6TYMK"?CFN&F]_[+=]#U?:B"B[$I9#SX>[WX#@L M1K;&8FT@IB/!='JVVUX91X*I4"56$DE#0Y@--1%@XI D3*D5>2JU$(^3^]\S MYH>6,/LMY77AIC5M;J?^Y(PQAOO*^\4>B"EB.@5,4(\#PVA"I**<^XR;+K;>:W$@)X:BV7A=LZYH;<@?OIZ-3?P:G?8E[[_D;B M=JVU$=D1(HM6T4ZM(BI-K,+$$"/2"'S_A)$\9X+$5+*49BI+[6.DDM]B$@TL MH4%"^;;LHFA;*>5()",D$D06D9T:LM-3?N/19_N?M& $S;,D9R3)7->G3$:$ M:YT32D46:Q''.DP?W/7I*77SG5(:9IQA4L-T_.-=)#7$6XI_Q!C_^*Y\WYDF M\&VFEK715\I]P]K\C#D-NS)& "-3=6^6A'#;H"[GA0XVI\46H>^>N(+C]H>B MD"8@)#0^T?B\W?C,J.5"YH:D,A2$)2HE/(DE8:E-F%:I2F*VC:00T"^O0;U\ MJ,K/A3;ZE\O?0<\<+U:;8XG9"0B,)C:3;C:1(9,K*B!(F90JFD;!$FLR2C-)$ MY#1F7&^EO.:NC*1DQND]&IJBKGPV-M*CY3MAQ[[;Y2?+N?Y1Z3G^".R\_%(' MMBK/@V+QV=1;">/M;Y1]3 VXGM4N(V[I(MC('\@?SW!*(]B/OI6,IN76R[XO M*W4F:OAK:3O+\AR "FJCEA7N$(^*FQ#3D6 Z/:8?#^'L?VB1Q2:*XS0F2R_?A"7CJKKT_)0_7M95.9X1=_;R;J/TUFHY:>JI;&?;C)R.]#52IC=+E =@94AU)'G6^#.$^%/)_[6 M,NCE>WOX611S=V;Q;5FY#T]6%+J=2$8\RY-[I$,AB4R%1!!91'9JR*+BVZGB M2VVJ0LD92:*<$R:4))(;29*41C+)A$SL]3C]?2( .U1\%(#-*2J^/:DLB(D0 M3Y,(<5&YL_+-I2\9:/Z]+"Z<8X\AM;$H73S?M+!FRXHUXM;*?"X2SB.^UO M@.>O]B,[8__DN.?J#M%'8P.-C5V_RVVGQ%48=<;C7E,\5N&A>);P M$63:H)$YNG 62O.Y:4*4P>YE@-8(6B.W6R.:9KF-64:B4$9@@\B$",5R(E+% M)8]4&O'KNVG;*X/X^-9(,DN2;1V.0@4VRE7Z5'U,,.?J<>L:VF(A%@K;DXR_ M(MF]\)V>(;)K^Q!A'B_,(P(5V0*G,<(\ME1]/(S_I(?Q"W :"S$/+I9R7JB@ MM-948$K.@H5I_/'\NEZ"=6F MNH&]T9'QEV([ B1G9YNV*O07*0,4]8D)*54 M$R:I)%PQ13*=*1>"LUG(MWTN_[ACR>.633]X,GW?<>EV#B0F;$:S:/<1N1'- MY3WC#406D9T:LGNNZZY\E]1&D>(K.2LTO-/+M_\46B0FB5)BC%*$L5P3SBPE M@M'4M9L_H.KF!E7,3 MP /!X*N,DU.I_MBJ"XVQUI$$_A!3#*;NF\-LL]C&8,38F#%7SR,@9@BIE/ M%#7;CH\AQSR,1$:2*':5ZC)*I(X8B:,L$]*$(3=RVY7JGDJS,5!L\;;BP4@8 MN.']3+SWYLP$YJNI5%%[#][[ZD%YX59/[>O6]4>"X<,*?JP*U?0^/<;&QJ64 M$=D1(HM&SVX+O2669M3$A&:9(BR.&1&IR(F*&)5*42W,H^U_O[0 M;W6\<.(O/KO"O?[/OXC:Z-?E^859U,*-V%5IJ>&R^5(#X7K;Z'U+Q-NI7C^" M\[0CFOI[1C.(+"([-63W7#5^;[NP)7Y$A6 M)&**F$X!TSW7'.-A^9N#M(+;6$;*D)0GDK L2T@>TY1DH60\S3.=)]%#=J9U M#3 .([3OG-7]H36Z/[96]0=G5&^I6UJ(&]&3]XAQ(_J1J>"CN6CKU5]S@[?H M[V)D:81Q7RS]."49[+EM]%VOFL81YY23,->"@%'!"4^CV/4YC\ RB:FRX7A) M=B11^OTK7+C/2Q^%,2)AH"X01GD-.%&Y(S(.)2$::$)S\*8 M""X28=+$*$H?',98N4WU>_NH80RVM3 &ZJI1+LBGJG@\% +V]]I!?Z^+KEYZ M("^Q//*HC9A[88HFY#30GY[QN%?6F5#6"'?R,0JUL\Y41@2E*8DSR2FGFDEK M'K%EUMN>>._3I.);:?U9/@LCCJU8D8E0#),0 ZKC4:"/ZGBWZCCE(3,Z(3QQ M'2QC(8GD84CB/ >EJZ56ZC%[1CV6.F9LENRV$ &J 4P9V>.(1K%0 &9M7,-R M']UP10K\#^;?R^(S+-@%5N8?FRI'9$>(+!I .S6 #$_A.2PDE-'4E6.R1%!N MB4EH;"*;Y3;=2@MO9_VX_Q^MZ?'CJI"+^^!PH3?_,+CR@ZF*$LREEG/?F/;? M59&"HZ_J3"P^F8^B,4?6&M5LJ50!6"<\WOWVTX@6Q)Z1#R*+R$X-6528.U68 M3 @>RC@FN7*9F#!)"+?2OW"*2K,6<0R5)=[$D?XL; /1A!^ M0'RO;XL8!*()I($76W3%#B_\0L;4B+'H;=R+V6/TT;+:;9'$G.<)30P)F:M$ M%?*$"!L:DK)8"Y7**-+)5=L[BS.=ZN<\27FL)1')5!C'@N92QF9\^CG;5A0#M<*D0AZ8 M.K'+P(>!OS\PY(%1PQ%N6.R->36>=?2?(Q8B6FD[M=+"*$LYS5.2"1$31A4C M0AI-;&JU2A*=\5!H^F>4,E3\4],UF)SR MI I&EG/]H\([65YE M=VT!(\SCA7E$H");X#1&F,=F*N*FWB,[H\?@SQ5@+59&E9_M;LU/ MIPE.#UMNE>!2)%QG>HT)(+FO-U/S(U,7(R1QRKE MH1+A0PZ5^Q+$G=KYN-8Z[^W[7IG\ZG3)1_=B[^WOM3ETZN9PH3<__[57-5N* M268\'5M,\J95@D%)E 9* ^T M -&: >,1[#7FO:,1[[(F;BM-C6>_+"LU!D8 MG;7/<:Y,L)[EFEMA46YV; M4#-^O2G2O:#Z+06XDX1-&V MDI\?:?:CG89R0#F@-D=MOG-M/AZ1/BRN@ PYK8@"9E\\]I'J<@'PU5W2A?*_ M-86;V O7ES-HRHT_PI.M<>9H4)\)L$YG7=#!)6#(PBXKY?IW_D56P9^[^3'\ MKUH_[%J>!N9)C,-VP?V14:U/W!]!.P;W1YXS9Z(TQB0-U&"HP3"NOJVXNDI5 MS+14),X35SF$ID1PD9.,LS1,XS3+E-Y*-?R5X_'>GC2E^N/PW.V.MG\&AR7: M3EW6;%L]\U"A3#%8@>D/^QNF"$A0F;G[5G AJON&+3!U C=;]G:-XF8+!BEP ML^7Y,"3*81QR0$V%F@J#$0\/1K!,&YIP2I2-0L(L4R1/,DXHYDA@G'_=Z;;?N+"P4#/3TSOD;$.8SWTJ5%M'D4HG*5 M(H("7N=3)>8^U\%E7#1GIC:!+19BH5RQSKH1C2_S7A]L12+1,Q/)B[\E5W [ M6T7[+L0GTQ(G$1;>X:68?Q&7]:L7P9]QG>_VG9]N4MVG^<*;HY/CO[\+3O]Q M]/'PP]'OI\>O3V;!\;O7VUFBCP:FMZ$\_?RS*?^YXIA_KCEFI'B_>W]Z=!*< MO@]>OW_WYNC=R=&;X.WQN\-WKV^J/3R601\?_AJ'OUV].[TY,K,T,7G M>]GG*[OXW?+<5(7JFPEJ9C(5A21BN0$3-\E(KL.04&:9C:.9XM33M,XK%TNC#YJX#^V?T#0OSJ;79F'N^1 ?!^^J3 M6!3_Z[$?FJLWPL<.DCC^-H#I[O ;.AK1DUH$;TP-0PW ,H/[F26X2370]T(= M!#^!^16T@5;UZG5KL[6_ZE<_!U]$[=);R^JBK'R":K$(WIBY^.*,.?^S,N?2 M5 %U"&117IP)>"WE M1P8F8&<[!A<@%T4;O"Q.2\U(7U5GT-CYB3_CO!)Q!0T,!2 M,6Z>J#.X?26<<;^:UJW[I%N+"?((7_VR )>JSP,[++W5@J_)\T S$!3(_ M%TT!WZA!-SH]J,R%1\O7S(2;J\8?&REJ*#?TUMC"^>:9?.P R< MHFVZQ6]JO_;=-:)RM 2WU0;HN&R+<7:$ S3MV&CIGJ9@1GC5V53@W[1/*]?3R I(6CI=2FW%6L M"]SG<%<8'^!3V^5\",EL]?AK[R7ZKB_N8;?"T=)P]PP!V@ON[;&&+]9+:PM5 MN-\J^#.\BAMIO;QPQ.%OJ\JZ@6E?P3WA]ILFSKFXA"D 7-K?=O,=VPP@W1U%\FBZGRM1N(8U6GOXG-W4UOASG]FE5RMU/W'! M<5DSTY55_K>;:'I'#6T>P544&2A=E5OGYPG"4I80$5%&"$.%O>TH!:=26Q,1 MFUE%6*9UVVXDEA$/,W_ZZ7VYYN._2E MGWJVW;31_.&N=SD3H*BE 0L?7NE"5.O*YY5V%AHHY>:LKX3N1G=1@6E37( : M]YYP!;[QI?L<+,/VN\ZP^'WAQW#2>),*)LBA)POO<<;LU=\/#S_X'W[VDPA\ M$K _W3V.2=' MK[O'.*NN1P3>$^P9>-R&_?+?])(55X3%QK?86 M $,[ 9S5N*Q\,&?C"YU5V2)47H =V]IK, W$I]8(W^N&%SL4?!CBYHXNVHGY=+\\OVE'XR$D!]U7-8/@@>G'> MEN*'9_O&A8!G?ZZ\<.9C9[#6*]=DT7LZ[C;K+MK=T7>'B ?#*-G +V[DWF =J>?WJ/_2,]MR\#R-Y5#;:/(*/M#;99VV'@MXWNM6W MNH81^!3+E7R=T)I+TD8X7114USW%W"X\-WO;;\!-?,5M/W.5$]89+)6R\I[; MVBOU=_@LVM!#&XAPEY=5#90T=SZ$=P6D>V-1@^7O_$@?//,C5D6EEN> DO,D M9QTRJ[G=+C>7M.,_D5Z'.4A@"CHI_6NI/W4"E.6RG6Y*5)47H0/##&;;M1G2 MH^9$4>F.!'JO:6,.KH*!,"W<>^AB[IU(T<+C?>XV!E,N*^4FSB%X5YY&VG=Q MCI4NK#5NZ(["6LIUX&MW#LK ;_XVS:9\#K:AC*>[#7-_;0P^MYNEC9,/3+]V M(CEA=Z'BLH*I^+FHP!]R:W8=[WS]_G^.WY H7^\KP#MJT,"S6<2L%.&_>Z:7-X$,7.AA< M.)C#9P MC'@)*ZYJ1+'Q'.'V.-I1ND$N -5BT2;-^:"'NX>;RT!I%6AK&"O< M9.&^V>.V6E5M#AT\%[3%HH\&P.,<<$WE0N+]5V;NL5^,4\YM-,8%KDN'>(>J M*T!2 NTX #_YZ,$,?(HNCN!#TLXL6/T%)N\?L-XW0QLNEN;5/3"/*UY2NJGA M\&Z?X9BOJ-V+],MP_4:K"=#M&3D2Z%2K6\1^?\FQ##S%D8>3;[5);"UP7\KE M7/?*="/L!.@L+]HP/WQ[M?IG X+S>N"SBZ%<)[D^8M3Q'%PZH+GOQWBW[4C* M/&%Y'C$B# ='4LKD$K6"^/_-&Z5_>MK-PYYDS3K5XO C>&@EF);@E-*3A;(." M#!@GREOIP4T1UFWP@DT4YSQV^(6",)J'A&=12%*J8V$LE2K?2FS33\$SF,U@ M6!UY(_@=L/V:,/8Z ]]D1G%A2*S3F+#(*)*G1A*>)K%D+$N$N9:!+TVN8\LM MX4)$A#&=D3QC@NA8AQ+F16*R:QGXW\-X?;[_HUM"FX4%+\ X&6;FA]],S$]N MSF(?NQ. <11B98_':2;(W+@KP$AT]. MSV3C#QEN, M;ONJ7+1?. C>+BOG!SF3,OC-&ZS --&3,XV0F8Q#FA$1IBEA@N5$:)Z1.-66 MVI3"H+;2I^KZ*OAHO#MW*]F,1]:1GZ?;D,#PNZ0&QBF^DK-"@RY_"4K3ACH! M>1!FW':\UCG)@>N)SC+#LBC-1&['ZTI&!VF\6LD;_VP[W7N:?%&UT_W>?.'# MDJ+JW)B5Z[ALSLH*1M'7K>S#E<,O@\?8!63:"*U[UJ;WVL92!D/K7,*;!KW! M5]T]NCCZ8A "[J-WMQ39]#<J7*A/\;CIJD\N MLZ0R357Z)!+3\7;_G2&L;08'^._7 \]3V,;?MO\;928V><*)UA'X"6$4D5PE MH(R421,N4VK45M*]7XOZ['"AW3].^< :YA*66.GVNG%G+K]\2&3[,13C[/4.XB;GL0HJK;M*SS3^[_"7X MV^\')P?!WTM@XT6[$_C)+-2ER\/M1NTV'+OL=&!^V0P^NI(*!DH1N/26#&'_ M"HYAJ\_=446GIM;[$I]%,??;+.K,J#_:-$ _[CN$ N&/YJM_\_$<^AC[$<9T M,R4LN/,IQK&=0!LC&=_M.!\B^:"#>IN'X?I21C^][B/G/X\0ZBJ3>T#Q_#/ESC.TAM0MOP M'IL4:S,,K)J!@?1C%N!YZ;=8Q6+3%G3&TF 7N+7?O*VT?M+FOK$V0.CG;O^^ M#4VXU'UPZ]U3_7DSGQ0T3-L?&I+=&!MXS:MC;+.X3)NQXXYGN+,,_<.ZY,PF M, +^*L7>!!NP]M&1WC3TL;\:+.!9O^?N M?FD/$, 3![ [6UBN,OK"7O2C\YG5Q?C%OL]\&B7!UXPS=3Q[155QX MX[!%/V9_A&02QZ^N SB$>FCIKW,JFK.R-M>FKS27I4_6,,&E$9670Y]OU>_C M+[PL-\1?K[.S')2;#M/"G__N@V57G MIVG.*S35WY\JB6/L/+JRS;(-3_=!N M.*$Q3B*YV74:".O"Z\' (PU+KCA?G@<*WK]H@G\OA3_2H]QA3ECK'K]S\=5? MLYKW\^*\6$MI"&A[-NBS.X'G(*R%-8U/[E\EWLXZD;G[^"RP879!) MBX/@\/JD&\JVZC/8G.S:--,VGCJ[GLG7.:RK/$%8FK\OX-%S'VSMJ"+X)(HN M+:D["^;(Z+N#Z$PDW6;0P)Q>M+3C7J\:IH&Z*&W=IJ+ZD.X%+(+V]%*;1.?^ M5)DS S/RLS^Q5@)]_N2&\G-WXJ@?,6#CTH[;'!L'=2? _I#<\+'=BME83;!, M?=X.IMG=,XSC#Y,YS79'7O0GA_MPO8\:G[M8^/K@&XSOO%B>KS)R80UTG[C\ MWS9_N)T#5RC.+TM0C"=.?VW<=?-.Q2H=W$?WVQG7S[$NX?/GU0&^=3A\(V7O M(/C8KYFK:Z6?4K.VAI0[)7V/Y]V0(=B>1776PK/M,^_K"*&>"@#OA\ME6 MQLBY ;730MP;%?U7>IE= ;"&Q7\0O%E6_777@OFS8%&NEE[WXF5_0++=CED1 M4?]"G55Q\V1H-R)\!EY1K:@3EO!2F54^\RJWKOOBI2_TX+,*0=I@VKG$@R#Q MKVI;,\//E:4_1?#TV6]IQK@T5I*,ZH@PG;I\%Q$1K:T(AI_G1A[NM]\T!F.ZVF^ZI M$G/E#MYW'O3W1-/J-E]\4;5'R,0\D&55M[&7%1>7NZ 23.X M=+A>?(#@MD4#_\*(+\HV%\,7)":E)<[):^_D7<_-M71EHL:[K:*+GSCW:Z7+/!!=R>.LI\( M[8G'Q>JY?OF"R")Z=5>P.V5X!@8C.757M?3=GCD\"-YVKSBXH'W$S0BWQXG6 M1[/:6> B(1YJQ^3=)/ '.4I3=T>*W-?7+UWWV*]/?F[X+5?C/_KAF73CT0(W M)[::A+(T-@(,HSPC3"01X88J$O,D,6EFXUCQJV:5-9G2F8Y)9*QKJYT9(C.P M>P3589@D*J)IN'FHP$G9"=E/@E_[*7^]OO0Z=_7XW=N-[%67 .=NKBSM[*.,5VZ#;]OVO6GL/GRZJKI31?3B]?UOM+/ZD]7>".D24[H-#Q]-O$$'.\WU4]$-:,.$N,%X M<&:5?S5]!SMBN>@"-ZNK;[ I9MP/6'EJ5IOKB" M"1NZVALKW1EU;YNLCREWQM&GRG@,P/RZO]GCXT*KP=]J('S;1?DX'+BWS]>! MEWO<[SFF:?(DI3)*)$E8""HX5&!1I#0AE N3&IGP+-O*<:2/[8GRC^L#_[@% M_QAQEP[G8 T;L _N/Y@6R#&T45?&<%O[_AZ%75;5J*M\ !.L&RKF[SK#V*? MJ+9$Q%OW8JU.7YVS?W?R=E!7=.-KQXNZ*9IE5W;F'T;,P9E;?_'X'^NS^3W+ MK^NBKO?Z#ML"J1_[H_.'<] ];CB#DJD?UT53^T30[LWZ&,)02WNOTB5[^M1Z MM]W4A4)N/9X_J+_HB5F:NB'&PG?;G=R5(]BY@>W1\-H7\/-A_6%Y/[]Q=F$J M;YZ[%RDE3"AQ/>+BY#90XSXRY)D?;NK'TK]#LW[CKD)(/Y1ST]6YU<86ZS(E M8E5^68'J+H%.>_Q\S,E?W,:8!K7+3MS9#W_SUZX@;[]%L1+#X&RYBI?4L#/E]<=4'7PTVEY 2*%-_QYS"_XXF^SS>A$GQO@"R2; M+H]:M,4P;7M:Q6G)JIS[2C:EBS:6OA[MY_[XRVVSKYU[O@RG2SRY'E0!(O]? M;UD- &YG;3=?NX,S;90ST.WVU;K<1UMT1[=;^ETMZ'Y<[?;PHLMZ\/G7O7WF M2W_>4D@+IFN0.1]LS$*\>98.6.K-FJ7&_!XO_G;0 [XN0^7"IF[/L>[*J;9, MM2YMV[D^?F[-W/1;D:$+S/L=0I_+U9OS;6GWM5?E0[ZJ6\8^GMN2[NT\OYI3 M3BOX/=XK24]KQ>*F5[V4_QJ"HHP'R#7MMC*_6TZ*XB:H&68+]#&O+I'/@&W^?!T-Y7+9>,S!E9._;PSR;YK=QP$Q]97Z-W(8ZR\T^AS M_<30)2^&UQV%%R:U2LOND2<;H2/#"(R]D-.T@# ^SE#J4TGZN)>\*>R,CXO<^V]='+V9IIN,Y%Z6:]GP$'P M=_^HWA=?F:*K#(R5Q*5I*UIW'O%FOKF/^;35+_I1E[<4Q=T\QS#(W>2CR=U, MXE1GN;)$"TT)SI9 :ZP>+O3 #S]J$6]W![Z3PWF7 MD6(.Y]9#)4$G(SS:]^/$]_&[9:R[F[WH/ M'G"K%YWSZLX=7*EPUK55$B[0XRH?-6UE]VIX3O#[5;U]4=_-JN&K0=]QD&^N MX.5+6O3N\S" L!$\\*>=%DM7Q]O'4]M"^G'58OM!*8;TE4?WOKI&\;;KTBS,+;HIX8O:M153'>GD.!N[9SH=]J=HNKO5@=F M\0E<43__[A")F;G"Z'WM\>M#7N.UFN;]AP?!X48!^L%,NE'3?G]JK5M&#*&= M#0+GJ]+$,%/^J-V.#LCKDX] ;?2R&JXDMR/6_7P0_*/\XNIL78F3]7L*_K;= MP3D?.)K?8=1^"ZWO8+@Z^>*WT69]6ZK5GWV(J;MC&WJ=73D#N0[W:^-%ZLX) M527O;T&Z% M><(7OD+2ASYGK&LP4IOAQO9&RPA_W-UEJ/?DY,CLVZ77@S&>"]T61&K;$_I#A8,]\]9]\<7XUKUN M-FKF73EO+>JV<4JA!WP\%,,JNW[8LZ./HNNKMHIWV1>?RF]6]1^&[V\I1M ] M;2-<#S/TTYDO$P\SIL-_V*=V-2W$O'2[I&YRK-VMFV9+JY#^,)=K;>LC F5G M10$5#W8I[J0$B\7GTLMO(UMN8)-XP#9.(JIR6;5-JEQJVU)?MCT$"M<'8*A= MVH3"KB%E=TBCU]S#?BONA.9F?X[A)-PHP7^PT9!MT&_$M0=90=\52>BGWM43 ME_W\(Q5_[J M=0U^69?Y''P ,@M^ M[/F[EZ\"._V]?ANNM?[TXM6B-: QA,[E(57LUZW;7*2&]K<"Q! M%[D4YZZ6[AU?KG<66X ^]#>Y/LBCDP\?!N.KNO/JP^/YO\Q!WN1$G96NV5XW M?%<5V%UP7FI0IYW1U-53A.)ZWTU@(TIPVM'=7.E2[9Z_O)[3[#H(8%T]N):WNR?. M$[T_'&A-YXOU8?$N[-YNFX"AHL#N.WA$/:=22SG+$A))4%S,AIH(*S3A2485 MEY%-9+:54O?JS.CEW/5I[1;(20OPB0/.,_*0D%U=EC;/\[W]N(+E@Y>%UX\_ MJ!EW[D^.M235R?="5H-)>5N[PELW__3:!I]">:ZVU)NO*N*HH3OIZS(\=7## M\;E6(;E&.+YVR?J\5?"31PI<:;BD_OGE-JR+Z6[6]QDXP5^Z2GGML[KAN6&\ M%,NF?"7=EF#EGPZ3YF7XRE].YN*R7#8O;?'5Z%=?"MV&AV$:7;'*Y,XNMN5X4%"[W1E>,"SNUT)XXSS+8\S/TCS9 +CY <93Y_% M..'7ZN9%T-%)ZQG>-ON_XW>XX]UM2MW+-K'._>&5;W&AQ+QC'*"Q5]_P7'MF M\53#Q\A__'ZY2K=*;!N@MJ^'N'I< 47W^5]?@/FY?8P[?;-Z\22$8;NZ9X4. M-NV3&^ 8B71VE@UY%QF?>OOKM];L.KIN=CWYJOJNQ(>V*F ]0=%/E_)0.,B; MR)L^B=QYJTB;>[8RT6(?D66)%OLC:QZ*FF>"FL?%05&]3%*]H'#&+ASDQJES M8XC+;[K+#X4S8N$@-TZ=&]%NG/#R0^&,6#C(C5/G1K0;I[G\OANR[3*H?BQF M2\-L1ED(T%,_Y[8=N=U1LMEX4MEO.V_YD%5X'Z']8&1XGY($$=\1KHO_W)& M;J3RL8C,9Y5>E=D/ 3L> =_<6R:/J;(B3(A4D24LHM;UE(^)Y"&+(AYR*NG5 M(P$ZE7$F$])AWUG2+S1=L:UG-%ETWW^XF^)YHX M$PD7H#VY(4S*D C+)#'*,,OS+$TCXSL>;D7E^2R5ITJX4C0!;2FDK[H2$LFH)D)%22I9 MGBAZ37F&8933W*9$6=>'S=B0<)T)$K&$ISKG,J)ZE\IS%G%T/I'?$=_]QW<\ M](KZ\UGJSSQ*A";8C,I22A"M/$IG&82G55?R92QTF>9"27F6LE M;C(B>4Q)S$662JEE:,4.]2=%YW,\Y/XX&]R/=RCIV>N!O_OVJVV1YE@";2CN/S/.+,QL1RFA+&C"6<"DZ,$0GC M<2JL2:^%&%02JT1)8K56\!WXB2?_< MV B%,2)AH'H>D0Q0/>]4/:<\#+.,@9;58498DJ1$LD22-,LD^.ZAEOFU'0 3 MBE3*4!&:B-,YE;$"A1RH&WQETN4AL2B*E MTD1G,K\>OX!^&[2'3V@B:,[72Y= M]YY)F5SC62^[RL?\ 5FBZ;93TRW449[EG&9)%EM^ MS71CD4D3;DGB.I*S*%1$A!DG[M@#ER*V4;C;HP^4;7?SXU%7 EIQ*!.4"6I_ MU/ZH_9]:^\IXCK-TE"HZ*KJ%Q%/+8R.*,59@9IC0Q)G(6@XA(GD221'&JH\2(F,6[/.] ""$[2.+X3_N*(;SWO1AJQ0P=A'VNM8H4,["J#5>< M,,IB(B*=$A8E-%&1,#R^ELIU'[< !G*H%"RZIEA\^E"5"_A1&=?^H/Y0S@MU MV?[W%)[R"U#('R\" YQPX41;+;NC6,5B:?1A<]=A_S/ZQB+[]OR(^%0-B"N= M8.XP,=J+W8A>%@T,5KURK2J%LLQ$(58CX$^Z01"RTJ70>_E/!/\--__<=7&D;JU=O#DU_: MG_6KGX.BKF%!!(/\%_O;O)?QM,"(>)<"8/X]?3"_^=C"<68&:BPIP[W"H MC%XJ^!FTD:EJ]XH +R*GY+5&@.QFM0WO?$3ODPPI"Q0A.:KFB^UN;>"H-MF MKZ=K%G8_ /D P-YH^\O9*MGV0GPRK;U,A(47>2GF7\1E_>I%\.?[8KQU(VUG M_=CN!/";HY/CO[\+3O]Q]/'PP]'OI\>O3V;!\;O7!]]5MHCD)I+OWI\>G02G M[X/7[]^].7IW'O\[O#=Z^/#7X.3T\/3H]^.WIV>]"3^T^O>MOQYA% _ MH7?V<%I\EC:=+:O@?,,H@3\ D&=B\0DN+6U@*V-J9],YX\YXDX" /JUKIU!U M\*4JFL8L B7F\Z"\:._QD_5W$><7^KSPK^JL3V.M ;/.7RX6ES/WF)_HS^T[^AC6 MM;O!9%AXT'1P(>#%JH5#H3*J_+0HW% W[:FB[AX"%E0+Z&*Q!#< QE"48/E+ M ^O"#:M[Z3?@DIU+^"%*9IW_4"S<8G67%(Z.B_/5E[\4S5GAT"QAH+9PT;7@ M$EZS/@C U)X#%+H#O/!O?>XDH8=W7%_0VG4;#VCGD;.< 1MW"[6L*L :;FP^ MB_E2>"_&@5+ ):IIQ0I#JH,%+)S5G/M2@.3/! #@'@16-'CYVH'KNLLN_,DG M+R"[Q.X53>T[LFW/J*? M)!I0G)?ULC+UP9ALV>T&QIZ$P.\1M^K"/V)8)>"N(: QZX[C17"X_ 14Y99T MV(4$P,F_XMN')$RGZML/?7?WLR=_KO@T'GH8_W\47 M#^[HC(\?1>=Z.X+M>7(6B/,2"+7T(,$#ST$QK?UQ3Z[*5(TS"0"!1=UNAS@= MTGPQ3L.6\[F095N1%[23V\0H+IP]T6MV:7KE[NC6::,:F.^S :LX %3@L6UD M) U39QXL_$3=O*VW4#YYYAP^PJD' ?Q< SVXT?=?]0'EUDYPFT'^IW8$*RME M$$: N^J.DU?:N5><0_UV%[7IYLZ=%>:LG:YF4VNN5*8?P%U5=KBI-\]$J[LN M3=/>&6[G=>1*/XY Q?WY"OG^;?2Z[_\$P;8W282)N*9*$,TEJ)I$6<+SA!,M M=)Y*FRF=7]\]O<A!7QIV+>RZ\ M7T0-ZV$!@,X=H&M7R9G_P&A+QR#RTD6$"]V;_ZO+X0/W>SL"HPD0527 8ULL M/4$"^<,]0,FU]P2G>=FL/$='L>[++Q5&=0[N.^BC[G6_^6CWYNZUJ\(Y M77[\_BZ%2UV V6,-*!W=?G$&BJ)N@!4;[Y\-[E@OY;^\1BKADHME!>YX#59+ M^V$?T!B^96M2-&MEN%;UG:\.GJ@3I3-7YF#1S )S?C$O+XWI[MH_)?"Y._6W M[GAT\N%#J_7[R64WA^\-J'8.U$N7A-#=;8B%!LMUYJPB<7$!=JV[ZB!XZPRE M^=IG!\!J%QG5WI!O)]6BA!D ]@KH;M#HG?FSGB_=D)8.?A>"$7.U=-HXD'Z] MK2:0T3SLU[>PC3HE]3)ZNU?=0&+O7;JCQ_[=>QIX7W]H$Z]0[J M8/M[05/0!\Z2M> E%\\+?EE4QMG9I85&,QN2@YFZNQ[W-PN0F_ 2N>R=(%H MO7(8NH7A0WYVM29N(')IE(#EY+Y55&U$R[N97U:.#@R#]$-XN0V#X&EFP*-$ M_?]/GQ[7"O!ZF1JQ;,H^P\T]&X3Y,GSE+R=S<0DR?FF+KT:_^E+HY@Q&X:W0 M[@O>0[RHSS:A=%!SI,[79?$T5VN2P]H?I<+PX,LN=,-MS_ ^-[#VTC1 MNUY:J74G;I;+4_=@XF//7EN1KN)>LBN^G1SY.C;$;7FTB4(:[&R:W&[QCFUVN>/LKY)^R1^@.N]^O;(ZOW M7X!8W_0QC8W]17<\R^+VL\O80'Z<$NL3;G!=(6LANON#[G@8!G7"W73"#\$Z M'O'>4J)"2YFEN7%9O):P5%KBTJN(98)2HVS,V+66G%&>T-@*2N(\RPCCE!,A M.2=I)J52DD8T3*Z5J'C8_O'ANR5P\DPJ^B)0UXH1EEE*.(\R(AB-K!(Y,R*\UFR#JHR&/"=9:'+7S=227*F4*#!F3!1SE>AP M?"8-V!R4S6B\38L&F61$3(*X(JY3PA4UWVXU7YJRE'-0==JUC!)I3#@5(0E- M9$5$\PP4V35G7H9)FAA&TE1IT):1)3*+0&5:8P1G4L =QZ?Y8I[/8-BH]_;. MA\<=\>'L) V#B5,:([4G31X-FIP2,R<- CJ@E/W#DXD7*2AX:2 M#!SV*,Y,GN;Y58,G3L-,1;F%9^6NKR9U;3AY2+3)$RF$$5K*\1D\+ YG+/J! MOAO(*5/E%$07T9TJNJ@/=ZH/>1;&VNDVKER[J32,B;0V(<(R&E%EI!;7=O-% MQ.(\C'(B$@'Z,#2,R#C."'5Z$GX+!;7CTX=)RF9ALLT '+*F,( N)7_:-1Q M=$M-#U?R ^-G8U/&CWRF"R6P:PF@R;13DRD)19K$64ZLRX)D(N%$Y@DEF0*# M*G#O/PC35/".9*Q+*5)(2+B0E-I%@,.51I#(U/I,I2F9QO/,MDWN< M0QS1>GA>'(6B&(TH4&&/1@+34]CCT<$//\6&3#=9G_Y*A&6(:G>W>SG[P[II MT0"\<0EL/&OPM&S$'.-DX]1=V.-[5&ME-VQY8+=OZ>G?E B8Y,(&@1H M$*!!L$V#P(B8<;984H38Z*<, F7 MYTDD212G.DK<'>-H? 9!Q&8LX3,:C:2> NJ?!P9YX&=77_Z6!D^WMWUZ;BU[ M'Z'559B*D&6<$9FRW.4Q*V" 1!"9I$:E3/-0Z6VX$6]%4?V/F"_-FW73L5.# M[:[NW^Z*'00.U,"C&OSF6P2U3=ZPY]4]%>MAVY#0-3A9]>33Q@((=6 =UJ[9 MK9D%KLNQG!?UF?&]#EU?JMIU.PEL!9,>-,4?OJ_3N9>)[_*T^K+O\&.^ @BZ M'C3@\]<;H5?S3<#!8]6?_!-1JJN[G3?K&HN[?4ON&1:\92-,$%D(1Q/:"Z+D=] M-RKA%7C;OV758P5N;\ >\#V-:C.?^Y[,_AU@ M\\MA.\M5-TN86'^8C1Z3,/Q#=XY,G2;P Y>-W5N_E1BA9P+^"^@YG[AAO] M\(%M+UAQPPS38BV'6-=N%5=_VG_J. M.-8]Y,JU1#OVU06PH>O;6KIV5/UO]Q(@@1>*$O:G5Q="N[9:[87\@*-8;Q%K MW(GU]T5Y;:F!%%MR7#7K Y9NX'.O(WNRUZ(1/8M6KCMAY7N+.4585IZ9C>\U M[32:=L\L+WR[W?++A@*Y6=X_:(4]WU9S2E35I0.[LVWLS;T>E:C!!NBT9@V* M^M(+W!E.\,?*M53OU;%K.M>VOVR5<&NL>-NELW#:OM;MHT IPA\O^K;3*R59 M#WLP@C51-<39$>#M-,Z,\U\NO6U0@R_CS?&-+M#KH1>+SZ#9O6FR;HO73[QS M<=FVLM.KD_%#B>VJ 3-XD%VCOGO[:%N?T4_7@>-^ .;7NN_]Y6R5TG(A/IDV MS$1\#_&78OY%7-:O7@1_OB_"6P]O[*S%R9W@?7-T)-_KG$4+]A$'-,9+B%-3\>;DPE[W5U:OP6;#Q M9PNCA;\I%W>WA8N ^';.VOA>Q_#)[P>:BCVQ[1%5AXHG7_W;<_E9]-M6@U] 7\L70V@U_"OG^V>P:H_%NB,=YE M@%NV/KSK8>Y-AIM\]H/@';SSK3:."]_88@'W*<2\#3/4PSA#;]B G^'"*#>$ MA<1-(2#_BHMU5*9>!5SFSJJMV^:\I7)?@IOJ-ERP[E4^:']],"8;9\7'WNQ_>*D]H,Q<_0Q MON%C7&MGO3R'-X-;W+P.UVMP2!RW!V.'4=ANQ37!32ME;-ALM(T+7&M-SQ5O MC.K^&OF_AL%/OEEWN:Q=-/OG[[?6WF,S8-M]M?-P%VVU6780WK%K=9C2.UV7 MT;MWN6Z/1K?G=JTS750?M\,[FQ'Z_[3I2A]\NA*2#Y(/D@_. MY-'.9,09&0,9 V](XCP=79(QQS.21!*6.%\&A M/S^#Q(/$@\2#,WFT,QEQ1L9 QL"9C#AC0&K:[(*2Y!SIXTSN/!%1EC M'#-Y) &IW]KB34@[2#M(.\]@)H^$=DY@A+YZQ:)!ZD'J0>K!F3S:F8PX8UQK MC.R"G(V-,[CP1498QPS>20.YMNR0LI!RD'*>08S>224\][5T$?2 M0=)!TGD&,WDDI(.!]-%0#X;%1D%32/Y(_I/G$N3L2>,\'ER1,<8QDT=B+AX[ M4!R:2#Q(/$@\SV FCX1XUEU>D7F0>9!YGL%,'@GS#-O>(O=@B&PT,L 0V7ZA MBNR_#S,9<4;&0,9XQO9BVVP460=9!UGG&)BB:R#K(.L\RQF,K+. M=&2%4;'GP5#(^]/C?6SE^\@:XK1LGCQ9!#OTCI;1[B&:\8@"27!JRV0D)/C3 MK^:SF0?1S^-?;5.3,!(A$B$2X<2(D"(1(A$B$2(1/G$WPFW1N$/ MQUMIF,TH"P%TZB?F@F?8*U%X1W$>5@'I0U.S$5CSJ6I@CB-941-<)6$J.1FAYW.B/4R!S('#B=$>H10STB8)$Y<#HCU).! M>D3 (G/@=$:HIQ"SNA)4',+:W>U>P:P./L<#_7U&2$GCB6_]5B[,90"O\(=I M @L#6IU/?^!X'9:$':0\'_XO<7+]X3=)#[+OO,A%61=-4<+Z,'/1%)^-RQI] MR DBW,X9Z8["R-$=S\K^3]SPN9/R_"%8QR/>OQ1?X9N+MY50COB"0O_UQ=M_ M1FF:)BJ+2,Z3G#"1:,)-F!&ADH1J'N94Y2_ 5%TX5#X:^]<7K_^9V"BAJ8Q( MEG!+F%&6<,HHX6EDE3!1F&?)BV AS@&L94T^"7'Q\GCQV=3-.%+6:E_6R,B^"Y:)H;__[/W\_>0,&,4P4^'K\(M!&%?"Z]5]?$/C-NG=O M_OJB^ HX+,]UV72?O_A;G*2S+(__\N?-%_T;L@YR.J*[/^B.AU)18SY#C:DC MGEBF..$L >V7,D-RRU,2Q@9\%Y7GJ117-69F.*A,G9$PMX(P%E&2L\@2&H=Q M)/)4@")%C3F:28R]5()2G298;(4D8B92P6&>$*YL3*56L9,0HI]<"H3JD/(E%1&BJ!6$\$43& M64*8XEFDA.11GNT@$)K,GC %9?"B)8"XHJX3@E7I&ZD[JDM!3R N*=[ M9;\?G!P$IP ON,F706W4LBJ:PCR@32YN1H\TA>;N?5)0#N.0P_0LA;V*7<9Y M1GFL- D55X3E1A*9APD1FH:::15%/+D:NZ0A2UC,8I+1A!$6F8AP)AG)(AY% MRMHT2W<1NXP!OY2/XVC"(S;10D)"@3P'@:"F'ID<4%/O5%.#5DV3U&C"T] 0 M9H0ETH::1%D:<6M,9A-[55.++$HREDO"=*P)DUE.1"Q"$HIAZ/\MWI217DOJFM.13(R 2"RFADT>TQQ]_B[ C\M&S''7(RQZ:Y[X;I):?2 )H[2=+F46X;3,SWV*F+-DT1K$4E"K>#NC(LB>9)IDN2Y-"RF,HJNG8NQ)E,ZTS&) MC,T)8YDA,K.2"*K#,$E41--P%Q'KG,XXVV;(^I'F/MID* N4!>IUU.NHUQ]+ MKUNI0J%L3)+,9(2E&2<\IQ%)F$ZYEMQD>7KMO&O.E$J%(Y!*)%+<&HCX%,+ MB/U8,/.9AL+N%VD^K&O3U ^(?>%ACL?7"/?"&*D)2_ON']0C A:9 Z$>C)0CPA89 ZR+$M:'F8NF^&S@U7Z*?L;MG''F MQ^\ONN-9V0](?7]6&SX_!.MXQ'OS.>LPI&F:10E)=)H2QG5*I$X2DFJ5VER) M)+/QU7/6N8 /(QX1FNJ$L#BQ1(1)2*2(91R)4.0BWL$Y:YAZ83B.@M\CFL+( MZ(CN/J$['D)%??D,]:6A/.-*:\*54(1IFY \-93PV.;"9E&:[J)#!NI+9'1$=]_1'0^AHKZ\F[XT43B"OB.B5$0"VJNE@+@BKE/" M%:D;J7MJ2P$/'^[I7MGO!R<'P2G "V[R95 ;M:R*IC U;D:/4^,\ -W-UAGA M01+"<(.ZG!=Z6KUMGHT\:+;MMHJ7=Q/PWR:=4.16I8I&WMK[^1 M521%BI(M2Y18%!.+[9&E8K$J(O+$B(3T43[U53ZV9)D:" M:^::.?@/D0A^)5$PQ'MMC.)<7??4.@K#M+?(XA00EW"Y<2HB9D4RV J18BB> MNCB&G0*DHI">*:1XZI[I8?<\=7^<[U9/JA3LV[4U5Q32,X449]0S/11G5)S1 MWJRY)SII23>T>TS+[O%W%7XZFMA!J<7HF^^ZEUQ7(8T>4I$A+8RF;A!WBS[T M9WT\H!G#8^MP]ZC'\\I8&R^4Y D%S#7B'BMD*!>(:(,IMB[%E-8RUHEZFY) M'F,"G]$*:9T\O%K3^6 M6Y<6NZ""0\)$@3BG CD)SAK+:(T/G!DGKKMU$9AS7G 4P?4C;FE".D:+N-*" MN1B\#+BX]>)*=L"5%%WT1Q?%K1>W7C8*MG=FK*#E+J%ET45_=%$\5_%:. _F?:3.ITB=H< M# @_?PHU$SN>O&K?"L'SGS=N<5788NA_BOZ;U9U#Y M<-)4HV$U.8N5]7YT#B]S"6!0.3NP0Q^KYBS&27.X6!,@BL5_N_S<^^EY'-=^ M_MO;L/BGYPK%-[[P#""^]T1QFP8)/"PVD\I%.\YV=KX\@CI;X#1;9&NF M-_=2K^PX5I]SUCE4%OYU/H++_A?^X4?-Y*""Y_9@YA<7X]'7^KS];++UN/O$ MX8H+OXX1QR$AHP-%$@OE/+8AI6^=RGXW?!W=Y&@8?FLEE'W[&UBYD\N31;\, M^&-N.V_KX>G89D=^U#2P9*]R\J?P-'_-:/FBB@#S%]E4Q]/99+MZ"((\FMSU M]?Y!OD&WOFWO1.]J9.1&@_"CABX.JRLU5BY+W+<3"^>.7*<@HI#?[^UH? *DYFJY_1[A>WP] MJ%MUG>9K[@J'=WF-%@[[OFINTG/?GK-SWO!$35--A^,(RRW[]#- WKP2/\$J M:;[Q]P6J7O?IZV_^8F4?&:Z/7UN.?&^WMG$>=Y6LZF=NB. E"79YAS^=+6KJ M+^RGV*5[D$WP'B_MX(N];%Z]J/ZC-\'!TTGX/M3A]9N3=W][7YW^_OJ[;OW1^^/ MWQW]6IV<'IV^^>W-^].3>;+SY^.Y!_BEAZ)^PN3B,BHNY3Z6;DSN2 YF/M4N M%2K=V:_>3^Y[28XAT&LB.,A=T>XQ3+MS['8Q22>NSBN&#ZH**:DO?YU M]+/?DO:W.//!IFZ9--PCD_ TRH^>^<;/=4Z9C:8-?++YY>4^H\5\XV$67ZSG MRNUT,IHG^_-W@_Q>XE?MY6A@+T?3R]'$ETV\ ML&,[B:M; ^V]7]QTM.]SW=2NSD';R_D];CG@UWTM!7DS_5,6V6W[7+/G.Z22 MWN4Z?&B4V.0-#P4E=[C.'-[I:_&AXG?[VHT_GNSUXTE\E_N!=IDJVKWA\?A= MKKOY^;YS3K=+(-[KF.Z]SN1^:S=9]Q'!=5\K;XI4BZ'V6Z3%4!=2!1GFO_[Y M1>XQ_-@U/G?L43*71D^4L[6TQUU4?-0&/>MASE9KN>[4J&37%/[HZ[$0HEX@ M8O$S/9=J,=1BJ$] B.AC\*'B])Y\^%F1R'G_LBU($:QY"+G M_LNY/W(MB%$LN0KR%.39 TLNR+-;^BK(4Y#G>5AR3Y G MM[ ];EO8%N0IR%.09P\LN2?(\UL[U:6@3MF'ZHT.2GJ_2+4T_]RR5VBG(%SV M3:_WG]O\G!?8XQ*KLM@>>;$=CYJG)F"EJ^[N^K:"@04#GQT&_BV/9NS_2MLU M[180+"!80'!70/#7=GI=_Y?:KJFWH&!!P8*"!04+"A84+"A84' 74/"_\N3B M_J^T7=/NMG=R9].1?V0KEV)U0#D&H=/6V#:]H;NE,=*/L<[N-TK\.,LN@?0F ML9UY%^+%J*DG#Z @]U'9#VX8/Z?AWT\@W;P@[HM53R#JF\'J!^7ZI_HKK(#A M^^EY'->^JL.?7[S]A],N4FX=DD(+Q#55R#D9D(H^<8.-C]Z_R$/J\]/\'M.? M7QS_(UFJ"74.:948XH9HY'2R2%#!/,,X. M]Q;7?,G\%'(NDOBK;>KF134=UMT7_O&//TY>0W0+I@,WA*<)T=<@@.;/+Q#\ M*V5I3/[\HOX*DIF>A]%D]O<7?Z$'6K YQ,]?O&!\P?@BW62I(A[+PV/CDBO'B-.NXK15B.VX^EX#,K>V-X<+5%9+R!^\]6,/U:8 M6NH8?T"5?QR>'%:G(,MF.KZLFL7B[&G+FV>[:!YC$>QE[:+&-GKA)8K>@9>S M)"&7*$5242YLTA1+=]W+A5S8F 1&A+*$>.0$.1H(TE)YSYAVTNI2NU@ 8)< MH,CU4>5:8IGM[CD%RP,5'E'#(8+!R2#'F4-Y)\I''QR+YCK*.XQY2M$C;#R@ MO/,>::(%!H2D*B4&XQF"G+T"#F*7(M<=TFNQ=-MU=-902)C MRJ#(F878)$7DG!+(:445)IPFLY:U>P1/=VMU16["U=_JBH(D/4*2(M5DC-99C#CA O%D/=(B,>2EV,Y4JL559[;:2U"B7N M'+@\%Y$3*B$G XV2*BR#?$XU9UVQ63495;3]J=EXW5D!A+X!0I'N$TBWA#M; M#7>(3\&2J!$$!@'Q: PR/A*D4F0,,\&(6 MW,+ 2$]!I$BW2'=7I;M[#K _/JVT&GBVRZ)(MTAW5Z5; M(+TTG/O&#A,QP5J74&+"(JZ\0DYZC9+2'BL3+;/I"4*N)VPX5UH;[-9N1VDX M]_Q\4I%N\?C]1)L2Q#W;95&D6Z2[J]+=/4A_5E&2BE9&PP52/B3$M7/(\6CA M/YQ2F;0U=FT6TR:BI*>HP\O[4J+$1+W D-+N;8<"T]+NK1^+IK1[VU#IG<28 M"\89(GG8(%?6(Y=80#IJ*3!3W*@U+VE>!X4&K9C2H0[5J;T4#V]9 B9&V&B-I(FS4P2*3 M,$7]!Y,XY+H^Y%4^J\3!>^B(,=*$2LTI\=KY7A3O M49 HYML^K/3=M4"%.)C_/VBRP%)115%%\=']T<#N^>C^N-TM]9(H2+<[ZZRH MHC>J*$ZG-QHH3J=40'ZC_;G".":K$',.XE9N"'(12Z2EP9R9*!59.W3V"''K MCE9 %C_6LP7[@'+)HLM]\8A% ]O60.$D)1 NZZRHXOFKHCB=WFA@]YS.LXHT MC8B26JP1#D$A+@U#S@>,G-4D))T,48\2:3[)T."\05H"RQU$I4=O +DLU=G= M[E6,.I->EM+\/CU46'] Z'0TL8-2Q]U/3[_7:Z2'"BCFW1?IKOIP>DA%]N%A M- 5"LUL117]WS)P"&2)J(8D@%'1%7RB/GM4&>*V:3,58J]P0$8$@[?21Q/H-OG* MYHMV>]*BYQEZQ_[8^G9:G3Y#E1;"TQ-%]&=M%<+SC G/5KNV%OS M8"%+2+RSWN9ZU7$_6MJ27DJ;/(%OOU>Y?9%K,=;^"[48ZY)<08KYKW]^05\\ M@HP?P/@>7^HW,KZ=->X5UN_'QI6^?C*N7E6Y6,4SKC1(/R@BH^::I2JU]''0BY_[+N3]R+8C1#TON2>;T:# 8?;%#'POP%. IP+,'EMP3X'EKZW'!G+); MTQL=E"1XD6HQU&*HA9X4>@)QT7S:?.$H)2XJP+,'EMP3X+F:$EF0IR!/09X] ML.2"/+NEKX(\!7F>AR7W!'G2:%P=CV.H)P5Y"O(4Y-D#2^X)\OQFQ_^,!77* M/E1_=%#2^T6JI??GEKW")$^EO>R;7N\_*?8Y+[#')59EL3WR8CL>-4]-P$I7 MW=WU;04#"P8^.PS\FZV'3?]7VJYIMX!@ <$"@KL"@K^.FB86%"PH6%"PH&!! MP9XOM5U3;T'!@H(%!7<%!?_+#J9/?22Y@."C[^02W*.MW-G#/#7^/<8*&X[& MYW:P_F[?R;QGV260WB2VP^Y"O!@U]>2IR4?/]?6]@;UWD?33'U>\+S(]@9!O MAJ8?E.B?ZJ]@]/L/[CC!7H/HO!*(!V*1\3JAJ%/@R@9N MG'T!U&"8G^;WF/[\XO@?.C"3#',;0 MP.._CFYR$GW>(*YC<_39U@/K!O'M:'QB!W&^==S;1?_?]>2L'E:DNHSVZ@#^ MBC3_4@!@MP%@-^3:GS7Q[[LSM?[Q577CU/H?$FA_%#OS$F_'UD_JT7#F)G 0 MV 2F$6$"()]KB72D%'EB'>><,N[D=3=!.1;,6XE2PA%Q$<&U2$X1>!1/!!/" M"#]W$],&?;+VXN5UWW#-<\Q/&.<"B+_:IFY>5--AW7WA'__XX^0U1*Y@.G!# M]@*XF:]! ,V?7R#X5\K2F/SY1?T5)#,]#Z/)[.\O_D(.E,!S0)^_>$'T@NA% MKCLKU_X :O&4>^4I.4N>6>&02BI[/>:1(T8A9BV$19)ASMT3>$KOI^?309[O M\K?QJ&FN#JKFNIF_1O"&\=1^W8C[Y,5U%H@OCL>@[(WM+94$V;8!??,U=A2K M [#! RIHNUY*I=V&H>*/PY/#ZA1DV4S'EU6S6)SW7SKW45E90(^](/:RZHX1 MJ; @&*D4>:Z@(\@*P1$+47,9*#&67O=X4C%G64K(D.C@,T+ 9P)'V"5GC8W8 M&E.J[@H8["H8_/ YD:*'?NBA1$];C9ZHCT;3Y)'1'B-N@T$.$XT$3D(EJEEP M_KHOL40G;.#*@+5'/ B+M&#@54)*(H)#(O(!64<@S4$CQYCW3P^YY\_XXZ(?7L!3LVZ,U5Q32,X449]0S/11G5)Q1 M67-%(?NHD.*,>J:'W7-&SRK/F:)(7F.-K/(\[U%B9*,VR%B+ Q&Y^#,^1I[S M*2H\&3DP0I>DYJXBU"/V7UR6Y^P^]RH4GZ; MI]_3==$KT1>3WKY<5[TT/:0B>^DPF@)QV:WXH3^0_]1'QGY AR7VV&[LP3"S M@5MD>>08HX%QH[%+ M_:B/9 =";+(^\I$60XD[BBZ*+HJC+XZ^./I'.P@A-(Y$2Y2X=@B*[BN8KG*FA9=+%;NBB>JWBNDF[=T+ZJ=$DX:Y'2WB NN$2.,H-"(BX9 M'91CZY-#-Y!N?9*:3G:@R"8/JA??LHUR3O@Y&T[7-BY;8CVG<,37E;C^+F.7YJJGL#_#S_' M9G(.HFLJ.ZFB]6?P]XM/8/LU*P+GB M_.Y@$/!.^7=+HH5;#V+3/OBP_=N57 ^JK&,/?_B4WVS4/8-M]0G/D/\UD_%E MY4"C\[_93W'H+P^Z;ZJ'=NAK.\@O#@^Q)_%,!VT4H7;@B5FJ5R,01+U M!7SZPEZVIMG=U@;P+DV$-_\$?X,+Q_%3WI\*K_.TK?!E=U/ M791K7F51AVDS&5]V-VY@%=<)GA-6ST:"[_FJQ99<-HK_(7Q5:X<"*!>M-\!3U3/%VD)=/>V%^ M>5B 62C9_L?P3""*R_QX@$W_C)/.+ [G\+B,1$\(,M4FX)GL)3X?3:J3>#&) MYPX,EN&#BF)*;E)GWQX\&S:L[R_Y/S<][P8BA>V]W,WQ@J'*)F8U"HY O" M M0SJ&'#D$)A()P8FUP9@I*A]48(C$E"<#J(B<2@Y9&C 6PA,J\?5XX=MMCX\[ M%CB:+A5F_ I^Y>.H:5'J5_ /I^ %"/T-KCQKWD^S;7U(\[^OEFW.ON=R.;1X M]_[MMXLVS*UQ1:\M=IEB#&]RW!:-']"6>72=VQ)%J2G]5Y+?"??;HG?+?N;[*5-S6'U)C/-!1$9QW,+7Q R![7 'SZ=S:G2O^#! MVRMF+&7F>M?\0W[M)@X&RQ];TL9%YA8=_^FZEA]6 M1TU+6P^6*04\'9#.@6T:X"4S)-=X4Q7JT$HN\YEQ MR%0T-G'\.;9B7V'H(*5)]3KZF7\DK7_$!WOH?!QVR8.C09XF BX'?(BVA"*N MK%#!PE_Q1I)5?7,^"!91=D YR]3$X8N_#$?/W?NL)(:NCPO(69__4U4]I]GW M,/GE[-;,YHD0U%E&D"'8 ^$R%$P7"Z2\D)%;RK'7_R!]9_BMB]I-DG_--T6( M9_<$;KV.E)&H$,:Y%#O*A*S7[=Y 4B%PPKU\"-=OYYO,T?'U"!X*POSCG$3/ M^0A@2O#;V"+"WT'J#Z;L5.PF:(:99"J_))J\GD(GG.I+/3F[EF9LEA*0;R.0 M63NH9K*LW@V;Z=@.?3;J\<4\V_-SE\GQK]Z^?G?<_1Q>_0(P#1=G=*[/ZPDP M$>_'T^64%="76']N.6].#JWG-)?R/E?H?S#/][4I11 6$/#04B[;2 @ M?$W,>;;AS3DG9P?MBS1G,>9,6::]B]Q@O^.7ZM\?"45ZM+?( Q,D!$1AU2/N M $E<(,"_K,K$2ZNX/M/"N"@8E@$Q[QE0/,>0\90C&Z7E0K&@9%S!CYE%OIL9 MY.\+>_PPO$[F0- &^R05,9O0K4]^_]\2&Y 5OO#;9;68_P^T'6 MW2[X!+NS&=,,\6NQ[!7;7]_A[4U2/P<<$'@\@-VO#9 CCD=F@D?)8P7SYY,+RX&,2]\ M._AKYS)/LL=\73<>PBYP\,TI?,-?!R/_SQ=5! 2XR$$5X,HW"A&^$V+I7:VP MML9F4J_CU(@[;#.AM%+G-6C>.?ZTR?1],&/MS\\O*[ M&Y7?7=R[6V0T+RGJLO0W-*"RT\EH7K*5OQOD]Q*_:B]' WLYFDY>IOIK#*^^ MU&%R]E*ULII=#W8QL!=-?-F TG*J?_[:;1EA=^L7-S6I^UPW=;=E_G)^CUM: MU77?*L0A-?JG++';"MBZ"\FA5.0.U]%#?I>[J4,F[O:UF-WIAH=2W^6Z.S\> MH?=^NN\T$.S)V>2/?FB<0_+-][ MU>N#5/-?__R"OGCT6M<[MO+=">T\ =.\BX97HKX_N7'U'W]9#OVV4M)\IP:U MNZ;OIUF-136]54T!RIT&RN4M M$5$\NSSJD9',(F%-P#Q1C^E:^<-]ROD?STU*7'QD+U#\$<=_E?S IM%@7KP] M+V!^0(+@7FFYGBNJ#YRGR+5'W;!=MF2?V0T>+=^7KRK=0EVVW*G: G,A!&&,/=)"1*243<0:(KU8VRVX3QB^?I*ZM_2E0$5/ MH:)(MTAW5Z5;W-Q6W9P-,2KE-4K>1L2#L>"MN$/!!HJQ)Y:M-TVY3X3^N&Z. ME(WQ?D!%V1C?H2B][:10LEE]I1=JDU.H'W41%-)6-%(T4EQ^T>N/S(==#6(B&SRQ=8 M(L,514;'%!RF!MNU22D/[P3PB"Z?%X>_N^YE.4L#/^?:F+_?KA'I_3"/+/=G[NSJ3V>+W-^%_12[Y8QL@O=X:0=?[&7S MZD7U'[VQKZVU>KV3?%^_.7GWM_?5Z=_?_'[T\ M09+O/YR^.:E./U3'']Z_?O/^Y,WKZNV[]T?OC]\=_5J=G!Z=OOGMS?O3D_F> M_\^S4;@Q_-)#43^A\UA&Q0W/^='$ZV2)0\X9##3'">1R/:CC$0=CO!!XK1[T M/G-^/HY'%T A+C\.[' "S.C-OZ;U11X9=1HW/;5+03<]79O8\;$GV M=HK%#:_5$RF7D12[-Z.@)R,IRNR>9[4:BVIZJYH"E#L-E&5VSS-9C*51T,XE M*WZU8/AV,AI?7J4J2EWCLRMRZ+ET^[,>RF""/2Q'\,9K);Q"V'&2SX:T.7>" M6"0LPO]3S^+UG+N/21FE+:+*&\0M$<@RZQ!C5%,K9,1:WSGG_K?QJ&DV5'R( MA>Y'+4*/3+@@>I'N*$:NBL\C@Z!#W7B.=9$)&*9R4]4HJ M?=U?"F:IC-HCH[%$G#&.+#4!"1Q\BL%K(VXHWWMT?ZED<9:]@//2N&B'4/]X M='XQ!=A=*F_(Q0[-*$V^V/$#6@W?*W77<[7U@0H5N?9(KH6];'E:KW+N8&TAL@[V4 MX0C/%".*7(M<=TFNN^?3^N.FMM12KT<*>BXA9]FN?NSMZFB;>#8:A*H^OQB/ M/L?,IQXP3[9D;$H"?@^ENWO>^EE%H,$09;4F*$_G0UQ9AJR-"5E)A3,L&176 M.MX$Z:BAGB$G)'PF^8 L-Q892@S%AK!$V18B4$-*_OSYXT61;I'NKDIW]WQ= M?]S7PR/3LBSZ%)^6+=%'W!(=-I/Q=$;SAA5$IY_&L7E ;%J2.CW*;Y9.^[NC M@=WS^,\JNA4*(MK !")!2,0CT4A+%5$*6C.7L,9QK;F;DH(3I2B2$.0BSK!% MFC", F6&<*:$(G8;U=1\D^5A3W4NK4?6OE\(5%31&U44=]P;#>R>.^Z/ARW3 MUG9FG97=Y#NJX@F73S53UEQS)7W5*\=3I-M3Z>Z>RWY6$;2S6 D> Q+.:,0) M%4A;IA!C/&).&*68;F8BRA.<1V9]&8;2(Q-^AI!1I%NDNZO2+>YNN]- )+:" M*XN,#1[QZ"ER03FD3#26"TT]W] TD'*<>%_PHNR=[]#>^:^Q:2KK_?1\.K"Y M0WJ(<'=?V[R R@9ZWSQMR=@_)[,31E4-XO>0/X.=!S#\ @SLZ'X&E_V_[^UO9W4:(G=AD M$J/LR?1LT?Y2=%F\8N$E?== X26%E]S.2Q@0#,=)0DGA!!S#>V2EB"@00I-W M3 JI-I%&ZA:+*ME=K=[I;V6)[>1)>D7C=^L\=/1Q Y*QKB? M[.9I1M/W7!']62O;:3W\ YK1D1UU$B[1E'--D@-!;" MK&\K;K2*YGW<#,(DY(0E8(@8A)WGFF$K/\44N(-N7K54_Z*16W\L"B(_@YSZ3_RUR= M[Z?G<5Q[^'>H/]\NJ)^>JYS@K>^%/(L5/Q/@O(6:\]HG8Q%E^XX1QR$AHP-%$@OE/+8A)7E]P9_XLQBF@_@A'7D_ MGL;P:VU=/:@G=6Q.LX)/X?Y_'8S\/U]4$=;[158I7'?;6N"'@K%O*YGNEVN? MR;4:7 DVZZVIFUP)-DK5Y"P"8@X&HR_U\%/U7RR:V;VMJ MCC0MT-R4<;73R6B.Y/F[07XO\:OVMV2BNV\5XI!K\5.6 MV&W>K;N0'"K)[W =/63J+M<1=4C9G;X78[V-YY.'QM![/^!W]@ATCPI@'W\@ M\CW69&_'QM_P6CV189[>#V7 M;G^61)G_O8>[;3G#+H-PB"LO$ \^(".C0C08SXTQ/KBU^27WJ:QY7T( 89T#Y^PPGCX;A]15*OOEZ$8=-W"2?D=MO M[](C(WY6<%'D6N2Z2W(M[FVK[DTYKKS5%%%PFME TD/B M]*VX-RJW/L:L1T;\7 +ULMW_R @Q6X+516[F P@Q2E4^_64G^1S"(-HF+@XM M7);L5S]]<)%N3Z5;>,Y6>4Y07(D P;L22N8#LQ(Y20(2$AMIJ<&*QDULX7^8 M ^:O&2_GVQ&7FV0W\")E,^+Y T:1;I'NKDIW]YQ=?_S7PT>@EF71I["U["\_ M^O[R:'(6QR7!TS<'\L@'JHH&MJV!W7/SSRNF]=0F'C%*1!#$ \WQJ?"(^2 T MH:]LW#_(K*)&E$@;-V;)I%!G.%HG(^^&"4Y1NI M!'A*.,,0E-1,;V@^ZB,Z>L-ZTJNG.)7'G9!QXV_AH_O8YG_3TS,P]Y1&CE%( M0-UYD %98CV2QF/GI52P'C8Q/>/7V#0QKM8 -Z?QAR9F?%>S>E?=_+7NKW=2 MISJL6BE^=^[%'0:-R.T);AD:R9/ZQG?#ZC=[65%,3#M9Y'AT#D][6;6$)(:J M'DY&%3R^_32.,9_'.ZAL4S53U\1_3>&?@\L*3!QD' XJN')V#,B"-["3T?BR M:A^XNIB.FZD=3O(E%KX'[H7.X;G.X&Y3D)UM'0K<"_QB_+(X3W18O9Y&^,Q- ML]K[0R^JNS_>]O2<==N# M*2@U*QM>ZOHYKY8=YD]/X1\60&T"GQK?MA[EY4_O9A1W"(]XH^$WX Z!SEANI4- >:)Z+'/R!]X@P MHY*@U&I_0P[(B* P0SX1#I_Q#&G"/4J.$!4M"4GPE5.O+6X=S5_G=/::P-]> MP\NNG%7'XU'39!#[.] 2^-_FH/KUU^/LP-I# ML/;B8CSZ"C'8)(+;>C 0]4U^M^3&.0\L&8H4YH!Q1-,<,MOG@161=VT:ZL909P_NSI_\#<[M)^Z3]Z\E+K'ZM:>'YW# MRO/MDGPTKTX%#HHF@:S0>9 MH(\0BY0'BU%6<,S]0T#R6\F$S"(_I&.X=\:Y%;-#3?0OPW3<6E[/;4[17;:S M5L)-"X+V$6,4&@7-3>>)1@H ]R%]N,CN]'3TYBO\(JP"G1N!3X"HO\MF M]5EGH_8M,KF+[7OLLODM OH.Z5*.R_.(EGH4'A/V2 R62P [;26X2R+@)Y+ M76K&J!&)2[DV@?A'O.NW[/&:$?9;06WVJ\J^O]EA,WM5G8V^Q,]QW*:-ZBYK M!,P=.*1U$!%YH.VV7LGW@ ,>#&"!Q;&OLW7"7Z[679OXJ[Z%U P:--H]) M"X64--C$4*(2?*].%!E+YF_!"@!!'/-U/T/A$YM)GPXG,(WMT^1 M=X(V L]]D_G-F00;P)2$PDA['?+<'%AT*7,2KXD3%A.A'IY)^ A(DY7[*8^K M;V7];B;J=\-6,Q]GBEE)+UQ,QW&Q%8_H3##_-UL053 .8CV-S MD6?.Y[W[3"!R[-^C!W7G=BO$=85/&;NY Z7SO[:[B& C>>B MAW!8'=UJYGV3S,H,WI7HM\]/W2$;P!IXWZL]F 45O'*N&>L>+3C1WH!@&%+6 M4G"2+B''\O)FDDBFM!+J%N/#P2:1BSF4*&B#N@K6#E9?6:<)@$3W6 M GL]T^3O;6;S;IZ3?_MX_R&YO6==GVW\I\/E+;H-5R5)H6)BW"&) 4DY9A[9 MI!F*RCN:O'4QK'&D354E+3H3_I8+!>!_3W-MV@^6*O5\=W(;M2(S<=8=V;\- MRO*?[0_RI&V\S3I#:HD?/'H:#0:C+TWUCZ>1EJK_&\.I+'29G\!2ML&8? *T/ M[$437S;QPF87.W_OUJ=V]WYQT^'?SS70_':IOYS?XY8CP-W7*G-H#*SJ%[?7 M%L^>[] P%T[;K2<'SGP+);0BVL_'P5T'3YTVZ3 MY9<^5>B40]?/XBQ6SZ7;G^59!K?NX:DI35-T7G.$HTTY<6N1EE$@$7A(.@IM M[%K@>9_CT=\,2N9YVR[5 _3G0WI;Y[BSW4+92(<;W9-C53TR[NT?D2H==WON M$A:,C>XN,?LQ\RC+M,AU!^5:6-16693 '"O!/)*24,2994AS1Y%,2<6@L:=F MK4;TT5C4ZVE\#U]S^B4./L??VKAZ,TU[V>T[X@4^=I4]E:S74W$HMKL&!(CB-EL-#)"]86"#X=J\K9J-,OHPU- M0"A3_?J!("4AM8MDBN\NF2J13X\2)T6N)2'U#*D3)S+(I( Z69,0-XD@(VQ" M1&$36$Q$1O/DU"D7>FR&/"E=,E'/CC:53-13D2>QN^2I1#H]S944Z99,U+.E M4U%CHQDP*>521%PDB9R6% 5OC$G216:?/!/U=C3=3&V4QJ4VJA\04E)1.\2F M3L\B"#)-RBCR_GG:>\FUS#[='0T4/K1=/I1/KRH5D/0:^) 5'+G$.8H2)T-) M,,D\J&K\UAX[-Y&AHXS!&V5$Y(!IN>T,4YF(V@<"59)2CTVC\JS3*DW;_O7G M]; ^GY[/CD_/^RR58*2?/KY(MZ?2+>QHJ^R(""QC4 D12V7N)LB Z9"$)+KATJ/S_*_-[ F6 M_-=SYAN_E 3:L]'EA]N;#I;HK)_DY6GFT?=<$?U90=MI?/4#FMP]-OJLZ)XV M&%LK$P(&)Q"W2B)#=*ZMQY$D3@06;A-T[Q:BMQ%"QPX4WV31_*,:_LXQNZ=- M^<'/N8GL#5WD0_UY_QKQWKM9]5Y.TOT]9QAGHSP6$R3ZW99ZN4-LU\"WWF\VB#?LN\^O=GG\6)2>F4I$4NY4%A5E.DO';;OUXU-R>HI$K'EU\TZ/C0_J &0M; ML2GX_2#+/R_506SRH&%XSN=O:8QCY:*@R(8\ZW-JG8 M81VEAXML2@%Q%Q(""R-(D^"IU6"R:6V6XGTM[=W[M]\QM=M/"/3;U [:T5>[ MX!*BS[.[!Y>'/1?L+LAR!SG.,,],>FX4Y]&@O6_CFP@1W"B9<=IHQ!7P">,2 M0Y9%Q3T31"F]B=$^CT8E;J_LZ;6-+1.*?;$U;ZV4GF#D>0"[,0QLS4N!E*=) M<^]-P&MDPAJL(O?2/9FL/X1+;M[6.4:QY MZS9?E=W5]PHT'X4CZE,6>'.0)Y<%L-AQ[?+\Y^D8>. XSQY_/YK$ MBAY4[K(Z!W2;CKM!1'"3\>C3.$>FL[G0]N)B4/MVPE?:PY/ AS_7F;J-/L/73. %X!MLGHPYZJ:@QP3 .%D9SMNRU-#, MYF(VDZO1NAEH\I#JSS&_$7RF3TT[ )9F<[7OBP&;GQ1XM3763XI/Z)($NU3^ MG\X6%187]E/L=E!0>ZCXI1U\L9?-JQ?5?_0FI?]T$KX/T+Y^<_+N;^^KT[^_ M^?WHXYL_3M\=GQQ4[]X?'WX7<8LD5R7Y_L/IFY/J]$-U_.']ZS?O3]Z\KMZ^ M>W_T_OC=T:_5R>G1Z9O?WKP_/?F___:58L)?_7P,=ZL!@\,O/13U$^[7/1P5 M]]*QQP9\I9VT$Z3S8<"9F[QRB>#_7%PX1HA"0NQR.JV?/ZQ.S[H9]]-!ZS\K M6T'LDI<88&K.,:^ZW'.XK :W#D\!_G]QF\I^L>-0V;:(SWP NZJ^>T MHWNV!1\)5;3 $>#[ZU&8/1F0B/$H_W8<_S6MX3E7'@=ND,=C_\\T?(HMG\CO M?6[_"71A)I>6C.'B?7"#(JA@1=[DNG5B) M@J$Z40CQ'=;7TSRSJ/3M>'2>W7A^B/^N)V?'TP:611R_&V9_!E9VU#2Y&CV< MVJ\]R -M??MR%U)6^Y(1#3PZFA)%R3"!N'$166THDD$Y8XV(@MOK2R5X@H.T M"E&6\V&<*V2$U\@I+J6TT5K:HZ7RD)W^[:=,UTC3:@[UH$H@T8Y^+2C9^Y.W M!]7[=W]O%]O;H]^/KN5=;UR S]"V=6".))N0(Q@@7;.$=,(*A01FS30/U*]U MVN&!86RQ0R&O DZ<0,9JAI3W2FNXAY'\R6S[>FT!:J+/!IX+1)LXO'5-BV2M MQ1[>.REX;^[ _3&'")4".RJ==VON+S(EHM,:1:,=X(#5R'(*/UD:$V$,6VK[ M\][O1S[*"1E0M(X(ITW$>@TR[[,9#^'3>=T>T&^.AJ'+@7V*0U_'YG7= M^,&H@2AWTUMG9*_VSLQAM23E=FFNR/GAZ<8M)MR>6IS=Q?F)7M83>%B?,[VC MG"3Z:"_S%A?Z/6\X =A]M./)9=FGO"?HO1M6_VF'4SN^K'(Z;C774C?-%"0, M3S\= B.8YGSF!9 /^/T(/C#,&Y,YI3@:CT=?JNE%_L>^Q'&>)QE$B @H'@'6 MYG/Q:TQ(4,&#Y]$XO5;9 G%<8(DX%+72 -P\(+?OG)S_L6#M]L%N?;;:1; &!F=!R"B-NCS[S]E\N]2R?S4W M[(P;W>_"JU]:D@>\]I\Y&0D^+J-+3GW':OGR;-,YB3^)$,A-*CL!NX>GJ"X& MTV9?HCE"F1%"480=-XA[:I"S@2,(XFC0SJ5@\74+IQ%^R8)'6.),39A&VA." M7'2.$$E25&M1S:J%_]4V=7,"+V?#A^%_V7&=P?YW0'JR8O$7 $8+DT=TV>:_ MTQIL1TW^IX,V6FG\60S30;O]5,$[YKV)!]OC+=S446>\22 *GR&JXBLDAHQ M%XF' #<%LC9(( 1I:.(244F U#K/D+;:HDB"I-I D!_74E6K!O!;?JEZYR$KJN1_-B:-QY6+*N#%'DNO1UUI0T7^S:VELW286,A.H4CVT@WFS MTYPKVQ,P="$F)O(4#1QRFDH19&S R(.U&QJ5HW[M_%5PS"O)(A(X.@CPX'++ MO8>E81C-B"B(62EC7%T(']LMQ]K/FB.>QO%Y\U<[&(Q&P_FO1G^-'VT=/BXV MD.^*D?3;YZ]W$R'GE6O=5B]$8.&S'?ILMI,.*@%5#BM@O&^C&[<+-!OW;VV= MW#KY[5AM1W_MIT_C^ D *5O\OC!YO DBF<%2%1(H8](F6+*+ MFI6.V:89^;K-:K5+_3H =%]QXR=SI=(*-9OO9>U!2NP=4\GH_XF.H M)80Q+Y#DN=$"30+I:++[($$Q3RU-:T1?69)D4!%AA5EWRDW'E/>]&0Z!\!B8 M*7F]C>7U%I9]Q\3>RO4EL_?V'TD(A5,4*-J86;H@2&/AD$^!,:$QQVJM):R( MAC&C(!I0"@)@; +2CFI$=0PD>&6,^ Z/*IF]VSA$5T0]:7'XL9)Y1 <7@F%( M85 \Y]$B2R5%4JF:7-YM.3R=A[^F(T0#6F., _@K@'9($0"9V\A<'(&PBSJUC=1XR3&F)(8,\>_ Z'GQREX'>4 MH!&48BR-U]^7J2@=YA+%W%2-6^!N1C&!&-!WD^ C,:;MOZ\YI#=Q[QU*:[!F7@> M$#<:7(1V$6E)M-0T.=INQAK+)[_\TM(>MN7&US.1.["$:JD+'\L;(WE%H27:[%"Q&H@Y<$.C#!1LUU*EX1;>IF I:6L,GFN&J>V=.&K:VDA['"^QX[_5-Y!)RP$X9B1!@#?4/\"/HV$LGH =[! M@#!>8PH)4T><9& 40!>XH0Y9N!!PEUHNG/$LU\\\;[3-?)/(>6>1'T;:_AMR M%S6NF_#JON?^9/NC),)$3I @@2"NHT&6.?AG(%$1*I)D&P'3I\^ZW#XBJ<_V MN91A:0._-E>Q;*Y@HZ,J-Y\""&USR>UXP#Q,L\W^9Y8P!%6UF9FA;_L[[4W* ME!-I>10)49IWX8T/2-/@D8@AQ/Q_T:Y-]_H18VZWKJXL]4,ZB> 5AY\^ OI% M^/W)F1W'TS,[.;;#)?8 UCYZTVKL9*&P$]#7QBS]IG+!73#U68.RII-BSN7Y MMI=8U61!YC\W4W\VM_:%12]C>).U#V%5VT5M?L-U>)^E_.95APT0D?G(W5E+ MUMF%2_L,BR+"68.T61K3-NMIS/7LY)TSFZ6,[R'YL:48:;Z=.9I.&N"A8691 M2]EAZ_TXATW+;OYF+)K"D$]+6 G7@02&CN$6!!>S Z 40B)MHP/%BX7X8UY_R!D+^;5??1TJ! M7U;*LM?O#':T+SXR_J*H[;.O'G79EI6S;+U3LV/>&B&R8'4 M.VJ4W>O.P7*M0>D)Q'[PYZ,5&(7O3['M\-I,1OZ?V9WN"Y3F-E_"&8$XSB,= M,#< D-0CIHACGC&BV=H &#@1TW[4>NV^U?R*$4FLC=-,X%6SP$0^PV'"M" MVA34?$A )GK3)J_RLKN[B=W='^C94W9V;S;;W*.NG2K1!A_M=(F5MM;VLG(0 MK,#?FZG[G[9?\ZCR UN?MVV@&XB'((09UVV,,6O+#*$-<"F@PE>=H%T.0F+3 MK!Z^ZFAP#H$&\[G47Y_7/=SL)P;4RT:+]]0P/KZ@M0 ME]P^^]R&+F+J0K?E2SPHI&VP;9O1$.YXN6AN'5:?\,P&(.+='?S8 (#E&DR%F?0#5 MCXX?NNJ@]B']"NX* N:C3^,8NU+?TE/M_CW5X*)J)M%J(=("RAM))US?9XUG:R>T%K[\]4IK<7!UO_.V:DA MP'=U-)B>#^OJ]_G,HK=98K8EG#_/[_C?1[^_7=SDL/IC45*[]E6K+S7H_ARZ M/-7\^0_R0;%!^%*'W-YW=&D'DTODX-L!AP^R1^H^UHU2R@+O=@"!^UMXWOPL MU06 ^KS-7Y=<&RYN?W7W&S[]S^'H"SH;?>FF-K23F6;3(\X!N'P-YO2_[6RG M,/6SK<9NV%/N63IIA[J%VGX:CIIZ]NW@;B;S(QQ !?,$O,/JJ&EW+.$9QITH MYS>:26153#9+KRU@O&CKL:KI11J/\C'BN%<]+YP,U$G*D24\AS840AM, S*1 M!A.HP#*NE20[;RE/&D(;CA/B(@],-O!I;(2QA.7V]FS%71SG6,6-QNV\K*/Q M.(^Y:'M&_M$)?78B9#U1=!76X&\&X_" >'^.\P]9 M'CN[.N8YJF5XGH* P.)G$EH, UQXYKF'&L=S\#_[E/,GCBI+B$(J9KLC)?\S$3!V6^9IFO6>9K M[F".:G[2>##$?Q#X.8]T2!:X<:2.1Q)U7*NB)21QQHU MP5OXC$TJ][\5B"I/I#&4F*L)?T^4&-EU6KU2X#=:-.D M2'#R'.E$ N*:PF(0(B$7E>"<,$^N[1(5Z_Z6=<\-=!&0U2"%W#(S[ZSE: K M-N?R%L4XUPMPKH*G4F]Z7RU\G(YS1?"B8O@[FROM(.MV2O1BZV!?$(.G)#!S M& 5I\FZR4$CG5B;1*Q\#HTS%M19Z7$JBA!*(>$T!,:1$VEAPJ4I+QS'GSJVF MEMY\S3,D8_BM'D0P\F&<0<2'X9$_JV-.,AQW&8;?XZ?IP$Y&X\MVNM=\)VGQ MP>;^J$)V&546: *>,EY,6H0!(,E->8>?Y1K$[7K]=KM0K*M\.)\KWF>W1RU9CY>2/+:=O:5V5\KT\I%8""] MT?75D_U(MRF?/;VS>;>OG60]G,+=AG$RWQVO&M!$,U^1@]&7*C.%0:Q"_2ES MA5&W_3<:=[N \VW]&)LY,;[A;OF;JO;S67CO87T^/9\7&.S3/CH5BF!*2)Z.QA'W'L)%Z3$2.EJG@I-.KJUR MI7'7>9E*AA$7W.2):@8EC:5,6DDM\(VK_/=.OK,UWN0-P[![2Z2B\6QPV[HF:X^&!I_<.O.H!9^$QXVF&>UMN6F,(MVYF^ MLQ#AZEN;.8E=*]>95^!<+\ELNL!W3Y:HHHD8!P$K+%%@L-A1Y A7**D\X$V# M4XUK#8&QX1+6H411&)R=MX9PUR2D*4V!./A(6.M&-UN=;[J2C&_QT/M.WTY6 MLWP(5BON$?"!/%61"J2LXR+1$)-?*_'\$2J^U"VC';D-3N@#&%G''!_T/L/G M,E7[BMC":IV[N\5Z[2J9=^%%UJNM2S+AWL(\O9XI:"YR06*NJ9?TWJU>6]7>,'URH#V MD".LC/PL=S?_;6Q'PS,]%C7=QNOP,$1004PEI(JZ@VBJSEU&@2CGJ<$,T)>*YC/M^! M*;+2IL2TMD:$;;V/=/ ^D5DPEACA?4 U5B<%_X20QIDDE5=KS3H4%@:T"F^> M]\R8M\ARC5'@3BH5C#9"//[[W!S>W.,7?<:\12R4'<\NL)/LNR9GX%Q:QP<> M#Z(I^, 91$3#O">XSE[:"[O]O>Q^NR8=@\MYC?5:SY!/<1C'\UX2(>:S^5%34M4X+R-JA2*UE(,OH80;%? Z_UHTO45 MJD?A[6A\.GOAZX7>UV.H,!T'>]ES;1J\PTWD*I!O4WT9UQ-P++EE3.Y;-)IU MOYVE?7-]HC^[ZIM@K^CTHS4]Q")QRR+*?8WSKAMX^]Q&/TCC9 Q,V/6"[@<9 MY>[T.&Q#J#NCAL$W:KA.ZQG G/FKPB@V;:?$D8?0;#X:Z5J%,B/Y8%X7[\P? M8M%1L7*7W3DV.\YIO2Z%V/:1NK6PNMU9\[-R0N UDWK0)?IM,[DZV#>+QL _ MU>/./=GV8SEK#U]T>),M;J+D[SNK^RD/.?-@HZ)< +TD^9 S3\@%FYN(@Z%[ M(Y-5:]GV'SGDO&C(D0LMSD8#"'F;KMU;[D9Q=?JYG'5^T%EG6#[+HP4^+@I< M3KH.,\/93S,-+/:P7L=4^_K[QZ+[7'#:A\X?1]/)V6CC.+P9Q^93:6IWBO.KKHMW'@34WE5=QL0S%VB2B*$R03.0"1Y>'ABKXR1&DL#8QT60X6W,8>0=V M-&Q!JUM15TOL@?W&*&Z/..]N9=)5SS'?"JFK8CS(_*CZ; ?3_2F^E=K80!A' M/K3SZ'(G]L^\ ^8R #C'>T M,JRK9=D7VW/Y*(,48'OYA+ B%#D):&BHI%&2H(E>2]'>Q_867.XQL) \ M&RB\5M.]CVA(DDY":(R\Y0QQZG6>T0!F*:1)BF.;UC<-'FZ1!1"_!8C+N?,; M\PG;.GE=PNK[Q'D?N]CBPSRVR/[N]SAHLU6G8SML.C,MT=_]H[_;HK)9!#B+ MRR"66[3&?S"\/SRGUSU\)B^"!TE-"FN#G"D3 MB7COD&:<9*?"D!:4(!%5-%99+7-(O3)'7; MX;K[=U<1OL@.MF6#!UT]0[^+3IY_E5T"5Y,JVL.8,!$28J()0EQDS_CF06"9*D46!"G_?8-FX*0"3T ?K;KAGTC M^5D.&G&L=DR)?(@D)6T )[K%,:7 ML^&:2SC[0&2]);<4L78B\W";1Y.9X)$53,%/F@;AN8QRK;[R/I.='N^]*#E0 M!!]HPI_)T<4EK?-V55OY]SM8U_\(>?<,6H9,.>XD4@06,?=:(5@ &D5AHXE"*B_6V' 9:/LT MI'&E968ACEWUL]=.$VE0BCGWI6+>#03VJ))@226;G.%E?NWF>5)]K>GP57=& MOUC5;9(!Q X .ZV;LWFKN6Z#_=H0^X-\9'DV^S;W@YKU6X2O:8?DZOZ7:I6C MT+>GG?[3#N>60O8YUQ2H*YX[1EW()WE> _-6?8KV7W&67!:(61 M%!$KK6'V\#Z^?_LO6ESX\C1,/C]_16(V9G= M[@B"QGU([SI"H^X>MV/Z>%KMQ[O[Y8D"JB#"#0(T#JGI7[^95040O"2*N@"I M)NP9D03JR#NSLC(?*83B3=V1VJ0'Q$O( C[]Y/VRLZ5BH@$QD>U3)Z2.KYLF MWM%B;J('CAOKEHW&=.CYEK5U1\MQ71(F@06L$X*+%WN!3DPSTJ,8C.; (\1W MMV*MSQ'N,*W=\8[A4U^7XJ,,W;$:NF=9=GSZRZYL2I$$N9$(H_(0GC(/01@ M>,T<&W9?,>WLFI14^YJ17)44>/A+);TF1P7"F7=!+UE<%Z5(%JYZ13,T0HM% M+?O!\Q)IB):V(%K$8E!'&DL2<=T+B\'+6=U);V8J*PGP5KS]K.55U]U27BB2 M-4=WL2J6^YC#PQA-7D6:N\ES+*0C)^FM-"^Z2 S7/<#\1T_?="IJLSL$UU.M M&];UV6*K3W:.@";WW"_#YY=JNPHD@/[<36 R?Q3,>*F<7L&PJ^G),%FN/+ 7BIAN6:)2LD@&JX U")^>:^=K7M_QRNB093@M5=3GBNBONO9 MS,+[J=B:)2%ZF)A$-_P@'6+[7;-UO7,*-FB ;\7!YC@(A.&)Q4366:58BW@&-><9:(Y M&WSFWL^Z"[OF*/?$P,=5FM3D\2I8.U88F;ZAVYYGZ@X+?)U$S-=I "QB!59D M8OOIS1YDE%@&=?4(KY\ZINWJ810'>A E46*X04BM+35S-!GU M%F9H4V)U8>P$UGN8!VXLK)Q?-)>S]>^Q<#%6#(;_S?&VN<;^C3T&7\_=09NP M)+)-6[=MXF&".9A4OFGJV!HLLFTK=LA6YVL[()'ILEB/31;JCN/[>A2&H6Y: M1I+X26!ZJYX;]V>2KCO:SZ6RM=A1.QBQEO#?FW3>-Y76U*ENU+'7/Q+A-MT>]^_)/S8,>O':].N#K@ MG8]@,5MKHDR4!U_II@,BN:M@T/YZVZ_MN.(8DMEU8"',N'[STF^=^E<'%D=R MYF8O]<[(6H^/8-M)F="V8ME>N&/=BEP+3O0C#;P5&B_&WZ7][N A[:Q+3L$1><-H)Y\(YK MV?[6W?NC]2?_UW]CJ_.V@I>YLZ'*JLGFD)DJ*9I21UMOS+U5%AP-HLD2MB=< MB=V5U[6A&5LWL !62W->'UT^MRA%:Q9NQ[8,G>85[W5?\9<2DH(.)^4/5LMB MJBDVR@75O>.7"OMH<\.<"*M@?:9)V_^)7>$I)^=^L* 6*7Q:J6^,Y_!^(NN= M0%(>=[TJ,K"T20G0X:VY\_X7, D*E8(S+Y#LVAG00[?-L!S/9(&C)[&'+8Z2 M6 ^8C6UP+>HD)$C !+Y/VPS>3>8BGC':9&"]?NM$E]"W:\6*P.'[AQ25_/.? M*8G2+*V7W]%SNF-C#75:L2_;!LA^/D?O;Y]=?+M^0;;MM)KX*FN1U>81I%4; MLN1M1$D>CYZ\/7G-9X#B6%_[WS4/5,B9 MY.)P$2?HY9Q&V"FOY'.#;#HQ3OGC>D:615.?).E/1D^O4UK/3GP.*_E\C!F] MBXJ=5&Q!2I"%[;:YX22&_J5= JRARRVX2JM44-9).T;O07B2=D#AL[KNU//= MWWAWHIK>\* Y]:Q[VW$'+LZ:.:1\RG#?US(/VL7-] M\*'GF3P-G &J^"N/EST\S*5([#;N&@:JH2)+ MJ;9N XP-.T^0!'0(AK=;5ST!)]V*U;[-!_ <(7K'*N04:I1<5'+QE[]V'K7B MO]'QWRT6N'3Y[F*"6X8_L1P#@&YQ@GMH0_R9?..AG#+]\M??93""U)MM@BWC M> X\!FV2#P>.N4?*;%;0?0G0W2F!AP)O'L3:!/@#I,H\A]3:G23C.IX?6':L M6[[AZ8[GQ#H)B:F'EF4[?I@8L;UU^]FR/-ORPD"W:&SHCAO".XGGZM2Q RGWG?M&;'FX3N_B8(2LZ\&#FCH/N* MH3L<*?RK4K*O3\EZON-%ML-TD\6@9(.(Z838CFXDEFFZKH-U(;?*.2=63)+$ MU6/#,&7ER2")=R!;5BH&H[(^&^9;O$<9QNOGI^>*S#:$97"P'-C M8'RVT7!DUYL7W_+1=B*3& D/C5#=\1-?)[$3ZS:QX]@)#)O2K1*+KD%I0 -3 M9T%$=,?!F I>T0.[S28)-CGVM@J WS<^\M\/'QRQ3&_B.OM;M0Z%D[:"+6J9"6.(T%V7B];4O#[5D.N)/ #-_!UFU PXUR/P3M>J$?4 M\R+'9F9@[BY",[C\&@>4@6,.)+_F=J89G5GWXL68PLC0,#(6#3\WV)H8"2OU,F-81?X&XL^["@]1-.KUU7?W_Q]6O74?ZY M6@MAI75<"%8;FV,Y0 8HY(W%5NT*KF>]DGT++)T;IPN<7Y3$+6"M)4Z]*M7+ M1X2'9P1VT"Q>4:%UCCSW$22X^8X^@D(@EF*'NFM=6&EY DL QJ MZF[L>KH#IHH>Q+:M,R-Q(N(:GNW%Z\7"CJWR)ROA]HOEOI?X?D_*')!8_3.M M9S.6T>_%UQ6F/^9?))(?IHBN.>XJNFG98Q,)-]Z9"P$WZ5?J:ROM92DP%Y$M M39"+6K&PIWK89E%-9"C!K+*0W_;SH@K[)A.FU:NK51TD<6 %P$Y@\6/*F!_I M(0D#/7*-T'$"X$)GNV_('5CPWF'"5B=\152NE?>3C/DP3!:,F\ED@4GY8;L$ M95M]>JWH7MU]Q_)8J,&U(M2=KI+%-=O*M*#>KDCOX9:?7F/?'8/Z(;7B4'<] M;!%";:H3.P+/T8W /74]@S)_J]9[G$2^ZS#=<%S@N<@R],#P8W"I+=\PO,2, M?>_9^^X8 $UC?P[FD)GB<3KN"*WR)%TV:$@2P[>Q]K$1ZX[MFGI$PU"/@Y!$ M=FB$(*LWB2JTL>F3E^@!"2S=\6Q3#Q,: S6"115;AAV%#]>K1G79Z%D- VJP MP36!Z! D[U)W[X6,>RYH1\9#@8P0?@ZGAOIQ$A I%K,=!W+#\ H>3 S9M M M-\Q1BNQ!MMS@ 8PWZ>OA(AH0.W'!F D8!1UB^Z%.'&"E"$MX^Z$=6/%60NZ29$VO\5L]IVTF"BL9C.\@=:]_S4O6KWC*'AO2P\VC7:D9,L#92URH- MM="JWKW44Q7X([":>L;KZF>DP;K=J*5:1@,/HMKG/ SG-&U_RN&0Z>,!S-6A M;6FW%$M [D0FBW37#U"O&TP/$@O^Y;JN%9LN,\.MFW-/:CT+Z=4&-M!UXU_? M47KQ)B,@P;HF(WDQ9KEUF(KG,?*(L7QO$.^VGE9/<,BYZPSS?VG:L:VT'KRK MQ-.5%#V.(C#@W8$3 3?K('_RD>-@= M[=^]O_CXQV?M^]_>?SO[^OX?WS^>7TRTCY_/IQM@5\ \ )B?OWQ_?Z%]_Z*= M?_G\[OWGB_?OM \?/Y]]/O]X]J=V\?WL^_M/[S]_OQ#RS#E]I56<%16X[G=L+G2[$GA%N1V@ *SID[D &^L+#UB>1+_& M\:_U">#^.3S/F%\RA!R>/[D3>=:F9:B,G>,S=CZPJ.0QXZVD'8TK5-Y&2\:, M_Y2^.WCFYV5151B-_AL@%,_J)]J??YZ+1GK84XM$14GJ L;E+;62!$_8^?K% MD;NR ^(O+'-[;;.?<\W8%T]*&']'SKI+\F+[2%GB4R=O-BA///?WJ#FA.-Q3Q M.HKV=*9A/$=_.L><>D%P4",VQSBL09UK'_2<,0T/>,R8^NYATS[X\H+PD >? M<8$O&'[/W.!/=:-[TL(E"LXW=K?R5'>K@<7V#L'P]QFXH=HGS!H ;R;'(]6U MH[_A%P<:&^+'*OX4:I3$5!+SE[]^QJP0)3!?$%*]^@9K%A/246%&B457Z!45+;B2%E/H6:PJ%%2 M<>Q24=F*XV.]1^S9JEI:/'3J'Q9RX:7K,+>5LBN6%8O-%&C5F'4(5:Y?(ER' MPP?W*%I]WR,/58/ZZ2]K.T;BNY87Z''@&[ICVJ$>&=3 AO4A<0/?A@^;B>R1 M8[LL9I9.#,/7G< S]) DCDZ=P& .@7^%R?:5+2%>SW+Z;B5<9;[U@U2C=A^R MV\1+E#%*=BNXC@FNPQ&=2B?>IA.'@ZOVHK?B)26C%%S'"M?AR!,E^U^5/Q13 MR_<2.]")%5/=2;Q8CP+;T6.#NC%ACNL$SD-<[%7^T+/+&"6[%5S'!-?AB$ZE M$Y4_-&Y>>MKV:JJK_2C$VA\L9R7)^ D@H?,T3ZNZ)%A!1[6T'Z::?[">D3 M$<\IA P,(4H9#0P/XU-&+\IG] +7\9D9Z*9%J.X8D:,3UP;OD5@LL6S##EGP M$*>IRF=46F&XTD@A9& (46IZ8'@8GYH>CN95/N/(>.X1KX7VX2G'.>J8N%^% MW^R!;5BH&@X/?N==DYGL'J%2+8:FQ(Z"Z[ILLZ:6B[*-%@VVJQB5'3$<1GGJ MS+$[X'!\-LB+"A5$/G69%9AZ8AN)[IBAKT>1$^A&;)JN1]THHEN)U\<<+Y\7 M55V=Y;1M]?,@L0'??>Y*X>N0FIDX<%H:QY\:6]2#W?I7[ MJ12'PH7"A5+B2HD/08D/!ZW*_1R/M.P?8 MUWY//D0/X>:3\L!9I17)>L]&K=\287R7,-R*:S1L(CN&+ZA1R&-=,\( M:6(X7N1LEUN-P24!C\+2/1+!.UX#[#%&"]/I:Z,X' MJ@NIJ?O@Y.J.'WEZ0%FHNX$1>=0%5Y7$FW1'(IN&9FSKIL? )39"6P_M( 32 MM0,O(;&9^/[CT)VW1G=ZQ6*D/53B%M_6%F,DO(F6LFJ!8LQ-3U;"H%) MXKAL6$\:XI<%R,Q2BP70M"PE49JE=2ID9<:J"H0J;/.U2$W&O#"QPD!G;@ 2 MD)FV'H"HU/T@,0*'T80%T2;U4I-Y3N+8.K-=H%[+=_70(4SW3#.*X]#UPW"= M>L\$(EKJ/QA6=I#4L-H9EGA=YU61U MFE]J9RU6JUNAJMS1W?3X,=?^3O*&E$MPY1!7S[$^1I#9+FM:@]9B>6YS*JNY'/,$W3T$-F M.#KU(L\)7$;";;7G.,R@\*CN4W1ZB>?JQ(MBW3*8%R<#]:0<3N^1O;/,AC+@FA5:K.9^E+-&^P"H( M9_ OK+M%ZC_D*R!24U1UPCT>Q5 IQ* M4.408!BF+T'M:$!):0'45C71OX!4D2M( Z \HKY4W.8>P9**F?7((R =(1C M#O.E.;0'CL*D&.O835W+]8.F>%?;&1M8J MV2(#B%&A<)'-X4G*:%\;KK3RACJTC)O5X40#I,"R.LV'X,$AJA2@#?#I]"PN M1:K$-0DEX,FA!/H1!-EK"O1Z'FBWA!#=]\U8=\(DTBE-@D>;R\D*@Y MW '<4IP ,V.:.",>%ML+) 8\M@(P\HQ@08F0/BNF@RL*_9 MFOA[-=QK^,1,$K!8DS GHVM #C1,_7 3D*#V Q-X'MS;X]P@(/OP:O.>)FU M(UJ$/:B(-5,3R#$'P@= B*<8J"0&%B:0;YJ@8L9NK6LC7*? O9(!02O!TZ"' M9J Y<1@P./&L'W1G%U%?=EH-Y^X;6C2].HJ^.XJ2Q^"2H,R .+$= #50H! ' MCUXBSS=TYJ-J\*/ I623H#Q&7)L:ONZ:6'#5])@>A&ZHD]B@9I00RFQO,[WP M(IXQVF3L2](_??E>DKP25%%]1Q_@.\SR>U;$/W[16!63!1J49MRQS> YFYW!#1E)6W"&3:E/@%/B2LS@H/R2N,L(!QQ\ -Y.9IEA77 ME?8&U%(]*YH**+QZ>_(0WL%XLU+:'!2>@M)1B4CIP:D K"?&*?]5S\BR:.J3 M)/W)Z.EU2NL93,H#JO(%()R,+"IV4K$% 3>2]8HP].HT7*55*J3'2?O&GFH- M8A+;F[I>\!O"8U\^DWC0FOI&>-!SH6T>\!R U'0/F=B<&@<^9[H'K<]T[$.& M RKSG,/6=]!X4],\Y#E8WT'[@/69MG7@^@Y!W*'CW6&!UF$/[@+@+75( LZ/ MC]>=?KNW2RLU#LJM"QY=B*TR..\@QH*A9B(K..^",T 5?^7'](^=6WI@ :Q1 M8.<)3@ /P?#W&9A0&@^#5-I['OM:2YY\UESB@ZIAC0WQ8Q5_"C5*8BJ)^!8&T+9OI<+W>'PQ#TJ\MT#/:K8 MWDB;Q@T(34IJ*>B^).@.1\(HG:!TPLOA*R6U%'3'"MWA2!BE$Y1.>#E\I:26 M@NY8H3L<":-TPF$ZX4Y@'0YZ=]?7,'W?-XCIZAZ-;=T)+$L/S1&^MVXMA!9(?,B6*FZ?M2/$P)VEW.Q159VAW0.4?+,>:1:+^.9VG>5K56+;O MBCWQ&?; ,38$&^B1\ST4!IX; \H4>MY28Q;!"KBQ;OIQK#LN=71B@%%$W-!, MF!-$OI]LFD(68R0,/*H;,7/A'<_50\MANF>SV'9@Q\P.-DTA*7/!$CI;D[@/ M:0QY^XN0#87L53,OA0J%"J6.!XL!I8Z?MZU+:,2NZ05Z:"2![CB1J8>)[^E6 M8)DNL6V7)EL-VB(C=@QB>WKBV([N>![10Q+[.O8L\EW+B2(S4NI8Z8!A2R"% MBL&@0JGCP6! J>-G+J/O>I'+3-T-DD1W&!;5-CRF^P%E41*8U#*WVLTP%L:. M!WZT10B\DS @"R7$81RX#W%P_Q3ZV+(MI8_')X(>_B)EG7!UVET0Q3O]\#NNO2SII:+DH[6C38 MNV-4AM9PF.9YTB?O@$EEL#VKP19ZD1=1FNB6'QBZXS.F!VYDZK9A@2EG6I;I M^ ^17G!>5#7VIV\[(@WO .-1R5W9:0HC"B-*N2OE/AS M&^N!@\D*H0]?)%84V?%#)"LHY:Y4B<*(PHA2[DJY#P2W+U^Y6Z9O$-X/F^N@=,FKTB4*(T/#B-+N M2KLK[?Z0VMWU+<>E)-(CUP]U)Z9$)Z$=Z#2PB>4$7D"(^1")%(^BW8$ZE78? MK2[I)U# WP1@]=<6G9^;.2O3&#[3]&H/H)RI:]N_O51(';MEZ_GT6Y_&S2>5 M;1]S[1V+1?=8RS#]B5;/F'9>S&'-2XVK%4:U-*\+C: PJYJL3O-+C5R6C&$I M%NTZK6?:606?M/]OJIWE%2G3B?9U-GTWU=Z5JV_P=3W!G;-RHBW*XBJEL)C> MF!4KK](8OA-5):Y2D'8:R-L8) =)[ 36"'\11F=]':H+5B)$K?"(2JV MV@U\"9N? QIFV5)+&-.*1.NLBP?6C\]'2;NU)"A)GX8TUD./.+H3$5LG#F4Z MC4(G &W'[#C6 MD9K1KZ2LE]]+ NC@2_@D0/Z!L0]%>2'1L:T^5TK3N-DC!OUC[%>;0^;RZ:Y% M/N'\6E\^@UXZBN [$I,JKKM@XK#8 7/*M"G85!ZS]9!12V>N3VSBA&"'N8Y.3,_274!<$#(2Q<%6E.4BGC':9.Q+LH?,E^E8FK-79#Z<7&9PWM4BY9KVHFKDML% MMD:;$K_ !T%&IP6M0/W &T 15+L&!8<2/2FRK+@&!0**IIX5305*IGI[TB/< MUN#B]M:N%%'2U$5KT"(\8-(3XY0_KF=D633U29+^9/3T.J7U#, +1.Y)B;%_V94U"VHRC=(LK9NS#MO'P>MS3;6^9UK?+3GAP9U3 MPH_*YM\A(U]W>RL%YR>$<]?!SU,=_.Z"G8%T\/L^ X-#XTY'I;U']U"[8(M: M^-:V,1G^S:2Q(7ZLXD^A1DE,)3%_^>MGV*<2F"^)*Y49/TBT*#@_AU)2C;C' MJ)0LPS*5YADGZRG4#!8U2BJ.72H:BO7&R7H*-8-%C9**8Y>*RE8<*>LIU P6 M-4HJCETJ*EMQ?*SWZ&7Y5!N^ATZ2^[8G(UJ5WGMQ5_P&#MWA\(1J1_P*+^-1 MASJ>:4:Z;V(//FH!XFP6Z6;BD=BR;8M8UF82N._$@.C(UOTHCG3'##T]BAVJ M)Y:5!&YB@@WQ#.V('7<8%_,&1+Y*FBOHOB3H#D>8*EUYF*X<#L;$K45'\962 M6@JZ+PBZPY$P2B>\0O_)=UAB)#;3@R"R=(>%1">,^3HSF!^3D/F1LU6J[)A+ MM(_O/YFV>O"A?WC.-),;ZHH8!#KU# Q/\ M$86R#>%;@L(@]Q%GHHQ0F/?;X\T9^V$[^>E+&4!5,%>Y>)>Z4R:%,#F5R MO*B(B)+5+U16*]R-%W=*SRH]J_3L*W#M8R MF'BA8UD/HMA;OQXD[9',KF4#:'\NV5K!Y"+L4C=0%[ MG:U'SBKLT+16BE;K5WH9\MKY3?"NHY=M\I4;ZUV]9H1J)(YAT76E+?OU^T9OR;X.YV)AW%%)VD-BXUAF4!)W!=#V^]S43/1=57\ M);7Z0S35]5ZC _$QUSZ1)0?HWYMLB8UU@W43/*TJ8&*-@%6 V=.OR/@V N;' M9NCJ#DL"L#8-7R?4,G1JN)[GV)'C)%MMTRV'NA%8Y[KA&Y;N&+&K$\MF>NC' M<9(0QW 2;_L(HZ/O=RS:88W*$PQO[03#/<+FMIPP\1PGTF%Q5'=B''S/(CPDP],5U@%\/WP"\+J1[8 ME%)"'P=;>\>JN$P7B-4]:W3!)38M2G7@15BC M91LZB:BE6S%SK3AV;#]RMDX8J4\\YGK@$5/836(&.HQA 3$')N85NS'SCUWC MD&D.J:W4N ^A?6!1V9!RJ;DB5C31T@2)KR5&$/:,E%G*RDZK;D;J-C\/G^FF MVO=9RV)143+L$\]*5M7(A:]$G^%)/ N]0+<3@M(_,?6 L43W"/5CPX\MP]@Z MDC]&GZTSS$<)Z&_ ,!%,2JPJC52<_< 6HOWG.,770(NP!\/1BE[PHVCH'4 M0JJ!A])IK.Z H&IE^4IG<69Y)<0? M&*;KAY&K1[YK8NP<['BP7G0'_DU\BT;$)/P&SQP;>T,%,BW4G8H8>69:M M,X^9AA4:D4&W3!]!V!5,#/1?%_$/3O75>0MT+3R)FU&A:Q4V%1#'=#'1M'>?^+TU[=2&_X_?\"H\__ W '7;V MH0$@?KIZ>?D?:!Z$C2 9:(:=IW:[_&\/C6ZZOOH#= M1?"'M?/;O00V[-CYTXNM76<4_V_1@$%0-."9@;,R0?2FI^ M>(WAZ7[.#Z30:-8$P<>GG!7,:8]^+KHAQ#/T5!@HL/#_ G,<9'*V!+):%&6M MP8H_ "@UT]#_BT^( +CCJ@C?*7Z/Y@8.L&2DU!AOM[V5*+2V"83"U[*H%BRN MFXK'1BDP-?:;L&28"U:1H374,[V^-6";.9;S)GJK"3M(6%^=IWT6\_B0&=KV M!)<'QC%?S)OU9]X*5&R\C!MY_S.>D?R26VAHA"%FWUR\/W^+ )/K\\3ZN*=# MJ$0_K [@7!DI'I6%-R2!5,B-VF_L$I:#@WZ0 M*_M3KFP'W2-8VE&^ >"T#V)MW0-\FSOPPLFF60B"C):<4*LFJL#/A0F0)F'& M:C?U=<2S(D.G3X833;))_\'.,Y@7)9MH"X(A3B$\8&LM"M'E1CCFP%5514H0 M<[ %"L16IU?<&V^?Y#2#&"]B6!CN,VEJ\"O0=T\+>I@&44?<:SKZ"SB&5RF[ M5LKW&)_AGXR3+T'O.(9=\QSM"H-T6I06"_#*YS!CPW.W02P*SW@!@H !Q0(/ M_,%R]OWL_*F,.+G)':7<5OOVIOZMV_[^Z8E7?.=CS2(#V96A%H$IL-,3QU)> M7#' 0P9:A4?Y8.A,;Y_5+@$96@WDR%! QC,8MB3<(B +CD,I@7 LRBH G9#Z M$4.CBI&*P5B@C)8\^HUV!Q^+BT4N5+.EB&DT%1=K:0Y#<]61-W'&BCJEH K9 M@L$<["< EJMH.32HOW.IBPYY>B)"F""@/Y0IHR7C0*C)SY1H;SZAO"1Q&APE+EQF+Q$Y;'D;PH"]AN#L'VP5/ @HM@L%NBK(BYM85DKM4E4%-[ECYIG9\: M#VICEF4P"0@9 JZZ1V4G*M!:[JA__G M\UMX&61 A0(>>;$2GMZ',Y38*???&G%X ?/ MXKW'IGWI@K*3Z(.Z1R8J<+D M%:[ZP'SIXE;P,2]R?=; 6WB4C6$0#)[@1="*29.5IW-T+"9LUFM@(/@S0Q,) M'7@"%B_#G\%S 1%8EVG4M/&?J$3#$Z<#S8>1!#2O?C#PQ,M+D)H:21+0SR*L M\.&,SQX7.9[X=)'"&9>Q,6,8M!*!DOZ"6A4+7-YC\A5G"W[OG37B8O >$((% M?I91KQ1$ KD"^8%'G<+^UOD:-W?%)4^W@#2/2Y3YE!NHH"**IN)+Z1D/TJC< M (7&/\#_\!09+0_&\Y)AX2+#K89QZWFW0B68GDHP?ZNS'$A$Q/Y6ZDEAYM$PTVNSC*XG33$,*0Q][AM?D^6$\Q("8,4O M"<@+W 7(AYBER*HRM@N2HBBHN+>+6#V3(E):#F\^O#M["X_!YB]G(CZC ]ZU M.6-UZYYW([UOP/UD +9/C*8QF&F5=@8R( :']/VGM6&J&&41=XD)O>)I0V4! M?G-3LJEVT43_ BDHI!FN5D0Y+]$7P8P'[D82D(K@=N9,)EB &%14]]14=YV" MZHN8="N% N*(;'.W.N.UQA,%D";_[)\D "$D:5FA#R#U+A4Y,VL:JVHU!G\6 MK-PL09Q;AF5-!''#'-Q7 <"C<[":%59)>&^ 6!Y;X$O37;!^2F J=^A8=XB? MM# \4%6<_E@7QH5#B!&'(J]Z5@ &D=95>%4->-N:,2L.7LGF1Z+(61 MP4/?%<9,I2%3B!/VJ[0N"VZ+E*DHLX&VD+!-<-UXJ EK8QI8U]M.%J'YUUHC4 MA'?E1-2+PH3\6'>5J@1SRZ.]E;7?49 R7X]L5,93V%:1^E24*@)I K(J*ZI* M\GG.+D7&#K\BG&3%M0S/]_(%P4L"OA>B)6:++KN0[*D=-A%5MW(LO-7,&U$# MB#)@^92G(?UJ>U.GO<0L#F=[J^++%4?"_.Y!.A?917Q5,1;K76T&3Q2*/&?B M:HN(U6'<,/U/&RZH:I(DK4R1N1P3+<(#!Z3P14;R''Z>:"5)J][EA4GKA;8# M%;#ON1@7AZI9/,OQM'G9.TE,*8\S\(2!U:'6%G'SI#F*>0$_9$H5[Q/,I]G! MD1.-Y9?D4DIXP&^#>6T-/P=MCV?Z+K,TJB7KP:>KE.LC<;">"=3UK&0 =]4L M> Z@3)O$*.\JPQ>%."UXMA?'#<^&D6?Q>&('$S"1<5F15LWA<_B"/,S'\@\Y MGM^"D !-P%'9@@5?JI2;/$XYL[(JD K;QHB28=J<0)QP_?0D382+S3.2NM6B**74@>"E2:N TYNNF,XT8#4\[H3VFU./CHLW!'867V$ MTQR+:IZ,+O/3N4G >5AX'53:$B*.*LFBP'1PJ>-$]A^\P2^JF_8D, PLD]B[ M,;FY%3R\_-4" !J].\$B"T@>0:")(%FB^4Z4WMEM\ &_P[\)J\5BRW*NY-F.#$">Q+Z86_)\E+F[S=>[,1M>%/7 M[>T"F;*_^#WWAX:F+=5EQ>W+BH&ZK#C".[##5@A<>?_D&20@]G\U+6?JKSM7 MZ-I-A(.'U1% T7=Y*"D_;^=N0Z\^2$0R+N'W.WC7\-.O=FCWIGH9,NE572/! M6_]%SHD!+W4"J>R\XZD@^P U*+_UO?QW/7?]_78W>767Y^Z!+C0(UR(I_9!( MYS9QT[E-0.M'EX#@:8I1=2D6Y8<#XDUK#B)+\ ZA=)/06N[[J_)B*H^(\93E MW@KW>ES')]+EY"OM.]$\L-L[\;P=%MP?%R6Z5V5$VER&W@O;?NL- MB_UVZ[1HT@)0"G!S_\.X$]V!E\>KR%+Z#/X\]W&WR$%ZY/ M-F!)TZMVX7*ON">$IN/_=@K,M +E; ,);[R1&Y'<&? ^CZ^L9"K"V"160RLI<7%*_18)U\DIP# =8V ML68-5O)O ^\5HHAMZN4 M-H3?(>45QFZ.Y,A0FU*NBLL&S67@Y<@4GU[HE2FV# ,+U.&?E%*NEQ,$4/ L, ,*S7T&1G5$([7YO_U+%0>B9AC MME4_$M%%O]M1E$UPSR:[ZSGO=PW4BU(IC.5:W[28K-)D,-ST V_QBR)F>):Q M&F>RYD(7JRRUJ?:WXAJ>*_F9@LSP%$.)_)R# V)(@]U=KJ[\%(C"E*>Z9IAI MVWTMR@:($7F&$5<:HKZ6R#V5V62\FA#7.[0K!8/]0Q<\;:; 6[N<:GE%0ZQH M->FJ$E9L04IQ(,[KAL'$*H1__QS/KCS2@8=+ZSF>7>KG(\LK(C.TZ)FX?9E3O;2MO$.P\$KWCP@E!B-G'OA.T+0JU?+>ZMAA>2D@7W M^9V%?;5M1?(;R9$R$0(%7KA9PE#PT!RO$(NPL:RBNN0#8K*YL+U$GEQ;N16F M:MJKC;)(J=%\4V[PM;[:%T?[#/9BY.RCD5?!@!MA& MD\/8-(UY4W8M)WPZ&&0S;+T;A%\/> J!P8VJ:B+/5(NHK1$EVGY@#=(M6A30 MP(IY>VK-"JKN9;GW+HO+ BR"COFUI19=,M.2\"-'(8)WP KOIF.A8)D/7UR# M[((G,6N37_LJ6EF.#7K(KC&X5 4LYY<%+UR+TE0:Q(L"O?7N5'15XUD^RP^: M#\2[R)?N9RSW@5BM>*H=&W.YJZ[L[M[E]_M8M%G,JTL1'-P]SC01$&9X-[1J %_H6!7BV+W!D MO#H/8DGNN\2\K7*[8[928W>HF=MTPO!V]84$ _N M"IUA(85DK>FVM*8*^"A7=' L("JQ\E1.'IV)BP7#FV^U5-CB+NZD98.M%@)K MJ4Z;M]76LFS4P;3BAU'Q ]KNXN:8U+7B1F-[,TJ1L2+C@0#K-C*NTKHK0]&U MSY#$KD;PK,N,85;2L:'D@P-I-RQG++_&" M0,+C5RN[ D,F.3\[!:*Y%+= 9?%!1=.*I@<"K-O,C*Y>)H^4BJ"Z")TJBT-1 M]!@INE=YO2-N>?UG'Q4/Y8;RX"^^A^KB^QTNOBOAJ(3CL_,L/VLNBX5>-/P@ MF4=^^;F\.'XN^4E:SQ)0JEY1\T" M2/7==5C:G6L7)$$3^_F19[*OF+HI+%* M]D3I'8D3["R@CC,4C0^9QM>S@SK!W'/.>AUQVI :KTF ;<;U9J&H6U'W0("U MF[H7,U)MYK>V*7A;:3Z*FA4U#P18NZF9)9A8%(M4"FF+ !4G:<8442NB'B=1 MB\3E25NL1^9#LE)D%F-QV3:G0E;8;7N^9FS-X&[J62'+T:U:*GQX=R:JEA>Y M_H_IQ73UAK+,%6,,!5C;C#''Q'[X/T^@[JXWX+46K*?/:7];_N\MBH'6>K]L MLT@_QKKV>]]2W*&X8R# VE$?ID(62*L9K[>\=AMD=75@?^5TC9="YZT4-I+T M17/9DNKH 2][0["2)Y@4)=9OXN?Q%>:%MY<^9.WX_>_RXM*\6:WL:=,U,Q!W M49(FRY:*YQ3/#018VSS7OY#*.6T&C,.[A&!VM^CE*HVK]HIQSSJ[;$"MY+'R M1A2)#P58N[V1=+[ 2GS2\^C:_O"[S66SD-W6BLTV"FW-T:+J/'&N#$0HE4G= M)=\530VV,VL%7]>U'"\LBG(?7(+A76)Y 7;'5?L;.P%AJG9&-^Y' MRD6(3.Y*WAZ65]DWNP/MF%#D7FU.I2Z\'ED:?28;W5>5[-6#<.6WSS'OC>$/ MA%='V',%O[LFBPI2](SJ1^C:IE%IQ9&=+5ML,UW4E8&IIAJN OTF46)@U[W] M_:VZ--F.JKV5FO;>(/WJ] M&L_6>C6J-A''R,(_]O>^[.[\RY)WZTTA;JJ1M^+E'?7QM@KB30ZJB#<118_; M65%4L9\L;OA2=ZP^:?)8%C#Y(KKU]AS[&SI^]HN9\R)D*8; >!T<65TJ8Y7;-JL98/"^Q!ZN*EP4UM^95_=)C#_;YIC M1=5 1VW+6=DWE/!NAOO;=G0%!61_EJ0D,&X3B]ESVIZ!'*&RVR3_'0TQ)SM: M<*Z6,A';!GB)0CC]+?6""1(BV;(O,615P.666)%-4-#)ZG[C'"DJ%&55T>OC M+AIQMOCI#=*KM-YG-0*3UY*UUTK^<,N-_.QF;!EP(LL4%67;%1&^+7O" HAV MGC9S+O!(25=]=+#T%!-2$EN,R0%DLT MIC=SM.'^@V)_)8W14NM76!5Q7<307&"(W88A[0W7@453P3?5V\TJ3Z_QLI($ MN*0*?J3*IP%HGQBG_%<](TMP=$^2]">CIR)*:AH<+O(%'B-<5.RDK=P)L\'@ M,'IW4>PJK5(1/#AIGY8/P5.TVR8?W/&G <;% 09_J>F>A\RI&WJW/V/:MSUC M3UWOMLF,J6_?.M #+NBV9X:_'OBCW*0!R1Y"7V\C_Q:9= VT)JX:GH@+A_C% M*6_%')-,\@XP)*YB'R>W/,*9)A@B)P?',/).S#P$.,7&7CU$ 7[XR__]B_?+ M(T!7"M%NRZX!"\;FZ2FX5&LJ> <@!H*7I[O"O&$T'X+=V\RX)^2D6W%MN>ZD M_3] >81('Z. .P(MPT'#,\M$ZS%DHB+ZQR=Z!>.%LE<'($F4O3HNV:SLU4>V M5S%F-6SC9VR(':,04VA1DE!)PK5C%<5R(V"Y0:!E.&A0%N"8V&,@6X4\LQP! 6YRZ'CJ*\$P'V,-)./BRE4UPK,%X= M3(=#_[\^3U+42-3("ZDPL'S MXT 9 \>+,VOBA\'P<'M\\K=B-(6,EXP,I7D&A .E>8[7/$YPY+&2$G6OA,T4 M,@:$#*5W!H0#I7?NX_'8AM(\0V>T1\AT5+?N'KS,;U&3;$[TLM)_RUH&2C&_V#;JU;;4.K*-X8,W.7VZ"H=' MFIR;'?-F7?A^02Z98%.=)+")$Y)=DV5U^HOV%T56_3VK?H+K2Q\Z[6E?;_9]'R(._KEKYJ&/1)7?=P3[5=OZFGP=(8=;=/\]K;NVC6I--JP M7G=L["U+:5J+UL[RP7X?7&RO2.@5]HGE8\G6O!_.L#OO94GF_8:X\8S-,;M= M]**%=3<)P>Z^^%M_0;([M6@87=6B!6[)J(9--V'T=Y_,=GA8+W_]\#:/HNW] M-2N9EA>]L67CXXK,>1?CM."-;K&V]%3[T)38OG:"#9"[%V: +=;OXXWK76OG M>_?%D4JTO2U%7]_-!<$:<4&R*?&JIS(^ES=\*%CS?D3+%N9;G8PE,*OI&A'1 MWM[6]]4V% =&Z)''KV#]= 0'Z\B+7(])-=/V-T1O1Q,0E>#:!0F.!R7K'JEW MZNVB(5K*GL^R-[?\(!"H^JR^\#ZKYNT=0HT#.HW:MXYC3QW/O;6-:! ^Y8(" M9V +.@)"JG'5LQ79?[X4E9<*T5@U6AV,4Z\:K0XU4U6AV5ZE!H&2Y:E"0"!,JP0BKHS]8*P_X\+2[G['KRI?\L6 M%D7%$V!.>(I,>H4GZ6_,MZIXY[!N7+Q M+C,I,:4@.S;(#D>D* 4P)@5@3FSGZ4LU#P@_2DPIR+X$R Y'I"@%,"8%X$QL MPU+,I,I0#@+PP^&+CVO7FP:8*?4B6>/9RVXHZ _D;%(I\CNBU9H$QS8_&%H* M@&(NA8:7A@:E808!?:5A[G%8Y'E#PJD2; H-"@U*OPP*^DJ_W*N)CJ4J"P^7 MN53;\1<6XQ2M=FXM_*1.!X:EPAZL8Y@UM5P4>;1HL.;4J.R(X7#1TY]WW@&+ MRAZY3QEIUW[NIGZ[D*O,$H4-A0VEOI3Z4NKKQM3.T#RR"X(2F*]&8"IL# D; M2GTI]:74%T>L-_$L=X#(50+S\%X^FP'9WS;CL;^=+K!Y0'[9[LA\(IC=$/MO MG^?\<>+[4]^W?[LGD+UC8(R@I.G5+F"&4^^W4YI6BXPL3Y*,_;R]M\&_FJI. MDR7P"0@B@#Z^I5M3OBT=-C"O3K!# [ZZ$VIKD FGUF^G<_C8%ARW',B88OW9AMHQ)^7B$ZE["M'U=]0@"H\M_WZ1?R\$VWAFQ6B8=Q M3:OF2'^PG)5$=+@YHT#6V,6'%[L8<7LD:VKWVR-=]O9(UO=X<(.DFWH!;7:Y M>:RF0*ON/>M=@6[8WVK9&WV!BO*2Y.E_>+.>?B,G_*UK/K3W#+%F9,Z_7( % ME<9B$_E2*V ^/N1=^PU5VPV'_$=M.+2[\=-JO6(X>%ILB>$@9'.[CX;O%3[2 MO&I*[,'5M>CB8"^+A%65@%6";9^P44_&+ELJB&-@S1H'J%AYE<8]+AY8E\*Q M"LW?5 0@; MKT^XU;VJ[[&0IBY:KZNZ?SNK-4^$CWWO!E?6[:V90N_V9\Q;Q[&G[@'MFWS[ M@%Y1#[8@*QC8@HZ D&H8H!H&O!B(J@97HRX7>XNI-^PLY['A?(SR3570'E@% M;47TJK_5D\)8F:O*7'TQ$%7=#49MKJK^5J-2'0HMPT6+DH1CEX2JO]7(6&X0 M:!D.&I0%.";V&(C<4_VM1B;Y5'^KT20E?-G*.#AY\L3V@2/K"6[U'*R@7E4E M\A%?IU+ 5O)#R0]%T@K8(P#V@$"KY(3S6;WON\PSP M1/WE*HQ7!]/AT/^1527NFQ0U$C4R'#R9_L1QGC)S84"H45))P72L,!V.!%&2 M?AR2WI[8[I%]*E\B RFAI& Z!I@.1X H03\.06\Z$^-)&QD."#6JIX>*W-V3 M??[86^)''?D,2]T_6)5*U0ULV#A0UL#QX@S0XQW9$^PQ<:N*P"ID*&0HS3-P M'"C-Q>":,I9 P(&4KS# @'2O,@JGV?HC/8(V8[J MYMWC=#C>KOBKCA>&HHT>Y^[P6&R!X7#*4QZ/*C/B*3!J.1/?.+(!Y..@55D0 M"@T*#4I'*1VE=)3 J#/QO*?,ZE2R<1RR4:%A$&A0*DJIJ->NHBP8WE$Z:KC" M\<8.Q!O0>,FMMU2'N",;]:U==G_7:UXYWKZFIC,U^XU-]_;G/+BM:=M4LM<= M%#OF$7J%/2?Y6# Q]M?[<-9VX>VWIXQG;(ZIR$N^!%AXDY"X%FTQ^POB[30G M_*&-1IV%Z /\[I/9CM]OJWE0ZSY ,#@FI7P?%'WNWEN==B$S=S0_G,&Z(*! M;^KU>M>UW:W#:]=Y=;W!ZWX\SQ=9L<3^GQOM7;N&R7=KP[K9A=6<6H_:A57) MND?JAGF[9(B6&DU+%M?\$8"U^" 0^&2=,U^X\AYKW\Q@ZOFWM8XTIZYWP#.W M=I>TI\9MW26-:6B$MT\5'-"E\I#E!+=WS0QM_^G6*D053TS1UV"7O7,?"FUZ8>#EN&@X25VY5!$KWIF/BF,E;FJS-47 U'5,6G4 MYJKJF3DJU:'0,ERT*$DX=DFH>F:.C.4&@9;AH$%9@&-BCX'(/=4S?L$#)5XA%'5GZ@5A_Q\7EG+W/7A3_Y8M+(J*Y\6<\,R9] J/S]^8 M;P<867E)612O'*;#X5]5:'DVF,0F.K3/R$CE(224%TS' =#@21$GZ<4AZ M:V*%JG>*$DH*IJ."Z7 $B!+TXQ#TP<3U5#?$T14 /*9JHPHIW@&)']T1DBK[,%3-HY^Z7+!DM0C_B]_L1QGN^&[RZ\*LM#X4'A M0>DII:>4GNI0:D]L]_GJTROQ.%SQJ/ P##PH-:74U*M74Z8S,8)P4'A5\O'P M1BJ;H=3?-B.IOYTNL"% ?MGNR'PBF-T0KU\O=^[[4]^W?[LGD+UC8(R@I.G5 M+F"&4^^W4YI6BXPL3Y*,_>Q#R-H)H7\U59TF2^ 0D$$ ?7Q+KVI2UJ=\6SIL M8%Z=8-<%?'4GU-8@$TZMWT[G\+$M$VX[AN6O_@G2?!"ZX_;J#RT@TYP#+=!K@!MK< :.V2?P_9ZTL:*-PP1UI+FKHIVXXCE78]8[D6PZ)1MFIUF:[: MP%0:*5?M4";P-2A#; 0BND)R3K>SRXY]%-[7TV.]<\7)^?79!_2M ^2#>6AV>RIZL$ M=>0E6W,#<+/N-'Q!+IFP6G62P"9.2'9-EM7I+]I?7FW#FZ&0U9!EMZBLV+;\ M6O7F6N_Y=8.D6PFPC:Y?17E)\O0_O!57OTL;_M:U%MN;!U S,N=?+L"72F,A MS_*E5L!\?,B[=A.K-MN)63UA_ACMQ'9W=5NM-\VKIL3&=EW?.[[=LDA858DU M)MA,#=M?9>RRA7X< ]'4.'/%RJLT9H_5!NZ@?FBWTC[QBH@^G@MJ459EX=#]9],FY&K'A/EK-:RHN(^0HX?+X4L MXOR;9,4U<$U9S'O"0JM2Y#24/?C'@C,TYR?@I3A=@+Q -N5.!;IE:=[P/I1\ MROY\;3,Z^"^(+L9;J@F?9JI=;,_!F9\O/FDX.W+)N%I6SRR< :PO9Y(;,]:V MN@1.!7X64FF":^.1*)P6()PP#@_Y([@R.>\X6&OWV\"/M^&-W7=WBZ05/J+Q['( C[]!)S7#'#^JVDY4[]; MV1BLMN!V)JED4\]*WJ?:K[;KK]#,&1$%%>\_BW\P4!I7P/*YZ$J[[G/: MKKLB7B'6D*W!?'$.&A$I\QWPDEB:.9'&R<>5,=1;I]=KZ8O4>D72C+>!!%K6 MN51*@06JFIMH%0/9"",P/L>N_6_NI;_FU4YL>QTX!\\Z8R!E=F]OS75/94AH M+X@BDG$1>>=>OZ0OP:E0&?AVQ_*=%!/ZZ ;QR<5S3RZNA&[:%\A\ P=)I)XD M[(W4EWR=B0J6=PTPQS7@ZF-><_AVL!W7F#6M5OUAJ1:!Q7^MFK4^6K/6P'C2 M7JW.- C<6QN-VLYMSX *N;73J&E/[?#VKJ;6[6U-I[9I/LR"0O/V+K0'+_TB+G[EEQJ)Z_2*WV(8X,GZRU46KPZFPZ%]U=]W'#740'5/3/52]6A0:%!J5C!@5]I6..US&.,W'M@5?;&Q V7P]W*30, @U* MQ0P"^DK%W,.-L9V)$_A#PJL2;JIZUSA#F5B]J]^5;6]K,758,"P%=0_(KHLS M:VJY*,YHT6!_LU%9")3)W!GWAO]CY MGO^Y#QJ_O5!@[-VS,W5M^^9=6Z])8(N'<4TG:0W+C4_[I3C/NJS:*=*3 .\0 MM]'K?B&;7VC%CH*BVC6IM%\M8VII,$R6%CD/L?_J3H/NBZ0HM7K&M!R[:\\+ MWEV;;7?7UK"9(7\;>WE-M))5"X83L6PYU;[/V%HTOVA*7)A6)&*1N(Y%F0+A MP&XTVC"M+OBLN#BC6TM_"+XFV&165+ //GQ3EK LVI2XRT/7/-%@[KB8+PB^ M+*>MR)QI +"TX+##+8E-S E\'(W\:Y9.23DR[@QW,YJ !1#\OX&DX Y 6[!"(H@>J.W#= "62;[U&XAA8"3:W($L4W7RA\&79 M ,#9SP7+X=F(9 C(->#D1:Z+R&4I@@3 MDJV&K.HB_J%'!-D*@0/C<[A-=\F#)V3XE4"ZI[PW7[W 7]4_Z0G\88M[3=L2 M^.F.*BY"X-M3;UW>VV[OFR,%_DXIMVA GA$AZ,5ZN$"K&' C7] $>'M=KFC1 MDLL+$'HQ8[0"L1@S4"-42\IBSD>=DQI?7^X==9O+4;V 5 0?ATZU?X(<)U<@ MN3)256F2,B$>5T-5_;%0-EV1-$,)I -P](JTHBC+UEX"#0)KHUQ^H>PJ*4HF M[3JM9QL3:(L"2&WY[#)#B8P'$AFKFU=C%!F]OFA:LN,.F10;?MBSQ>XB)B8] MR=!Q\:^6ZTSMOKJ]@>T%^Z0H*5K+!,0%XUP.W/:)VTV=1.+#FY8S]0\>_@Y+/N2>.!@B 'R9%.X*; 3U@P2+^3O*&E$N^C.D=@'LW M@]40R'" +=O-[0:O<_CV>_L].W"_6Q)V%++L5A??#%Z])(-5(6:_88Y5R1V4 MZH'4A/>:8/O+7W_G/D(A?!GN?J"OU[GA"_!;)NBY1BQ+P=L#7B(U?Y;]3(7A MAO)CLI7QQD5C[JUXMCQ@ X\.M1K%&Q>F&";&<5K_"$2;]'9X>!F'Q9]Z$5,92%X- MT +E; M (+"^&=B1'XGCGL875_/4("U3=K\U"P&^VVBE=(#6),KXI1*QE9HV5QJL+,8 MA&:YQ/ %ZR16_^!KXPQK4ZIQQP191+#4MBA J/RWXAC%,8/AF+SAH3TD M;LX\_$"\I?+NV!=L LKBE'(#8]&45<,492O*'@BP;M %ZY(??FS0FA&1XV)E M"^VP8<6+\SDK>01A_=656E!LH-A@(,#:S09@V)>7#$^!4;)CNDB;-P-S=+DY M^!$S@EA9X0ER^8/5?3M(D;DB\Z$ :S>9HXR?M"$%D6Y68VX94GW%&(_=?GAW M-M'>?SH3,5DPVP79E^RRR0BXN$N-+#",HBS[9T>RXH@'X8A*>,&8=)EB1#!) MLY8_@*(QQ4B$\$C-G=W%(@.[GP<6)Z %TAQ#;>T++ >>B%O#"7YC6<;$P0:, MM6!EO=3XC8E*IH\F3)SC[GQ4+QGP'&8P9B2=*VY2W#048.WFIIJ5,OUY%;9F M%=[G2*M9RR)]EJEJC$)=\@3F+"-14;:,!3RV.OL6*JB",3,"&JBIFN?PDAKX* ;3;I:6PILO&;*8]F_0)B)SMKN(T$^D7]U.6+^7L!;= ME<%@9=PIAAH10ZV,.U)5!2@&-*-XBG?$N";:N#FCB%D1\T" M<>VZBPJ]+CA M03"LBEQ*^V)),E %"[(45A&(\W_BN5U>@1(XRYIYGFK?VGMK'W!+7*MH;_YY M]NW#VXD&?KRPL:0G+ZROHE0R7K'%4("U)W+[LY:)M"*E\1JO5/)<#21JI$OA M2$CZWG.&4;-XEL/"+]5AA2+Y(9.\N*;+J(C.KCP :>__8)@MFQ/A' M\V&Z.7@"\430.IY<3[2H ?W *IF .V=4'&BW7H'B!,4) P'6;DY(YXN,4[JP M9M:O@F-$M=QTG-,\*4E5EPT>4K.^+]QSM2>]:)*(6'447S P'6 M'K<@25@L3O;P(]ZC!>D-.RB;15=8!67[59&!-.=FE*Q6$Y=@!PG;::4&1+9' MFVZO_2-/D9$NZLZ#N"[*C%YC\E]WM??\RW]_?*>;H8:,QN9I?(I/*LY1G#,, M8.W7%EO*8I7CE_Y'&#^]G.\V"T0>%.Q-!@%K*Y')(VQU#WV##]0=E<-0]0]P MYS)QQ(D7.SELV14K>9TLO,\$B[YD.>-9_E43 1'GM;CE><7R!M&&7)2Z!G+W:4G?F^9RT8F[TI5,^Z65MT%T[;Z X9V\$;7,)@9[>>'/,8?_^@N!M[[5M.W37XR%14 MN,&2<=]%49PVLH1WQV#G)4FQ7-?*OVC7V.Y8%"3+>#)5N]=RK4P#WV^_J Z^ M4EP#DJI9NA ."ZNZ$S=>RV%69!1^[Z[D\B'QJAK\3=.L 1;M719KC[[%E;!> M=9P^Z+(45B<#P!U41 D)QDMT\2W+/,=LJ1&N2X4>%:DK#>*7U[8U@L%6^>P.OP=9;.4YZ&4_ *;'69QG5K MO/;B(#7Y ?L&&L58!Q=2G"9$*D!;7XS3Q@J1N$Q^:A'A!R &1@N2N2 M-;SBFL0+_(KPZ$RZ"PS%SO@H? L_ R=T*1F QR? J&IBQHD(5\UVT5 +4"S0U.3M.%N, MMP[I%:MMB!,0&BSG4@E91 (QZHHF\"*"E(%:G@CBFK1KQ(HYL#T8J&:]>U#] M(_'5_< MQ2A/\:?:EW7*W+,-N:@5MXD2?:(.S:) $812&\S+BO&4FI+P\+>>*5KTNBBK%$II"#R99<2WK]>RHY7G0G=P7 M7/\&K&QZ5UOG''XM97F(+V!67)(5O9\# Z:U*G]SM"'Y,=<^L*CL2F(),X^; M(A@N11G":\KTE+300B(7MBQ^\N(;(+E,:V+[AE;]NT$!GC#&.0Z4GTA9PJ(W M3(2/!"L3K4UO154GR\^"1$[QMFFO0$WW$BCP59TMLZL+*XT?L4@ND$&"4*R% MPYD8S6,Q-DKU=DCQ=%II?E<@A]>7Z ;@&Q7KQ*J\7+9C9A9:A?T)^:#K7 M6ID!J+0EZ%=0!&=Y+@J;8$'!]H2^*[&R!L)?C5Y)7QB.#X'F2_0O:783,5@K MQ[@M9O\VT189"%%N-\69US_Y__QT_+,,/3 MBI?_:*JJK4$-3V3+*NU"0"OWL?-#9?ZYJ.*VLD.XP5ZVA=MDN<75ZUW). QX M\&B?*//&P(<7=[-$N>S-@LW_F%Y,I2>&Q:GA9[00:5N47M1> FLI76" \\T? M9V=?WPIKL%=F?Q4RV[6@-F)084@#3+ YQIC:HG."^/[5D:*(G?4B9KR@(BYH M+HKD8Y)"5;&:1RI%?("':=KXS%IUI]:V12QD!7=.^05EOC%N@?.A^'.]T=K* M_+MV,]6^Y-RDE0X[X",502;&PTDRYK%G?_V,B7I65*RSX0$P(DS4W\C>7@GM M#GE!OXB7'E^;%' R2ZNZ*+DTP*?+%*WRB?8C+Z[!$B\Q B> =246QD,=!*0] M&L(BF5749)(X*;L2GE16 $,+NA!Q)B&[>6PD+>-FCN'RN W1]HA9D";F@/!? M./"X]2_#ARM"(!$>GHO."V6YQ!]YX*M' 5MHZQ:*R@E61[%4,'@(A/L.(J8@ M8HN3=QF MI"NEV74"V104!XAQ><0$_BNII'LNX^USK&"+6;>]9-S% A? =[P2Q%/M _>8 M*:L 6HM6!A>W0 _=7.YT5^!=?P2!IIGX&O8\T3Y.-*&UXM//12T.L\X+)%34 M-Q^Z#5ZLY+IXWCG5\ 7-6GW^G4@5]U58C:0#R$4SGV.D!'[KFR([S!4Q&#W= M6V078?\!!8EIZ/\EQ)=_OKTPY=_6Y=5Y_U=/5JK/,U!'];(?A+ MKZBK.'ZAK1[Y6A:\35"#AW9]+U8G4D!:*K/>Y8^YX;.]B2S>#FJ\E/5@Q0D$R\7M MB);*Q2C=PZT$AA?Y1 M%M>@HL[%)5'.1XT27T>)KW^*@WU8&FNA>RF@*Z_@3OK!-'D*_7=P3WC^'3]. M_UW>5T$\E'6SX$8$?XW,11^6-W__\OL%?ONVJ^PLL@_FPBS>-[?6\'PJ& F] M6?SOIB'@:6]$G8D*#0@\E]'Q(&B]JT*2)OS *,4;A,*W$@*=?7TR%)"B9TW_"\8#SK1W,,IX7^!2DC H2C?_F9 ML:4@&I'L0=="*[VS99B3E%2RD:LL&_5RNA;1$ M5&<=YB*TT*LK#:O%-"IQ/3TO\B@5"?J$7J45YMY?%;S+P;XEM16[+C$7*\=3 M51+/&DQ0:$\=98K$%>(Z6VXG8_8EQ]#Z)JAHPXXDT-:O:L7>9(^$0 <'4T)Y MPA,0%!YH(_?"8#RA#@AL/6B* 3 *'( 5Y2MLY(DYI$"L\OB?)TCF)*[;$B'] M14AAVB6GBC@!1@!6H\JX0-&EAW;K7/7X2$M86!&3")YD6!N+B6,;/ ;'/$)D MP(KQSB*MD]WQF&"Q0_8'_^5AOI)A[Y1)KTU/=^C>]9H]:+PV_+@F2[?">WOQ MI$)O1]L7''6'ZGI.PJ3,4DRYQ0!!'&-KF^1$>Y.^%0D>V$>'DDZ)]W3_6HQ+ MQ-;:UDN_FE/#UZ*N%W*;LB'CXJ?@98 < MQ@\X,IYV1GG0I9QT/M>Z]<3C+Z85Z58O_-+%5;BHD+/R=&*Q^S3I]O/_L_?V M3VX;R9;HO\+8O6_#O@'U6K9G/+Z.]R)DR9Y1[,C6DSSC]]L$2()-6"! V2W M>/_ZEWDRLRH+'_WEEMT]PD;L'9E- H5"5E5^G#P'R93>&AAW!VQZ_,53-:HH M0I7CV\ZWZ@ZAR*&,JI/PT,6VJ. ?L,AOOF&:/N1&B_FB MEH\/)_7EC)/ZX&;U@9YY4:[_[__!'8+_^N)?OW)057(J\*+X%\CD]-\6-3W0 MM!C2I%^<<9?0TUAR6GXYNR>W<_B=)' MFWZZ_92.I?A>6K?5&S[5>5KGM-Y=MGJ!TI12( B5Z^!.!"EUUS!:=A+X%5W1 M7H2RL))M2'<:-ZO0@*M"8-P:?B&8W.7ORUWYW^8ST6^9P?RR,+%D%!5YQ72Q M5E&=##$-YY77$+?YY:NM2KIRY<,&'YJ%9/00:F/GC2]UD%AS7:#G@_[$2Q1. M*8_E>W)#6WJ.%_KGE_QG8)6>-^U>>\ 6GWS_XN7S3S-VB4'7@W6MH637^QA- M0IF@G'[B\1];=%N9:.:6WMP3V9CM-WEP,FETA_88?/15'(.DJ-8-^S,<167GNS M0/DU9J(L_8=L(+Q_SF869XNW2E.??(!, M8ZS]L:7;<5>%Q0(G?8(\I%RT2V)3OI=6C#B.$#--#11I[':!UYCUAYH?XCT1 M,M/<+Y%E64/@J\#BV%$L0.M,5X=,&*;7.UG ^NIA M'>M&*P).*SM?;$][3HD)]N+I9Y\I;F[?E+B6M+)HEZW\NZS["T_#9"4:F(!V M8\$C*M_FZYO G1PN\D%7GZ-3_N6_M)32_0LZHVOV$1^DUZ5N^)=GB^%\T)W*RG+F'7#.U,'.OGO.WBAYCN2B<)NX2O?R/SN@7NC) ME6 A(+GYUUJ>AD-J^Y#"(&/QFJX>P7GH"9&6:WJBSOH6^2SF7*-_4-947ZV. MNZ,@J^VX.]9P0->&9HMP_83'CO[RG-S:S>*[4"7\$;V7[>(3(7(W=SN6$=-. M<&G5;#^5RCI[9O0;NG.&R@O7N_'@XB^47:]>&EY3?/]GY GK*PY"*0(V-R_^ M>EO)/ T?OS"ZUG\7.H5\*DS^KFX4*KO8TL@!7 WF!CCE7O+I&2ID[(=RCWM3 M5R>/$.=OHD=\V35,NR'-XKEJADDD$9Z&+L\S$(K>%EITF FZZDKD,/P-*H;' M*SA<+IP\D(6'/*^-D%K($*T[ 5<@,Y9FCQ*UZ(.4.@)$V4'/ M(U8>@.5RVT@;K9(L>(0_"G5X44NNH[FW$ Q!!P;/EM86%P$3Q1>'WEZP:>2<@KW0X2)W:W@BN[ MM@!8Z%B[0[]H'=S);=Z%N#>P=[%WPWSX733%D^L.&GP_N]U0N16#;NTFWEJL MF2J+*17=1'3W.A.'8C@7?]P\/ 8@W5RO'M:K_S37JQ]?O=JL"LDQWK/_59)7 M_"\72C_0O-CK9V]^6KQ\::TW/_[TM^_>/.34V.+E#]__^.;5LY]>_OC#(TF3 M/OU759SGE>1("SZJ'W22].G9XN\\W@=M!:_C7,[IT3N=,]\#]\])0T94(I,0 MB"DUAP!"5,1"3 IPWJ-IA5$OG%$#+6V8XLA?DPNGFC"&G7J7&EP$#E-F:5*8JGACQ5;#'=YMGB#'&&EP:-JCV=^<)S7D:O6X6JQ='/L?&(% MVLF=).:ZXG 0)1!1.\B8I95^K8^19 Z-4S@*RRI/Q&.I #W-_\75V'_IL!_T MMO:,WOJ#QEIU[Q;?W^+USUO:]+YYI*-IZ7P))\XSTINS7S!?V)Z6&[+4K-*]H0-T<. M%Z&UJ(F%W1EZHU$.J4Y9+Q>?WA]DFROZC#8H(9YMDFNY!L->-S5F10@TE@R< M*>AK7*$Y+["IA62&['&^OL11;!Z[+,>X*:1[$&--FEDVP)H(];4KQ<=!ZLL" M7*C2;'%V_9QG5TVXIN*UBV.O9!2=EOOU/%H62?3.K7 ]!G-.!;ZLE1-GA.9' M\2?[MER-]Q\D]PM0&6G!EAI%*#,J#L(=R+5FE(1?6K\6_\Y-'W34!;ME6T;B M2KFD># 3I%I)[2[,Z-DB]%'AP=8!?95S+R6]IL4G__FID3CQ?R9T2637W'$5 M4C:A8U%IR]D#* ],^I'\=IHY9)0XY*Z\(9+F_2)I_;T%E\C#/ND?YD'Y!@O[ M363[XH;LOW.1B?[SQ\ U^S>P=M&F%\DG7H,>6_?5Y\JO_\8U$,UPYGLY=/7H MJ_2=1/[?K;T3Z5>J-8U:TV97-5T7N&\DUMB1I9TX;%L)([I0T$F1$!?T M:%N[ZJ:Q(XP16@7*'[*7(VJ!< "HU0.3NO2<"W\C< $!+IC!S>A/)S]Y^SC_4;J!M[Y61&)]M-EV>RW.5UO51P%VF<-E@I< MG;3$11". .-9>0 E7;FBTPU59R,BE"+-:A4BQNA%0+TA(&&! \"WH@#1A1+K MG42*P9V8]M/8YV@C9621W6!?<7\"^(

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®NL?NC];OT\CK!\*092NB@FX;98RNMK2QH7,3@F("Z^)<2SQ>0L)U'&5QA'E@ M&10=HAO2!SUWB\'7DO:/4:,R8FP ;07I/OTBQ[8YAKV"HC6=QJO:8$9>6^@I M\60A9#6[Y;'M1.I+V\K+@V&2D^^RM)E,*BUH/Q0,4(YO)ODW'NIR%1>_-#P M-+C-F9Z_U^C5 2[/ENI Z[?2?IK[@8?]P$_G?N"Y'_@#^@]CFCRZ9BV'F2)Q MKL,>]Q68/3A?M"*RE#/;].8$N'.T#_@JX@J AT&:AE5N6C8'2+:AVC8#A M:!,-"_8Q5.%J7YTB#=K4DZ 9VK<(R#&+ ?YO;+RB<^Y@>4.?0'4N#KQC'DPP MR/PHX7M8C^GYJL"F-/8<*[NY8ZR:]NKL\B(7/#<^?T 11G")@'J#TZ%=*4X> MSG1Q/.&$"/V&B2IQN%P6"4I_S-#+=FQ19G8[H58]=LP #[>Y[()&QV0COO0 M# 6H-Z4(Z>1U]!>J?%F86/K88@X>-ABW"E:\6EDWZ.:]3DHN/<;9XHUJF4:!Q=.@V[(N"&0 7V_)< MQ#2/M3:A8ZI9P-$0U+P^R8>VYO3>.C_6S)J)2()]9 K0Z)?=H5S-RFEW)77: M]%Z&G_&\+6.,>",2D(S\@-#>*_]X^>9;5B13UX)>UN$HL1E=5_H?^5(6*B8] MLYF9\XNWK[Y58W([LN@40C\IJJF.2%O>Q<3U;DW+-3@Y"U;0S1ZY/MG6C9)! MIJK*_P/T*+LL"(H#$^79XB=3CGL"\DOZ<[H585B2KY#$BQ'.*#6M":*@FUG= M'=9W,A:U1.Y(*&**2)N6GD8#P457G5Q5>;GK]UH+RTPR8!_=QTYMM,N&?G7D MMVH*MX*4%/3S<,AIJ0>W4W-QFE1:?(,NA> M>8U)6;@TECB5!.!E$5@3ND6%7&!0B)OTKJ/O@]9W"P0Y?^;$GLPR6?7T6A?6 MF^4LI337:!]RC?:R, )I.@E6RD:C+DA<9]@[1>:;5THGUE=P99M MH":2:]!4S#3P\SIXP.M@PDOFM<%YOG6;7\*_%JR]9%=BGK.W/F9+GRW]@4S6 MK2Q=L]>^*GJ9M^RZ=U;_#ED8R03F0';T[5\HS1C@P[X1>\P('3BK@7*92HBX MVW3YAF4KVV+?M*$.C2\->4E"A$>'UGG1G-.T;#ET88G0BHN^PG7%L:S>;:,1 M*>='Z35K*%"V4<9\7K'SBGT@DW65CQ8$ #FY ;@#9TH+2Z\LSH\@_CH>*@FX MC7)^H$D";G)=1Y*%BE0^^Z8[/(F^GV:NYA4RKY ',EDW7B'!6:-C[)38/R-- M%&#$3)&S<<_&_4 F:]2X5R-TGJQP#"S;+\=:T&"AG%#N: \O@U)ZRSALR7VO MRHN24\CTGP=(2]%GN*R""+8%^!ZM@""Y44V1'0(PJUNXXV-N0YC7SX->/W[? MEU,"F@,@. X**A=*)[(V--9W6=W_868@D&E!K7K)87ZY MR^@][7D2#&E1X>!K3XXV66I+HTCO*9"'X9?IK_3P*Q29]L=E579;S7.7.TDZ M\/\"T"6.9]X)BL7*DJ(_(+M/5&""];3)T9[3F(0&@9$C&XON'*[>0;^B%9M) MZOT[L^P-3G^^^PR]7W_+3,,!&\:=K"B5<_HN4HZ#M06O?TAP!;3_"VF M:#L012]+*.QP63JY44YO^J2T_O3JZR?1SH34V\ MC7)/BA C T#-3C7I]0# MJXIV*>Q8J7D:X4Q ZBE:BP_3MJ"[=JYC0[=F/+;=R,13XW8M AV-BHD!!P$, MR"Y_5X 2?;=7%Y=% 82:LF,H8[6R3N_AJ+N0[0,V%E,C0FAQ+O0],H(#< LM M,J\%M29SU>PY*WFL%5G+:-J3-K"TA?P7@[J => T(U;:XAF-(!2!%7><[E(" MUPSOSEZ)[3>2#,7PI-U%-24$!^3.EJ BIQ8DY;G0(>/G!! A43+06>/+_WJD M5;C1"KA>F"[">YW+T>(58I*615''F>*92&=AS?"/FVS)>,=MP8?['?:_5'E4:N.YQ&<797/LJI-M\OPXROO#<-HSV_#]QOH[[IR+N6WG;FT[ MG\]M.[^U;>?:9_[(O)C><3,M)6('D.F< D+9\P%2,=M&3C-X 7H@A8NJQI^< M-&X_CD[RB*2@=2+(J7Z]%TT[M 1@"97&LCA<\E'E'CL+.VG?)\,Q%O=I1>-Z MF-\0*1@!@3,$\(ZN];%EO%ZFL#W?F^L+U>?T0N'9]+3]N+![WA:FP\MNWHBS M6/1DK< ,\7\JIMR#C 3()749U2F4KE ^.?@7%W/$=Q MWN:[S)29&$QBB.9V''1[799CX32'+9T%3'B-CGB:1G+\JA$1'4_YS@GG;:.5 M]&&$0^\E;Z5[>M2%[ZG1^6#EDC<+^N!PVFO%GNQ4XP4W G'-3\W1X3G#BX^O M^U+WJ74A2/D"EP;H3 -A^_DEX_R]D)9_7/2L0*O'%(WU47=L2@<%]GY]ZO MBCN%A4H^SVJ+KHFTU5%9)$*'PH:UV[3U-"RA(IO"%6OE4)H=TT4\ @W71!X> M0A\RHL+I<4>@XW.2[SZ2?#]=Q[[1+:JB/C]L:2/F'@K95:0;2UMZDY!_R2V7 M/2*2L>M?(4B$_AL\1,:C&K=D[1[;1,5U\+=+ET[Y^@)< 5;9,Q! M&QEENDYD]S\4EM;.4E\FEC]&LM9SYO"NZGZ^L2P+Y&VTP[)S(N0K"1<+$';X M5^QNH)QR[WGS,=#F']:,".+ MVZ55&'-3<-*(!W- HHLU,R A>=Z0V=7\>-P$F5*9C/"2T E,^^,>IW]HI$-- MY'1-SYKMS8[>,3E\I&%?9GSL"CT78YM5SKQJ2 M4%\F"8K @:&(+[X)/T9X01XFWEJBANW@CNMA%8USY6Q$V-27>%$/(+ MBU>L%G!R]6SQG7*X77+UHRH+[7?R-_&AKR37ICU'7B=\8)<=SNY847#MQ(P[ M*5?(>0%ZA2K4*+=!E&:;XC-X%L".O [&VX6W1YI%"8>,FGRJ:[*7ZIAB?!AK M*DX+-LFV,]&9P.WG-V#)Z[>?IUWG>J]06+%6!VU]5^BS[TB(U5@=_16O4YV, M?3@M6D%1.P\.7GZ7U-/()7L"OPP3J/NQNZ\V13"5(%M"OCH-1R4AMM3"FNC0 M5=HPH"_Y+*3,\;V)W#!5T2\%2'Y_"R M$<9!&CW6FE'RW(*F 10(UUC_U+ZF08MX,'1)!2"((6VDH9]CW[Q#WFKN?9Z! MH0]ELL:!H;K:- -O/MJ4 WRBI_[\LZ=??].%5"6VTI"N%(<0>S+7S1 4)YF; M<6#/W'\P+Y,',EG#91)(+GC3WRW+\V-S[$*6< J+$IEV'%I'*,(+B:@J]D7@ M:O :898K,+]8D63E0KM;\7AII"K^H!Z'\P*;%]@#F:SA NN8U%IY2QT#'.*# M49(L_DI;4^KZ.[/K(:ER?$1!?E^@@53+!'\4V8S8B&EDOH,NHT MSNMG7C\/9+)&@$U'SBNZ0I?/FUZ?\[S>]Z.@ZZ1 I^ETSG3:$YRM39!(8(Q$C("RLE>-%J*P:X/J;6QXR]OR'V_HL9>W\+[/V\[<[; M[A^^9N_'8W&8/C1=$9M=D7B,?[1I)O/H(/%=>AYTB7B*,T<1N$(0S$Z"U M*&PB"C MZ9*^3FU%%=TA+M#SC;BWP_0U4EQ?63MHGA_JS!'U&X'<&^489G70"$63&A6# M,GTG15,S"\>BVS'8#RF0^D"OV*E-5ZY]^4JP8:^5R-IIVB(%>*\%1ZCH\6$' M4MX!AFU8NF--4\/RJ$ZF9A1%%^KD*:$%4'=T3,"]NK)%*38L3*H6.>:J:WJ: M1]5/LBNXK.8>Z-]H]@Y;# :T8YZ8[CAN2(%X JD-.I+]EH2W':'O0O1!;1U]O&:/_ MY6B# \<9"BQ> O?W45M((VVQ1<\.PE &/\>8 ^")9&(^) $>^SVKQ8.EM:4LISID*HI(^1;,TX\YQ-W-@>T+;M MG-P0&EHCL2'JRVY1%[R5YJ;>9.!SJZ3&S7U"E&JDF0+J3T-1>$%.UX,^XFRB MH7.T1=,I;D[TZSM6_/B:T(8ZH!$<:]],NC-OM]/.'<4WZ"A^_N,_7[YX\O1K M6@TT:[MR90ITU[X,Q_,8#\2L[P2$GS3^:Y;Z2".WX)L@N!-83Q$".C1Y!:SV MK0@DY[[<$>6Q%[33P,/DB#R+AG"9=\IL(/LZ&,]H:Z?W)*U!/Q]IEZ0?;&GS M.%N\+6MHW!=*I'%1ML>.?M0M.AIO+MVD=,!%.>E%OFJ9:Q2\Y$U;K?WQQL[L MGSZ3'EMY]>-=M.*.J:@>__UGOM+B;T5>D;7\V)[GM6U#44D4JGOA0;D;)9A] M0G'&YKDK\@Y4:R"3CAC,V.T+EUQ6 9<>BW-9 +M4,="15F3!:M7#[IAFI.HB MJ1SW0S+IAM*PY.?L\:(5"HI43#872?U^/>;L:/ %73$UCMLZ#:7# 4]YC!%#]09VR1WLUK?OU!YQ0#%FJ>#=H_&MY.&']MCF22H6A?\O]:3 MQEYX(TR*!Y5=YHB>/7F&DV.U+)YH9 ]DLD8667J>*'P;)\U59-2+]3%T7U $ MV96<3W.:[B'J:NJH)32O@WD=/(S)&JX#IZHAQ&<)P4_,2R"+LF=!>#/_:.K' M ]##KHK0HV)().MP+_GJV *3 B5.KDA<$)E7I+SDGP@DS5'Q?"M)RY17F!96]X8=!*8);]G,55 P]4"*4FP"Y=ND(X9^YO MT'1[KL]UBZYH$;_EW%"OU%Y*M,)HTN[@;S<@).B^\>>$]D,FZ^FQC M^WU7G/JKP)?6C,5M9*$L=DU='AJA%]:H#.@0*T;7G*5@,A:K]0%IB1H>*FB1 M_1>T=.#_=77 S,[#UA7BE)FN]Q#]T2D'\04=T"I&)C("4>I)JJK-:G5LH>K! M5_'D@R[5PC<[;Q5IU[L3AZKSY^7D^.A[3T9$Z62'MH<"P%'5X0])EGTU4T)+JN0+Z M&!H/:"P\-W,D-:^/AS)9UZR/6+;=M+BH1!V_N80;([ (JX@\WP$#3A[3$OT! MZPFFOGDES2OI@4S6<"6!7TADO+4K+?9L>NRKI=L::3XNUKW&9I]Y3T,"2&.$ M:W;;XV&Q;B[KSA]8T=O'&K)K66I#R)?YR I)R3GE/J^RQ[/*7*'Y]B7F@&&_ MMQ*S'%FNT'S;$C)^<9/J]+PJYU7Y0";K*JQA[%%TPBV=:;IJ.,59\0/9?(=> M&!:62]I43$KX$&D)I 8M)R8#+&G;UM68Z<4 M=QPW]7F#RMB$>K($F7\WZP8NT;JSY'"HMFR?7L(O252J-_]PTO^GD5 MSJOP84S6R"HL-L=.&"4L<\@UG]6JV!\<_+>_"GUCZ'G!ZE#[;2DTMA RD,N5 MK4F@,WO%+Q0:=FL-[&8FG=\L)-85SMWPP;GNG#WTF_6ULK(H&7NS.^E6:/(O MX^VK(X+HN-Q=9=#G=SDJ"C<,[Y"'5\_SD+\K:EZ8;0'91L92:-=R#-'HK_F^ M7',[)0L\%\)" NEGI"7E^!N/)7=0(X]7C5Q2<)'3,;&1.2961*Z+K@+3!H!!B+OI<@,< BNF)UXSUV M)H:YAACF9R%VZ(KB'>T->R9%0A%'U/VN(\Y*--V-EBI\]MVK9U:9E9WC;/&W MYI);U@.A!!>(:L=TY%F+C!H#WS$]Z1T;3:Y7#6H">=K-._SNV-*N1\.F/]-8/_GN'Y]FN+<]0:%,C1O 1ROS&I6A<< VAHRVFXGN MC*Z\+@1@]H^SMV>+'^6/+WB:GJT.D9$NO6NN)&L\U&1JRPWOS65GW_"4, =R MCY@\HN5#>DSZW0YQ^ODY+:D6'%UK6EJUT-#D8P1JC'HO+O$,-(C//R.3^NRS M1':-3G[A]QOG]0%%V\B%SWFXP^N.O*[++;-?'/!_F5"M43E>;!:2;P]D;P>% M#G8XJ-2%"_;Z.26Y?Y M>=UT)9.-"(6;PF=@&7:AG#S#3?'DL,7\VPZ\VK8-_$N8!!CD) 1RUL,0F1+& M%N=9_PB3%)4P^@U$,1N\,WK0#3%-&4_M#6V. XQR.Z:\\QP9UC@M&M=GQG86,\ M\/:6+X1?G5Y)3&?$]18 /PU:CHZUG+#\LL4X-O3H I.XS-OUH#5#&W(/^7N. M/7*P%VLDT!7MDTW!!5HT1]&>.DIM*7Y=[]#SC](=EQWS=X+I5VEBA?-L4[:= MWQP"I,^VQU'SI84#9KN>768^KNU@IR]Z/T[F4=M0BFC^N=8B\ MU'0PO/AP[L@PA5=*^=XF:6W!_)'O=#]@ =223.Z<0KV-+3[&+^KP,AX09S6Y MO5NI4U=ENSKNN@/O! [@E2\ZJ_'ID%CQQS)'0<>:F_B[X#NB2=8HM3D; MR&]T6Y0,REK8T]_;);Q=TL9947P-$K[B("^18E@ Y,2U'>Z6.,WZYA,?LD(K M$&W8>*"N\6=:,E;Q=/3VP25;%_1_=Z A#*>%LN;BJ?WC,KFDHWPE=U*SWW$>;F,"]NJ3LYU/$-/8 MYA-:>C",>"T(,4XZOO>40_CX6B?^-+=.W*)U8G9>;LT.KQ( 4R>)D'_K/IK) M9N3_;ES<0:!8=M>#X9QM!Y:27K/;T\:(7/9T=C@HO?B]([\*O$\IYT#&TD_3BFM,X802)G^.IQC&,7+;875.R;"94/FJ: M8-Q]?+PAOAB_8U,'-T7W>ST)]'G,)P!EI7@%,1?!OD.MH#HFBZ>C"=%?E(U& MVNT='-!=_HN!=THZHRWPU?P -^*'+,G '$).^E8GEW *5K<^P>;8Y![J%5,K M>]T4'9:ND7W6 IN^0Q7[H_D'QL*$C@G::KB&*DIG8QC%U",I2IN@V+4ZR3K8S#JXII M6=2'[+9"9L$Z=A4:7">CE'2E^351%R5B$5K:+;G7W2 CA3BC29JMM)U*_K*Q M#&7-P6,(TB2M69]B?&CNZ?!"B6*2"-+,Q:![*@;!GMC8&; IH7NPJ''>+:% M$(ST1:',"S&]*L=;D(M0K3@3_8LA$0WHT-VA33/^M@I73^G!B.'OO!A&)8"*W.%+(]=$B !I)N[ M8K#WT,9W:"E*9<3#-N^ /^1WOZ=;'1A2+'E3)N,(%J'2'[W=D+:C8QNNSX!A MU)[5RJ#7$F$)KG)HJ5J[?#:VT^HM50TK/,2%IIS&]V=16IG:MR][MFSC4.JM M*+,E^5"YI]XO4';QLJ*9UQ&R%Q<_":U[2Z8N(;?O(J<3AOW'7KWUYZ@X(^6! M)$,<09OQ!; %@'_D "C'&KZ3TR(37MEPY_@X;"'CP\C"F9BDO-MB7\!MI]4# M4J1U6[+KK(%Z4JK['M7EQ8M73X>V(-]2+;56C+PXL-/'64E&SB3VGHDV:UYQ MVB==";H^W(H1HK227WA,K^C1"X7?'6@B>!#P34>E\:0]]#]U=1=YRJK&F M-WXX*K1^VU@.)C@FO2QEA]PZI]'XB8,VEF#8EOC!NFPYU/%+4D;8P2:&0S\ M1=%>\XH._Q!_*PR33*;INP<_0R^);MRJ*'=O.YK&/V8#.Z"EWF]4_/ M48;+][A&<@7Z7DF67.OOG_[I257NF_5G6VW)9VJ4P)#ICZ646_B)O M?OKLLZ?\\S7= ,7.-4N+DBWGM!_C/S?Y@?:_?%6N^4H7GRY>T3W;T_O)@=&: M*,^Y^/O?.K37KY^]>7*>[W8Y;6Y-3:L5%OO)!8WJ[WE;DJE,7NSY3R^?//VS MC'%50-2R+@Z*K=T7^P,CI[___WX0:JXE5Z2XQH13 FF$]Y]NR?3Y:(F[@H[,Y7I\'7>U?9XI_-*>=S)OWT[\7[HNE]]GI# MIDEOZBUM6>OBV[*1T_-9SA%.2?\]+^0[+F1I/P.>WI7D=YJNPTZ.%TS^0H:5 M^^S5C[IN4;.+ELB6=LYA[Y)M\:]O_\\73_[7_WR_WGP3EYJ8-2^VO]$%&O+[ MZ-7AU...M/1RK-!"6S8GFA9?('[?'Z1G;>C_P%@TF6 M"V,:&;>8>DY/!9[O&Y@?#P!Q%\27.6;)Y+IOU:4$7><='?/GFAV<< M"CR[*->Q(U_ M=%\X\27^WM"M\O#,\B6>'+*B-L>.T?_)=S5M G7>GS,;>N^I,= ?BN.WO-OW MGWSR-^#UP$MRH0A=Z*>V9&'5WH4$I;9KJH(<$R.ZSP6A __#WG9-FSB/FUVJ M_L_H'VMM_T1)CHE#5G0[<=BTKY,N\O;4-MW8G*]O/([O0H3@GV/>/._L!4GG MH(\!D'^)V#^)?!&EQ /5Q=(7:5CR26["< S?%OFN=SH_?_/R[>LWO0^_HZO0UQ6F M1W[.2[+)JBKS_M%..VP)DZ3E\=;. G[^M^3+Y[O&+_?94N]FJ:]D;%*ES)4.$TT6L92A^VX?Y,RUMX/D MVT+IK;8*0,QO*:80* E58C6RC$$1=$TN#GDZ@,D::KK?8!6 &-I$Z8#2G,XB M&^-CB@,QO5KK(%;D$%G6H5MQ?(.,T4"B.!1^NJ+W&)J,$LECR8\(]G?J%:A.Q9E#>F;/ M69_Z$(NET1=SFVK7:[9>%NBH26JG65)2734UO=,2*3H4=]@@ZR[46/D9]55U M#8LQ)]>R?+NSP\[27+KIAF?"IK_WZ&6NX Y^:GMULZ3[0=N]75!4Z_.KFOZ_ M#)!KM:*].#D>I6T[J-^H?L>=:#'CA.Z&$_KSC!/ZK3BA/\"L'K9;T*^BP&F< MJ-+(^O[*%V_<%W_KHTA5EL<1U"HQ0#J)9S_BE\'K '@=$8G"$> *($ M"E5PDXB\RVUI#5SD=9J;P1KJS,82:R70,J!@A;[+Q)MN0*$ZD@7"/_"=&^Z% M7:2D+@J9D)4U78I+$$J@_3J[--/F0EO+1S3=J4V)7ZYF.[BOH.4C++J;-:1, M(@-2X2)]Q>99&YD(666^N,A;(/FXV6[HVSN;7A[7YX5DX,V6*[8-+I1=;9QI ME4Y==6 D\Y/E"+E+8[$!9X$(5^2'([OAF7/)Y4_[AM;C29GWN$RN7K+# (4% MBG5XDAAM4]$D'%&:D+(CWUF ]XXVLY>+:$?0=N208!5A1ZYQLJRWA69@Z5G*M?:Y*^D!GSUS&N!N2^K:K3V\WU": M[:KFTJ+((JWW!CQLIZ5;L4R)C?YW@);) HR_'#$G>_G25M@_V-/-=/$]<@0Y M5Z-IO[=8I\HI)+5[1=_XNH 0Z7H!4I/9KUX0<-"X?+SS[/%YY\] M_4L6&XG=0-&_9+2RX3:Z!-F)4IH.'U:'9[/,F4ZWIE*V.;IB OD>][Q@0? ; MB5)QLDE0]!?^'M=5[/!""\O:CYA'B\%"!$?:/.6P2G,XCI1E?+/58\_MN;IB M\5K< ],*WY5=)ZWA_G3$X^8!_QO9S/3MUA_DM/S8UO;;@H'OIB8XH'I5#VS M8)(EN\ XKW]@X!KV.,F[52!3OFZ0FW)4RX& 64^S79%S.U(W-L0ANPI.&4B] M';QT' X:)O51E_%PT%9@;G>J$TNT6((3*[=:+@*^G_1;(ZM1'UQ]C4:"]4F M%U>SBJ5]F8'-0FV&121KKLO&K^G(A>ZTMJ\;Z$-=^W, =S,B&F3_UIA?:TUU M^E!DN&3GQT+[E058-=(LW*1@>W:*\[)R/%B,O10L21_ F?PT05I*SM3U:&IA M/[")"0M%'BH,X"8HMXTT!&L18(ZK[G10?*M]69>%K$XSCMBM'L&'K33UJ-4( M7I,I$O;2LXQW?W3XRP 9X4N@X,*]I/!S6'@,7S9X^VD0,7#O>5'QOC !+G;F MQ$GTEI&9:$?3T5C^ZH8Q28(HC-S*;(G'1(F>DZOK PB2(]'1]6,,$&8##H?< ME:P][MD/*3?:2>G&NZ3J2D%?C-ABHPHMGO,F:/;(Q4HATDM(!5SM>7QY;L(9 M,!BU]'H%8"8LQ59CS([$Z1 PL9D*Q0ZL=BX""UK?E:!";$](Y<=WDHL26X*_ MB07V3>LW#6W&29Y9AM'QSJ<>OL)Y-)X'Z]ZD>23F.\;1U;0">>82O9\R:Y(\ ME04',/4I17/K(]ES6#)UW>!'.;L<\-P,_Z2LPR/3#&X#H&OL\;5_\XH]/(59 MMTS6^^NQ[+8+W(P'IEWL!^V4'YX"(W!;SAK0><.5,6D34&>B.0$/GD!QR=E; M,0X]R@:4IDX(PUH612UG0NA9:HZ=+41D?(3:I*G2%JE^ ELL+CX.0J_!X\QN MQCVZ&4I)V6.>8W;.#;T_>0U,3@DJH"9N_R'Y-+Z5IMT7\TE_EY/^Q]&C&>IL MTJ_+K<;;!IG370E,='A5*+A?<=9EBQ-O/KJ#R[XWL6-. B@]:ESHQGS2YK]F MU<29VORA+2G>V,A/CG4 Z>B=.&@<<0IWZQ7M(>3.+TT.E\5I9S+_V>(?QF0- M+?[*@(?.DDSHK%OI96<=]@S^@!%6:+*[W;%K@"QB84S)YC/&/MD.[2U8(.I> M1S*]DX(/C*>P$29L3]F(B'.ZU5_+9.NN.D+BO9DCY!E[R]/T2O*_HJRG;]>)U#E?O7M[ HPU:[S7-T/*9#_YIGM]]WMI& MK*6T3'#@%Q3&*K-"4Z/ET M_#-0F.L1)*W+2N0'$)GA/G*S56=(.H%"KR$[WFOFFI:_R 883S1 ,][\Z/E6^IN>\LRU6N8Z=G$C M=8QC.C?:#"3L*7H_N7Y;V$#7ABZW#LJ_X MSE^?O^X]9]132A21Z;OG1PH3L*W2.U(9U.4I(K3PS )NI[?^S$-AQ$Y?"6I, M43#Z8="Z^ Y::#2USVCKS8(E7T],:53@O/ZG&>VXG#(2J4S*=^@CZOJA"1N= MKU#D$09G5+@"&$68C5*;/0G93&;,,_QZ :OMRV6"^[\\EP[G),YRG#46S6D/ MGSX]#&.PS2G+3:@?.D-QBX ?E'XZM NPY#'_B/4E!&'0&RJ#Q1.7+LG85*R7 M9:6NQZWY2 UQF6INFV>2%$KB^$8V?VT#B]2._$RC7.==#_\[IHIJ8@AQX\$, MFT'*_^+Q&;YO=5:LU,1M=HMU]==7M%K=:I1Z+;_(8UOTWZ78JU^[PTD"-E+Q MIDJ#-> W\N#2 !P;RP_=A@)QS@"-(?:#?,SY,6WE!7[-#A+Q@ M>LPT=93#0#2@DGH7K.:2K\DJD"UDF+) &1W6J7^.>_"<2J[$II!AM\="!+!E M-7;>?Z^"/:[ASK"]BC8;J_BIAIM)_ZB'H:>%U4=3U>V$W2P!)CWK^5=X!CCF<^>2N'(J6+/@)^1E\NK?<3&,+1,( Q@A$!+9 M" L9BA=65*K6^I0&2U[8@#8;PR@'_;I!Q'1MU).O1>>@2?L.4=V?4)7#\,KP&XL!RVTH\^-A4UYWT)7M7H0IK]U56R&ANZU M!&AK;VTSK?&S.I#GO.8Q??#=JD':]22")#&L&? CPO[3#?=OG#>>OV*U)6SEJCH"(X8 MDED0Z,KI/HY[X7A(H-)]ZSG0OKBQG_]2-#0I:VX23''/<=(Q0I&@90_E%WV[ MC2S?<2$:$%TL>9./0;KG 'Y81,DC06:OZ1&4V=5";&(QEBL;$ MW7LYBXD#V\Y%;HV$6+,>])'$12%G=J@(#4SF1$[MA/4:J-F(PQ^W_PDP[\CM MINZ3(-ZRWKPF-4'?ZSY#$>^I1F"F:I%CXF/J:9;0U7C^H>E4BT!0!_27EH"] M(F5GYX'>PA$]&^ >_1%TV'%+IORGPU-RFX-7081;I/0[0;MK3L'?0PI>CF%O M&?0OGZ0<+ST-C:I/9'%CM(%:$VZF-.:QO\SN/I*YWC0I%E]OZT8DW!E7RF/D M(6'$4<7/GK,\:0_I+1X/[_9%A6&B>P03Q]G-NCI)&7ALZ"#2 M;.-,L[O3%86X/LK*_A-KG(=LM=6ZI->6 _%%(I<9WOE0#4USNQ-#;CRS5T)' M@F(;/:Z[#-(=!BR25H8.$8JNX=13Q!D2!$TUD,G+86S8HZ50V4DY;2NY('ZVTU45$B-*"NN878SR>SGM'&^ ZDO^&5M:&6_'7[&I06:A"D MYY+F;@7N@^0]ZM9*'12/L-""T""\CIP 5TFGN:"$I?^$@8>OR6F]Z'5Z)]9R MJN,'&XX,#8MRM @;-<64(*"1E6OF2L%&C* M['_]S_>??_;TZV\Z.WWB23-2]0_U;\[ZQQ# 5<$MJR]'Z^W+NJAMEO%,-#6[ MP;'H;Z\!7V*;^L80#3P1N?&KYGJ?=] EI\422IWNJ?3$3X;6RZ F^ F^5A2] M! WLH))Z!>BG%WX%?9VP%D9"]5@6:38*.++Y+- XZR%,V57&-_:P?>N8O>D[ MJU*BL*E\*%KV55/HO8:\K+I^O5_%4]-4H -"\,)LEI5NMU9S 9.,O#G^) 19 M!BQSC(!&ZX+T8DC]K)R?;*5G(RSI-&G3365M8@O]L(/14P@8+^!FG.HF5.26 MV%%4,MWG%F15V*@"S"]SQ!F7/GCOHPP]$;,4 P*K Y!J![ H!"WR,_;PI4\ MK30G^PW2#R&(O4RZ@"TE2S='E<'UP,OTR!!DDW%>BJ(:J ME'6J++IW9251GY,\\V"V)$TT?MKJF(YU^>NQT)1#4/A3,Z)CY1S';B+XCE1U M$0MJH2YZ"A57[*-231P;JBO ^E,%.^UB0Z\.F$8O5A!TH3F,M6#.U"H$:V/I MF &D$.-(GJ )IZ#B>HS;73D&E#)V^$,H6X,^M+%TWO QKI]\WTOD7QN-ZZ*I MCBQZ5E9&QCARI/1JZ];AXR_%BIZ;4ZR*6'[OK'?XQYY==^SPRN M@8$XM6[!R[:J)L_P% ,IX7*>"GH'?!?K\M!CT+&NG/2.),+(44'!8N,^B1.C M,%IR/AK: P)^C.^!N;!JI^B']6<#JS?>-KRR/N&JXPA,VG(3O>G($WL-# MH[\(^>?L -R=< !]_6[Q12?"BLQ2#U]GKH'2SM+OG-E0>+6'- MYP!4,>KO^;NLKF>>5 WX<$YP7F&F*YB;MQ]R\W9"58#*O3_^C,K('0IVG"1> M...<6*&$_4T\D,D:K@E!_R&7RHC"@WA87OTI](1D$H8Q1A0B24.\5'9E53($]/."F!?$ M YFLX8(PD+M0+/IR<.A@]SPMSDWSD- M&+L-??_G\C11X9K7Q[P^'LAD#=='VM_<+%9(1_=0=0!9KCA;NLP/$-B=]/VA MMCP;_&SP#V.RQA(^K@3;;&)!'B4H8;P;D)1-H@Q[X3022 X;N"[HINLA4M%: M^%&'49_JJCZB&_#MS2T0U[1 /(]8GUU!A_.Z<[ BQ^2='OTI[XDGRF.NH-"L M.DLMW&TU/NO&\D= $7%!(1!N^,Z2!M3[O&6=#[ETPBH>T%H.H.%0A0%MS&Z' MY@4*S5D#CXG5';60M"<.&I>C:E7/8,2V!(&,#JYT*:F&W(#I**'N M&8E!VPQ(HGNZX'+D+GA*,ZNNLJ18F+=UT_%$,/Z#?DJS@4N)>7HZSYBC3EIE MQ+B[L\5;-"GK(I$^M[1' RCH4O +BN=%7LDWM8%:T7H<2X- MNIJL3"_ALS;\;1;+MER? \T^'*4\3Y!<9^]*U.9%;[M_AP ;Z+7>*G^9C/)Z MI!EF-#;H]BO$-SD"I4[>$Z^=Z3KOB-K^>D9M_S%TG9]_^:>_?.'^WV,X<._' M*^(].J"O QX;(CK*.^(V>MI9&/<6$:V.')KS'_OMJ2MIP^!$^9[.6$$.;)L. MZC7\3\C$K?AHW.E;;SZ\S-5CM(P[8E.O MZX.G^N-"QX:C]H3&)73V+12>C5CW@H\8)NZ:;7VV M]<=BZ_38Y#,))R P^&C@(!=GS=FW[J!HB7F#GXW^W\?HD;LF+YW\;T#]C750 M(BD-9LC3V1]CH^&A%54C8=.P7AW.UX8X2/7ANU5;+BV7'+X^KX]Y?3RF]9%? MY&7E. / W,2U&50N+%QOBW*WY.944?D$'ZI#)B$5$-AQ(U%+;_&%] $OH%PH M"2&^O>*P7#,C^;(K-#2/Y%C)?9(A)B.;%]^\^![3XB._JZC/18+>92A9OYQ] MLG)YQ+&D?!F_#TQIMO#9PN_/PID CUM]->SH6%]'3QJ(!SCET-\!.?08"R,? M0M;="!UN1F<[E1;/C GC6&_RBZ95C2)RDF,SBJC,]$EMILYO<@4JKK=T*9GB M+G]7,.XE$L,+@2L>H6#:R?'Z0Z@$?%!.U<=H5'=L!#?6Y:M>88!PB!:\O1;X MC+G7Q$@%01(/C_F?T.S]!&3\.SL5&2M"EJI<6IE*-]#FTH)60M$UF?$I>"81 M%=\Q51 Y4<&>$50 G*: W4SWIO*B@ \+3GHC+CUV_?I19WP>> I4GR(IB2]D M*8>")[)6O87I>>7;4F Z7LN3\>IO_4(7[[XJ/+\U\#E6**2I4AZQ8[MONJ)7 M5@SOKW2$9RE]_8W%D+C$V18\RFQ!KL)YJ5''YDJ?/@J1E>#'$ :B,"[CY-CG MI=3I&*C&9+L@C&43Y&^W07(:-^J42PK((\\W*9HG6:H4S#BQJBJ$,%WIUDX> M\4:S*UGBON/&/#5U!QX21O&4N]ZCH0K:V:L=D-$JQT<6.>3UM;JZ-#!/%T4; MGRB(4^B7=Q3%,3:-QJMR8GX(;2"IN6"P@A!\HO.D\5;N3<&BN]AO6T@#8FE: M/H)19'+1S(QN";%*"%>,S$!>L>(-:W.(H4L9&BLP(=_3B]$K:\A:3>0+U!-* MNTI+3_H"(H53%-KX@=,^R-TK=;.#CH#71;A/ENBU68L!TPNEG41II-IBZ06N M\56WI?G*OTG%X#[E!1N@5,PS_I%35JSR2^6A KF4P"0Q1G[B]+M,B?4^-+;A METK;0J:+0C\+?="OL5I,B"C9@_$P+2>V+H58SU 0;%=-!:4-F7X=!78(#<[_ M46/3$(&\#\JG\O&X876/7]%K1%-=R]7M5I!",_FJLD!0I;FQ";!!Z2N?.79L11W.& MZ*%GB/(H%$$!%L7JRL+"E*#B2Z%-8D[KSR;]6$RZRS?D H2T@40M O:M'"I\ M-NG9I!^+2<-5IF"00UCS*(UDSFJZLSW/]OQ8[)G32D_"#CU756?K?4S66Q>E M"(9"Y!FZ&MS!J//M: M"MC23,8,L>3T^HS@RS9'=WTBJJ:U _>! I 1!4KTIZ+TG+7O I-X@%_2(QW; ME,&$GF&WY^2WTLO?!,,F=0^D^\@@MRZ+_V1SQ+B%HQV9^UE1[%'VIG_YV=R; M_LFVXYMV@< 21-0B,'881[TF#HQ!7VDLI30MT(9>TU*; MLPK**D>S^J(NBK44BM+S):FAXL*\0=()P6)?]4IH.%3ZZ<,6"?[\^6?.,+[\ M][6+M,K.AZMJ!0DE =>7V6@B5AIGJ0IA17\AD0'2XVW8RWZV^.Z"3N!RX[[5 MJR>=,X8E7':\3I$YCIJ1^IH6XR)BP$ F=L)JI2,*HST)U7BI4AO^F\R.#_L@ MIGN"0W&V>&U?N-PV"ZFB:YN%)=&D!FA9B-"6I'Z)B-N+'4<8>MF&ZP AX!K: MI1-/ M"H521O@HT57NL2RQ:A6[[EEH3R^[+E;P\;I!B2R!8A7T5IM=N7)Z.#"H-2NI M7_30,XQKJ 7D5+ <8B7RN"FJQ(OEND8W%SH^05EH50#X0OS MIGD_PLT>E'/KR"!S:+J;&.Z]1SR \#& AWG$ NM>=H.F)%_+7FTT-5CI8;Z272Z"F_3.:U%I5P 4[2FAY!QWTS:J M4T54ET?9*KSK;*%:VYDV!=$K!4Z%_E=&.!8ZC1O%03Y-S/+'X\' M:[-\W3;".TV.[VMU)=YB*.-4- ;&"_:^\KH<4I1).:YV0BVC0,P,\N M4P=U.CB3=:VZLH%U4#3DKR-@UY7BLOIGI[CNNT*L[+KI+V=>5Q5#Z@YK+&$.P)V>US MR$UQY^BAU3G,TA-"74GA1X)[QSIB66!THC@O@#?IZN?XT&G]!2XHUU2?43QH MFJ2LHG<2;LJ.MOMG#(6759&YR5&7>;',6WIOK?@MRX*GK6#EW0@7C#T>0S91 MA0DZWR]LYVC%-!HH'C.CKXLHXZPO7G&I,7NFC(ZB8EWVD/[Z$N%=[DS'QV0G M1QEK1U]6#)X*[1P:_K:D39*^C7P/.W.GXF"3@UCN=-T47=&(Q5FEQB%WIP'$ MY[F ^ON4-S?/EX?"?[XK3!39ZY#RU<8G85YV]R/">4"SI(8C/?#V3@S)D/V6 M@?%TNN'(MD230XLN$>YSVP:]-^D9X103MV_X])3DA"Y*/C'(76@TDEC22LV1H]F>VHMM^TW! MZ(SS/O-P4-W-6W644V2 T1:,VC4,'H=:S!($$I H*VT=43(M3*'HW8?]-B=; M6"$- 2_!YG@'P6#5@=&'8)T[_FOOK*6';RI( ^@;D&.U&I_JQ)W@^6*3G$XL M]L#H\>E%'CCX1?H63H*]/W "!F72,'XQ.M\4*@D1U:"_EI.'+WC'I]*T5ZR>'5"H#VVYQ>:Y46B M8<39GDX0?T :XD>X!=]/3_5+,0YE%6W04IE0PNIO2N\;8DAK4^3L40[\6)3EN7P M!WR_Y"K.D;?.[+>L!JF*IFW22,M0+0WE4]WIM6QJJV#>]3[ MKO"F;@"T?/LC)UARS;"[^30DM+E M;:2;7 4%W3(WXUY()6 GO!+Y87C]$!SNRLZAEU$$XDM4#>>NYXWQ'C;&;[5, M&N0U,X# HO%=]).A+ONIQ^Z@UM1_TY*.W'&N0 )R080= M@*.0*]+K+P[A)Q8-/ 1GM6LJ:$W,X6Y KY7IW'-GA MM-%%P32$HU.#)E9#A M0FO(.D]KJ0!?-NT[OI9:B!N9G%0,EHE[5&I5,4D[-=K>WA45AX2T+KF:)G;? MU=R$O SQCNYL*KM$!RF?:@!N#V&L,C<#9-XJLIB3VM?*]\1:7S8P0N=O!%(;(8@- M9+6_V4UB5_$(A)AP>X4(NE+:%65"&HE@N)()G4<,(HYZEY^L^+DP8C(CV\*] M! ZHGM/9@C%/Q?N('^_E);L$_NDCP'0%1S 7 M$UF$'/ODY9LQ1SEZA$A*0)BRZ_O^O7?6<[RD4FDAY8XD:9*J8.'* _5R1+4L54\ C86E0ZC5[,+K?*][+.EL.C!899 Y$J[#Y2< M\7)7A?66IXG#NC4EJ51T-.:SQ'F8GSG)Q8,MMO'S)%NY"'W-/ISCR>S#.6EY:6% MRM$8/5!V#-RD"E$Y=&2A*U.$V!QKS>.'2G&R4@(/FT"H0O5ZM6TX4\('^+%D M.KY0=!@;,YT=;4ZS?Y0,FJZ^S%H4RE6YUW*M_IHKV_)N0J(I1>^@*<5*['_D MDOO(?>.?@J8CYY8X0KIHJHO07,L]JV$+MY09YY>NW5JWPXET !4I"0/ M. (:&(,K]'80#+,W+$Q+.!,GYJ[L9%!:2C!NOH9+8&'_$G24G&^QV6_/J Y> MI!7 _Q5.F.L/_2RUJ1Y\0'I_OKO9J8NF:E+[BRXF! WA)T8 %OL2@%^*@R92 Y$-K4K M=ZAO%A^>QF=>"_-:N#=QE+@6./L&TP[&[.#9N81'[(5%#3KVN^@L '1]9,GX M;TJ8H7@@)02/[="NB\..E]^!S&U>1_,ZNK=U5-%H1+LN]"BUI^@L22X<\K[" MV-];:K[_<']D,N5% C[B@X>F(^A@:V7@0IOMT;UA\;2TG;\_:'ACD0B#X39- M53;=[T0W-Z^O>7W=R_HZ9+A/L^9W_S#,\@P3N4(]3L3Y:D!PVE'BD-H+T5_)O#5DA,DB\#(H8D5R1# M0<[BTE#QDKFX+"2YJ14%D9)#E<'O\SVFI88;B:H+3;7&0O-E(I'D^F/)U[IU M8NQFQ0ZGOA1+'6OZ=0/W#%50@;PRR#R(J6%Z,/IT7+XN.)V)]Z//-#,ETRY) M,'3+"JS6$:_PR[,\Q"BL3ZM)FDQ268I3<_3PM^0'N$5,K05W-6X*5Q80Z'4V MBOL+]-FR7<4\#BC;BZ!&_XV,.+@QHJQ.2":BDQ(6<8NRF"]5A5JQR\R( M&%5:4!^K%%L=;-0@?1[(TKQW;+*<"[&W*\0..;58\=M+\?GF[HZE).F^SU]<4K N(,6,[FHT%^QB=IR"!"7N31Z3Q"FI@603%]00\J&Q%+M#EQS:8-:!O%E6\":CFV EOO-RL3 M'$17J6"2HWQ%>]_SI"6VLV99@(?1CJBMC@D9$9B\))0:5_K#C].!9)KDBU]W M';W^1J&HLBORVDAVA[\RY( L*QDOEJ.[+3=H)C)/PL A0G?0M(KSA'F'UXHR MF^>@"-R]11<<(KHDK_* D8K?-AJF5D+$I%^:SO*W10%4^IA4HH[5NJ$B(<90 M.S*+3%5A]$UD50BPQM )[A^GB,I]A^-:C]E5SQ)Z]6^5WAS6ZUA0<-P:>3HQ MUQ0CL6_GY.=.$CK+/_L%/[1]LZ=R4$:8@[P A4LE1'GHR&U\&SA-,D!LBJ>X6U3T*1N[;AW'_X_]Y [#4FRB9ROW*+^LG?P<%C;I*/\+P MW[*/5IR7J\6S &G]8#O,O^F$C\7-/\?\FE\!O@ I?0ZT@#KC:N9BA[PBP/W# MJ\DK:36/Z;V8UOR0$>RC>%^_#OAKI MT)38?#?V#C,I$!3:3\(N/B*RA$).[*&'.7>V(ERWD>_YI0-+>0>(-8E0DXA#<)O8Y.O^)UK"Q_ PKV704M_*>XE_SG8F*[Q M ,3QQQ4 !&HNF1\N!)B4E6=;[G7_>5'5_7K[Q9B6O$20CMB,G6(.-)VYB2?B&SNT+X84*'0]C*>R]9P!NG!5L/ M>C#XH39*J)FWD6"(,U]))UR$X+9J7$>>)I3DXC[A;A=5-9 &>_[C/U^^>/+T M:TOE)_DO[MNC'89/@=CN?,E"+WWNK[0;C^,W",%'I3++7?'9E]&Y7%7-I4+R MPSORFP!3Z\DKC74I:]EQ/'IXR28!6A<'\%7LE(]7$!-:(=OV+X_/)/(,'B%^ M5J&+&ZUIT>+0\!O/]3DBND<'_9+K#33'\-92_ZOGW&GLW%EK\53!B\D?1Q:X M%KK;_F*/<;"/#0;KWN.SA&Q(S 2Z'7*JVK+QC;;CO9"L)WYO[MI'%CC\U".Z MPSD9WN$HN_@$' +[BM4FO!_C''L3M6(+/3K0$;8YLH4L-=(,8C)K!>7U.N1U MORF;'N-J1.\9O_$MGT^*#Z/\S"[]Q0B/ECNU46O1BN"@',BFS,.P/9OL,&H' M_:R;,?D/"4E>1"F*$_K_L_?^S7$;2;;H5^EX;_=>^0;(M>29L6<=\2(TLCWC MN^.QPO+L_(WN1I.PN@$NT"#=^^E?YZ@U-C;&(MD-% I56?GC MY#F]U)>\:'/6.OZ/,_B7K O%U26G#_7(QN%4=-)(;)[$VC16T$,H^)@M^1%; M 0*1R&4;A@'F??1V]4!@AG_Z%[5+ \A;1;"(2^2#0'UR5.7F&JQ["I#5,<0R M[8EH(.%7W%:'\&(P)].EU6]=D^1=-5Z3J0#7KGV(]9IN;RL$C^/('XBAKZ%Q M7TLOIPA":=\>W$Q.3,6YEF/8G#(3S-#C29M\X[ M%#[A'!-C$*1"ZK+6+]MAWI>@@))6/=2\,E8RV M$B:0K>84C.CW!A1:8QJ,F3_[VU:WY7Y(3%\:ODTM-8<<\Y29+%7A;X.5R]Z= M!&K)EKL_?.1TO?!H.-L26]$2Y=K,C"J-P'7%Q'4#WG$Z34;B"11TB(V[DMMV M$#LBR&ID\0]G[()9*#PMV+R9_L5TH,AGGX@\X%EG"#X7ET0^%J$=Z8#SWN]Y M2-[2>WNYI'8>IZB4.I2LK$*YMI\-1' 1FW[#JVJJJ_98JQ;#MMT,\/C3BCJ' M9DA?K@F3G,K;<0,,!^-4ZXUA-,?Z.A;8F#TE&'(*]N@01&I=#MT$8F*Z1/%> M<>&(&4T;ZF%I)'Q7318Y2JL^VC$:7V4AZ013^]BOCC.6>>^T63F$/!%%5]V# MF\D#ESKKKC.1=+V7J" MAH14J) OI1'#Q-G8Z7TPQ9L0?&NB@YS^QA@44L:42(BPT^ATX@F0[>!$E&04 MZ+BJCR;I \-T+-\F<^)3/H+0G6!GB2,0MC7*68JWJR^FVLO!/C\*]9/?X_X1 MO.K BXFTRM@_]]%9KE8G^.Z)M3=>>KX,3,SE]09LU_1(LYFC':L5><3WS$&X M[L2=.V0P)2Y*>#=$V^KQV=&KKD&-*D!" M8S3C""RYBO@RU]4>&$7F236O(L'@^Q2F:/&T5I,\!%^GW<)&#^0]"M;*)>5< M<,'9QSWM4Z&E):_SI",578FI>A33R^Y.-D)%+ACLX!1)&O=6QS[B?""J"3P, M:[D"@.Y^*X;>@_GHP,ORA@[I[$4Q]/XQ)5B;H]BTS47UH<1(*S#\\+GS,2;"^5A@^$O?J3AF#?6S&L6'TMIG%P&I !8.R0'9$9M=]ZU#I[) M<"-.>A&C*;4=+"6<]] Q DHF:L1"O2"XF+NN'+;Q?;IW+*H%'V@M7:Z^2R[- MKJWZQ9Q&%%XK5L*5D%-Z*90@RV"]G*:/VG*25$&['DG"A87W]\LWEW&U<3*6 M!*Y7*E^4T/#*O)R]@!^ DP_F.00X:$VUC7UYIRLZ#E J5VGYA[_3M23N3LQL MI$5J0"<_.LJC@+]9ALZ,.D"A?R9%1NX<-^VSH MT=&\N9SLRXJPTPESO*4S+U6HD5IA4=E?AS(^17,ISR0].)5/D7A MRX>6DY*<5J)U7O<]?J/ 'EK%M'HY0<\KKT2Z72F3*/7(#$T#6!,Q#+"F @+!D MAZ-HQWQ[I)8J](Q?5@88GF.LPFYMB5 M-)ZV_A6IB(+/AI,D!K&,K)1I_GR:Y=N?X;+PC#5RE]:BP\3O">1+LFV"U2D#\=JR@'C;;5=OQ-@"X+KR'MN&?)-40;IE-/!*$B8Z\2QSS M[/2K[Z#-WG$\P#_4VR*1$;+!Q&4_?8F)/A#Z"B".6,N(,LE21L<+*D3I5=$9FWU9 M'T2D$7H$1[?#+3 &1#B!U-A58Y>P$>C*T3&3-Z?5WZON))M!T&:!.02'-^R_ M?0#RM, [8./ACS7)/70Q))R#CO$),ML+C7C_MGU;1?<4@,B1VJ\H10)PH9*2 M7D;9NIBQX44 +9U]F>DEPG@T2.S\LJ(C.&LV5WNDHLL)A4)"WCPO5/!12(+J8*ROKZNW!4R-%N;B>PP>] M$.&1CN-YK?>EKH!$F]K7:44-.GGIO! M(FZTAQH>7\UGH^SAVF32-)O%%W-7YYQ=5G!RPI^Y JF\V?;E7?W5%EI/DU>(.75;RL MXD?7((D>2=KI-""AIM"KQ0(O:_=IKUWP8Y;&@#75DAP[D9$@XUB@/A#]EOH; MRQ)?EO@3F:SQ$O>!XZ%M6&HX^!Q4#T:S>DQ""6T1!8"+U[$LZR>]K$?]^ ^1 MM/QU- *65;VLZL?Z(Y5RLY^&[14C:EPC&[DZ#-@(GDW? M2[$^0@;6V&_A-]MNN.(F)A2R*1%3E4>^GC2M;3-R6LO[,W[PN)\<\V?&ZY33Y9VTR1=[,F5/4)X&%S:5F8(MF"^DE;%+T7JHM=E.N*51_,GJ M?6?$S^<"+ZFSM6_V?#/]%Y7NAQ\^,COO+MB+L7I'"#X,;@ASCE@"I71_/ M@-KXYO/>Z*:Z"M-(K(3%2L"U:>F_7*V9%"1<]PY85Z:X>!6?8QYI,5]N*L99 M(4)_X#$5=5AIW[.B+5*U*&6]T/@D812R 3H +GTX>+Y=Y*+HC]R SX 00XER M8_6'@LQ]M$O^@T'FZ. E)DI@4U163H"J1&[HU!S1+6+-K"FT!3ZZ$),(D)L9 M$NDGN7YPX/?$7[=-)"(GPZR4?3 RR?HJOY ]G"[_S^*1/KJE/,V@W50 R7(W M K\T+]:YKMO8R,< \12.)6T+Y)WR8NH=QU"\DRP4+T\]6B)!IG$)/ M2$$+UY@P<^\0B=4]>E]B4.ZF:U=#($6<8-=6.1:T8;64E8NY<^ZK<9?ZLGL> M&\]I(XFKL5 TO=^/(=Y*0;+G])[1V/ VX@6TPACIY;TJNWV_IGZE5[0?VJZI M2]DMA_8(<;T?J26CJZY 3]<36G(;-D^'ID^F2CX]@)V/:;) 65MNJX.L2](E M+;O@5VC3 [=&O'*,>.!T>1OB26_-E>A.:$!J:4@2I2 R\Y.::M=U5YVU!8XS M^"SCR;*2'X Y5MZ8Y2>1G9Q)>KKZK^AG@4,Y))V4[CETH,+*9H?\_YZ,^/ M8U5*6$$[CVB_5 B1+XT/*0T="=I>4Z]E<.W"]%RN7NZ/UQ2)V&IP7\JE$910 M3L:7':C<<3/]=6T_!2%BV!C02+5/&JE252I!GS_1;27QN1J,]6WE_L+WBJ^P M$ AYA_^V0WS6*/AC!0.&E&R^C$XU_V;[I6J%K".LW/-LMO7*QSVK^?QJ: MNNVHPW1[L:?5PH)N%?U6W3AP?]Y!0+8__X5[W;.E5^K#!'Z1T]05@Q*.,]\V M1']W8A&)7B_J#RYA;4%=U8A!2T45E6M?97>O0$N1,;:SFD3>*/>A0KW?6._0 M2UB(-Z0N"G+%SSXM5B\^??%<3N;MZK//O-%XB7[@$)5PA8[+0NP1YD="[ F= M)I!1)CFCUX/ZLOK%*B/<3U=T96@&O\QV\HZB4$B6Z;9.Q,N[2TK/ 7YZ;>*B92&ISN>=XEUL&XI&:VRDK-#OO"8K3U.Q!D/9B%%>=IA)&C18<4:9A%< M4D??453>$2DQI?2VY2DLI(LMW382BWGMPS!][1&\0E[5QR[,Z2C52)2#HM=G M=!==DN2/6_+?)H5OK5/[!>;2*&UW53;* [\^484#1(WA>FFTR]]QB9#AAF/9 M$=H_H]:2[X.Q!7^^JJ[O* LB&9=C?:2\/]WMQ[!,7@UBI/YON^Y7+\/XGM&OPS\^05KXT&XY+ ^& M<.H6X9_?(;?XXG-D)3\M2&LHWN-5VX5C]+;NAG!UHI?[@72F=_QT7P?+V%+= M^@UK\)YX *]>_O#U&QD""$9WU18YO?%6")/^[&_?_[7_I(@OAN:R_!G3>@KS M28)J8=D!RP20Z>JK8$LYD_J\D DBG3 2!@T;J^:.'-I;5+)AO2XZ(J@E8K?K MJ^."0_XX<(Y'V*>A.O56IZ_Q*N\GP5OKP7>HOQHJ$721_[S'^, M@=?T]\O15S*_\=@>F3GZ7_RM\/*Q_*2Z7(,_-XSNL\_#0@(M'3$+TX()A^)P MK"G@V/*!?L\=P_C^94738W=[R+G+B'(<[F&M[LN[2^8&/_M(R;R<>Z;BS$.A MF#K[FB3%0'R 5\39%T:4/#]P$1CH; 'VV0__JSSCJ^.#L;/T*ECYXHO79VZ>CO MUM0O0''-^%71H^0CS/C2:0AARR#[ITS9Y98RJY@\ILCG9XYSC=B'F=Z7C,E[ M9$P\(R7OP#>5,&5_]L4+3/AG7WRF*.MO&XBNAD7'0G'![]\"!/#\CU_\@?$E M!Y#;%Y)'Z&CAMIP] >JKURX=?HUAFW/:T B@:?UC(%T M36BE$DB"3G2[-7"()%[<5=4%G>%TL;K=%L(T;\_@R(G26+\&_JVZD'N.=DPQ MWB[W!?X6L?#%V_ZH5V?_ *=Y^?,X1< 9<'1 ?4+L(8E+.E\R<>3VWICYKZY MV=<;3G1EPQ.I-SH$Q,B$9VH&CE-M[),^E@S=>JH I7P30O+P9M [D"V*2<51 MF ZZ2C?L.6,KYE27-8_*Q(NG'MM+%\P_:G[ 0=!.LGC2P,UXP##7I:J6RX/# M(\PX8LNC2*9BK]")HBJP\B9Y]5E*@G>"([=FMS.X?$-_PZH3">.N+(04UD7@ M[3WK0K98W\%40'TP H3,!A.L\8Y64M)K[ #QX,NO9'D99'+HR^@LNT_WLP>^ MKI)L>;!'/>--TP;DMOAJ1TC=<*1_-JTMFQ BT-2A/X!V.AW/W'S'I0*%!$V? M=%/;,YO89UIBYST82L$0%$I0G9 MUJV1OEYC?2)<"(\Y"MG\$:OC?ER33;1<,I"=8(J-N%_[+D%O4Y\$^H:8_#X7MTP0I2LVO"S(:'VYRB M:!6?H>[+4W)6TYKM+!\$ZAX[/+G6RGHP#$L(TX+\' _"./S!N>*K/:;6LY32 M'I?[" LP>:4+<0T9-%WDK9E\N,VM0 K(<"LYR_M-<+[0[.L6 M,H#K^6HO_.FM"=*9_,X]:](A MK-HH.01%C$;WTR[#0+OY#A-Z0[1J.U<3G M("W%^U+5I79A*U=*AF&CH6^^OC[U]:8.*^)U>>)^JS<#68K@\+VTAFZWD_XR M(>(1=V)/G$8G@LX+HV[7QD)F5P$JT&PCT%%F_T:=Y4>HF20Z=B#Z@+I-09$I MU5U5?!RZ4^C@$PLY84$]+!,?5?!E3-8YO4Y!H''(,HGBITP_/VRB:4>+B+N=G\XJIE%-F:;U8T+9/[D!]Z/G!6T(%/OMI MN\G]%TC@ K1]LID;NATQK^X#TIXAL*1RG:2=OIA M:,0(KYY%&TQ_4VG38K6F8YJ^J?G-KEI3;?*3>5>3(B+Y]4;^#7@IDB?,0_FV M)OS;T3KF(>Z'?%Q5RQS0T14>H6-9#]#]:=B1U)9[4?B0&3W[Z]_%-PT"K6+&TJ5;>[A6@FS0@MB7VU97U8S3X, MG R@1"HZ@5FK&&Y4W>YA2X\).A97A%#L$;R<\KE%?V*QNA^5U?6N=][U\PW^ M)M1I+S?&92 %<'%WMMZ!ZX_[*KR,NZB6*\4S./TF!V#1J,:M=-UIT\XY]U2) MEJ\6+Z)$V?%9 MH%/2!P,>WPY#N=0OL50>!2C 9$EA:AQCT*D7(T,=H=D)^RF MF%[)[D.#=N*N/.*"?YD*R^(.)[SD MTSV3E[GC]$DG! S'%MQ\,HD\<+^ *EQ.[@]X5VCD/-TH&PW^C MUIM53SPS(M2@1:J3#ZG755/M:N/0P=7F[DG[/ZP1W%3\/?5/R5.C?P\W'E-" M';8 88@OV9SL;W(YYUAREH,H,Q@ @GPQH\^)7XPH^G?%RGG6F+/QH_2:F],6GG_ZQT*I?W3F(>.PL)JN25B@Y-9#480B?+^E7V*DP MT*DRE&$*2.-$ EYC*J@1^0 MIZOC6RD2"C$6 *AOR\V):FS9<[+79LL6-/9++.^'[? MB._W#6H<7W4#E\1?M?VA.@9CY?*=]Q2? #,/$=)1*T3D!-7]NE.BA1TK?15" M"%AO^H1I=%NQV[)LFV7;/(W)>D#(Y/OJR9MM&V"!J0S)GG,X*^\![Q36D!\^ M2[5!]:M?$B'9%J?+*SJ-\5G&A?=GW '>K.(-].8&./8?YI^6S2C;;FY7]@,U M1FC'1PF<8GU8#UV/@7$54TN2A=4CK=GTNMYON\JUSHR#3(["N&N,$/E)(\FK M[][X0]6$[@D9*$]VH[/JT/IT>._D08VP_$9?1+]ZILU$3G)QVPK/"\[UGNQ< M>T- LV/'/]VTV^#8X =I2:F[]D:%&P%Q.+%=(PK#/PL)DT,GE34.)6!'1L^!Q[@7'V@RD M\8@)1H6$P7_J.?-?$7$&.XL71#=FR@O^8QD\TC &>9GR4\_KO#^Z>UD_EO_V MH=[>$1WL&0/ ?2#6?Y>/$1SZ0C$[C$+/P:=&V4]E MR' (,*3.8]IY9^+P<"C9-=/Q.X:#PM-2.<9D(546.D'#*N:02AD3!X*PK=&B MC+)>=CQQ: [%@!P@G%B>COEL(040#,R7?AYQYLE)FDLN12T7 ZG']-VT/-,I MGH+A42B1VBF*'2?AU5!OL;TC\#<<=]5M"8[%Y&,L6M"UAV%_51YC&F*V2I_T M ZDV1S3X7CP.I79*T=V#6]7NIPB[$CZ^+\^LQ71.R0?)/!/H+K'<$NA8?;A. M>A\*VHT+)HGN,^^'4@W(PUZAV\R3!SHL&SM56$FC0VXT$?$$$[0KHRN^=/ M M^E-VF.*^PQ9 SWW85YR:W*U4._-XK6U#T2!'"MDDH;DE/90];W=6ZA'W]B*RU3=K98D+8G^=R0H8#V?H>_-GINO#O M:8F?$# _II,MU\#*A;Q*H\N@(D<;0 M+3D*.*GB:M)VR43.'_.)ZSCT,PTG3O8K@AF]24#AN$B+R9D^B/O>MCR$B>[! M5TW_J7X.UT$6'Z 0>$@.9;<;4,:90%P7YR'7\*FTQ&HH;0M[42F'(F?X6-+A M B?XJNU4^(L(M^N^53BEU$>HU&J/$HSB<%0-(/(7Z!J8@.MJ*Z22M,!BZ\Z, M&85Y)K8",@725R^4EKX%R%A/*E&" ) Q;[\@\=?(G_38SMFXLU-VUPX_U6] MY+Y*F]R@H4G/"N(U ")%[4RRR7!;!U%^'LO47*Z^85H.%H7FK+-B8DL1HE<\ MKM%7!6LA17^BY74[)S$ET[SU<&._I[CKLF3NO6A4L MH-VK[J--$5ID5!S3=^TLFC0)7U>G>PR!;O9"8"-D?M(MWX<;C-H!;;-+X\N# M-CK[_VX7YG,F%G 3+#T!+<[1?DRTGR5O1YFJ&:K&0H!Q!2_TH(\#\GZ^ 'E_ M<7K0WQ)MQQ2=P]=:I8D^KJ_^H*?9BZV9])YHLX:#!M"&@9EHYEITV1=[."F\ MYZ""'FJO7M8F. I7+,B)TV3\_476[Y'"O91I:Y#=?'.T%P$]9XUZTYYFEEU5 MWNTN]J/;"KJMO M-3=)&?L92!Y(]Z7!S]=&E?!#1?%R>.?\(]C?PY/NHW;63 W[ MD]5=N(]L!DW82@6R)X%@2L2+SXM]D\I"\[;@B(%D7#PI#KFC<,SY <([O,YB M?G!!I!E_\=3Y7NLJ>.J",[X-GOM/P:TT-S\\<(AV)/M+ PE/JYR$6O,L@8CK MS]3P+U??-ZO_.S35ZCGS[C^/F?LWPPU%:JM784<=*4PD !K@L7:W%=-40%") MOQID:B9N+'32;=261VF"23&#T]]51_+(J>^.3S!EZ71]U&&9D;&( M-)TE'%M09FGIBN M;M@S-CQ,;]D,5%QY\87JK;X.HP)@;_4G^D^8BW[ 81[?MH*3&74(I3=,O928 MPQQU87VS^BKXV$8M(&S/8HG*"4P# 4GLI-HE.C@GF34C?U;P(%,826%U%2E)TTU# M::M:)>F-UY=Z+QN:TTZUR'\.P1EJ:BJFC8^!GQ.3RG2D)8MB)WE:'\(Y;!G. M)&*@Y$DU<,FV.C WBY*V_(0]!^1^2;CY&-K)V^3$WEW;O4WR(<(.H^/EHQ3, MLF&G1-V>-2A .^>X8:#9@YQ[VSDN9M(N3*4LSVZ@-'PV6Q7N\6K.5"7TC(YD MGI"^J^OV+B8?W)4C=>7P9KZ?V><1O<1(\O*/*A%& MKZ@L)[KW:B[.3I "I6PZV4S)TL7^PE:^+DV3W6Z^>!_O3SS-F27OWZI#&P]: MD T*[V!3S:_[Z#MD!+5A98O-"T?3"O M]%3U9>B4&(L7GY).N($)JI\W5:3>6E'74]N166*VSYC:_BZX0\)R;]?*^>_# M_VYY1[WZ_C^__>KB^1^IPEY7.Q_,&K&^FI$5,=7V/K_,J&&KL(;Z$H"BMJ!4=* M^K8(=1G'I-NT)PDKU!1HU.QZI;YPW0#A($>%3XL$GYXW&<& IO;5&LE\4!8G MW)&4:7:CE;H &P;D4@@ZX7GI@&<= 5+%81$LC5&SA0<[WK$)\I"2"$0)NYCC MIB1)+*>>RRK+GR/LB*D;JN-UNP7.4!I:,+K+U4L^L")\6+E^5S]VP^$F/SD' M<-;)](>SME&C@HX?HA,RO<'DU?(X4R(3M@=ZYS5;1KX4T)B9;]A'U^ADPL>W MBRK#8[=\;?7SSU2K9'9EE$W3#@AT=7F,WI^# M2H\VBJT4^%!]5;T%$MI6DUY4"R#)S2.,S99/1MB-7OBO7@*^5G( NT/IEJ(! M>OKXK#H%1=3T7/TM["\^M#[5/_)!"B27EL]W2ON"3;$>ZCT[$L$EICB#VN(Z M8>1'>UOS+"\%8>(-6(HY#HFB M!PFH6&>0)'XHTK2EE- OX/7;88<<9&(-Y]F%>4$/F?[J,Q6 " \- MYR:<,RT.T?HH4'<>%@: J)?#/%JTI [K7\+DS >+2JDM>HN2:R>5D8MV=T& MO03D7XZNIF'UKOZ9:.&K*@7%V%DT]P9&IY-D5L:3S D#;M>FITSF>0CAU#Z? M.:2C)I8]&B\L20*'@T@OXBY..E!B>@76*EJ([^BH_J:\;6F!_$VH [_[YF^? MY/9*DQUWR&2'LSD-1N*$T M*FG*1;M)N;WEW*%A-[Q12N?M>6+Q:.KC4K/069/VX7E)C9..^M:BE.>?JD-. M4WTSK/>,YBAC6(1Y-@LM"9@^V.VM7?8[NNS$ZP&U%)\QN,?L!HLF>I0**U;_ MZ__]['=?O@Y;L,5;?M4>;BKNQ5#/\^4AW)BP%-S>?"KP%79!#T3&$A:)5PDJ MP\&(/33VW3!DOXDQWO_=CX>5'"!_U&D,UM8?.#38KKJF "E\\S4915HX+[=; M^*WA')F#)>PSE.X=B)^+N*8K%D") MZ&COQZ>9)HNNI'H3W$<.S60A"D@FCB/C"[/O0_"'YBTG MNA@ZG<@ZJ:ROQ$S$:E?V25U-T=UJK*H4IN;"$T9>M0(@S$]92,Y(AQSQR OO M\F78@%U%3P^L7TZ;G( ,N>7+4NG6(09,4/(03'RWKK>JL85L/_LYVXI1417+ M0&;#-#YHY$)A4*6#K^LM9VBI#-[#=3?A'TZR]NN[77 JC\2I?+'@5-X7I[*$ MEE/ZY@K/TXSXF4Q]+*S".92TJ[*.1*"AYF.3BD&1F77D;;KZJNVH!5228&0 @UT!).""+)V;?=6) M$A;90B^^U;&BX;N>:X:+_(6.M>GX"$DM.H."6RM))*VM3,"^^:WRBPL[95\,07C:D/ 5;[IJSW0Z?*7MA*U.+)O\P:%L?]"Y(D+%P[F^OF&8/] MQ;-!CR-]I]E"/<^W[FW+8ZE4.P+#T%2'1GY@'*(:D9"M0<&R*N&;N9WH\^ * MD'[FA4-UV&J32$4I5.X5W:G\3<,[TTW@2I66) ]<4>#JR^XJ4!* M#>RRAR'I6L.@H'R"#Q#TG 3I6:Z2.J9") C&@@GB0*-&P,>3!FZ%"0S].\\= M%9".%%=6HE>F>_2XT-J :^?6;>$? M3QH=?/>_:RD3+(O_S>Y=EM:T&I& 0B.BOA3'0%NXA#E@--T MH^#E?Q();ARD9G(%)PU5G%X'+> E%0:DE4=\6LK7"HE!W6V& YV-X$LPA;H' MM,))YY 2:?*]EE#IVI?F1A 1)[!B M&_;U3"[O[IK*QKK3P[+=\0 ) 1P8 L<_.7 !#9:$?: M!:(*;E2<8=>Q K%BB1V!5BYG-B^!W0F PT#]B&7BWU^IT7\M%@3X:'SHU6NC M22:P[:%R-08'714@#\\L?6EU1>7W=!!<1!=(8=-<:A65J8.A/ZZ[!0NH2$ZM^8C4Q _R'X+;9#YVP)ZV+-FO3RC MK%ZI\63Z)O0[ZUGNLYJ;^O.8 :RJ6$=-MI- 0GO)F1@'&'?N^.7GBX?)2<4Q M,/6;DS?&KU\2+^[UZ*O_@=^)@<]>?"HKX?4/+S^9KS!]5G#"EM_M2M>.9,4I MIJY)_-H)<8K+.#G5WO#$=9,JM1-S3W^-8PEMP5=U(PV??5O8 %;/@/$A3FOY M)3V'@3S)PC0"$5X/7;A/3]W%>I(Z,^!IR#($YDI)N%==65L]B5];1/]R?BZ[G%&I_"("4Q'_+_"\[I0,:+GA 9 45"K3V-"?M2-MH"Z M)Z\(V'C,AVDCW-ZV&^LJLKB:#M ;&2W;JPXJ/CSDV*ZLZ* L;]=7^]V%LW,Q M3+>D'S5M[U6&S;K0]TD/OXKT4BX!UC0L.M[D??)&S9T+.XOTW=/>:>[+-Q7Y M,OF[[46$.,S#UUE7?<,"\IL%B?0>2"0?HR5!2:Y]]?7?5W]&_G"_^HH^[KJ( MHG@YFS/ZZ%>O?_C$T.(2S/U'N-:V/?SO'G_FS_[]/_BSG$[&@6YK[-TB%/;H M*;E%CGX2?HI?G9_B;JQ1R>M0,0I8D.5M S#M"S1///^B,$$#:9!+0@#&BR"Y MH-.6YAB"E?627!2KR^8TVAPC!W\9EO[JV==?T\G@&##& 4MR_.46D8;4M(V: MG*-C*PN#&6XT^WH%$$Q'OP1DH]Q\&4ZGL&[V0KGPNW_E?E0BY%Q=[=LU8*#( M(_.I+3-Y[P1-1*KLFW@J[W3>_ 3$#$1R97^JQ<8,& GR.R-HS"\9%I&TUT%@ M[@X?T@VA;]*K""=H%\+W7 UL/%O=0ERJ]EZ\SPC5 @M('S .,$DZ$#MKXK)@ M2[&@A/&Y:DAQ=TTM:\U5*7"3)-"F1^%2>A+XN#W@PIF$ZS-=PBY&I>_BBQ*. MARM]_9+_0)%YY#V)A2:FAJB:2!:A44JY#:\3M9%H6"@.1K_RW&*8R!2IS:FH MYUJ/^7T;ELRMS+QFN?4APP22^U_WAPC XNV8&[ W&FY1FQ5%_'UU/.[);?T> M=NE\JR^RV@Z53K8-T;)*['2DGQ(OSA)9PE>19<)C/SKJ M2Q:)A5B)YV4+G%SLNYGS+M?4)1 >S3A,D@6ABTEVNMCWPKN4N"KW@*0+T*:; MOV24M**SQV095#2JG12-P]>8H$RM;JZH\*63*H5%V12\9"(?D8$8Z8L#:GOH M$?*U+;=BR$7"H\SQ1-%9@@;3$1O*&:JT_$1&[]SBYCS.S7F5S3O:%L[FJ/,$ M;5[FXDVE:1?F<:#")KD+*(0313&EJWUD4S?B_;-#G;39IVWS02GA]C],PH\%H4O*IWY=9]N"8RX14[M3ZXQ%LBY@LP,"59-*8_R [KT5DO.E-VQ4N5 M$U4'%@&&% ,]H+C7I@M;'UP,*)"K4XASW*W)4FK'Y>GP*XD_MXD'0YF )-&7 ML1M2L,!QWAYU)87RK!FER'!\Y5M<&=^BZ#56S;88F8%S6Y-K=5%_,87IY(GE MPC$WAEMKZG62C4_W%S.Z++BT=\6E_3__WP](V?\0^Q"_#Z_B6P]^>2W@EP\R MN1\M#NK#8/Z^M2TX- K^%+/&M8$:V-)@82A)4FL?^0B(E'3Q&)4:0BVJ ;2J@(L.7>N]6L.AH'&&S5NFO+;6$5%&H_(GO-FW]+99CV M9H(PSQHA--]"8T(N#B<%L"R2!,@L4/!/.H>-U<+6K<"?]LRYL;A'K MK<&._L9\4$L2Z'%+B@XY8ZLN.>2I #[(<0%C%HB3M)]?E[^L;/N2K;$0 M]>U854$>4*B:+0X8I\%!U0.CG.^=)KCC>SBR4,:N)C:18>RD.9]IPU/B)WIE M"J,K(]?JU #)!-.!$3U%,1+2 B']RZTQ7)/DEU!T"0H$']!O(?-<@G7(GY(I M@G*&BK55&C1(7Q,6AS5SA:;;G5U%&','_G$F6J%#A#I[BB15K@>NV.XP@@HL&18Z>S4!YL8#."%M M=[JK>"LJ!D90E"=Y-CR!XP&5"A:#DQF/!Z_UP.5LCCS7D H09-FQ;0&PV> M3#@.@F"J?ZK:&P(C_+%5'P@BW)D!(^?.=?O# M7DXVVB<>P.[(&$+V- BS0G1G< X! 7I K'T$0OMXNF&DCAZO<9[;;CR:R]5W M_A7Y-VRQ*\2?=DP-8S3JR*\P<5^UE?=,H"PZ0$Z<=9')V+859U;4V2N=/\HN MWX'111ST&!V[W4\QTWD*)1D0>(*V:MWT*VK61^D@'IP;>DSI:TK99WP$AU)& MQY5H:0S6[L9!XSI2A*<)^<&I27%4^MYUK\J@]AAZOT7$NHQH(1;(4A?7-(+7"2(EZG[ M*#CA\Q3LE[.GMYP5CY=[T(/7V;EP0,QJPDI5BUIL^M5UN#>EM1JQMX7JUO6* MQ6+H-8>[4F+YKZ'J8QF"^G$RL#DCZK"K!(M%2VE(^A:TLB$:X!NFE0\FH\_[ M)3/F^?@1QRBFF*QM?!0FMC&F+>>NI#&!YBER^FF/?S]J"Q&5#G,K:;&,SVG$ M;A=, WII?N:#HD\N-U$&12])&!]E;\M?=&>\^/S%'Y__P?[O\]_$1O%^KG9> MU[V'#5IS+S=VT"I/EI6!.KM*Q=J:-L^2W$5APEU6WY6\45KFC;3I7H)-G2AQ MNB=U/@%M37 M1XGZ^OVG"^KKGX/Z^NT8Z"0WS0;69\^$4[1D7P).YH.-%8IVT:TW6B%1Z;R+ MN7E$TY-9P!1O\\XCP1! _]15U9::$ZR44DSY89<65CZHZM%.H/V! 3K="($H M_!,C\F2ZU>=?K(+7?KPF(:\C"/]1;VF1R4S0O(ANCG1$).*A=Q:Q4^%3F#[D MF#Q1]P>&13G)JN,H:U=W/8[8 X&3.>*XY0;HGL-=IO6*Z5C.W\^'^S%BGKP/ MDLIH@QJ5R?3MQ1%,4$53M$UG>B$?"R?U=7U3<+A8<*@--AX+M6,C0*Q5T.>& MRAR!Q.^D]S1^_=_?D^20$K\IH6QCB9'Y,O?E@L9*KBE73P_#][_>$0LW%=[;?I:L2CWUVWO"YQP>Z8MCU/PAS[L5TBR#\3"_YUVX$) R=,_B7N0',X)B%E%F M0AM%ME8)&%G14;=E>)MKJ3EJ1*1=?_O35#C/G'7T4KG%ABKH],NW576#Q>_+ MT:!*/@;_F#D>'<6=%,Y\N7*\('*IE/N*^ZCI/T'@Z9*;> =Q*CUL/*XR=X-/J&(W!+OO=@")K?289@TQPY'$JU\68BEH?962+B\NK&HPPR2NLR@PRQQWVY^DLXY%!=F+NKX6OTG2FA:AW<;_$: M!,+DZRZ=Y*118N MRR*O&@RF2IEUPCC"JN=BMO,BTWPU(JO)_ GTDN^-9Z?:#(R!NI$&,)([,L\H MY?B8O[]Q2!@01Y%6V9X.'G:)+$L*1IMV#%,@M585J!813 W%PN+/Z7!9"";! M]-_OR8D=F'#F?L&^H8_1>?LPK2X1Q2(D"[ I:33M*R;.;F^EY+]5VK D&W8F MR\&T% TJA$SM/$] ,=D$;ML$B^:A@$EF@ 23&42=G^H&&"J0^IC7$5+>?+= MRY/_D-917>.C;NV9%@ >=G?[3%Y_'__NB;I[JJGYS.@03:K-7@VKV M8KUO-V\?],4S,W?/A% =[N?=I^O/K1+G7G ZGJ\'GEAP'5 M8PTR/+K\[[+2EY7^SY^L\4I/X)9I"IS.(UG=M.[!_[6L_&7E_P]9^5H2=^#N MQRUZ=LV04 QE+>RU!:_K1)D6EJH_C?432E'-0&.$KDFZ[DC!9@$Z,BP M#BHH+7MIV4L?VUXZ3J:A(\$?%<=1*[S0:C@KH1B\;]2<"NV_2!*(X^@,E&E@ MK$U]0JMMH_Y06AB:M**!EJ5I0B["(FGST+1+RZR>+SU6[]MCM4!-'\!C^,$Y-F9." 4;#1O1?"$.NY$**@$I['HS((FLJ2U =S.TG/6A<^!!PKCP<_J#$ M#M9X4ABQ0R(1!%>L9$>(KEX12"2B$0D7*/HB0(F]9 M\#IZRPEMSIF.E^F&EPP;6,5'/0D&+N)Y8@M'#IN8ZGQ $%P_L ME"#RF6NHBC68WZ,R]:(%;%LYC@RA&E3\"PU0Q2T,)!_&.C@%-;=M2&=;7,.2Y&0X\2S16_MKNWV MVU\2G?=1O)G'N4FO74,+M<65(K.%[M8K_C9@_D;#V'X8G!K#G.4Z"L1[_;B>.-U%/Y7A!+" M%:[K=2U,5\;U&?G*SZY1ZRNWNWD.KM30B$.W)P D<.K@% TVKI':QM2$G2'N M>1A@_OP6FZ3S,3$1TQ#9BRKZQ/!>J93*D=0.9]I;YIF\W?F;^9FC]S@_L\JL MUH?X".@)X]]%?30VG&31 BY#- * M/',73$@=W#$Z6$_L<]4:+:D[7QSAZ.SMJ_10U9=1P/G M1A@_H-$86%C0:]=HPU"OM(NEM;--+9 ?P??FFI,26G_^O4CN3+L5<2LZ!@5^ M(V<7MUN(3O:]\W33R=JL#D;)? -2OH7$[7&GS7\*[4'T/T6I4QIIPN)XYU:: M^ZRPVL%LCQ(.G0G?^E-/&6MFS41GH=Q(L(V@>#QG%R<:8Z%=>=^K031K(GL&^LFG@.S MH-P&Q(ZXE<-30T'&0E&[X:8:[1?K)MO6B#"O-9G!'#4N+>%[ZO"(;M9B2VT^ M;:.(/"(<>Y21RBWC O3^%P1FMG-7+S::%_#9Y:FB= MI5;\8P(8N-?C=94:]J2M+=P$IIVP1V+H'7]0;!FT]N691D6IU*H;U"J5_$*Q M^DCC](TZC/#\PX;:0ET=H9MR&6G2>J)GR:6NL6U\Q&:I4M1S[))#6 %AJ'M- MI]'Q'$*#$\P";4XO?HW&_>,]G"F)-@!LAV0]9R0SID/%R]4_KHE.2R]$[8'L M!(3]WYWR9,4[79M-QMF=I*3]1H)18LIP"H-'38@ST#%'6][:SIPX1:KL5V1B M%4,3I_MA&V9):MV3U'H%+?+>,3R%<_K=F.PT33MU5KFTMLEU'D6R@,^+";V" M3'PH7^8?2B3M-Y8T>RDI=F8-E @5K_,,'34?K*J#14R(P:34($T0 H45J,4F M[$(6-<2:W7T2-;SVQH,*;W;HC^"*$ YLT Y$.Z:""QPA"4&VLOW5 EP"\Q4C M XM<2)2S)O0I) @=697;)E6=8[%4]!08CO#&CE-<8K,YIRA"#(IL?"!CR48U MLC]*ZH \%-MM9[9.S @58FP+HSPHO/[ [PD2LU J-[HR55K-:W]#?<0-1!F M&B4T5VR-1)_2V"X>D:OS"MLFWM[!]'Z%U>Z!G272P[41J7)O(TO!=L;%]-5Y4X@Y ]EE(@ M44S3#'@2BC*\IRNK/SPT>K_CDM9\F(I"H^6I=W1'<77Q)Q8\)\ QV+*IYC4I++?9'G8'53R/ L1]L<) MTGJQ@+1^<2+LWYC;I)8M&([VCDUT9*B-I+1G.&FW0^=P6MZZHS8IZ2L^)3?5 M%BKVE)0Y'L,DC R599N"!RU1K> 0&*\5B6TSWED]_4;4M\44=VTA"6LEO?57 M,V1+L5I7F](DAL($$7W@K1!\!4]-XW$YIGN=DNE1LMO9<1*+@1?3ETI/>ZWO M"2HB"A*F'8@I]HC2=C$I=I(3V^LFZ('#@P!$-WQ'QF^#]N47)77ESX2[7[?D M(/$-C:6G8FY8U*-CM5)O8H7"*FTB8AH:HY*HWAEF I]>8H MNBVEZO[YC%GZ_," '8DZ\:AT>_%1TH7INSI'R#!.9> A*/V!9 ;D9CQ>RH;M M&(TD4>/'!)I"KIF4H&&;?[(?KP?1/$_T?0Q?X//B%>@COY.Z Y@OO_62%5CHG56$P$*\=@!CF1SH:OE+VAA/9& MD\\E/Z;1KBG+2$#: Z]* 99QT$,@AT&HH\$O>;!TYJ&2,-87:L'Z;1)NB(KB7-)_V+JFYD9/S3OHI3 F OS\';'V9& 8\[QFZ4@T* M^7@\[UA M08%2V#*2X^C%%IRH*TT4/K ^.34+G@C1[),F+Z82Y<(J"FE7I&_:4'&K9C5) M&J6F)9#Z$(Y:O2NO BFS3LWLY>I-[7I7'J9^<8 D;QJ."[6X(P.%#" AHVL6 MM,/X,N$+$<:(H@_S,$OF3TND>B?D)R27\ZS^1)?!5(R:RY5/H^GE$7W9.077 M,Y;(57Z>U>&^LNZC<*Q'\F0D@]D3J?:PY=Q7[>11)#CK%!E3SNA0\O?GH$\* M/?;H88=YFMR]$X MG&'SN7B7V*9\(')ZJ8PCJ49VPY[[+WK:)Q2?RME&HD.K3%.R4%O*Z5T[.XU' M; 0&C#TQ<[@(6OAW5?FV:O1R4>[$0RX29$68O4'-WE>5(GF) 9[+KJ54K;0P M3,_^JFVN.NP"^Q4'DT56/#[Z+IU]>7H[2S05R=J@<&P-@27_G@ MC"ADBHOJY[M-*=Q,;#_3X9,40N5ZF MOIF(_,C?R+?BTM++OF\WESC1OVOW%58=I?"ON0GE]G+UW2G8I.WJS\%,AU49 M9NG;9G/I9C];C!7\+>I/UV4BP6:[^NIO+X.#@9M4L6(?N]9<45PJ\NMJ7U>W MKOFL3?N/N X1@1D(38?8D)&*+EF3$HBA5?UT@N.4Z$]U#9I(JJ["9+7Y%;E* M4@K@FV1MLU&]11/82U7\ U3%TQJE%LW2+)[:,== B))CC=9&E%=-,$OR)U3] MWK;!P-$EG*!5.'TK6H GL^ML1I+PC2#@LAHC+"U:986MY?!B/]2-)I?"DAPV MO,HK@JDU<&]W8#1J+O+'X,R='\S2M_*XOA5$-_6&5U358(IWT'KH@BF\HS"H MXE?8##5W%53B5>I:XI61K !\IDUD$O]M.A)@"9BADA#QIJRW::YZBM59\9!U M] 1ZPKJ%>]Y*FF-?[RH$;&G->W8@XG?8+?7A]-;G%KCJP'"XFZ]57\*19JAIXM9K[G.EUD(L94] M)H"^BT?S 3R:;\_!>\0SULI9#2&3+?Q/RBQ$Z0%NIS9:FFDYO<4W>*S$Q#F, ML->9N[^/TRDM6HWV[#=BQX)+\MRCNJC)HY'NHAF-^47B0\A?3O[ALX7X:R'^ M>MQ^E RW]I](_AO-;!/Y?TXFP"\RAE>4>M;#,?XQ$SBT;'F?YR R0C_N-Q1) MWFIO2>SM'(GE AA[(&#LLP4P]@Z L<4P+X;YG[YGIRJ[Q)@PI8K%.>P4B)04 M@&'/\Z)K:J%3>I#V'/':>]OM98,M&^Q_U@8#K.)LKD##E!$UW[))EDWR1";K M;'@PHR8L@0#!FO;!?VR8)2Z!!!&P8^ ]47DJN(R4\PBR)\=]<\ MD4SK? MAV8&-.'<5;?MVPI=]]MZ5]._E&5:H6>YU#LSKNB)1'3%S(.@/5:]EHY^5?') M90LM6^BQ,5:Z5B790/!TJKX8@RXWJCI<--$ ,'JJ]DRRUO\@Y6Y/$!IY+LB] M:JS_T5/[AT.H(V@H<[."[2C>R5&;)@ 'I54B?[0O&>Q,SW4H?V)G3RG$F.)P MV9#+AGPJDS69&51(@)'L)^WKTYU/5O^,L.QEF2_+_(E,UN0RS[#[:2M+!.4\ M3AW<@T)_-6F_!T@"?0"!OV5;+]OZ:4S6>%L?O3A2RMA=D215I1I0Z,#QC,!, MIL\Y?!QU21I2FK^($8BA)"4H M*R7FVPU["?X.Q.'!"<]A'2S%ZJ8-_WN2GGP8'&*YO:,;7E>DBT'^]"8\S+)W ME[W[5"9KO'<=];@ M&N]3/.QB1%H&4\(;[H:4*H9&Y:6@.E4D4E0RT*Y\T$X313#<)N.-BERALH3* BY$RD#O!@:4U/92'MQ:+YJT):1+GMR5(9.5I'7')]%2(4IH8A@9*+ZU8(7\>DH/VP M-D'$,S)CE?@]"B;)K*8M)$HII>JL=]7 M7]*OEM6^K/:G,5G3L;SQ7>U6#LRNHLCWT07&"E9MWQ>N,*,SHV0!'PGKG^@B MDISV+;)0MJ5T@++8NN:K).Z99IRXG-ED"^? @Y;!FVN6<#$2M)X59>4%"2M* MN]D,3).I-.FN> (=[>Z0K8X/Q1NYT'K<1U3FNT4!MJ<$2?J%3W5H7>ZG:;'2RE3FA%A\0@!;[OE&%L.H4C 5%^L6*5/+-%])%FW9@B;7<$_#"/9)WS7"QS@*OL3_A[WD3#A M>87/3V;CE(:;-QV M;YX1;4W>!#\E+"_2OXB7!'U3B :9S#7X')M]VT.= :"-B%CT:R*]R^7J6^#Q MHR@SW;%MH&BN*9*T!=2*VW6W&B)YEYLUO@N5TGKE(;RK(F6 M=JQ&@6F8A;-W4=P*2QT3@+8=3\L JH?C(AX6EW%X2%D[^8;LFY\%SU7 M-\-U6#F4(+#&,%T&Z\$D3Q;L^5=#0D%H43]4WFZ MOOBJW5?T6R84/#/6:16U1]S' M:+*6"=6A]9))O3AQ^6ES*HVLP2UQOP336^;"VC/!/=:+,1$F=PA*G,^-L_:# MFXUO4_908H(GA=!!?(IMN^K;(IL=>)7\",Q;R_YTL.75?A=6IP03M3Q.JJ35BCT*,UAP^%*FM24[;4DFK+DJK=E_:&I*QQ"ZB&98.>_#T4(QG*-@98QCC3ZPNG\K2CER\.S@ MW"MH(OBVI 1&M>=$1@5(2"-'W[07,FR6/9W@'#!B=.(NA)?KSU]>J3[&F3B\ MO]T9C3S' 3RF]D)@S_:>&N\'\B.'APTQ!DL$B]-HQ(1X#/"RQT<(7Z/[,HZ9 M9I-?;CI)+CH>#;?(.??->^TX$W97]XBL]FU]C-FPI$#BGD(9YA;BTU\D0_*/ M1,%>?2%-%1(8>^W0\;AP_H@Y&!H%J\I5L^X/1<:I6DQA"9LP=*0E MA*6"6S84-1MO?Y8-%E8\31MJ(PH+=NV@SABWR4ZYRD<;A.,B'K8**KB]PFF$ M!PX+YUJ"!PQ>M1:N(]<'2T3WU&A6]]?5ULGHT.SB+ JF@- EU95!]WE>R=?8 MZ!IZX+!,,86*]"V0_1V):4(7ZQ;7M)E2P>SYX8EPTR3LD1GWA]YQR=>4K__O MBJC@;\CHD<<1WL1&>,"O@$3N5N:0W*\@%"[$B[JFMY>D!^)(N0F!9+EH@"8Z M5SH$9US*Y"%(&HI"_ZOD3(\6=N =@*AYM W>YP517T?5I>JD[#LK7_%;E0#$ MIB1'KJN"06ETEU-BHS\JMPOY1ON]4J53TC>.,YXPX2B7BEA\1+%/VW<8>SR9 M..NEVCUGOR4J;R;CAD5%T\\D-95'%O(*O)M_.Q:^D,58L(F,?I"2A MVD?\]; B^ZIZZW2BDIPXHL%V[Z7JBD1VPFD%^I4S58*84P!(FK XSKJ[-M+ MO9X0B4IV[++?M?>6A!\P"A6?I(?=QUKSJ *!!GV- 2'X(;$7=K[C:WOX-PU@ MH@]8%7%[N^GE*.&^1X4B.5E,%[V6$S1?Q,+"0$ M=$[\ Z(2?NKOU7FPM#]A*[.L/M,J3-DN\2$T5U CMCQ>0Q[#@K'6CHQ1'.:[ M;?RQ5LG7)E;";/"EU8L)#;HA$MB28^:?O*#M1H+ M=$YO36LG]&*2]ZT3O60LIK3,JC9R\^S "&<,1_434X.#H?HIK)P-[Q[5*H&+ M:C_L? %'U3]&6T4H-VH6S0LWXD/ZV+9O5S?[DL1FNYHE["" 2&?S<-,VKE1* M,LAPHWB.X".-)VHY0QY=UJ8%@?P[;=QV7,SNLR@,NU9 00#3W>+X2*0'(Z.L M3Y&Q5S:I:CGS[9F(H[?5/NX[BLE([WM69Z"KO$J3"F2)[GMQF79UB"@U])+H M'Y\(<]:1A1 R&ENS-*0[JA@[LY7PP9#5:E-PAYR+S">3"C(N2_O]2Y]9RH\# M!NETP\H8+_M$)7G>:+/\;Q5,K% ^LJ-3S#I:A?>R"B$X,@'@!ZLPY>5Y"5/U M.<;6'X<2,QLU7%X_)['-*8U[SQXY1W@"*-M,(/)M?'B0G(D+5,6^IJU[[BTG M;M_#UX''-GG^G''(;"Q^**EG-BVS5VA;2>+VM&ZVYK[G1&Y'A[8QPTUH-T8< MC:V^>6]H[+F>5321?1&^X;>!HL6BJ.0C,]B+71K9I>_G\% =S2Z+S5KV@#9# M"*!+658I/SNYU(W4-":2>ER+T";#L6\FFC5@M&BESS">GB*^G$6!E".T/"7O MNYA\M#MC:?,%KNN;+,TN XF7<5+G@*%FJCQJT9*MF6F402Y1-XEWW7G]SG7G M]]G13\Y%W;]3_F-*\*XXGQ69@] N:9$/<^Y/<-'>3:3>)4EBCB19Q/!BRK[E MCU!+H6PQ]UMX#@7AXC5/^#5%=[4E"[/+&SJTH'*P#()T'5T)'6D34OZM;S7N M3G@HD'-4UZ4O#QG1O _\!C[F\=#QC+?#1?.3+0/T$K W2T\* E*2S$AJ;BO. MZB8.:S$M 6C8#H4.-:/L@FN7.,[9L<86@$)F*!#09O(RP5=C!=D'[ M+KP7O&1*)/$WD 9/G.T%<_5Q8JY^OV"N%LS5!UY4ZV O^NG2CB"*IDZ*V1@> M.LJ:.)M,E2;UE%$GS:-+)FF3#@IK1FK(:1 * RAWU@$;IC&=*U"+(R5TN5L':4='6+("6G6UR\QVWCK^K^9M ,?]D1(FM='>\J M<#O/-YU$GKSI/*!+$DTT];B*RJ)IN[3]/KE-D3!32L@-,&PPX+$18]RK%G5Q MD&"[H:8*LF07VL4$\MF%;&M9^T]ELB8('J2I3>J-P9U11#L?OM/%%D'0*;?6 M"O0JD[7KG=L[B'$9>4R>4U99<%@XW6'+SEEVSA.9K&D9#JLJ]* 5QOG@*S]\ M.OAJQT+"N*SNCV5U;^OP5BM %"S*Z^_UB.Y0(8O@-(KN^MU)*GV3UUQVPK(3 MGLADW6/GM2D:H!S&;+N=L*SC91T_DL]G-(;^< \$:4W_S)4C M(Y2*TM>UH@'C((P]K-]4-\=:RE\',ILW^RK+#TKS'X$%]@96Y\Y%YAW(/D]< M1M''1@HEIN^Y.M*471!P74?,&4%@]G)\)/6 MUN3M8.FM/F=%G^D88DQ256CYRG +OW97U>J[MJL(+0JTRE9+)@#03\]1CB%- M<=_:&<&TCF7=Y1T:UNH2.P.0!^N"MWDE*PQDPEI")3#AAE::1]9,%6"3MKMS MC2#O5(Y][Q>Q +E^:7/9W]1'V^\ 8?7TW;'N7X3$Y&E0IW'?O%+#JN'8",; MZLMU[2O>!((=C^,D0F61+A!6)I"XT_F"/B*XNNK0&H;K0S EVWX;,2M+U[N<#D_3>PX@?:LZ94"J$RK;]6H5"2+M+NX@&(@P MHBV=02UW(';5%3$*MMV)FVYOR8#N'/<=H3$+U^Z KO-(\=$O.,S_ =OW&[@E MA"FD$SK\=PZ*:+R7'M28-WK2#BMOJH&H)ZVGR+@BX (YM=J,W: -EJ+#:7RV M'6>JVTA8=.$>)*/.X:/HNCLE&!OO<,1N3&LYB9VU\:H.SE)P,-JASW"V&=.C M]GN/C2QOP];6 W08G[QC3*OK??\19L 9,$6S9D\8@9OQ$6:GV'4F3+0D\&9G M3A!NW-=V=OJ>UJ+-_/NCO*] A3O%5LQ!N6WM92\_;B^_#*] #MND]3G28[@. MPDE&'EY3\K,N@[2-.G$4T5DDI"S757E;:V]$I6M R$8L0S^Z)OAH7Z7#]3TO M8:C-$-8GL2@3GY:M*F:>B2[$ O=9DC=/;DNFK4!PDCR8GXB#0^0MDC';BCU" M;1ST6\BA_:7Q3UC?J'F-!2^3/;24!Y9=\40FZ[Y=8;WA3 IU/SM2ZI[T*D-9 M4:I$M9EH9NMF@&O654VX><*WTTUJ\UJUVX2:JB<9RL)@&3\A7J![,>%3U&SH+38)?2F MS8D*UU[7C>";66\^Q&",UQ;;0<\--JH^:;-#EEZWQ$6Z=,(C)>TIP!!$M&VCH$)@:2!JW77%)R MK>,-3ES0/]IVT ,>?,>$Q27!BYJE 5P/:\+="X>@ZJA[1U!=./DHP"0IQ1"% MGCB#JR08,<9<-MJRT9[(9$V*'/+!Q SH4SQ(H_R(Y\S4^MX@Z507]87MX%B? MYG;!4VE!??*=S7]8.IO?H;-Y,:Z+5LJ! M/@M;\53B7O\+Y"+!.K -OPJ6'FELH17'91!S(RHG 4"GPB[!!YG]GZKVAKIB M_UM(R&_#VMVJV,4[#PIJ(#>MU7!N6EHME.O8UY*&6)RH99\_D2;_+\2BXSZ0>L&S49:,^D>G26K?BDMV+J;K(\XA^_[)F[BM'*FDQ/P%#6KV#8-X_+@K=X"*<4 MJ-M9_S >6OOR+J/BVH3K,JUB!U+B/=-G5!"_?J>VH$72[N&2=J;&9>TE4PQN MDD>HFTW;2=W0&F]\7TS^< [L*VZT^!12/O M<;!+CBG7=7M#R-9P]8%Q\F'&@EGL2(B5\!-B"% :4]X.*(4&[W6KO./]6VMY MZB,M]+QLBH-);O9E?5 !>G#EC!6"+*VURVGG?X3R2;@!4]]&6L(X"F>EF) 0 M=72@T+ 14O50(^R94(R8V"&7JV]Y(PD3>ZY*EX[?&M/6KJU+:B=NF*0[6E.U MD6*)M6@9RI4XRH?I[*E7JNJP902[0U\+$P):QKJ1\$1XB0YM[,T 9AP]?$4N?F-V=&_*8>OA_F[/KN4@(@X MQ:Y1!O8.:Q+Y%O%M57U,M2#QP4.Y33[MI U94UJ$D]KNN&OW==LK#E( >[X% MIW""E305DBFA_U^SG$=T/7R?*,.&D52A,LB:Q3:,N!][DPR[U)N+%>E<'%., M!AR8765J0WFCZ5OICE$9KM39("LGO+9F[K:L['%CGWCR: MFDVB0,[4$0O6Y>KUM(3;]+NN]GW%@F#HUCO=T*F^)_52E0U%X]S/-76]A=\_ M_R*<[LWQ.GR;RL)L-]:5 M2)F%^Z [*,R^-/24_2IA"J#/7ZY>B;'E+>6?.KYBI6DG31@"U/3:8H@OD>'N M*BJ=T?O9L:$.:W8(_]FG$YX)JLW(Y=TWU^*"Z-L6=OK3ZA1FI ]_0;,GW8^= MY1;2[(WDQKE=F5N2HF2%DZ\7?1Z^!RVNVVI[N?J&N* M9%J/^8X1>;"FO;-G!EIZPV!)F9TXB3LG^,:LW'?AOZKU-35==..]FD')Y\K> M-+^AU>;\<#>TH,+F2*O8Z%46']@V373N+?UGCSS ?_0^9)EXD?#$I;U%! N; MG'E"^3O+.W9'[X(="U= D\R^[5F.)EY776S^,>9Y)T2HTASDS$C/(,QN.@F+)GFAV2:HPH*W*8=X%_(K-VK0)\G^8R'P* G]MH$E8(SE<@@ MH&AW4+#_)H$> SVW!RB.2X5B,,5_],F3>8'J)4?R:%G".,'6J<_Q,A)_>-F% M;O3QL9;8K$(/N*D0W6>YR,Y0KX5;>O,BXI&-V@,0SV2>/0T((%WAFE>1&(@S MA)).IGS&(A;V<4+J/U\@];^X6-AOS" >ZAY)N&!F0#W#'MND7;I<_34!7;*) M"I8F+90GI$8S&!K$2.)]2;L<6<=@EFM2("+200G)4*HG@WA5-56']!1$'8&) MF3YN"VA"$B@.K(VWG">"9U?>DM-7DYKDVXII'Q@IFK!*Q)2S0_($!R+R;$5G M&'U\!$F0DSK*,W+X8_#3\.1]VS35WHAYPSSS.X,#2N$;#AL5L4Y(-+LJ^AI( MFFU6% L$OU]T\^>FW-4Y_D]W"U0VG1H4P\-O2478D5G\O5WQM)(1^9:&U$BUTWX2E* X0+X84E M9B3[LI\P>>-%]C#V/N=,:DM\[=H:^2VY1 &=YQG.W?O5][% MNFYS$:5)6$I="8>B\?UM:%\)*5Y;9'U)=,85D\N)%TN)A9.>H^>%_"0@F$IA M6$[4D_S%!%*.(I@)6J;CD(3 4)X]O&+UD)F"\D0\$ZQS%R]Z<. * M35L-CG9FXI[G9E"TI+,4:\%I-LP^NL5JQJ"$#=\=E0H0J^VZO1,8RF8?SERU M)N&[&_I]1;DZX(!:T!)CE7"I,1BEPXT:'+M)U?S4GGAFTEJ/EW3=T9YC#TMF MNG3SZ'+6YYZ\6-TYOX(3@=ZY69_D<=MN2PS+J,O1Z1DS%CFWP40"@XVMQ;VC MA>;H/BY7+_=@ZN'38XY+,U<=9Z..H\G- ;R^#N35+6I5V4"R76Z,1V >2T6R48'G;L]F'/;4\,61"3S-53VG?> MY!18QU; +-W&,?Q07>VW '(D8 "? YXAP16,,I^%0+[:.DXU6Z:^''>2')SB MA J)=%\DI9?"%VJR(DI:PH&70TY.U#N(Z(LIJN%O 2$L]SVU3?<]RR_0U\Z[ M!2/T!-X7<5\?X^^ET*42!_2Q'-SZ(=R<(K=A'.R.7L?H7IDQS "U(X3-L7Q; M>>P.G?:T^C)8BE3KJ(Q]'_+F?CS)O9AI?,Y8!5%A4@#U8>1:M MN;A/B<"M/-K0U&0'U=.&$V5U0P-D1._ ]^U5R@P>_!AFM#RWF8K)!Y:JMA@R M\^U= T+$ER22+!';HORVV1?XP$"0P9@_J?S3JT_BV,PUW:)B3=#/<3@D!LA M^AE^9PJY\@3#*EL:G#\8]VZ4&@4I_RA-JP>LRPIPM")8>/:FC P?B%!U.9VS MSN5I91&7B>LKGP[P<*BPH+P5Y.289C>K1:C,Y:WV*(DV3A3,Y'8*VM6ASL+")<;9-)2^&[.M] MF9\BOOR26XCPVOLD3>J@NYX*QB$ #N'2A[KG)>9 =UL.'N/]QC'17/(WR?2N MN_@*RHVS(;XPS :LVKMNHEG2!F^^]O7O_XO>#V)^PXT@3!Q@+C10? !=G;@H\U MW [I;GR;SJQ@&RZ8*T]^F90"?LPW-$Q16F'#=*# QF43&)AQ,<*J&%-3-S,= M$>*HY]>-1B3)H.0D^7J@S1L>7]H0OJ>-4JV>??WZ^T^*.*2T[26\%_J4.A&] M%!!79O##IT\U+AW& M_%.B+&,YY0AYE108D"#)\I*K&CCTOIA%V7@G Z,/!%'[[2$YOEB0'.^+Y%C. MKK&6W/WE@1S2_ELL#UP\A?+ 4A/X3=0$IL_31U0#(HY8$$OG8[V(0XJQ78I( M*D2&S*-9@$OFF_T;6MFP[F2@6N2EI3&Y3[RRE"QF2_$2R@+>UX6A0ZA@6^-F M+B'X@'*'EFL%3;W+(B"T2^4O+):);;LQQQ)C^'UT^6%6W$Z8'3B<]PFC4<^ M>JU5!:W&;458-"DHV2QON^$J)B<3GGC3Q1M+)/LW0M[>(;Z/^';]P]N"LEE M+!"VZD"=BJ^D=N"!Q1,(POEP&=4"9'$K$FX:PYDSE%@=3KJR,QR9=1PU[UX! M6SHE'L;)(SB6NKDU["11)0TUH_K"FSXBF=-I+.SH-#*,XZ\AN*9RXB#RB)X]AU+- MY4!D)F',6^[ZFG;;J(%^"N-CBX:;SN^#_S[L?'Q +I0K7.=J:A%.-6JC2Z?X M!A#AC?J%7@&9F0M6IE/OKS\T>\V3,EV M=0B@]T[Q]9_+W@NC8*LX?=(R5B& MIHC=K4VVJ?U0;KY]JUA>IRPKEY!7/,9>I7F&N_@>!>GIV'[,\^,2=')!W,4N MX^W*^?)%^ V5'N$:C(&;TW4(9C OF]%3Z:.X H7X0^ZNG/X3SIYP6#)V<_5G M;'H^_LN8&HR),+-\83%SF\[6M^0>JLI8BGJ*#JA)*0QX@,ZT[)9#E=78PKW? MTC>:-GAH9&7;-0@ &*P.5Q[!@>[(\-9BCMG:Q*M^T]4WG*!.GJ.9>'!^4SX! MK@_D6)C)J25/11+R@H),.LQ3=BWZ\W6%/D^I:WGGP:"[G")%N+5%P:'N]U6) MJ:#)XN>4M+N[&:< V^&( V[7[O=<8N(6!GLDH0#S+W\\ 7F/ LC M$;_1U",%R)COP?BVJ-@N!-I')2R)J%L"=+A'BDT8]%6?(T]4H6D:;^B-%[%6 MR[.P01%U\+7/F+60K=J47=?>L:"8G[4/_Z3:E' E^R*S3SH@N2M7N),K%?D8 MLR'$9_.$)+@XG8[QP-B%3=:SR+T$VSMRQ+MUVW$T,UY^_.'/?H_JPZO+%>78 M/O_RQ>?/GU6?/'O^"1T75JK3W2&9@6F =4DR#G!^)1;>3 MLG5GC?D927I!,^\#@9;W/)B*I8NS&R%GL:VR\Q?O]U"^51>!0!6P%A)?M/%^ M7EF2#])8+=@PU&9C8^(=34$U!;D!0:3" ]ZE6IW8P_P$^R+OVXB&"1<<0 M2RH((_ML1!LI\?8E[8=PU82E[4@JY1QCP-ODBV2K/J)1X>CR *?@3,#GSB==54NQKS2NQHB-VQ%;@&KC' %-GV MDM![?$+O3ZF%X\1))?&,=D?"O_&F*JU&,6.8@B3(P7))O[-]:9.9D"6+]ZA# M^+W>I!H/MFT:EJ74: @K[13&N_48R<*%MBEYM+9#I-NY=8FSO/$OHU$\FU>T M0O11R+TORBU))1!AI!BSM;D.Q(*)Q0G/'DDQK09U I@S!9VV75V3=2+ZXDB] MO:Y ?QL.F:H_NN/C!AD9[FG ,1*"[!!2,?EB;7/A -X'R?CQ44$!6%]W6GF] M?POIWND9U'J6;_=,5O>^9FZFF_YYNM?Y(6W="Y',QPD_^N,"/UJ(9#ZPFM*O M3?#P[4@_R46?,=?!2NK#5F ;'0]/CH,:;GL?S#7'EO5124SKXV"64)@BA.RV M>BN!&XPN)==A-]',(I>ES[7[80+K3=<>$F:*$'NT&ZZ<(Y8^2/^*$Z_AEY.S.I(>E(".J,$ES45Z M1HQ1>PL*Q%P/C. 13H>'(ZH)Q^=U?9-HII29+31#Y-?L>AYW8\27K _9M#F.3\>$O$\4A1'LJ[9Y143=[ MYY0Y;*Y*::#HJ^ZVWE3B?\;5P$6"FLO)1R]5WIL_3NHHK9CZHO MR;!P,AA5NOR)L *%YA*E7](^(\R[UAJ:=M_BCVBQYB$@#M''!2,,&\MT&CF^ MJ"&%XBEV,Q\_:DR[/S"IBS2?K5R7ZMG]+)&,S8421"*K=N2'2?I5Q]M/2]<9 MF"L6;^9W)_U0V=WYX9)'>KDG-K@K='0?^3 +YP_+'N461:&YMHRD A?QO),H MI!EA[V+UMFGO+J[;NTF@FO#]\TP'[^:N[=XB:>=0A8*>FI]\>$BI]41O%V1[ M&!PBQ,%4^ @75R_#RDKL8-"O@I-1;T0>(<2,724)>36^=TK*CI[C;1V69Y@' M?M_%F1=>3+QQY //O_59N73*-F2O/7WK2W'FDU@ZI:8J1!^R/]'\UO=BN&8I M(U"-Y?KBW.6R)HQ-V]VTG<00U%U;=4!@&:3EW;<4K'UF2WUYPYJ.T[0.;@9: M,BY*@>#C-%W)[JJ;X2B6,8L]Z,XK[G*_HJ+2GE4V,?0>A29N5!A\E3=1W"W4 M*V#-GEA*"$.I>SGUR-5TUAY&PQWO,)J1&<35BII[FH\+7_)RBG>SI?BSW=J\ MW9"%U,R=K\*\\UZZ9Q$%/HW_'"*<=]\ E?1\LR=FF#R,*OMY?]98I]' MM=&EIP^E?"("F#&1OG2?LT5.'!=R0J,2/[G@$L:4QG!?NNR*_"9G3X>"S47P M?4LA/IY:+<&D[2,(8/*@\Z-".0 LN:+R6 .$%:+L6$3.F/%/VD0PN96*=,AM M,I$J-9GI^62,'8,-AHIA J:*52_6PQEO;-O,C#?@1Z\//(N3Z':"@47 1:$T M+4XVC%=E2[D!.UNWB8Y:TO. @5304,@[!6;X07FL_O6+7S@0\]6#BB MMG1PJO.O87=+Y7FTOILQ\A-S..S;?(Q>QP__&=?>!=F)*$Q',RY468.^X^,J1G>WD9!HF&$;"(N>CT1BC#GO.<55EYH?/-2^=K,U[XO(I3-DR M?(Q5%GP4QI(D_?+QA@^OQ\UB/L1<@L!',A_/&[@I/T6<#Z2.M 4PS:D@X6*9 M>^T/X+]+-Z6D&J Y2J>,G!#!<5< ?>[7,%N:"BE9ON^JX9Y@A"N&ENZ%[E_X MAQ1@Z$M+<3AX$C3Y-+E)FK"HSII./*1[,CZ"!#HQ]333):KL&=750Z22LY_$ M?)0E][)M.7UP\MW-1F("%$R) I7OTQNZ][Q\;"58GWC.& )^;)&$583+^H31^R?=<18,G]?X!BROC5J%!!'4INN8$ M[!_.CL=5=T;^7&LY>(E<9&UEJK.W%)=K1/O@JQ23EY1!W+IW=N^!/G:1V9>\ MCY1\[+M-Y)?G/ 5?"/AE3WE?@1CC_A*YZM8\/L34^;<=#FCGFB]VKX^Y'?E+U,*8# MA+34D%F%>3) Y8Q(@-6UQ 182#PP>J2O#8NE,"SK: +B#+UB-$7)N\D=A#(9 M'&10]3 K)EI!+ZP5-!(^6DO+9,N6E>81TC%9)"'/66 Q$W1.64VI]Y[6!RT? M0;H-C?[@PWP_O5'L0_@BHTOV@+>5>VVT5[7D8WTE4EXOYJRAF+(%O/51@K?^ M\.D"WOK%P5N_M1A"2IO[=J,^-YJB01I,-.BX-G1,T+["9]*.H?MS>2Q- VQK M$A8F9Z,#,R42.5TX%8])VY^R]GF'B7L#RV#P]PXBQ56 8Q>L&Z>%T/0K7[0N M'Z1>7>D_"T@K;KB&I/P=HTP\\?/DV:ZBTBG.Q7F$%\(";Z3 \)F:-K:?*F<0 MXN6D[;0\9M J[R\XR2!,P<"--@]Y/%?";=__R683)GGN>:E1?'!*EC&H0'D% MTL;E%M ZO, [P=FE'<7>E9[.>"Z%@_?@CIT'WZ3UVBIWT>:P_%K2M-:$NDG> MYCU-%-2XR8.9)EB13/VZ_?H#I&U MV55D^2LN<+C.8O+"W:(-UNIF4*V!LJN5O8\BOGW-.HM$8^OEL:2,9M)Z/7=N M[HAA'W%71+[0PZ%;Q9Y*LO(H$O>"3\(Y1*1'JSOT4>JO&E%V,3H28TB:0*M) M4RF6P8$ZZ;J4[*)(GLFGC4:% 7^G>X5"T.V2MN-H0[6?M+ $$NL0ZGK.\$:BPRFYJ\B%'ZV$@E!DI856P8(WI'>A*)SRA2M#J:2]SY5 GV M6E?OF/>_WX3EJW9/, C:'CE3YG&DO6E17Z$46M#/\"DWY8D^-M&<+,@<\F)N MR_V ./I\IY-FOHQ\,3'BF!-S)D"F=/ZZHI))*O82!C^&JOU)P1_<"C-#NM0. M'J^'SE@=%0#%PJ!Z$FOIS94;<8CD1U* :*F!2(#V>Z% MPT1-()_FD%*%9G*Y[+YLP/?&FJ (2W8<:4ZNVX3E=(H(R+Q0I[S$FM2CFHH1 MNZ?."34!5S<* LQD3"6PZ1)V5YIA1=+ 6V]FO)ICHA,F1AL07CHVZKO(V M*D"$I\*)2^69@A^DOJT\\\0-+5GR;"<8ZZAKN>9U:G;.>1'JT#W"@YBT+1_0M"RIA'M2"2*9P=T%9B2LDI-5C"=3//)* M)T(.H0FTJT4"'2K*+-F$1QT-\L:43H-Q0V!7"R9C.W112VA4F^+!AJKI912$7?;0BT'C9F]?--W;F>#2,;%3@&)4E??"H<-:@PK(@5 M>%=WP>!$7F_*UA)E-5CN_XSZ/BQDLB@BH9) ^/RA1'A'EL4A2Q ,% E3,@,F M"]OL0@1Z-ZVJ)CZ7K&8[8KR,(>(G/&RE5#M4O[QNNR, \/1@[,!-J$4*Y:<2 MO7M.GD3A[DR$CG9@UEEHS/@Q]C48_7H9X5;(1.4Z_E0-)M.EANM(DKFN M6T=MAY=''#V1UB[F!PI/8VC]U7;@2<<;(708I^_$J*3\YC& MYT[+TD[@1YF_L+)1O:D3NE5J?X=W$.OPS$8,2!^UJ)5=" 2["R*VTL"'=!'\ M= 9S2D7X\'C/7O_X]2?Q:=VVQ0-;J$1,59*Q&+]4IXL!QC@, @EN5;'*DK/EW<0/:?H7L,;V5RHW$;IHDHZ2V)3RDO"1,*I$: M;C4:#7.QVK850YCYCDIT2-6F>+&C2@7RNE+2.XQ-!37\9W4C48X/#TH6Z*^4 MK.2(FJUF&2)$8B0(PT#:2U.87K:P)Q'.X%^'S4[&/,+0W@Z:OBDRVLEZD<'DV+D8$U;A75B7)6<+2#$2&9"I)>">.X@NBC MFW8]*6ZNRUYT#?+C0O!&A8BWDB&C#![O- @ZA!DGOX+<5+DQ?_0&/)48AS\: M,]G-F#8 =D@OT8?/][N3OY%G<-9\8]H;(C-,RP?/0H1Y#B+O-[YF)?__]KZU MN6TC2_O[^RM0LY,INPJ2=?,E]NY6.;*3]:P3NZS,S/O-!1)-$3$(:'"1Q/SZ M[7/K/@V"$B7+,17W5NTDL4FPT7WZW,_SJ+UKJ2.%X7F$7R[5\LE;YTB3/=)= MIW%R798%D#$H(Z&MF33T>M4REM! 6$;N&>)+Z5DT@]2&1V-6YDAMND# (B>R M#37LYC,7;.V8UQ>4[5]IO1ZVNB/Q'A8'IJX'7#Y"D8=Q_VTM589YG:ROJ.&J M\)O ZI&VF[P*+P439@%%Z%+9'*S^]@H&G"U&*DPI2\5]$MG5;MDALQ\[9+Y\ MA\PW'D^_46T7A%R,V5GLPH JHT]>2U1,$!$= N&C1J[6=%E.^@+XI#,,DJ;U M:34RDM)*R@KKP:)>7 ^@N%J#J=Z[&[+XQF)Q!-TCI \%:!CRH^BS%W 0X7U MWCQF&$N3:=%,^\4YS?@1+KR-@^R_2Z2&?\9T#-1T[?)X.;?U:+C&BFL6!'3M M&DQ#J=+IG0!XNS572;%'.O')2L30=W#Y+7\T]3X%]K:"2[TBQ!"+N4JS=*IB M-3)@D=TZ@$)JC?^<_ M/6A9EO@)%TU3&P0G0U"3&?C*/)*&(#BC[Y(.ZF)J*&/E19 OUSAH3W\,P5YF M]*HRB3*% +[DD\*Y X7*GKSS%+P@!?C9R]+B;-K BSA[=7:?QVKHW3Q:3#-&VAON=L:7^&*RXL"-UJ& MQ>HZ],N$D#MTG>7I@T*&Y().>X@88:EXQQ$NY^IUB("W6 *1Z04WV:!^AT8 M% ?&V%/IH3Q?RXOE7_G-U&?0X?)[@#U14-4+,C)PJ'!I3NLZQR!F",!W]:M$ M^WDK^QG"DN"EDF$DJ#'5CAO4^$-898(=RQ?AN"S>%DZ&B"K_\=7+E&M;&!-C MQ?5BJI(-@DU&.T%OE+_"MLJ')2X8@Y@GC>AJL%]>813SFEZ>PRU! 7 ME+ZHE*]2V6X'Y(U9@_A6:DB08)^/)""\#9U1-_2,6JMI\P),1A);4'.\*\D# MJM:HT:0LQYN!=A182^HR?@TWQS)\)0>6K)G? MB&,RP<+RC)*?ON]+088B'2Y/1R&N#F:-9Y@D[ LN% ME_!IXL-161EOQR#[E3(DM"]WO .R'&V#78 MIU"6E5J'P#;0W-0:/V>8G->E-T96S0&KEV).&&&/%X!AL@ M4\9NQO4\8X %YZ>JQ^"$V=6/5?<]\@5]:;Z@F"4)K/R'HK4G\L&41 1,QW3B MR6!^IOL(U_6=[D2!Z/J8H$9/ %[_V\;?OIO\U,N*$%S(NF%[,NW^C.$_-2U. MT-]$3 '@J7MNI06DW:WQ]D@22%8#A#DULJG!OS=,O'-GN%/W]_;RX'>P?[8L1@'G]B;,Q>U?*%*XZ;"\@;R(7]%_CH M+UF;9_].?BKKB5W1B8'^,+G-H*'QIZ4UA8JNUT@?4S2-R1U/MLD#KEH>(T0I MD?4.YD:BFM!$.A)'">94UE'?.='#VP]39-!!0TVT"G>AFW[59%TKA^H<,C5$ M=5Y#3@B=P(;-"_M"SM9@:Z?K(8PZZ#,RW70.=$)\F_@ .*@5HX$WTRHD;@]S MD OJSDZ*>HC^L0;_.A6@&;BU69,R5LDE.']0](?._PYB;2T->&E!!=4SP.]! M112(!<8T)!90;R8<-,+*FJE?\\L(NJ,XTFO53Z:H2T92>Y^M6W!K>>OH:VMM M-14 RI[VQ<8>5;\P#31\S&1^6F#/R8AGV.JVK%V1'N>G58[A^>"^Y,6Y""?+ M,\@MW)BCI]^]@#&],EL^GY7F\GJG"_JM;. -X!P08N&WK$ZPF_\"K\2.E>1% M^QQ2J_#5T0MD0Y*=BR+OYO:_#X_V#I[Z_WM65-MZOTZ6"ZLRW785%6[-I+3G MN-$7K]BY:S8$BKV7L[W)4U?N52<:KF=;-FL$E@ 9T,OAM<64S+][N/]<)?(U M;?N6_+]1BJ,4;X<4>\]D8(+$7@[DF])'DAMSEBD*>13R+=FL52%',>ZQ: K. M^9D-7UTM6,V0NBH&UN\F6?7)9[XY.42$P2^2*.U1VK=CLU:E7>;6L.\909JI M(VC8:NJ*F4*!.@K7H)A&N:8257T4_BW9K%7AETE/-[S9R$0+!/"J>;KM^CSZ M+5&8MUF8%?)1,-:W9G8ORG*4Y2W9K%59[BN TID69YC\;*%HWK=)F\T,H;=, M38,84$%R5/7:;2[N<11EPU&4@SB*3:)^$GK-K1M2Y3Y+TOH. M&LF.T"]3'1[9^&!Z,VV9+-&HLA*< 'XHJFY;4(0:5W]:VZ M71L>7_<==<0P@#/U ONG.&0+;+6E/Y^^:,RL;PD% T9=Z(_S%TEI"$"TPQWN_)9LUECIUE\L*,)* Z+O9CD]Y:.X7[IN/4AZE?$LV MZTHG$A%,5WA(4-<@P42^9 M()MT98W+(ZHH/\Q^]+3)HMQ'N=]BN1]$\-05 M..YZZ^Y'28^2OB6;-1:2DY Z5O!L^N^^: 4''.=/S6DQA6YEY!M&S1Z,[?I) M_LD20".A WP9NQOB);@WEZ QTZ8O.DDDY4!Q+Y[[)[.$S%);5Y4IHQ1'*=Z2 MS1IWUHU]]WI!_$\P=) %;5+G=M&89!3L*]I9LUHA@\SPI3E'! M! B[%V=-44'G0TFE+ROMN8F>1A3E;19E2 QBJ]E,(=XEL[+.NBBX47"W9+-6 M!1=XB6AX%Z)%Q+0G%)Y'B)P(X'DTG3M6RHF2'25[2S9K7"77U6DM0TF;6S_WUB7R$W"\B'0#,"M_, 0CFR%B'4%@ 9P#4+L@;K9N@#.!N5X>J%?- MAO8/$41B4M3K,#MV";!+/>:Z;] *9>$D6L B5P'LH$?N0+C6%B$E&VQPZLRU M:!Z$K:S6IE&.>(4$EZD1CF3<^MHU,YN.5>YS>_;ETF&B#.F61VV$(^HZRX"0 M0P>IO"4(;:RV?UIF;JH,8O3@;/848:;3X<_*5<"V?4%X=0=BOP]M_Z[VBAO=G%H#]'O&+;YY M/>WQ[P6KVC$J@=%=&'N8]E?;K*2N8NNY\4>%'N(WM'X"-6M-8]62?6$N:4)Y M!XZBCBTP ,/"R?=5"V3$!/#GJ\(,^@Q=#SC'/D/^OS'4*O1.!#EK OSBYX8A M9 DT:V(0/%L83>P#JU#A\#Y'@W!']#6$' E'H$T[2 _*'X.8C2#TI2L.Y!4X M?CF.@YNHTF^GTC>!2N0M9G+'J\YT]20] IYUO^AS7%!1BFG5D*#UT$8BU(20 M!I3% .H=&YJJ7TP(7'R]<"EZ2- CJ,P&L((RV\$A#ZT:S4<]M1XMDF0(I\:( MY2.>$&?O9GJKP "UISF.,"YWX! M!?_"KENK[#7/2;7')BRF]E6(49X1\\&PVI"MYGGB)IF;_-1HAH P\+IRXT;W MRDM-\"3FQW7TF_O/]I(+36LK-42*1N:>Z!C BCL+[BM*\ M8[=2_:T-1Z$S,L#.5-"97#@(H(Q'\#%Y8Z[0)J&&' G4G;<4:$ROJ=2BAG(W MNLC(V7B[0?G#."@?.1N_L-/[(U5SR&% !A$>PAS7'0'CQ%G?3)%A./2?_-"G M_0 \K!,L:LZGV@] *@P:QLNL0N84T$BLA(I*CW#F1=E+UHQA(5WDK?D2AB$1 MYWGAN<@IKI(T##]<)S- &(Y.^*V4DR>P=JZ:)+Z Z5#J(\;Q0M8^ZXZ]226D MMW,-3Y[\6C.S$#(= U=S!JS!V>I/ 1N.E5.0L9409FVC%"V%8T2JA 7*()M0F2'4&! MP%]L>8R_UJ(9A$UJD#ZR.U19J?/KH2L-M#FBB!P5SE6/NBN.NF^M+/=^H,'! M T[>V[N; B[.R7AJS MDIJ%B,(*4H9$\>#X;A0\VS\WS3F3KSJ( 2(\"UZ)%)A]B1H@ XB)H^_$Q/8U5W@CE_Q[CIN9L2%,FL[" 7E:>X= M[+=L'#!O_W%X].+UR?OW^"\/O7Q2.*CA)I[L MV7NTMW?57I+$.)^'M0]*N6?;<+*;T"NI_Y[IL#\WD"G"LFXV [@,: .[(Z&& M=X.W_DQY%O8[+X;[=R""K\R4XNG#?>?2 1\Q%T[T[\.5WT\/@I,)LBZZ*,(_ M_8.(URLG7O!!H&KBJC'26.;]E&1<>DU1'F1O\$HNF?$7E@+B1W_GPO"5=P]S M=.SUD ZLE=@0__(5CJY03&WBN\8(Z XB(.OWY37S6W:&>)K/@/6O /RJ"GH) MJE6Q;HGGLS'VG*O6^;Y"^,32"=#>8<4FDN7>R@^QA\1<\T@.+8B.#FT,]]\> M!OB%?/?LO:T<8A+:,S^5G/JX ]6,#0ZL]\MAYDHS!HN'^EEBIT>5UH"P4&_D M$D@6YTIPY)?!I+:&D[:XNMWDI9.>0I5AF1Q^-^;4_H,8;@&TET!# M[56T%ZBQ9JSFJX@]"FUOK1;_>*UOK487AQOO[99LUAC>"L4*T&Q:UBTBK=C+=\I3+?Y^^2XTA!*J6L*ZC6-U M4;ZW6;['[1*D/ZQ!J&HK(D7%BOZ\:,%\G-<=YJS'!1X+G1.,ML?ZU"7W?@I_ MC'S*V73>=PYJE!C3=5\@?M'D<:CO#H?ZH-%L\S!:!\[0?UI?M#QT10#IZ)QP M^@LJQ-"88L\/JXG>,[''J.';P@!Y)32&+Y7<.#CX8@.9^WP88I\UQ3FD U78 MW%>8AKF 0AO DQ>-758-WU@R-P'WA6*] &(-JQS/J7:"XZ0NZ,>.!!S^6'F& M?2E'5U"@JT6G,\2Q1.3KHO,JIAK_DH/QP36EE3%KZD MK6J!6"5_DCP8JU#/K!=DE3C6!,/VY5DQPQBF@J'+%FJ94M2&$,=T*J&_IHGY M84HE[.M^U[XAE>4N^$Y2!=3^-!3L[0NW2()@*BKW6/DN#3SNK_N[>T^3B=TH MU('VM_C'L+C>G]7JN;#W.?0"YS28_] ^H/H&L]TT?7K MG^:FQ, 2C+TO@&-'N;&ZXZ]/]_:2!>T:_Z)O,/][7YGD< ]//K=;>JYVM!Z> M$]3&[7;Y7B7 M2O]F^#"EAJFOS5HK! ]F,P4!3BS9W;8S>?7PDK)H.QKH 97^2];FV;^3G\IZ M8H_HA-SRG]%TI52?&\B.A_:?U7X*D"2"AND XJMOX A3YF^!_BSH\DT#[YC_ M4#="RJ.EE2$OO=)(UDZPR[+VXZK_WMN? MMC[+'BW[59WG.S_:??N4_ N&#$^Z!@CA/D (LL"E'$//IW4LD_>-O5O4P@7> MR8/!U^V?/4PN[*N:*H, "7OI9.XSP%Z04>]3*.E4>.NH!60TLR#@*YA\;@4: M=O7'Z?AX#V0W,4*#0%5GK.DLX">9]D<]M,4%9RT%H?:?X@"VX)9"ZD(5FBM< MU>42_<+6[N\' ]8?Y*]HZ;G@K"P0;\M>)!RENS+\MJ?D _#:BP@AV*@00I\T M%,8RB1ADX,ZNK3\CRBZ[H^ W<0V;7:KI]8.:&&+X4KG&[!F+;:PNAJA4O_RD M[Z0?X[3/L%%ST#'$K1I:B?N7'GG9MJXK[+#,X.GYJ6%<'IEFX,O3F,F2[Z_U M52_/*&27F\X 09*D0M#6=D$7@IN<$@\G:*KSHJDK7)'<3?D4@.YX_A$2:#), MX 2>,]Z,$C5(I35TN2!&M+Y]/L2Q@4W4@HD-4*-Y:!=UJ"?I60UOU=CYI>NV%WHO1-)S=:G1O<(N'^P'86!?R)U0 M(&/7MH/=\ OO0[0=Q-:CF!SCJ\+G%QT],B_ D($GA#\-?T3R"O<7K!XEWSC+ M.FH"[0LXC$LVAM+Q EHXN&1D88?P2<@("LB9&<-OBZ"CC+>.7W *6VX/.C:[ MW1'NA3TBH',)]A\R.H@]!1) 9%S4M^]T ?=&R"#3AAT3U+ZOP&R(-8:D&N\T M)A1[U 1CI=N$\,I\#7N%I1+%FQJH)X14"8+G'6I]+E]QXY/HX-^1@Y^*DE'I MKK$$UYB;3&DQ+S?\T=#_E>@ /SRJ3>47P(?&=N(\+.#JY:1!*F]=1ZCH84IF M7NHX I> #A)Y%^35T)NLO/5: X#F4/M5JW8JB%ZNMEGI%0;+69=TK>VBBV\= MJ:D9H*@T: V8>5IL>2K\@/Q6#+>WZ_I3@,K6_DJ!>J8P*E*7:&=%%KCGT0#L M5 W^*;H/UK5$+EMQ')V"]*%$[1I@"+L/QK@ZL[E*'#I9@6*UZG%JJ'AMMQ2=&?H1V MM7>Q$;V9CVDA6^W;\B RPM2)W4%[2U):#("JPGC/PBHGG"&D]X$',4:+(A%S M.(\ 5F)%A;IMX<%>U&'1@K^XZ5L@VSBM70U3Z;0XS#E:Z[3H*2[D_,VB!R8_ M-0CFD05]8!G>'X'A<:>*L[+AT5K3!87HF[4D8J -.]LHZ4B=W*;BB..3L2PC M9A[][34=D$-A3&]J]24CCVXE'COQ58_/YN['>>#MS_$[YZ8&L@!:&:-+]H@),4HRQ MJ]0\#@TU^;%O"%SPPF2?X(^,^]!G>ZO2#(FX?_8S0V #&N117(CR7MDFGV:AWUG9 MJ<*;"X9([QDEW_DH%R1#3*'@=ZA]DK\F!$_-W[A@:9.SL(7EF;93 = M_@BN]TAN>)?429% >ER'#IH.,-%2S6!Z;NK>P;D _HG>C5%&7=)1%_@C9?$) MQ(!0JJT:.L6,#9^"% ("(.RQ>O4@TU[,),[H*XU@*H8*;]1JVC EMW$IZ4;Y M*K=.;%R<<)Y"F 33YX\N>(:N#^Q3,-=P!U+H?2+O:I%SY:[S"2?IC_:.UD== MN\FZ($YD4[\4-7[C%!9?3G5]N3F<=^\SWP_.WLH>_"M>"\9XJ[U:\#_W(V11 M]_=V_G?WSM(*MS/ R5WE$;XUSX427YQ4%B&SCF-!@[H#^4 [*DC LR;K\W1U M5'C< +M4%!AJ\'R'>#:;J[Y@WH%'3N7I&D+_WYGI;X,JBQ'5*00L-7VEMO?+IFUX?I"G8@5Y#!,H\6 MNZE9^-HW/C8?W:[YZ'%L/HK-1W\,HJ**797C.M8HC68%,J93!DUCM<1*#VOI MOHHL7:8!S\U:RA!G04959 0CN94:N?$)KQQJNMF)CIRC_R6A=Z!&_+'337Z\ M>EEC5(227\;";+EDCQ\:_>T&"!S?<#JBPBX@1$%!M_C36>15KTR^P3FM.?+,#EK%O]ABJH9,8#'ICR,%3I$.# M*5\#!$?!V4N?5]'RE[G-1Z=[?+ODJ0VG&N>++8JJ@*H,!=32OH9_1_1' J2C MHC3,V>-'' T2M@-YY]E7C&3Q5%OR?[%K8TM&[>(8LRLZR&!(4]//[O?\[/ K MXFN3K7UI/=%E6^#>^MMQ'&S_![_][]SVTQ./7G"/E9I^?A^(=VQ)N L;>NSO M:)==)F5VT9*:\\7+$/7$:/MG!:@G\%-,35N7?2$HL"O1Q361!0(ZSPII W((-E_6=0Y%3V) M\VA,_E<;P9)?[4J@A"D;@5V=07,L7SL>%OK'[LFN6SZ\&F$:]D6.FMGU<[Z1 M$/\#>S(GU.:L\K3P%)50(+,$)7HUFR3+0]Q@.H">#95@:67X!==L(=]PNV7M MH\E*VA>W1QX23C6'CFS/\U'U5?E=U_X8_/4P08WW8,4!#PC@C$WT! MZHJ1K:5CNB6/2^J=V)8YV LN$UFG"V8_^=QF)D=SC$>C7^E8U\L ?.B5HHK8(LC[[2*,Z]EO[8Z%KT4 M>PF:4ZEOTS>"OAA>I+L<_$K1\-^%X?\',J67;I(0._/MW:@76"=P-6!GRUM# M=TD,.;+.8#!AVE5SOL[C5N"JT73?OBGO&KY7;NV\FA.$$TT%+0K#,>O#=@26@=A&[C%P M2YC3EN9,MRZJD>,W4(W0\$D M8] *(K&B\YLP5#2G2P\K%7I9U#N&K@@$Q>YW\OJB GC4U),*NV?JH0CL!J8: M+&S9&;S6E)0(;6*H4?SRD4]!CU,P2X(Z<=D.OWD&C3R\"I5:T3A#\QI,G^/L M<.WH%GA;H8EDT 3)?9VN[9'_OL0^,>N:^$H+4C8,?\<_&+LRN'&:!RK0Z;(N M3W9NUXN59@-]<&NJ*Z/Q#P\%RR-OM+C9! V36=)6$ MA2##]M:<4Y?>F SJ.(&F'\(P0?6S9YV;7_ CI:SJC;I2VIGIO++KLEI(VH9AD#/KLI32<\+0UV._;Y/O@'@LD^,/[Q2+ M"E8P,T*5)ZTC=!3$:XN-5<#)U\,(FR.' UT/>A0^5@)01 W-U=DG'EVC57C! M#*R4%CO=B*6(5.33LGX:I\#)M[P 4(16LF'A=6OJTR9;H%<,#64+H-II8>"' MVZ]TMVRI6UM]1.SKX3V/]]$H(E9S&QY@"UITSFI,_V'KDK781-A(6L*/#\F& M7Q3MJKG -C7=_A?'I#\'V9C]$+NKX "YCC=$)KGZ!H$/,VLR:R1ZU*[D8EEA M1CD9F>1#W0[VEO([Z-C04$+7$[*+\G.1G6A1=,XIZ8;-$ ^\ M0P=SGZ#1%6HZ: 5\:$\L&@DX[J*7U'N?\< M$*)"PFR?M\+D@M5N1'$K,:Z&0;C !AB<-BX98N^C8 MJ'2KN_K*M&=%1[6/83_PS-N9A;W(U)I/U"5,"P 4)PYFPER*K"G*$^R=Q\E7 M9O1<<\=DRFBIA@GJ&]A<^MFAK4VTL?5V4,M9%K(_H>;2IN2\+R'JX+Y*;., MU\V;[CQ;H+GEM8K)1)LE3J/^FU;FB^R;EK.^8EZT*K.:CJQN!@W!D RSWZD; M'."^8-*:#IHVW4R(XY@ ]=.@KN!.JM:1SN%%9KYZ&_HW3CN(WH^YXY%/SH5[Q MRAB;J?B'Y_9&X5?;^FP.Z7$:F:EPDW8H'9IR6)'A1;)+J!M$F$,6 ^:7HQ=M M7;3V/7UY;N^OC&3;"J[=B-,\/6L QUB%=$I4I2=G97+ MG>D<2U:D0Y1A(Y0^2!10^D"T#74>NQ#(!F0]= K)<&+*3A;\$[,K&$V:E")9 M-&_H?=?!5(38WB&[*I7/<0+)!Y C,:OU""D1!>3U@"2$?J)AXE(*9V=Z#5U- M/H&LA:?SV:CBXA!>U_K=R*2DH$4&G@>&E]X_#T<]C"_-]!IZ@H=&>W*/P%33 MLL3C\>E0'PK+#*=I0,NKXMAX..W+C9C8,IMA 4:W=I34BYKO,6=MDF7=CM: ISIC#MSUC[9KQY_P+TJ9>/1\15D;RT4XV!_') RN@S, MG,/\ 3;N.. 10@_-7/?& @&0=74XD)K9C8*>,:VZ^J:R:2GH?:\@"3F;'.V^ M4@2[8@MZL0!:CZ;2<\B2ST?N@O1THS0*>.[8:]>83F5!;YE*2=?G4M:E.=W5 M206,PE^R%3V/,[!CG2^^LG3N#!_ 5:$\;+ZGHTL/R.Y'_E[-@*(8AK>!YW5P M;X,@;##3*V_I"@_IH,"B>SVE.82%!@,IC(CM#EA5BP*-#\.F.L9)P/8-^P=8 MN3H'%M9.4:WV#,PD7"[3NFEXZD<(PYUW@SG;\(O>.%/3A_OAE78^UO8"$G>> M33-K?6Q6]ZXXP-VV*R!B8!LRF$, M="O6E!YS]8*^(A5X8E_Q56%.K1T_MF]OU6!59*(#]00%!&RZ+X8Z7;1\L4+$ M7.0;08M:E;]TG?2I_"?[8'8',O!5F/.6?=K62ONR9DF525#V3J!M@P6NIU1T M63(WF-+?."7J7==@#ZD-.]Q"UZ"&=9-B[POW9TZA RLXE^TS[%!1D6J#Z_A8531X$]W;X!W!*S@>"JI. M$[UX%?)MME%JT1".]OS,T#%M.8,S;,X)!"#Z#'=(-*TF]T4U87^Q=L_A\N^ MZTUQ:$I_L*@KL[0W"5UK3$:"4]LX**;40P'H)A.*[<8\<51@X*3.$(F/[7_0 M5@LZ\+RHRQLXC]$E&+H$7^M\DP?<7F'#-X@D?\5/OK6??(A!_+R8%-TX J)G M<.)\41'$K39@PK 1ZKB"@@].2VL\C"05$X/*8E!S'.G/(T^4HW3< >I6(BA9 M!@M//3LHI.-ACI.Q9M%^F0+KI:YQ#Q-_/IKF77?@6F?X^TN'-IM52]R#Q)14 MNZ91 \J*,S7WM#@KC.(4%C3SQJ'WMPB9O)O\TUT=>)3??[QU*GC5Z,@-M"9# MY1@;BC$E:%\)G _[IUQRM2LO6FJ*#9-P) RPC,*>"GPV-Q- (L$/PGB(\4A! M4.NE; 'EX_%L2% !\R0!-,U3CKI7$C#Z +7*\%QFM.GZ ,@CD9HT.0<8VV:, M(.)$; !R#O(&X[KP,/_'GD[(VL0:^B;0H/7$$57XMA=:9=V<6I'^7>D^K,4S MK"J802 (HLL:C*CZ_"+D$YWK)WBLM>NC"8/!F?)506B-,[UMU^=N<0.#+-D< MC\#MFX$9XM_>..N^5>C/ IRB@RUSV6%5@5I)I'JU#R@U!@&T,O&'*?IP5X33 M@"5G5/RN2,;88[2*2J@;U3< G@U#:;&C;#<-;VSI4&=^-U1P.A<"ID]5?5&: MG%HFR4?R@\'1%;ES&/!@?-QWVT,2UH9>)9-OM=G,=,M1.Y-J:"+$>%1.#JDQ MA =D_<6U&)^KW[@:P]-?5B:F"O,KMH=^;FW.3_&%&@Q%0M)9[1S#)QB+H[B; M-%CHTE8P&@->Y"T%294DL'F,E#W\=YE-(*4"2>D!*"&L>V[_I40O #/ZT$UJ M%9(U>= ]Y"J_0)I;MPC(:[_Q>];DL%21-GK:!81U5D>^9KLXZ*LL*NC(HD(2 M0Y?Z)Z'I++/%@J=0^+GZM:9S&(^2'YL44$!"[8];D>5%G5&ZW7U[[5+0>DEA MRR\"7T J;J3L>5"G]!V= @4YM%=8'U.[1%FB\1WR-5U3HL_";8LXOL$>189_ M+FBFU6\]C+3P,'$;O.2_%+K9T"HQR#=@IX)KQPE[]KXH>K[B]_PWW1CS\.1B MN]?];/=Z&MN]OGB[US=F#;VN(YC[T3K/M8911A6=KA4(]*6J]I&^(R)4P706 M;@.)3G3K4TAN1K2&V*XJJ/D<*<)OKT:1SO^*/4RWG'NV'DS=G\X#9HB+NH$^ M9S=W%3#*>7(D=+,A>NS)SGJL>I?A9QPK.NI<6#JL!>,H-.C?WL2H:0>$X9]D M.5(0='"[@L@N=$N$N]5VOA3NY+9@\>2 SNV$?SJ\8.#_A0-?77U93.W_0F:+ MBM<8 4B=M&T-PI_)"GH9NZZX.\S#]9*7Q_T;SF?Q3E6J-@."\5'W*MZ&VR'J MZCZP0'97N;X*15*AHTV9Y?5X(+<*&V168/5QHUE17"D218G2I7(B1@B^$!+, M9NM5D^NZ]M&HML=S>ZB,TS 2YMJ19'9C@N,N$AROC#V>C 2 C%_ Z8GEL052 MDTA1OB,*$: &Q[8I5*4 4$65?)GL&?W69(G"0*::8=F!=!.Y @TV0F'RFMN< M+RD, Q@_39;$7)*YL?O22@ER X#BF/6X=9\&HG1Q;=V)S/#(L=0.]1FH;:,- M7X6(BIAPW1(;[4C:V&F%_. M%<%[C&Z9/EPAH+MUU%A5LS*:T,;?3%*W;N MF@V!\/IRMC=YZ@)L=:+A>K9ELU;U7P;.M[4S"'XWJ:V73)2?Q/;:BJMC-<(. M: 30E:>GR(N#(#,#F!348]24Y #@]'5&'XJ4 GQJ86#)>VXBX-!']<@C&>;]N>$T:,ERW8A02NQ B2B$&U M )H*;H\/ 381Y GM-91(Z&G!> (^E1IXX&OG-3&)PAO"Q2T@C]$%KH 4A\-K M/<&D O&&!Q,WB%]%JZLO*GV3[9(0OXL'%YMX;^.]W9+-&K^WYM)>&Z0^Q_MQ M]?TEBJ[,DZ)C@;LL[1^=9_9N3)< )\\X\F!.,3?(R_?=9>>+NB4Q@GJ<^.NKEP5N!,X M)]]VR9,GR<&CP^\DK\V1XUE]0>" .*XWXX8(4^T %B'P#&'VUD6UZIMX)U/Y M+S<7AAEW'KW"-%2*DT\+P_GV,,-^N^2OIC7 G),B@@\;1T7]7)$J%A5$54[T M088J"-P&#GHUX@_V+\.#:<0 2;FQ2P06G0$@.,\P(($!5QB .FEA#QN6$M5- M5#?;L5DC'GE^CAT?@#9! Z72F,L=4DB %C@6=L.DF@[]PC4WCBID&,$>'@^4 M:S;?V,+1L:F?H &'Z6(8P"YXR0*L$LA.SZ@-Y*&12 ,+*0H,@CE9W M!M G:_1"[%^Y1?_*V@IP*BSPJL==:,\/]@Y=_?>GX[?2A:)L%\B7A*Q)"5PS M@5CB?+J?H1:\U OL=]]__-T0^EY;V]"^HFQ"RP'Z\@T7@1VW>2_#[([D:##( M_G*\_ WKKV$2J.>A\Z+UKX?P%9?8K*#^$!K!<)*N.,7^PRM-- S'+[UUQ PY M "9=^QUJOL&<-:7:BD$.;#?Y'^NSG&/LP.-H2%YQUF&KYC-D+U>'H(:. MXT8X"NLS,$ZY(.ZBFRR-:6,1L@\X73-(L3@S^>9-1#22XH"GJ# +R9ANZ,6P6]O6N19G!:)E/!_ "_-S7,5W(??.MA]!O.#R,3C#"!M M-WS9F3_$.)H!PISZO$.3 M]O[5_D\BE>-?O&(>>X_<.7UJS9?2# UHE)PBJL_MPAN9,+_<"SZ,&)E*D#W>8GL&O*:G-F>H!:$'MQ M;]^+^YF7)I4TWZPO2_"*&/R:(!-8'.PI SQ$"2'+A9$"(5POJ!FJ7&&+\;L4 M#*PE+A%)JW,"RC2R>$OL1X"-=8IP7[,UU^T!7U6B @/0VME-'U$BN+@$HI3] M&%QA!$"]J28861GD>3%S&:@A!/&Z\O?7JX,K=HUNM M+=J:2=4&:L/]B&N]7=4=Y#X[U4$XI6XOB+>Y)N V=N#L7SU/'A0/"4/=(,2+ M!T0-'YA,&A@1\VAE9IZ5LQ?VZ_S]T2_1S!,EE7 D"L>8'#1+ELR*O)\6R#O8 M0[;YPC,I#FCQ:FSK7IAQ;>7F3?P@6<"@'I2U8=$W6[4:V>*I[<]<'> +(/R/ MQ.RP@KYI^XRR!? 3/O>@DC&W[1B_OA( VW)^Q:XP Q42>:<(B;],$U-1,5(R MC*ZWS_KZQ#UZZS+'1BN^:L%92Z358!=E^Q T&HY$7V]1CINK+*Q?V%\/I>@& M-5KF87OJMSVD2BQZ, M891]ULR>2*M8A6<\8-UW4MCS'L.&7H8@W*J0BQ)KSC^3""P%\:$Y^Y6F'D=" MC8049D&MZ:@E+[+BW.0N;+,*&?)W 4Q^ZT7;)9*Q7Z(OS1A*O?4\\5[L)O^: M0TM[,.BG-;0SZ3EM(;$YSFO.!:Z<&GP?F@"(SPX\@#0\/YK/A_*%_4V\?ZTQ MG]8[$?0A4H;7E@YA MCJI7M)':U#I)N0K2?]"U(LJ:]X.\=8YI"CFBD9^*X]]W!+7K!EA4X58I &PZ MDE/W.)<1X/:V3I4 T:<;[#+F'NL9]&A/ "5;7&L) S*7>?-QO/6U$3_3B#8C M8$M?<<$*L/MI5@\(16;_:;C?M01M49KSC%OC>@"K)Z?H#$!-[;[TQ/'K 7#9 M"5?0^DK/4'&'%G&.6*_"XP%0M/8#.$V-:-^(N#@UI&\TM.H(E=,JA 8F2*SY M1&13\K1\0YNR]QUS?XHF)3RA,._I^&8BP/=MM94TO,E50-F%*L15"&L<$_6O3RP%=ETVB]Z8E,2NDBB=Z9PPZM= MH2:; KA1GM*2K6.< Y_6PAXX48T1X53=#!+QT'G%6]C2/ :.XO/?^J $WM#M MYUVUCK1A!UGPF!<^6,_OS^L+N6UE";RN@JO.K$ I MO"/XPI(&P<*!.R234@9M8GUL&S2F8\YRC:)D'^O>31IOF(T;!&YANNB2?4;J MH*@@:JE"QC&ATJ99@8P!"_%@?NOSTX5 VUN'"Z.9G47V":%K*?:99=9)64KY MUW[)<; 3K#U168I;!8-%R&-/*IG9;J'1?<#=%R03D"9O. 8DK3>*[MP*G:!8 MNVN?VOB9+HU TT#EQS;#&%EC*2#[?CT )N0J19NOQ$EJ,:;]0E MLR[=2Q=B$J\ 7RC>I6G16#7"G$ID.VL]BU=,NNI>]CUU+L6OKRA J;"?& M#NM+(1%85BXA $62DQ8RA. @84\B$M7Z-+$'4IQ@M58%F*G/Y2HX$\&VLX%S MOY"4#8?YT5._??^J["NG2(2$.>A'Q00E,U3R%(+0*P2 F.)!4V)[0QDA ?!% M L_99@4-744DF9O9=:M'NL<@07LU56BT./%"E/*SD=^=(CO+\-.K\(GC.R&9 MPI667J2[A@4;/8E!>(#\RQ=S!>P+/M I$O"L_ CV+7SV!0H>2:]$JR^+3[!L MN3OCJV[-U3N&AIR=(5FL'+_]U;[E^D@#KD1N%AR[R3_4^I,36#_HG=?V%<;H-[9E]38$/-$V*D_^ M01'4>VJANJ/D^5=T4PX>/T[E__?_P)T=[&/T]V[5.ETE/Z//0B92##LI PJYQ,7Z8/E_M"M+3G;VDP<_0A+UEWHW.3P\ MW#EX?/C]XZ.'Y!I>9"T:Z@PN-]%U0>J&,Q\GKX_A0<.5@O>P?Y#N[>W!_RL$ MB17_ ,?X,L(RZSSE(DYZNQ+@7P_LCNU!.H4>-< 0+MP"\,>1,@&RP-#-!-DE M?@/^VGSWCIJM_@BK?@W.ZZ\Y V M@N$QK7N_E&J)+J6:G9XVX,.:D>]>)0=P=G\]>&IOCG72RI*[*\ A[O23Z)I2 MPW#* -&YD7%XMY7$OMDB!VCK,NA%V[I6"O=,+&VFQ'S\UX/'1[N'?@&_U/YS MBB,#,F%9D:_A]Y2>X&'[* 8BDD5\0$WB1>.;0MJ'Q%"'>3@W@;T73&!C5QT6 MM 7V"(WO("B2!1#,B?!3$D5!*&[B.J\]%7C7GZQ>!>BDDVPZ;Y._98NS%\FQ MO7]OWQZGR&OCT)_@#W-OW!8C'"="AV7^Z+_P)&O#NPDS=/J:NL-> MKP .)%QU=E"[( !&I#(C^OEYBO^+?8]*1LA:.B1,78;1=4Z?^A6B,N!%"[LEJ%S@5X+E%R2355:" MWED^E)P! 8U?C$#R(PXV?E#''7*6XF M'3;&-;VK:ZI.--I:M??MF?W#&NT@#0(4K?1-"B44E 6P"0//Y5+IZ^GZ<.> M/VKFNZ@9D=^J4QN;5U8 J0X)NSJ@!-Q\?[_>94)9X_E#[/ZABB/Q?7KR@\X3 M&MW@VH$/TDZ;8D*W CFY$(;"/@-*K,#V (7@W#&YH&NB1?Q#;X_\Z.#HP>3A M ^O<>*_E"7DM7/?"EB4;&9QU"&6>'.XI]VN>Y02W:+N[H7Q&X/!C;K 8VWX$V*./ MK:F*NOGHU?HVYP,.=Y-7O/KD'V?U-F< K/>%.ZOR &M%9 #%!OZ4EIJ=H]VG M1]]_]^(,XH7J-/A<#&K=CO]2WUFZ]XO?PJ./T/G_D>C)/JH.@6V^?4>[R<_0 M2WMB5[W-5\]Z1Z]4ST5,$=WN-M$P8S$%=_:^W*O''ZTM4_U]VWR='N\F[S#L MV>:[],;O9;Q(7]LL?7M5R/U8A?P35"&??#27"&>YU>[-D]WD]3:K8M["N]$E M]UO0*<4V$CUE?5>_F"!M,/XN\"CNO<"/[Y39LNZ[Y[/BTN0O"&-Y?P\WBK\ M7;3966N>M^8L@U8;>6?D^*%G_P5^WR[ Z2&8W:2YU>?R??Z0_53N=@)_[AG\ MF-VC1UV^YA/[N_M[!]=\YON]W6??/PL^9/^E&2Z,CY4N]^J*-DK*2,3)$K._ M5U0O+NQFD>)]3NH7_N %M%;#"!Q+ TF);*R3F8/'=C&(@)PGX8V17Z*MEM\: MD:]UXBZ"A)+U[(N+^Q]G.0>JXMD&=^8UJ0IU:>*V;>*I]9"4U;LV=@FWX^+H MWX,?6'>#MN?&C!F(NW$E-SE;";+$G&SUX4:M^"6N]RLL\F _QM@=O\*&LJ/R M1QM1^X7/O-5?R>_;G@"2KOOJ_Q[N[F^%GK^7Q_M'ENJV2&W?F[/*DGEC9E9[ M==U9^_S1HXN+B]W63'=/Z_-'+YOI',9G'YG\-&L>Y5F7/=I_MO=T_V#OT=[> MWO[^]X?[!X\/]FUD=/#X\%&^O_=L[^!);BX/]W?GW>+6%_UQ^OWWJ7WX360% M7RV'06G,/S['1BBDMKFA%+U4.$$?!"?H.,0)>A.@M3WPL$$TB>G(D:$"S/YU M8K6(M!9^X#Y(#:MQS/B5'PS5B[DG\MG._Z;<3T!- M(%\-"']EFT3=^P;3J( MMBG:IC_G67T9VW3P)[--/Q!IS:96Z"!:H7L@^O?+"AW%""E:H3_K6=V%%=I[ M]NSPZ-FC_-G>LX/'U@@=W>, "2T"8+/3W-$)SAWI &DS2W1T=3ST0<^*G8S- MBA&G(EG$T#H='$3K%*V3LDXQ1HK6Z4]Z5G=BG9[N/WGR5%FG/UN(] 9GQ6I% MT_P!?KQ-7IXVAH$6)S1E-C'=!W508NWR]K3:@3K3QWL< M2/F8B<$XWS?66A1G66D-@R"3@N'YL:BR"EE4WA'"0/)^,$[:)ON'V<[^T8., MB.[V'^?\7Z.\.P$@L?UANP-'&$Z]S(F_7#]?R.@/]PX<1G#63++*M#OO+DNS ME*<<[.T=1)/SS9J<@VARHLGY\QW4T.0<1).3[#]#H(_C76<<]@\?[UUK0;[? M>Q(MR#8HG&T#6=C?V]]]\\M)-!_1?/R9#VI['+G?$^._R\JAE[^,!W!LM>YR54V;83MX6U:<)H"A'G?O-ZMQ7KW^, M5S[JW/MX /=&Y[XR,X1 C2IW2V3DZZK #W1N6^S2:FC-IV M*\3CZVK;]Q]>Q\L>M>U]/(![HVW? V]FU<6LPK #Q +[V 8A.LO\$B.EK\+AE WG]^W_0#@WA1A_O[0G<: AP_>S)[I,G M3[_[S"U];C,!Q*__^/#Z9).3WG).WJ^A0/3L"H0=#?#I-L91LVXZ3>G :>@A M#DP B$GSOEPFTZPG,O ":"41\YG#W?W'UWWFZ-GN MT<&33>E!8N8R#N;\F;!SMO2L[%+@[__K+P=_B>?V-;R&V_A;KPR89&0>S\Y, M;[>W30$G?/=^5(<619Z7YGZ*P!9=W7A=XUG%LXIG]8V>U?;9M?M\IMN3$'EE MP]SGR2_U.11EF^1[PA>,H*KW^[;&"/X>7<$?EL^_?E7W:Y$1_H'EAVT]_T?M MH^3O]=_^X](3)C_OOKHG$6;4U_='7\>SNC]G],MSC1;Q/MW<>ZQEXUG%L]K:LXH6,5I$U[O4F+: K4$8W^-Y868* MVI?!?*-]W,I[''5N/*MX5M$^1OOXY>X@?1C6]+SH[(*G=J$/-D;!OW;8<#LL MYWW."?U9IN"^.2T;+6(\JWA6]^"L;C:(^M4W;C29TO M__O__>>C>;'-D[3U9<^.XT>_Y%8A?,EO?RK(]>XUK9U(>'QOELRV7 M96^2IRV8A"1D*4 +@+:57Y\&>('B 5*6;2K%U%9&)KH;?:'1:(#@SW]]7@3H MD0A).?N\=[A_L(<(\[A/V>SSWOUD<#(Y'8WV_OKE3S__>3! 9Q>C:W1-GM") MI^@C.:/2"[@,!4$?)E??H']^O;U$$V].%AB=<2]<$*;0 ,V56AX/AT]/3_O^ ME#+)@U!!=W+?XXLA&@QBXJ>"8/T^;QG2T(DG3'U;(30 MO1Y\^@C*PTH)^A J' M@PR3L'!QE.](8VC (7E6A$GZ$)"!!B/"6$@.CK2C1.A2J!1YBN6#08:'ACO= MT\>T)U!MCKNGCW%/!X?#?UY=1IZ3 >4_5XN"\!_'.KF!RQ) A[*P0SC99&5 MN*&$'9_0FBR47"D6^?,D]8[J:SO1?@Z3'@7XT.#P"=>T#L3W$ M2D=!!;O#ES&1V'8C)E+'V)2)Q$BZ]^^K^BVU:J,>996WZ1\#_:.VSX*/;M:I M'4*2/YIWG@M [1@HA(@A"934?PVR$5K%1%5\:P#,]HH^3 M87U+IL@$NF,L/,$#4A\.ATO!ET0H2J0]91@"78JQ5+>Z-!=4UH7TR;2LTH%!&ZT4^2V&Z)K"'@[8" XH7!@XCGV9 C476 MU.^@'>D?][,)GPFEF\R^'!_I_L(:QEC/I3\Q\%%%#%KF?A^M$ULB'DOAC]L7\7A]3 M,7(,4H.X9J;&>'E_+D6+'R;V>@TK3D!BLP@ZY?'POL$"VN9$41"S^5C/HSD\9#GVJ=*FZH?EK2#@\X(>F'I#K ND^T(>TE]X+MN % M[%&O.Q\" @O\*1%"MW/O=UA0F7_G//")D.=_A+ 4=H],OV:)9[-P5]0Q(/." T7O6_5^]8K&+YD#GKU7AR^]M/+?$TV]+5^ M=MMZ7,-R?A'PITUFM2*JPTL^-?82((T,[7X6:UD>3)?\8S'#C/ZG4! L!ZBW MW.%!H9Q@8_>&:6.8KUA2&#[V/H&.PTD9: +T*(0[S-2)9_89*9O=\ "()&E MAGP108?A#PN&-[WI09K;Z#"Q.ZLL67VBK%.4]-H[3!N'N29*)_0W1$SF,/V5 M^L ZC,.LQ?(@$(B6#4 "&1J]D=H8Z0)3\2L.0G)%L/[;S&6EIBJ'=!CL8\%@ MF@PR=)!-J+=:&ZN-(!N52BMN0KRX%EYJM%) A\V^*]@LHX(R,KW%VLV>644\ MWI2HF!2+< Y[?5\RUUF5W59J>L=,_+98D?RG>O>LVW&2F_",B^;LDC M86%YSI #<%CDQX)%##:*T7O+M+',*5\LJ)D&)"3JL C6R3%AE0E^';S#;C\5 M[&81,UE[CEQOQS9VO*2>KEZI\0I #HM]*L:^B )*2?16:C?:FE4_ MBT7[S6G4V_BH6$YI5X./N^G]H(T?W!(0@O@W6*C5'4Q>$GOKF_0-@!V6+=9+ M8DK(D$(VK=Y\;U4V>[7R6<,RVE&QWK*-,AKZD/SJ:^-OYDMW&&+T]CTI)NOP MHV(9:#M^%/7>>U'3I>U:N=7V"1>0P\+%HE&Q,MO;:WLEVIKA7 ?OL&*QE%11 MKNU-N;6Z;8TE:\ =ABQ6HDIKN+T9MU7,K9U>JZ =1BP6KTH+N[T1-ZKPED]^ M=I/#/,4:5?0"0F^.-RAWU(RWS2@YC%TL;VU4^NB=8ZLUD!HO<*#4F_MCL=)5 M70_I;?KFB]D3WS>2X,!Z@;-^6_65.G/XT>N<0P(R&5/V.ZS9"V^]+[Z5+V90 M.N #)>+KMQH(Q =-Y_Q9_R2OY9SM>G=XZRN5^W(O;QH^!_KU=!_9G**8U=Z% M7UK5T=T'H$W_$K.L QM,S#4C\-6(YOWW; M+AW.6JPIEE2S9R]"D[80Y0A^XH$0(E9+*UF]8[:TE%+*U-I!$LO M?1LQJ82YJD'&@/Z)2G''[%9;3D"(,=&IPD-?M2^':Q:+H55EM%QHS&Z]L[A* MX'V$E4T&W#/E+0[3O4.V=
>U1$!S0_Q#_;["< WW_@BG3 M1UIT0(#\, CXDR[+R LN3L%25,4-S,\\:7KR"+;1"P7(UB0.=-_K/OO>[#C< MNE@=+B\JYIQ:L_TM,HRCC',4LXX,[R:AB)C\%F7\(V -11+$K0;0'@00TQ,Y M!@ ]F( D%E<2/LUW L\F)YXF0^,7KJ%K[2#4EAX<4MP\:>$C<6_F-5KU[M-GL M:Y.1N!'JC?U=_3:[[5UFYW*#8NU_.W?9]4[2T$GL%X7:!(#& M> X'*);3E>K._[^&B#:+%]N@[W*=8A-WL(%+O8N_J8FG&>4ND$M13 *UW M%:-K%Q><);CWIGH9TTKRP=46G7%+G#C0YXSC:DDVNE 2F+4() MW_&CE//>T[=[&*]UU-R(D,//BC7;CV MG:#X0>YK0N9;0O'']HSY];=1?K/+LOK<&& RCZS(GY M>-NQGCG8;*3(0K.WAV0(8%29CPW^(GBX3 I@.RAZ/>2",K].T/&#Z.[JZ%O M&I@=Z,][2N@[2W#<8?SWL%JHPKIB39[J]LZ)$A>K*_;AK$*6-7KAK[@]$?BE M5&RU0!8 @TFL7J"8Z,-XJDXO4QR8;_D8W(?(_S[O>>;40@-]C9@B,'H5A =" M'W478Y8>:;C@8A(=S2BY[2NGL,W)=$5C/GEHI##]U4\LO#FXQAEY) $WVV:Q MPY1[4S.4KBBB@>L(@L=34R'VDUW$5.32MDBV]%.CQY KX[>0S2G$> II/]X-:<'6Y:<96IH@[,[NC@C#RH[JGEC.J5>;-0[(A82 M$I* J)_1RQ^Y4:"K+JK)&>N3)8356V#TN[$ZJ*T^9.#B;#18;VR6>PE M%#JCIR8.!I;&05RO4&;2SA^%N*6SN1I/[T%D+:J6N_2HA*6Y+9+LC"J=+A<= M)$K6[GH6IRRJ98)GI$O\>B!;VMF_8!ES!6GC_+TG.\.T":6@"5-'6Y>HV-A5 M268P%0"#3%V0+#86'N^2U\$((A7#)YD/ST)R,E5$:#M<\%!DM"9HC&-C*+EJE-(.7S!O]_;MHEPUP+:4"9/O+F>X M>"!B/#WC"UBK4$^O:,S+Y$KO0)^1)9=4_8T$?BIK1;J/>YD.6$FEV22345OCM#- I MP(0$@;Z\0D31*KI?]!LNS"+!-BAW56>[8>(;Z\$'P!F0U)ZE&E,T,CV-T9$15G6W(Y^GH" MWPYGEW2QC.>V\=3E!\U@.R.[.S$R,UGA/B=K#_'K*@.)G0).AK!6@&F%&A/=/JN+&Q_8M[* MIAY M?]5+,38#.V,1K-(6ZP!QC)0JZI5[R2WH#=%W]YQRB;Q]!L!8&>K_Y)%M5)FK<$/E_73W1Z'R1DA(2W1N?I>(H<[2.E[P0 MT4 7;N2=UX()+!LJ(<;=W4$S(4I%(./I5SH-A:Y!^MDXJ-"+&VV'55(WK5^3 M)]-4-6J:(G=QU*0%=UAN9>+EGW;&K,Z55_FK7HE<5:V[D^.62_!K],QX5"ZP M-0;?(0OG#J#JXU&0^'EAQ?Y24^A=E5^O1BD;,V)O_=:"[(ZD-3<9V"^X,Z+9 M3T-S6ZPWWT!UO8_2\BW8$@5LBM\Y55CG]]:8C^;=@NPM$#HG;'85]?K+4P4Q M&X%V3L!3?L'-&X171&^$9_ZZ]GB]@.;S!::OO=WO9GZQ#&$EF-YWI_V+3]43 M3*+K\K@A.RIBX2U3N2Y:-41714IBH:FM1SGZB%UA?=[\[V&P.CHX_*D@9 N< M;HJM+RT&*\5W%>E3R'+,H79"="'J3B?A^0%;8724:'U(HO.#"%8[9^) M<+8N8S5$)T7Z.V9'!T<'YKU3K\)#ZV&Z*I8>4\4(4M+030'BV:=$@I*6SHI0 MSG[G65]/MO,B5+5V4A284P+*Y)+^3DR?A0RA!J"C E4,C)*&K@I0RGSG&;_F MCX:](O=E+9T4(2Z.W?&[)ZY_K,UTET'4[7Q;ZFC&@12J)-I=@-<+HN]MT3M*S:".W$ MV V18=8\7RP#OB+1 :Z;>)C6^GESU-U10G[(FG.F#77@P.RD"NYA#>3IS_[= M"+Z@4O*R];8#J)."Y?91\^*4-G52B/(O]MY+?= 9N%GH=Q'-YV]7=^19?0U@ M\"5";H2ZK@25-+WWP9?H--LRH*I*WCJ(SHK5:/?;?/6]U7YYC!&)W6I+T5?' M\Y4^ A\^F(W)CNR:KZE@$]P.*\.U#9Z3OB%PA\6MW@[/">H$VPD1-[OLW$A8 M#'%;IMK9L)A%LA+CKVNE(7!GA;6_ E00KJ+QW86)[E.6X) +_.6_4$L#!!0 M ( !&":5,_T@>>J@P >I 5 9'-G;BTR,#(Q,#DS,%]C86PN>&UL M[5U;;^.X%7[?7Z%Z7W;1.K:37B;!9A:>>#(UFHD#)VFW3P4CT;8PLN@E)2?> M7]]#^299I$3)%Y+! (-D8O-0_ [/G13YRZ]OT\"98\I\$EXW.F?MAH-#EWA^ M.+YN/#\VNX\W_7[CUX\__/*G9M/IW?;OG7O\ZG3=R)_CGL_<@+"88N>GQZ\_ M.[]]&MXY=W[X[04Q[/2(&T]Q&#E-9Q)%LZM6Z_7U]*?.ST48>?JO'W>:78ZS?;E4^?BBO_[=/[?;5^UVBHS, M%M0?3R+G)_=GAU/!L\,0!\'"N?5#%+H^"IS']4/_XO1#]\SI!H$SY%3,&6*& MZ1Q[9\L^ T!P%:QAO#'_BKD3/$5WQ$V&=]U(X7E[H<$9H>/6>;M]T=I025OP MOYKK9DW^4;-SWKSHG+TQK^' ;(0L>;;"0];-WW+M7R^2UIW+R\M6\NVF*?-% M#:';3NNWKW>/"(DK2'\^-]C!//*1>*&A!X.&?8^H8 _Z'&"<<1@D,FS M)A2/KAL>&X?-=6^<.S]6Z2-:S/!U@_G368 ;K(RG4T07@]%7 M%,74CWS,!J/!#%,0E'"<-+GST8L?)%_U<(3\@)V7 3WH0X[%"F$=D-F 9"6=ZX3.6*3VX"\'A:QM-/C MZW$_G&,6\8$\8G>E7AN-NR$L^D*3*0#?%/A_8.^?).#>\0L"*]D-/3X_F($S M(:_<"K%;0L&- 8;5%Z%WBWSZ;Q3$>##JSD$UT4N 1X0R%/!GJ]L"0P9Z5-G; MHDU;]95)VX!]H'B&?._SVXQ+$A_Z()I@>A-3"MSI IQH;0:5A/-H3S6"5P0, M9[2 X7[^/?9G7'Z.P9O2IQC BZ[KTAA[>6=Y0$Z4/L/DR.04@BX*=8'' #*6:8W?(@R];_PK9]EQ@GD^'L&(NM3-# A1=ST6^&]N.-G,9]6B MQ3CO>&]-B!6F:_H1)=/K1LR:8X1F,#[B?IN #X3DEMND:+'A&]FV@EAK2L*D M;>+Z&@ZA0''=@$3X%?/T$++BAA,S&!:9\4>B8,EKG=A26K5R/R)L8(I(#/'5 M UIP5[YI:1E"$301 VR M8P2"N:,1\+@1/DO+K1SB+U@!KO1#:)T ;; (B%= M8A4*9I8+-H!)"1Q,CYIMR\'1&*.02RR;K4*$[ MY6:Z&T74?XD3GCP1R$+2K#BWA!5"=>5.)]5&H*=&PRN5Y6R]:>-FA;&3!4C+ M36ZR&C<8/0-83F$'.#45'?+,/<3>9T1#@,L@6(JG<5(8Z.&1[_KO"FT*W;)$ MFE[0Z(/U^"9'6#JN!E1JZI8 Y(% M&/ E=4*S)36.D '$!-X(L9<$XVH824VJA8.(K3])JF_-=F>UB/YCN:P&Z 4' MA<"T#3I?CQ(..==,VX#E.>/.D 4-M0U:5AD3#ES2V 2.E[-:(X]%\2B[>8S!2[HE :4[$XY=UH=5?2"IC4<\DH M],V;0H5+/%/EA-I *=2SA)C*Z;1!*JY@"=$4DF@#4EBG$N(HHM &HT;E20BN M>C_ZM*J@["16)SF!1CU2*"U)U*F\FFZKD M9@*4"VMUM-*^#''X*8&LDM@88G6KO0*CVXQL>+G>O2I>]6(8.N7UL1Z>XX D MB=>*P@YSN<&Y#2S$2.IE-'Z(HHJ1"QED S(E"?Z"0V@5@ !WO:D?^BSB-'.\*\-&[RE1E&$!0_+H MFN;!*Q=1GB5 VDVR?*@]AUH\W*Z4RGS;IIW&U+70ZDNRUB(:_=S/"YB,_ZF6 M&F>@AC>2S$OUGK3!%AJ"'4#9-MJ&6NI7A(,OH]);%"VPL/+"J)S(FJB\X'5M MW:Y14!K;+:ZE'>6. MD0Q55$*"L8"M^:YEP8A-OEEB[U&7S5@S_#\0.F/O%R M6]B,#"(4F)1?I952?+?OB@;Q*'(F-Z7'>)P]1CA_@H1NTP1,Y*-ZH&3N P<^ M+9YAS/UP$RDF9RA)M[<#V6AY-H,=AEB"=G7^D@):%V./\4"SSUC,WR/NA] < M!0_Q2^"[@]$(<_FTFAG+$SS*F;&J*C^1KOM[[*=/_A *@X$Y.4>_LR4.4KR( M^BYHYFK+7/:#5,NE#0(+1GF=MH>7O^'O9:X!2<<$A6,\!.W_#&+A"M^>J*)] M%HO4'OK%(U<0+!KY+P%^H*N%2(O>Y]O/P/8P>$O73QYB!UYCE4IHUVS@Z)YV M.J54CRC9I[E:(E^D3E"Z)91_N8VW[&"-L<(FM'@VO#NUG[EZG"!^\!#C6T6F MO$*2-5PV(M_+=R7\8,E).2!7('20]/#=X$(V\:F\#WY8.T=#4CZ=,%'A?V,B: M$E7CAUAE].R>1'C]^D'Z "L[WF[<@PE#/%MIRV!4RH2_VB@*JO6'Y'V&?_DA M_(PPF-I(!/N]H%XJ0 ZR<-;_]O[@*VV&3IO+W;7SO[]?GN2CV-4>^/767>%> M^ UG/KQ#&Y%HBY0O0GX(->GR'?)&+C9K>5FMJ6_30!OK3K6Y('FW<6MY!(>F M=8S.E ^J0Q+VI+B2TJ0,CY03F!,OV57D37X]3[4#G6\E;I9JA"!2#4R;B8*8 M6&TF1!WHG G592391"G2FS:/!:4 M7D4=:!O'@M7P,135T2B]62)TU=1!4=4 MG' 01FE_X2*7L@THZD7CZX7I!2PAEDP3(^:ETCI)Z?Q4Z4W?.522RKT0G:2Q M$7-WA.)[!0T\U#/-<6H%97@U%R?O0.$>9'3'S1C-'NOB;B;:7&Q?Y<=%6FT9O#:Z(NN$W(R.L\WNF9M1(#HP!$ M^] EED*V$BEHJ['V(E5Y25U%UE[O$0,JK)=)NUV1AOQ^>?WVM_Q0>J5K&)-8 MV);8HAKFS"G4VST)\/]@N< 7>NG5@_(7E-2/I/M^/\$A@:QDM!J4)9$)QX[O M*7RR5>K#=&^=56\D@Y!=FJY ; ML@,FK_8*^UUR1)J3OXJZH7*)G/;PXQ"7CV@//XYV]\B:=HBGR.=;80>C6V 8 M"OX+FF='F')TW@#M/8CBTRL.YO@K":.))4?NG((S7$Z>7HD=4<[)& *V&=MQ MM,6I6')+8FK'@0]U.))$+:J$W5&$:8XGRJ= &',5T+N_ZZC$.=:'+.[0;"8( MO>!>LY[KSG@&;)S=7KC7O=@!=^G*]@><]&,%Y*59WAMQTLW!,NJ:SB6?6]?K MR(Q<;J>4G'Z3X(FBD"$W>25OD^.M-Q(-L4O&(=\/EKSN=P-MXB!Y-WT,4FG2 MVE]R;2?\Q\O8$\_ M_A]02P,$% @ $8)I4Q !5<,2)@ 3Y," !4 !DX,B+_2!Z_G+X[>%H]'!V=77XC[__X6__<71T<'YY=7MPBU\/ M1EX:O.#S(/'".,D(/OC3P\U_'OS[]/[ZX#J(OC^A!!^2=%\^.#XZ.BN'/"$;L[P?G*,4'GS^\_W!R=')R M]/[3X\G'S^Q_/[_[ZT\?/O[7^_>?W[\O=8OG"Q(\3].#/WG_>NX-1&![C MCR?OWA+_\(#.1I3P;VM\9-F<_>JGJP[EQC\=YS^NFFX,_?J1MSWY].G3,?]U MU30)FAK204^._WUS_< A.:*3F5* \>'?_W!PD".'B$?B$-_CR4'QK]_NKS:I M"Z+TV ]FQT6;8Q2&]--\A"G!$R'_2Y88=C\QU/Y8ZIDNYOC+81+,YB$^/-Z: M)OKO.&);X\C'$Y2%:4<*A>/T1V\\0T&T/;F584Q3RP<_FN'9$R9=26T:PS"= M4SH<\;(G?+0"IB.UDI%$-"\)KE/+92E.@N-BE,F]]Y\^OC].T5L4"E0FB\_BR*??Q?[J+\EX0O](3X T> KQ'>4'$\)^C[WOHRC_ M_VD<^O2(N/B_+$@7YW@2>$%M)_C)ARQ8!-0C:;(;(83Q[H> &%'T7IR//B+$JI2G47AW1"<+)NQ>:,CH3]LW@V MI]/-Q[EX8_^*SW&*@K M2(/3U1?>:Y9N<7H=)\D=)@]3NI:9ZN%G(1Y/1I1Z M/V!ZW0M^P%Y&@I1R%G+:QY-SUA#[M<$T0;9"3/_(7J* M_(+"#-]@Q/Z;BYG5*E@ISU=4RR-,74(7$E]\K2$=@HK^ ML;RBHCE)&7GKV5\Q<18GZ5="I_I;1(V<,/@=^_^DHIH2^Y7J+PG=H6P=X(1: M)?$K4ZB3RYA0>\@/TN*'R%^S.AF]4-Z8U)O$)$$A^[8^W$ (M3,C(Y]22K<@ M6TZ4IAG?CZU7;->1!SN;0C8U#U.,TX*"U03?D9@JH>F"SA/3$N:,B:XGS59? MZ7_^KZF4P&8F7'NH_KGZ2C6?]!Z_X"@SQ%S;$0=:Q53UF 5\DS&A0E5?IJK@ MR-MR%YO]R@"K./"8UC5Z)IB?C(86=(=1!YMW/2.G,&^,K@7C7X:)V4I.W]-C MC 0>546Y LI-S-DLCI9]O_&#KACK.D!/0<@-RP'0-4NC97O7X"+=YA.645A- M:6%))E1ECZD]2I7,;Q&=>KI"DBQD G@EE\QBM#T!;1&_3/1<%.0'1]TICS,BD%NQR"/8-.&Y(QL*2B3#V*I2'+& 3 M-[B6-=%D?ZF#6?QYS0O%"U_1?UU-&C5W&3&KT%2J WVEMCH4S)>2644J.]H:&+1/^Z#&_9(UXD1&XJ$:(Z)XI>]O= M+O28,S:.N*FBL0\:^UACI4:-=&4UMW67= C[8J4Q*W9"O9W%M5\_\X4+?J.A M-:(?,9UX0E7,G)#"8,E2EB7!G*@"%I3=K#&TMBKN4,"C&/,@1:%T$ O^"JBVBN6LZ7='\KR.T.$+)@Q,V.!OE%*S>BG M+&5JW6.<1X7UUJ/&.-98OF?V683]"T0B2F(BG4)!8WLR3E,^ !((=5'%A.]5 MDF38/\]8\.T.DR#V>?CG%K_R7T2:2J>AVC.^Z2U@?]'\>HZ\B),M!K)[K@I@ MSA7AA(>H2TKQ.L@E.X([C]G7E!9?8\'W-&[P'>9_TIA2S8%L\<%A-L!&/@ZT MA9D3:GAEZ@X*#0PMN=J7(!UBGCORMKUT;;,5-U;,.7Y*1Q';5YB24=>JMAC( M+A\M!:3F<+V=X#A-0^[Y&$].@TE&/*:JKTG3.;M50QBC7;9'^6_C.8]87+QA MX@4)]BF.OU ,:Q,3'Y,OA"1V87[OXS&+!V/]RF!*^6(L_QO0P>DLO) EE(!XGF^<+AB\W\!@@L($ MMV92=!%(P+$H4%=FO"FZ!)[YZJ4MH]RO0@-046BZ8%5%0!PPK+"NBLS!Y%]R M94NP#BJQ]<8]WQS,@\E_2Q$@BU.6L1"$U,!CH"4)M@)A!P2"-%Y:E0D;44EG MF=8]]S>#FF99WM1_++.L#HG"!* /R;^I(\#DW>0F5T20S0+P 2( ^G%G9\'H M) ITPM-F$?D(<'F( MC.>O4-#9)L!O%I*?78:D<-V;1>03%$1,I1(8ULIAFJ%#GSTGX$Q3.P?. M"1B]?)L,!\.8@-%/M\^6,(P,&#VV6\Z%831@*; ]9W$8Q@Z,ICM(IH=A\, H MPL/E=QA&$(S>W']"AV'DP.G7M4P.%;M_.ZYQ2P?_/MSE\]YK*EJ_'KHQ6?M+ MZ(:(S9Z2P ^HOO. 6)$_Y25T87M[+*P)N44S^J^E@AC2JZP:'7>1*?N7=:_N MQM);;.O?[6_B?7&&[=*=J>* D]-V90O:]#1&:75TIK>SXG^L7&03=9+6AK$; M=<9.V1-VZO;:?"K#*]J 6PVY3\/=F1Q$L3X#DW?-_$.5FE;!0$-W ^&-!'1 M+!H[D)&HKRZ6H2GI84 Y_Z'S\[?-3&^E@#F+@88G5J;:PVHUAC-W\58%DI6%YZ MJKDMQ)DZ7:Q1EKCTVHP D_5IR<_'1ZI=G5(ZOG<^=&O#&-L<["5:JN-.VVT2C5X.>G!U M]<**,==-]7+6N.]XO)4A$^@P0"'1B6?WNXEZ^M/40RFX?Q B_S]GEV_P:M M[&5>KWAF>OV\69ZASN,6*L^ZZ:\ < >884G/46_R6_924'EV_SJ&5A K\7') M>D!C0^KCDO?9'5;LN^N6YS25TN?X!8UE;^9[NWBN5'26 M"#C3[&R-N:\XP@2%%/B1/Z.G>Y*R=RM?L,ZLZ?5UT%79T[G3OA**J#L/(0)HIY+0N.@U\!A)UP2)J'8 9>$EL)1-24UCG-GX1A QNLJ M#C!]%WTL*4UM [B?8NVBN,4INS%-%P2?XO7Q-8K2P _"C#&WOF-^\>:%F8]Y M*F+HL1*2?&6=LX;8KPUFVSDA9^&2+@2VF+.T8&)9[G!)OLHK86QX .Z(+7G1 M\T,8^8@](VH[ZO.2HOTLI6)L5Z$Y730/(/'M]/E%8# J'_MN MKY4FN2Y7))TA<7MS5ZGSHDO9TV_82Q_C>SS/J"*/!/XDDXYTF]1 'A94IO M,&+_S9/[5EEL^U"71&6 MYW^/(O\Z0$]!R&=S27^):-K@-HY(A0>5']7L-^Q=[#3 ALR/:FY\^Q"=+E;_ M^L\ $Q:C6URS")WL=J]>9_O,E??_)J7R:[VMQOAQ6+7O(EM1=A51U3#AZ^U$ MZLN1];#GD44)BX:S_V/5@U]06'\.M.Z,%7>PF:67DL!C9?T;J6O^JRI]K_N0 M>R#R(>WOTILXPHL;1+[C]#*+?#FK@L86\VE?<%'Y9R4[UNJE,*%6VLF>H&'. M&':W(67//9WC>9P$J3SL(^D!2NQ_:"WV/]AFX]O#(^''[&)MBTFYD'0 -10FW7OW%CKA%FA1D$$T/-B@>M3+U&=/2,"_ @ M24L=#(/2#N3^=C(Y&P%K,N" PJ*UT]0F72TE>@N3 3Q.LLTV'% [L-],F)9E M.$66F;, ]:Z,J6U-1T%J5>#KP/L&&!H9[+S@EG0].F-YW,H^ L M2+WLN8^ZL(")9*]/GO7.;E'PKTA]QPJZ.O;+*Y,EE3,[H M=@S2XH?(7X>[)Z,7%(1L)TYBDM!%1[]M[_'"=;[?DBI*.WNI8XW#QI$MONVB M,88U7QI[*+J4NE0C51:&UND)P(7^2+\EK0VRT1 (T6=4C7FF-KS/Y%4C%; MU-3>9;<:.C7L9C$5:+]C7D. FU."!=IZF'V,M,=9\[QLEO'RBC45GNGNITP' MQ_RU^"Y3J3FV<] PJZ4O:*IC [4&5I9 E\@(%W/=;"""1T%> MO,L,##L03-1W!EB*ZPR[051V=^5.E,(J!(^#;(N8 V('-HF>_;^Z.MAHB3O+ M?&?]HI5'P/&H9T?]0KS+8.)A?J\(_3#. K"U/M[>O>-L5+>;]K&3 >Z^EXVN M?\G9:^W6 *QYH' .SFJS*+UT\.X=7:Q>5TFLK(]X.FS)RJK\-3U)CB*_^*TRRC"?":)%W M@]Z"6383$EC]?5C2Z,DC):WRN[$P_W)G4>N3'DB!U^BX_"<._1I)+3L;HY=J MF23CC[MB0K]YCSTN*3"@RY[#[G[!";]DLG:ZPF2O+X]U;?J=\\ZJYK:JGCC'GIE@ M30MMZ20Z9Q^YABG%:N&I6MXWN2$Q%3;H813Z[EL;?[[+M MSEG2=!>RAYM+A*E\.!H= 3P%)*12[Y$?17=K# KIXH[VMC.6=X+'S.E"4 0)YB'F*D3D%^%O M_G?A% CX-#:\,7=/7LT>D]70]#,/\21]143RFHY&+W@;ZA:+ID7:Q1HCUQ@E M>!J'_M5L3N(7/%/6YY3UL/G.%RMJ[K$%?<66]#/56^5\2+LXZ W45PJ;'S-2 M:5TP'0$:IE W8%3:&DPX.KPLI*=M:T%3UOU@XJ.7'MU"N=7"96?2I?L#QF%_ M:@G?7*=1.TYK3AW0-.DE&LHU,[Z[TT?&1SI7SWP)#+%:EF[VSZ M:T"28%WA(_=&J7A;-XB;"9/YG60^8 MR5N[E;0E<#WE.X;N=B[_'C&9!5&^8:C"T>1UDG<8%+(S]H8M)G-$Y1U[MTZ0 MN]C8;-@EMWHU< 5H#D\7A\=7B%0>;32T?#".*1J(78#DU#$A MR)*_9/L8 M7W#5L\5LB,< Q6IG_K9F2K#:[C#QZ+Y$S_R9]BAC>KG';F[BJXA_^ XMN/'5 MM-ST.X.:A'O,SJ_R_F@Q$0V=03''["UV7M]OBF3M;M88JM+$;D\+6&AHZ M2]/NK#I&)+:=<][G7[+ /&OSH=_9NN%6=#7IU57+F7QMD"+NW7@ZXWR-D:+8:6B,2+9!::OS@' M3;]X_!4D'FV]6V8Q^1DD)FV=8F8Q^>0<)E5?FF'%"Z;_0>:)%+0NC$C]8I&JF[V*CPU4R:M6"7K8HV1@HI+NG^6 MVB8K%7R6)6D\PX0>'V'&S&WV.B8/F+P$GBB* MW=C,!J'LZ<."AD28OB!NZQ[)]N\F'3 M/>@KE9ND9RE0WZY:">T"1:?3&"A"2N^W[#Q>ND0EYPIXMD7AL*WXAA[^4H1_ ME'I">3=43F,GV74]UJ]?N4O#'JJM[=KZAPG ;L?P>IG>?44V(/ZA6MTL%F0+ M>.TO)GWS@IC/./*,ET$7UQ41?;]T9TK@$>HR@LF**.KO-KE^VO:V6K#\BE^Z MXY=3Q?6@&AH"(5IXR4/9W'4&[+M-?D$D8 N8Q0TDBV>C&0B"I9@W-'21:/M+ MY(Y0#8,1)/6NU5O9*U$4HB093Q[2V/LNQ;JAH;%SA^K'['"F1\8+*WI*9_2. M-L>$8)]_3WQ93+/GC^Z.V_M4MZH!FM*-RA,X2WM (O[%[8WMF&]1PNK:\O3! M69 D,5G+%$"3@RGI 8T,J4.5]C*V42_Q$ M,D18I> ;:AA./[P_^71.T&MS&3JM+O8VXC0F_-;$\EU+V29L; N'=.G:$+5V MFWSS%\O_A2*V4.6B;[.1-1A74I@!(P"OVL:@;;]2D1@2R562\%KJ-XCM\W]E MX8)N\Y]E=4];]#NNH94K,5A[SH%+ MY.'1C.7F:3D'2LV!,,!?!7Z8$XS\<50V4$^T&))T-[9\Z99E>U6^>C<;F=O4 MA;!0B.W-5D"F>/EP.KO!44J[U)I?45_C^AX3?G* !2V-45)E_(Y:ZK$?>$5B M-M,.DE,4AG$<+?\4G^([%/CKW.XFJ@V,"F09K=XQH4N!FXQBSCL,8+/H]5)1 MD&@Y]5:]U+UXP"'M\'Q' @_3OS],$<&/4Y2>H:CT?0ICS KVI:47S1_BYE<) M#8YN=17F!+(XZ)@$ST&$0O;7_"25'53R?D!8*M!GVNERJ_#)*716/?Z4@UBT MQ2@9?-4)S:]5 XLO13:'W<#S+BOWO1WST//* ME*DJ'2/U8FS<34M2A67+/#<%%<'S+-L&W9B&OOPU\HW%X>%JV>U:'-99?L4A MVM6YIQM !8H!R-S#?>:L00FM#*%6RJ(W+'B@S&OR2&[E)3!1X!$\]S+=;5OV=T"+ M4T245]N@(<3K',];NC8$T6/G+AVT/A+;Q:R=Q:/=N2 /B<,$80BGAE3)@ F+ M03'9E)+@'--F;R6!8\_0,2!.F'"NF&(OB,@R,& B-(1X%*B<, $Q*!@;DEV< MK;FIK3,W)-C 9'J(E;_I*(>)Q=!R4IC&Y&P-5MW](C AA2KJB9DUS6VNDEPAA^_*6 MKLSU7TH>^N;K?%U'^;'8-7^EMK[^Q?>'!"VM3N);WL5@6(<$L=87'*E]P&,\9=1=O<[9NI-M I^9I,NZW>1Q=O&$ORXO5KC9B$ZF:/?<5*AH>R\ 1)BBDNLC(GU&2DC2? M9YBD]*BXQ\]9R,9=<#_.;(:)1T_X5<=&UX+)X8WS?!\O4)@NEJ_1L6UW M&9 D77^]*!+^@)H=$]T&LGGYGS_FD*%P_!06AZ](M6QL:\]8R1$N-J;(+JDV M,F=UXV%O7=P%5WD^8Z?-Z<5A-UV[9MR_PH,)$0>_VC-0I7.:]M4\2/"JR6S5] MP;(#MVTZ.J?7KU4+O,) =':11K^XO*B4?AE@2*A7AI:_N;J10L-KRY0./:7 ME;\\!0J#XB).6^=P:8F(_;1 H=A7H'"X H4B M/:B+$:7M$W;S$EH72'1=S\XALN.W#COK>9IN;YB ].9.D%H-SMVF,R0-:H$& MF##TMB0&2^\?]M9="R3$.C-, /K8$4;#7# O8O6R;IR_?K;-8FD9'X1YAEC1MS)'@B:AV8_7QR)4.!9*GK#N,L\]'=SP? MW9EG:+L]&7&*J%BGBB53)7*?1;I8MRFTT=$K(C[_!R\7%/EW(8J4CW?W M\BF;-UA2$C!-7;P"Y&VMD;Z$4"((*DVL$RI=5E 61 =B[;])OMY9XK50;;.7 M5-T^97^N'[*G)/ #1!;,9:"A# C;VV-A30A#=CS1?5)9HZ.]:YUW8^GIL?[= MF#[S^!H_3N,L09'_^$K7[F(\Z:A#3?VL<9*C1KINF]N:_$2P&P61VJ%:;,=!)+SFBBC+)W&)/@=UY\! MU.G1QPZ^")ZG*<91;>MI[UUU?PC@WR$R)GGIL%]0F*T*(:DG0=C3L'EXVMD\ M5/:TI]16J-'< (I._9YBLWD8+S#.9[Y(4^MPC"F& 3(A+3>%9F>+AS0E*Z\Y M=9X15O*,.W;S%72+7_E/XM-:J[-[CW,.N[QB#V,_N23QC &&Z&DPGI2$J7!E MJ?K9O'C8+%O+)'5=#TUXIK0?R5YY*$QU/D*-MZ(F8(E$ 7NR'E#8:"GP M='N#VV^"A=9R]XE&L<;N#_4:59O0B#9W8.7R 245H3EA4]Q:'_&+-'J0(OF%.= MY"H:3^@I37]O]!18),?NXGM2,_VTL:66)CLSIRJ&2(&#;"GV\T'W=G!^.BXY M8WH&_[/I72SZC&LE.;9-F&IZW+!%KA+0*WC[>]4_^!/N.H_S]!?9KY4G:$K9 M 8J;UL9I2N4ILUP'!3ROLBHN[9@%7YM%:X(;$W0V'B@POGG 0R9;)U8P@[[< M=%\SZIXF74%8G&L$$QY-/4650E7!0"-9"2@8&F>V=B96Y8KT.M7)6<[%>D;G MU"J@6+13W66)5>4U($A? HJ!>CU(T[&JMQ8WDI^<8]J8H:N57@6S@(11&:&1 MO 43A8'U";F4@0F1I7TDCI$[!U-K+XDZ!P]F!9(AEXHJIP\F0I;D3=^%6P98 M0-LHKJIL2C>+N/2WFX:2O11._0^JY8=1<-.7ZRUXW#*Z3BGVOF>V& 7;6'N@MX]TP MP"Z:&&8SX0T#ZI(Y8CV?W33X+AHU?:;6&X;71:/(?-+]3EE M'%T.1&6!T;[?^ M"Q5C7 7H*0HJ)Z=JGRX%9WG65WMS&W9CZRG.LVIW-/1*K M^*2PG*E>QWUYNITO3[, MB>_F0ZU)7@M:]DQ)SGW.-??IZI.VV=6U:WVM=8'2T[A:IS+,)%"].'@KQ6.P MP/?^B@[$W.']=;\M;--.4JAW/<6YA%+[6#8K+3"SPWH!4JKQN)D 91J'!GW+ M+>_//0Y9_)]Y7Q>EBV&)V8=KC!F@C<2*?#S:W>S95:N'E$3S<+JH_-+@'=IN M+%.L)R0ML4W_J\ZRX(7>@HGZKX.257LA>X.PZN_#(];@4JO^9FW]7C)1A:^# M%Y;DD5)ZF!=YE"0X36[0;S'A.?E*+UG;4:RQ>XU1Z:VS1.H :VX+<:9.%VN4 M)=[;-B,8\W+<$3Q'@5^\G9B4Y==91LAF>2C=7A:=J#K"63(/+08 P:1TZS?,=?29S-KZ_/Q'71Q8T'/:Q65[&^XOB9H/DT\% H M.+S$;8UZY4>,Q()T>_;V;TU5NJGH;?+WYDI[I/B9BLNI-C'U[Y'DDPRNS M;Q3YXW2*26'RE5R_I7./_I?$D-QR1(/6P())*9D%4&Y@<#8W%DRSUT/5VAA% M_\I"!12U%N96%\%H/!E/)IOO FW^;F[FXRB=AHM+S.ZH% "CR%M0\?-"/]28 MUJCL8TX^42T@B'AL@'ZM40956QC[LD!UK; NPZA5?WM9E1ZWD);:22%7J!BZ MC2.O46RUZ0E!86,ZI%I%XZVLOH6SOL-X@]*,Q??.Z?HIW7 2,*'7%PAK5U&* M"4[2>TI>?B]X?7=#BS_I .:(-_TZ)8W&,N'*O3K/$*]NI$K>M]#W<^AG,"V4>-*[DBW MP*QS&4N"J"R#HB$R"I0]:>Y?8Q1UR5^%=:#' MB&<9D=:@ L5*O7S:R$?MH"Q,-)2ITD82VV]F%M$4K ]Y/> MPP:FX8#^9D%+,2,H;"D)>@-E6ZEZ*&/B2U5$$M8%SWO33C##O,/K7BM6SP H M1\>!GY#%QZOW-@31:*#WMA:'RH#W3D BP&$CC+X3S&IY%[:-XCN+ ME,8IT90, )/?X3PM"D,#YB,08!Q1D$$R?KK(TEFX"=V>^U;E#,+$87CBVBA4Y=_.]\P*JIW?!Y'Q85:,42W;N99/."Z%=MAU, M7(:7*@*/EW-/P&R32*.5P0@3$0L+9JBW[ :H0;W-HMG(#W7N99MMN-=,-W7N M.1MSF,CS5-U[O*9[)H[!3%CWWJ_97L1(,V1WHY#3JE[W.EW+BY\C]H#L-^9@ M;O")[,L\[;OM!BOKLJTQU++..Z>DWI4;2.7[!83QGBZT0W\(M M(^L#;??OBQUU+W;D1KV@UB Z7%K-=@$9X0W97"2T.^8T>ED#^BN.,$$AE7$C M?T:E.34'44KEN5PTJGI9O*27I"R]8:F8"^C?:+:_@K=35_"@A[+WM[9<6B[2 M+:70+&%B 2959G]GR]4[6S_HY:3]S>'=N\CB7GZFA01$^[$'@0S1L'L?UTD_]? .F]J>U%-1V8V?@.^[/XL_L'^S)KK__/U!+ P04 " 1 M@FE3O[D_7;6 Z% 8 %0 &1S9VXM,C R,3 Y,S!?;&%B+GAM;.R]>W/L M-I(G^O]^"EQ/QXX=5[*/Y'[8W=.S47J=UK:.2B/5<6^/XX:#(E$EMEED73XD M57_ZBTP ),CBJXH P3I]8WOGR$4@D3\@ 202B>O/C^=SIXN;V^_^E__^3_^X_\Z/257-[?WY)Z^D9F;^J_T MRD_<($JRF)*OGSY]0_[/Q>,=N?/#7Y^=A)*KR,W6-$S)*7E)T\T?O_ON[>WM M6V_IATD49"EK,/G6C=;?D=-30?XRI@[\3JZRO7E+RM?L-@5JL[3"D0; E-W[HA*[O M!.1)-GI";D/W6S(+ O((M1+R2!,:OU+O6TXS8 C^&$@8[XG_Q\1]H6OG+G*1 MO3]_I>!Y?XZ#;Z-X]=WYAP_??Y?7:BP!_W4JBYW"3Z=GYZ??GWW[GGA?$38: M88)M]VA$%G_?*?_V/98^^_'''[_#KWG1Q*\KR,B>??=_/MT](J[H2SKY;87HP$4@FDC MR@'=EN''9L6@9T.*4FR\_ M)W26)#2=K:,X]?^)\^KZ?4-#%.NB6_[\U<%DOK,%^#9,:4R35##R2 ,0A04(=2G5IW/+%MA@GE1QHR M\0QFH3?SUG[H)RD(ZRLUTUNZ&K76F3/7C;(P31Z_8F8W%-<&-8MZXH___WN!AE3C6"=O(S6FRQ%IAD )PX9I.2!QD\O3LQ@O:<7C--?&V:B@8:T M#3'239ZRYW]0-UU$CW23Q>X+&ZM/=/U,:T>VJXJU ;UFJG.TI?0I95U4RW]; M27N[W3"A8#H]O4WINFD?T$9^&N,ZWP"?_4>W5'YB8WSOK.E5M';\<*^Q4ZI- M#%!OJ;K8UA.8O?N&Y+BUQ2]@#P*EQ_C^@XW8ZRR8S[=)PE2C*\9ZN&)\^9'W MDQ-D])Z^X9E75^.V&L4IJ#NH]TB-K7J.:RUJMYM?HL"C<7+]_V:,E_LH MY8OITX:Q=AF%PB3\"')RUM;C^Y"Q!QC7!];Y'D@_4[E1_&9:"611,XURK<-[]=;9NZAR336H\N['UP0D> MJ1NMX$]8$]H-;>RD4OK>*ODZR5L3GDMGXZ=.@&:/CB^UR (O:MK&]2'F&X807FX5"T^+4?2'K6L#0$_:J) ) ]1X+O;KA-9 M6PUK,!I$N]W&U5%)F]2@ 4*,/A/0:,UVS525 O%MM@8K3)T$[4G!WC G_=1 M&,F>Y-7=9H;=@X UD!TW!0W(NFI9O(M)J!.[+XRS*_I*@V@#ZE,[F/8Z^LX% M]<<085(K[!7L3,84/9^)"F/H)RXI>!X+MOD7-L_64:A6JCU>F&W1=,_@ 6W, MCM'4H#U]E+6>QAE>Z=V&;-E9L7%.6NUEK54L:G5,H8'SXRW;3J)7/!6UXVBK MH?%.A#4" TY#%UL ;Z3Z"Y"Z@E/3+O=3*VWK^&6VP,$,=,7'W1'H76U2@!XI M&'75V[(]8-54UBOT,[8LH" #;3]$BT6K\#=6F,))\8HF;NSC:MUU@])5:V)P MVDS!;34F-17R)4<8OQ(NWAZ-Y\L;-H&=H.;B60/!:7;"Y] 3BQ9X!;BL:.TY M>QBM:4*7PW65[;/&UU:?)L!/3@H'X"U.PGZ&J_TH651%<[48M>I&];-2;%+C ME!PR),D$>G]!UYLH=N(MOWRY=.)X"_8&G.RS-(W]YRQ%28D>G!8+X_YTK J< MG^)\9XM8@?7+B7RG.SL+.VGZAT%;#XB5; I8Y^ =6H5=#<3>"L:K@I?Q^M;[CA]3KTZJP)C>5&8Z\X'=ZP7W9LR2TE1V:1 M]T\_)M6RQME,"5BEF?OWB>VTA M2LWSHK&HMG&*#5)9^ DW5ZO^U*9(MR+ M;<%JBU/K/A3LGD=R8VZ/.YB=LA/PKVUX*Y?T,KOL369J/K+\NO= )]EJY;%4 M3+Z\/=(-O-X%'T[*GN(5'O-'Y4K%J\Y]ZX.A)R!:..BO+X73,HDC0 MFUQP DK5%7T&_W$92V'/,>E)SBXF;6C,S7B:I@%JAO/EA;_,8A>4J8*I/G.] MBX1%U8MQPAG;??O28O96Y: M3\WU9:=P^=OA?%@M9^]-J^?A*R0G@!M"U--09O>T5+G M>6!T*;RSZ[-&M=>R+T9W'2Z,-07M/K=-E,>K33SOE)N*+\V0A^@'D9J:.1'9 M:SA+%&X#^UD9>]*<6E=P*=7<%WV)6E25_I$)CX-%U* #(8CGZAOW1\KD/O%3 M!B-^]5W* 2MOP-M\.8PWJ_.5M;)/P A#R-3+J/Z4WE+:GKQGSXGO^6RE>G+@ MYJ-316DL;P]"P0A<%\Z7RHU-J\K2HZ*]6($/\U9EI?BN[VT>FRPTN=A/>=JG MIF9.9P=SVEESVBMNL9NH:TAC1*4A)/6ME-C<7_W"_-@2^;1/#8.A*\M1,/* MHGA?W\7U &H:=Z7(I=3#T*\0C4=&R^SL\3[UM''YR+J%>SC.E_MPV:N>-BY5 M[8SO=>@1GU]^='&[5WW[)TRF@CK)RTT0O75YIK=6F5H@A]QWNXC#T 'O $+V MG(OC:.FG$&BCR96X*#"-G0TT\M#U [A]YG9&8&X1Z1D[(TU9Z[@KNHFIZ^/Y MI@%PJ66K6R-^!>Q"8$7C+Z2%]I MV&@_ZJYG;YG!+NU(:% J8U.K8-,AW3X$3@AN(V#)QG!)]XTO_EJK6-Q ^>"W M'9++92R+1ZM<6'00+S(2L+'=V_FE=_4I !2SKS^D:H6I9%79*W>*]37G@-PO M4TORTIOW*3%=3:+2_1BZN<(4>KZ[RR>XKWZ,6T_P;94LNN>@0L5CRH>X]$&" MJ4MV_F8G[9C'G(<#-=N[V/^\9M?T0RC9',/<4@JW2&Q$9%B6^7+VZO@!+*7%);0E..T^84_*_ Y[S;WPI+61QY]8:F?=>N+SME#U P=W8\ M"]J7RA3@JC9/]G? [6VAIYK<&G?-[GX81GX*_MA]'?!:J]CSB:\F]G$2WX6P MS9#7AC;E6>BJ-;%3&>.L4]/N4W-JOO2*2.WG4*]6M&@O>DZ5>/45_6L6!-$; M[-/LOR]CZK5>O!U$:CJ+!_<(Z;MNB-+VE@R1$$YR[\!J.A[PJ_Z"4;!JW031MZI1X*,R<8/X<^*NVR\7ZLO96R<8C7'E]Z+!U M[4EE.K'.]E7#]B!@\6XJO[>](DBQNOIAJK637Z7V_AZS3L][O M\M2;^4G8+&LO10Z\2]'JX5[CO2BUT!TGQMZYQ7I3FHK*WB>M]UY5I_+,B;$U MC]&;CS_.D6>G?B^;&FM/!1[736=9^A+%D)JJ'ZR=6M."TZJ8M]68%HQNXT1G MM:D NO/9/YXP"X$S >2#Z0>JONH43H%[+@U]:DX!5L\EH:V&39^H:$USY^MN M%[?:TE.]+^R T[>VO46!M0#1 Y'-Z_<4+.A, ;CS&STJVVK8#Y$N$\%VC$MS M^>E Z,OZ!%@N;ERZF%9*VGQRTE'1=A!M-Z5+?XFZ@V?/FA.];VB+Q=6G MY@0L9+#'M3PIKRDX$:9%6%1QW=O^'KN[HKV+D7?8*S(_>>$3%^, -H]'8_%) M 8!N;H^4UEY)V\($&J@?SD,*L=F;7Y[7%=/&@R"[B!9O$?Q1'R:KM>@$@G,OZ#** M:8O3DA;:1]F=4QW,]IVF!F3D?EROESZ.V;- MW>\6S4OU>1LNMNJ7%MUG#P*3 -FJ =44U"8/GYR8%4HV_J^4+2+9YN[NLEGG M:"X\ZAJ3GUT_TF@5.YL7WW6"AC6GN>RX+--5E8G:(6\OJREY EYJQEO.M?B/ M(HF"^.&7RUF%-^7#!,YUB8B"+N.,Y[MBER6]-X$I@(0GS\AED>AQA]_0NZ0Q MO,<0B;GX'7SAC]*5+L=8<]H6J0LG /?*IQ=*TSQD=E/6P.X*%H/T;38\&KX3 MJ"P6G=>9OW@O$MH&X"-D5!.7&TTUBNE*1.X0G'6L$5VUK-Y] M-N0_+L:_ ]Q^-*8-M6NR[$E$GXT[)SY?WC%%.E22K+5.GWX5M?%9;:)M26TL M:SG=0H>X3]>K$6+>]1?E_O4G<9Y1SUR=S@ =U:P!^LSDG:D]\(BL\?%CN,5:^]C'+VE+UT9$^M+C\7J.Z["^*R/QUUOYG.W MZ$A,[O$^MF&OM.*3):3UV_NR]@ M,&_(^%U;;*0> ^^8&)Q_0?31QGC)K6.7D=>\L/BZS#Q';1X+_]C>MT[^VL'%&803A5J^!M=)GX\S<,1K! MPTL4-N\W.T6,,W45N1E:6')EAJAH3/Y7Q@[*- ZVG3Q62T[!8U6< M-M@ 1[S[^KNI-E>U'.:S*XIYN= T0M;VXGDRL3#;4F_L$^:ION;D#&;]K8+[ M4-!X&Y?XR7S)NC:!:R@14.ES0N?+ZR3UUP[D\HC8(7O;:NL^A(PV#/P0N G\ MM ^K+:6MAA2!2XUR7(]V,/O5G<#]=S\XS>5MOX]3,M;U@])=SR*DA#JQ"X)S MQ;@,(HS<(596SF4CJ.Z:-B\:E;2# 4]/G_2>23UK6S0?OXDH!I"N,HY"]J>+ M&I7@L1_.OV9O M,A.0F>8W&C)9$X^[B0_8^HO&@63MO?>-5TXHGHA=,N6;K82>7 54[58YPO9> M:/30GD;*#A$;$J

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

UDR^B.([>H'?'"GQ^X[ATMH9%0E/X=B!(.,7I M8RC'P"K"=HS%.3L;^\G3)J:.-P_5L(UGFD8#&R"\!?"_+P5S/#L^F#O1]I6L M4J\2FP\['CN:DMAHQ,HRQD\B\] 5!-T<[*E3'4=)G0!YLQXO1N&50XL)3-[X M<&Z%B( 0/J60Z5A[&B_9!(]&RALQFJG+/-*VV6=XTJ%B4W .[RD#]GWU$',/ M,SQ>+EZ<]-()%>\ AC[BUOLGV*$Q6_(34V &:J7EC&0)9X5L8N$<2!*TV*:, M'>(Z(60ZRMT56#]%\F(HR7DB"6/*E%IKK]ND$:+H+GR1R[L+>8 9(0S

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end